{"609c5bf8f3ce3453a1959728802c52a7762cb019": [["BackgroundNeurological complications of SARS-CoV2 infection are increasingly recognized [1] .", [["SARS-CoV2 infection", "DISEASE", 40, 59], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 40, 49], ["BackgroundNeurological complications", "PROBLEM", 0, 36], ["SARS", "PROBLEM", 40, 44], ["CoV2 infection", "PROBLEM", 45, 59], ["infection", "OBSERVATION", 50, 59]]], ["Recently, a SARS-CoV2 induced focal encephalitis was reported [2] .", [["SARS", "DISEASE", 12, 16], ["focal encephalitis", "DISEASE", 30, 48], ["a SARS-CoV2 induced focal encephalitis", "PROBLEM", 10, 48], ["focal", "OBSERVATION_MODIFIER", 30, 35], ["encephalitis", "OBSERVATION", 36, 48]]], ["Here we describe a case of multifocal transverse myelitis following acute COVID-19 pneumonia.CaseA 60-year-old patient was first admitted to our hospital with typical respiratory symptoms of COVID-19 infection without neurological symptoms.", [["respiratory", "ANATOMY", 167, 178], ["neurological", "ANATOMY", 218, 230], ["transverse myelitis", "DISEASE", 38, 57], ["pneumonia", "DISEASE", 83, 92], ["COVID-19", "CHEMICAL", 191, 199], ["infection", "DISEASE", 200, 209], ["neurological symptoms", "DISEASE", 218, 239], ["patient", "ORGANISM", 111, 118], ["patient", "SPECIES", 111, 118], ["multifocal transverse myelitis", "PROBLEM", 27, 57], ["acute COVID-19 pneumonia", "PROBLEM", 68, 92], ["typical respiratory symptoms", "PROBLEM", 159, 187], ["COVID-19 infection", "PROBLEM", 191, 209], ["neurological symptoms", "PROBLEM", 218, 239], ["multifocal", "OBSERVATION_MODIFIER", 27, 37], ["transverse", "OBSERVATION_MODIFIER", 38, 48], ["myelitis", "OBSERVATION", 49, 57], ["acute", "OBSERVATION_MODIFIER", 68, 73], ["pneumonia", "OBSERVATION", 83, 92], ["respiratory", "ANATOMY", 167, 178], ["infection", "OBSERVATION", 200, 209]]], ["The polymerase chain reaction (PCR) test of the throat swab was positive for SARS-CoV2.", [["throat swab", "ANATOMY", 48, 59], ["SARS", "DISEASE", 77, 81], ["throat", "ORGANISM", 48, 54], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 77, 86], ["SARS-CoV2", "SPECIES", 77, 86], ["The polymerase chain reaction", "TEST", 0, 29], ["PCR) test", "TEST", 31, 40], ["the throat swab", "TEST", 44, 59], ["SARS", "PROBLEM", 77, 81], ["throat", "ANATOMY", 48, 54]]], ["A chest x-ray showed mild bilateral ground-glass opacification.", [["chest", "ANATOMY", 2, 7], ["A chest x-ray", "TEST", 0, 13], ["mild bilateral ground-glass opacification", "PROBLEM", 21, 62], ["chest", "ANATOMY", 2, 7], ["mild", "OBSERVATION_MODIFIER", 21, 25], ["bilateral", "ANATOMY_MODIFIER", 26, 35], ["ground-glass opacification", "OBSERVATION", 36, 62]]], ["Laboratory findings revealed elevated C-reactive protein but normal white blood cell count.", [["white blood cell", "ANATOMY", 68, 84], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 38, 56], ["white blood cell", "CELL", 68, 84], ["C-reactive protein", "PROTEIN", 38, 56], ["Laboratory findings", "TEST", 0, 19], ["elevated C-reactive protein", "PROBLEM", 29, 56], ["elevated", "OBSERVATION_MODIFIER", 29, 37], ["-reactive protein", "OBSERVATION", 39, 56], ["white blood cell count", "OBSERVATION", 68, 90]]], ["The patient's previous medical history was unremarkable other than hypertension (treated with ramipril and felodipine), mild fatty liver, and ureterolithiasis.", [["fatty liver", "ANATOMY", 125, 136], ["hypertension", "DISEASE", 67, 79], ["ramipril", "CHEMICAL", 94, 102], ["felodipine", "CHEMICAL", 107, 117], ["fatty liver", "DISEASE", 125, 136], ["ureterolithiasis", "DISEASE", 142, 158], ["ramipril", "CHEMICAL", 94, 102], ["felodipine", "CHEMICAL", 107, 117], ["patient", "ORGANISM", 4, 11], ["ramipril", "SIMPLE_CHEMICAL", 94, 102], ["felodipine", "SIMPLE_CHEMICAL", 107, 117], ["liver", "ORGAN", 131, 136], ["patient", "SPECIES", 4, 11], ["hypertension", "PROBLEM", 67, 79], ["ramipril", "TREATMENT", 94, 102], ["felodipine", "TREATMENT", 107, 117], ["mild fatty liver", "PROBLEM", 120, 136], ["ureterolithiasis", "PROBLEM", 142, 158], ["unremarkable", "OBSERVATION", 43, 55], ["hypertension", "OBSERVATION", 67, 79], ["mild", "OBSERVATION_MODIFIER", 120, 124], ["fatty", "OBSERVATION", 125, 130], ["liver", "ANATOMY", 131, 136], ["ureterolithiasis", "OBSERVATION", 142, 158]]], ["Patients and family history revealed no signs of neurological disorders and he received no vaccination in the months before.", [["neurological", "ANATOMY", 49, 61], ["neurological disorders", "DISEASE", 49, 71], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["neurological disorders", "PROBLEM", 49, 71], ["vaccination", "TREATMENT", 91, 102], ["no signs of", "UNCERTAINTY", 37, 48]]], ["He recovered rapidly from COVID-19 pneumonia and was discharged home 5 days later without any symptoms.CaseThree days after discharge, he developed bladder dysfunction and progressive weakness of the lower limbs.", [["bladder", "ANATOMY", 148, 155], ["lower limbs", "ANATOMY", 200, 211], ["pneumonia", "DISEASE", 35, 44], ["bladder dysfunction", "DISEASE", 148, 167], ["weakness of the lower limbs", "DISEASE", 184, 211], ["He", "ORGANISM", 0, 2], ["bladder", "ORGAN", 148, 155], ["lower limbs", "ORGANISM_SUBDIVISION", 200, 211], ["COVID", "TEST", 26, 31], ["pneumonia", "PROBLEM", 35, 44], ["any symptoms", "PROBLEM", 90, 102], ["bladder dysfunction", "PROBLEM", 148, 167], ["progressive weakness of the lower limbs", "PROBLEM", 172, 211], ["rapidly", "OBSERVATION_MODIFIER", 13, 20], ["pneumonia", "OBSERVATION", 35, 44], ["bladder", "ANATOMY", 148, 155], ["dysfunction", "OBSERVATION", 156, 167], ["progressive", "OBSERVATION_MODIFIER", 172, 183], ["weakness", "OBSERVATION", 184, 192], ["lower limbs", "ANATOMY", 200, 211]]], ["He was unable to micturate or walk unaided.", [["He", "ORGANISM", 0, 2]]], ["On re-admission two days later, clinical examination revealed hypesthesia below the Th9 level and a moderate spastic paraparesis.", [["spastic paraparesis", "DISEASE", 109, 128], ["clinical examination", "TEST", 32, 52], ["hypesthesia below the Th9 level", "PROBLEM", 62, 93], ["a moderate spastic paraparesis", "PROBLEM", 98, 128], ["hypesthesia", "OBSERVATION", 62, 73], ["Th9", "ANATOMY", 84, 87], ["moderate", "OBSERVATION_MODIFIER", 100, 108], ["spastic", "OBSERVATION_MODIFIER", 109, 116], ["paraparesis", "OBSERVATION", 117, 128]]], ["Babinski's sign was positive bilaterally.", [["Babinski's sign", "TEST", 0, 15], ["bilaterally", "ANATOMY_MODIFIER", 29, 40]]], ["Cognition and cranial nerves were unaffected.", [["cranial nerves", "ANATOMY", 14, 28], ["cranial nerves", "MULTI-TISSUE_STRUCTURE", 14, 28], ["cranial nerves", "ANATOMY", 14, 28]]], ["General lab results were unremarkable including a nearly normalized c-reactive protein.", [["c-reactive protein", "PROTEIN", 68, 86], ["unremarkable", "OBSERVATION", 25, 37]]], ["A repeated throat swab showed a negative SARS-CoV2 PCR.", [["throat swab", "ANATOMY", 11, 22], ["negative SARS-CoV2 PCR", "DNA", 32, 54], ["A repeated throat swab", "TEST", 0, 22], ["CoV2 PCR", "TEST", 46, 54]]], ["Magnetic resonance imaging (MRI) of the spine revealed T2 signal hyperintensity of the thoracic spinal cord at Th9 level suggestive of acute transverse myelitis rather than multiple sclerosis [3] (Fig. 1a) .", [["spine", "ANATOMY", 40, 45], ["thoracic spinal cord", "ANATOMY", 87, 107], ["acute transverse myelitis", "DISEASE", 135, 160], ["multiple sclerosis", "DISEASE", 173, 191], ["spine", "ORGAN", 40, 45], ["thoracic", "ORGAN", 87, 95], ["spinal cord", "ORGAN", 96, 107], ["Magnetic resonance imaging (MRI) of the spine", "TEST", 0, 45], ["T2 signal hyperintensity of the thoracic spinal cord", "PROBLEM", 55, 107], ["acute transverse myelitis", "PROBLEM", 135, 160], ["multiple sclerosis", "PROBLEM", 173, 191], ["spine", "ANATOMY", 40, 45], ["hyperintensity", "OBSERVATION", 65, 79], ["thoracic", "ANATOMY_MODIFIER", 87, 95], ["spinal cord", "ANATOMY", 96, 107], ["Th9", "ANATOMY", 111, 114], ["suggestive of", "UNCERTAINTY", 121, 134], ["acute", "OBSERVATION_MODIFIER", 135, 140], ["transverse", "OBSERVATION_MODIFIER", 141, 151], ["myelitis", "OBSERVATION", 152, 160], ["multiple", "OBSERVATION_MODIFIER", 173, 181], ["sclerosis", "OBSERVATION", 182, 191]]], ["Brain MRI showed no inflammatory changes.", [["Brain", "ANATOMY", 0, 5], ["Brain MRI", "TEST", 0, 9], ["inflammatory changes", "PROBLEM", 20, 40], ["no", "UNCERTAINTY", 17, 19], ["inflammatory", "OBSERVATION", 20, 32]]], ["Cerebrospinal fluid (CSF) analysis was abnormal with lymphocytic pleocytosis (16/\u00b5l) and elevated protein level (793 mg/l).", [["Cerebrospinal fluid", "ANATOMY", 0, 19], ["lymphocytic", "ANATOMY", 53, 64], ["lymphocytic pleocytosis", "DISEASE", 53, 76], ["Cerebrospinal fluid", "ORGANISM_SUBSTANCE", 0, 19], ["CSF", "ORGANISM_SUBSTANCE", 21, 24], ["Cerebrospinal fluid (CSF) analysis", "TEST", 0, 34], ["lymphocytic pleocytosis", "PROBLEM", 53, 76], ["elevated protein level", "PROBLEM", 89, 111], ["fluid", "OBSERVATION", 14, 19], ["lymphocytic pleocytosis", "OBSERVATION", 53, 76]]], ["SARS-CoV2-PCR in the CSF and oligoclonal bands were negative.", [["CSF", "GENE_OR_GENE_PRODUCT", 21, 24], ["CoV2", "DNA", 5, 9], ["SARS-CoV2-PCR", "TEST", 0, 13], ["the CSF", "TEST", 17, 24], ["oligoclonal bands", "TEST", 29, 46], ["CSF", "ANATOMY", 21, 24], ["negative", "OBSERVATION", 52, 60]]], ["Further work-up was unremarkable including PCR for herpes simplex virus, varicella-zoster virus, antibodies against human herpesvirus 6, Epstein-Barr virus, and Hepatitis E, antineuronal antibody panel, Aquaporin-4, and myelin oligodendrocyte glycoprotein antibodies.", [["herpes simplex virus", "DISEASE", 51, 71], ["varicella-zoster", "DISEASE", 73, 89], ["herpes simplex virus", "ORGANISM", 51, 71], ["varicella-zoster virus", "ORGANISM", 73, 95], ["human herpesvirus 6", "ORGANISM", 116, 135], ["Epstein-Barr virus", "ORGANISM", 137, 155], ["Hepatitis E", "ORGANISM", 161, 172], ["Aquaporin-4", "GENE_OR_GENE_PRODUCT", 203, 214], ["myelin oligodendrocyte glycoprotein antibodies", "GENE_OR_GENE_PRODUCT", 220, 266], ["antibodies", "PROTEIN", 97, 107], ["Hepatitis E, antineuronal antibody panel", "PROTEIN", 161, 201], ["Aquaporin-4", "PROTEIN", 203, 214], ["myelin oligodendrocyte glycoprotein antibodies", "PROTEIN", 220, 266], ["herpes simplex virus", "SPECIES", 51, 71], ["varicella-zoster virus", "SPECIES", 73, 95], ["human", "SPECIES", 116, 121], ["herpesvirus", "SPECIES", 122, 133], ["herpes simplex virus", "SPECIES", 51, 71], ["varicella-zoster virus", "SPECIES", 73, 95], ["human herpesvirus", "SPECIES", 116, 133], ["Epstein-Barr virus", "SPECIES", 137, 155], ["Further work-up", "TEST", 0, 15], ["PCR", "TEST", 43, 46], ["herpes simplex virus", "PROBLEM", 51, 71], ["varicella", "PROBLEM", 73, 82], ["zoster virus", "PROBLEM", 83, 95], ["antibodies", "TEST", 97, 107], ["human herpesvirus", "TEST", 116, 133], ["Epstein", "TEST", 137, 144], ["Barr virus", "TEST", 145, 155], ["Hepatitis E", "TEST", 161, 172], ["antineuronal antibody panel", "TEST", 174, 201], ["Aquaporin", "TEST", 203, 212], ["myelin oligodendrocyte glycoprotein antibodies", "TEST", 220, 266], ["zoster virus", "OBSERVATION", 83, 95]]], ["Follow-up MRI on day 6 further showed a patchy hyperintensity of the thoracic myelon at Th9-10 and at Th3-5 level (Fig. 1d) , suggestive of transverse myelitis.", [["thoracic myelon", "ANATOMY", 69, 84], ["transverse myelitis", "DISEASE", 140, 159], ["thoracic myelon", "CANCER", 69, 84], ["Th9-10", "CANCER", 88, 94], ["Th3-5", "GENE_OR_GENE_PRODUCT", 102, 107], ["Follow-up MRI", "TEST", 0, 13], ["a patchy hyperintensity of the thoracic myelon", "PROBLEM", 38, 84], ["transverse myelitis", "PROBLEM", 140, 159], ["patchy", "OBSERVATION_MODIFIER", 40, 46], ["hyperintensity", "OBSERVATION", 47, 61], ["thoracic", "ANATOMY", 69, 77], ["myelon", "ANATOMY_MODIFIER", 78, 84], ["Th9", "ANATOMY_MODIFIER", 88, 91], ["suggestive of", "UNCERTAINTY", 126, 139], ["transverse", "ANATOMY_MODIFIER", 140, 150], ["myelitis", "OBSERVATION", 151, 159]]], ["Repeated CSF analysis showed a slight increase in CSF lymphopleocytosis (27/\u00b5l) and protein levels (1177 mg/l).", [["CSF", "GENE_OR_GENE_PRODUCT", 50, 53], ["CSF", "PROTEIN", 50, 53], ["Repeated CSF analysis", "TEST", 0, 21], ["a slight increase in CSF lymphopleocytosis", "PROBLEM", 29, 71], ["protein levels", "TEST", 84, 98], ["slight", "OBSERVATION_MODIFIER", 31, 37], ["increase", "OBSERVATION_MODIFIER", 38, 46], ["CSF lymphopleocytosis", "OBSERVATION", 50, 71]]], ["Repeated SARS-CoV2-PCR in the CSF was negative.", [["CSF", "GENE_OR_GENE_PRODUCT", 30, 33], ["CoV2", "DNA", 14, 18], ["Repeated SARS", "TEST", 0, 13], ["CoV2", "TEST", 14, 18], ["PCR in the CSF", "TEST", 19, 33], ["negative", "OBSERVATION", 38, 46]]], ["There was no specific intrathecal synthesis of Anti-SARS-CoV IgG.CaseInitial treatment with aciclovir and ceftriaxone intravenously was discontinued on day 8 after negative CSF results for respective infective agents.", [["aciclovir", "CHEMICAL", 92, 101], ["ceftriaxone", "CHEMICAL", 106, 117], ["aciclovir", "CHEMICAL", 92, 101], ["ceftriaxone", "CHEMICAL", 106, 117], ["Anti-SARS-CoV IgG", "GENE_OR_GENE_PRODUCT", 47, 64], ["aciclovir", "SIMPLE_CHEMICAL", 92, 101], ["ceftriaxone", "SIMPLE_CHEMICAL", 106, 117], ["CSF", "GENE_OR_GENE_PRODUCT", 173, 176], ["Anti-SARS", "PROTEIN", 47, 56], ["CoV IgG", "PROTEIN", 57, 64], ["Anti-SARS", "TEST", 47, 56], ["CaseInitial treatment", "TREATMENT", 65, 86], ["aciclovir", "TREATMENT", 92, 101], ["ceftriaxone intravenously", "TREATMENT", 106, 131], ["respective infective agents", "TREATMENT", 189, 216], ["no", "UNCERTAINTY", 10, 12]]], ["The patients' clinical status slightly improved 3 days after admission.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12]]], ["Because of persisting symptoms and after negative workup for active infection, methylprednisolone was started on day 7 at a dose of 100 mg/d.", [["infection", "DISEASE", 68, 77], ["methylprednisolone", "CHEMICAL", 79, 97], ["methylprednisolone", "CHEMICAL", 79, 97], ["methylprednisolone", "SIMPLE_CHEMICAL", 79, 97], ["persisting symptoms", "PROBLEM", 11, 30], ["workup", "TEST", 50, 56], ["active infection", "PROBLEM", 61, 77], ["methylprednisolone", "TREATMENT", 79, 97], ["active", "OBSERVATION_MODIFIER", 61, 67], ["infection", "OBSERVATION", 68, 77]]], ["During the further course, the patient improved rapidly.", [["patient", "ORGANISM", 31, 38], ["patient", "SPECIES", 31, 38], ["improved", "OBSERVATION_MODIFIER", 39, 47], ["rapidly", "OBSERVATION_MODIFIER", 48, 55]]], ["Follow-up CSF on day 12 showed normalization of cell count (3/\u00b5l) and regressing protein levels (734 mg/l), no Maike Munz and Swen We\u00dfendorf authors contributed equally. oligoclonal bands.", [["cell", "ANATOMY", 48, 52], ["CSF", "ORGANISM_SUBSTANCE", 10, 13], ["cell", "CELL", 48, 52], ["CSF", "PROTEIN", 10, 13], ["Follow-up CSF", "TEST", 0, 13], ["cell count", "TEST", 48, 58], ["regressing protein levels", "PROBLEM", 70, 95], ["oligoclonal bands", "PROBLEM", 170, 187], ["cell count", "OBSERVATION", 48, 58], ["bands", "OBSERVATION", 182, 187]]], ["The patient was discharged home on day 13 with a slight spastic paraparesis and hypesthesia below Th9 level, but normal bladder function.", [["bladder", "ANATOMY", 120, 127], ["spastic paraparesis", "DISEASE", 56, 75], ["hypesthesia", "DISEASE", 80, 91], ["patient", "ORGANISM", 4, 11], ["bladder", "ORGAN", 120, 127], ["patient", "SPECIES", 4, 11], ["a slight spastic paraparesis", "PROBLEM", 47, 75], ["hypesthesia below Th9 level", "PROBLEM", 80, 107], ["slight", "OBSERVATION_MODIFIER", 49, 55], ["spastic", "OBSERVATION_MODIFIER", 56, 63], ["paraparesis", "OBSERVATION", 64, 75], ["hypesthesia", "OBSERVATION", 80, 91], ["bladder", "ANATOMY", 120, 127]]], ["He was able to walk independently.", [["He", "ORGANISM", 0, 2]]], ["A steroid taper scheme was initiated.DiscussionThis case describes multifocal myelitis occurring shortly after COVID-19 infection.", [["steroid", "CHEMICAL", 2, 9], ["myelitis", "DISEASE", 78, 86], ["infection", "DISEASE", 120, 129], ["steroid", "CHEMICAL", 2, 9], ["steroid", "SIMPLE_CHEMICAL", 2, 9], ["A steroid taper scheme", "TREATMENT", 0, 22], ["multifocal myelitis", "PROBLEM", 67, 86], ["COVID-19 infection", "PROBLEM", 111, 129], ["steroid taper", "OBSERVATION", 2, 15], ["multifocal", "OBSERVATION_MODIFIER", 67, 77], ["myelitis", "OBSERVATION", 78, 86], ["infection", "OBSERVATION", 120, 129]]], ["No other causes of myelitis could be identified after extensive workup.", [["myelitis", "DISEASE", 19, 27], ["myelitis", "PROBLEM", 19, 27], ["extensive workup", "TEST", 54, 70], ["myelitis", "OBSERVATION", 19, 27]]], ["We assume a post-infectious etiology in terms of secondary immunogenic overreaction.", [["secondary immunogenic overreaction", "PROBLEM", 49, 83], ["post-infectious", "OBSERVATION_MODIFIER", 12, 27], ["secondary", "OBSERVATION_MODIFIER", 49, 58], ["immunogenic overreaction", "OBSERVATION", 59, 83]]], ["Previously, others suggested a direct infection of the central nervous system by human coronaviruses like SARS or MERS [4] .", [["central nervous system", "ANATOMY", 55, 77], ["infection of the central nervous system", "DISEASE", 38, 77], ["SARS", "DISEASE", 106, 110], ["central nervous system", "ANATOMICAL_SYSTEM", 55, 77], ["human", "ORGANISM", 81, 86], ["human", "SPECIES", 81, 86], ["human coronaviruses", "SPECIES", 81, 100], ["a direct infection of the central nervous system", "PROBLEM", 29, 77], ["human coronaviruses", "PROBLEM", 81, 100], ["SARS", "PROBLEM", 106, 110], ["infection", "OBSERVATION", 38, 47], ["central", "ANATOMY_MODIFIER", 55, 62], ["nervous system", "ANATOMY", 63, 77]]], ["The affection of the peripheral nervous system and muscles was described for SARS-CoV-1 [5] .", [["peripheral nervous system", "ANATOMY", 21, 46], ["muscles", "ANATOMY", 51, 58], ["SARS", "DISEASE", 77, 81], ["peripheral nervous system", "ANATOMICAL_SYSTEM", 21, 46], ["muscles", "ORGAN", 51, 58], ["SARS-CoV-1", "SPECIES", 77, 87], ["SARS", "TEST", 77, 81], ["affection", "OBSERVATION", 4, 13], ["peripheral", "ANATOMY_MODIFIER", 21, 31], ["nervous system", "ANATOMY", 32, 46], ["muscles", "ANATOMY", 51, 58]]], ["Cases of Guillain-Barr\u00e9 Syndrome in association with severe COVID-19 infections were reported [6] .", [["Guillain-Barr\u00e9 Syndrome", "DISEASE", 9, 32], ["COVID", "DISEASE", 60, 65], ["infections", "DISEASE", 69, 79], ["Guillain-Barr\u00e9", "ORGANISM", 9, 23], ["Barr\u00e9 Syndrome", "PROBLEM", 18, 32], ["severe COVID-19 infections", "PROBLEM", 53, 79], ["Barr\u00e9 Syndrome", "OBSERVATION", 18, 32], ["severe", "OBSERVATION_MODIFIER", 53, 59]]], ["In a series of 58 severely affected COVID-19 patients, 67% showed clinical corticospinal tract signs but received no spinal MRI [7] .", [["corticospinal tract", "ANATOMY", 75, 94], ["spinal", "ANATOMY", 117, 123], ["corticospinal tract signs", "DISEASE", 75, 100], ["COVID", "CANCER", 36, 41], ["patients", "ORGANISM", 45, 53], ["corticospinal tract", "ORGANISM_SUBDIVISION", 75, 94], ["patients", "SPECIES", 45, 53], ["COVID", "TEST", 36, 41], ["clinical corticospinal tract signs", "PROBLEM", 66, 100], ["spinal MRI", "TEST", 117, 127], ["corticospinal tract", "ANATOMY", 75, 94], ["spinal", "ANATOMY", 117, 123]]], ["Only one other case with suspected focal myelitis without imaging or serological confirmation is reported from Wuhan [8] .", [["focal myelitis", "DISEASE", 35, 49], ["focal myelitis", "PROBLEM", 35, 49], ["imaging", "TEST", 58, 65], ["serological confirmation", "TEST", 69, 93], ["focal", "OBSERVATION_MODIFIER", 35, 40], ["myelitis", "OBSERVATION", 41, 49]]], ["This patient improved with empiric multiple treatments including intravenous immunoglobulins, prednisolone, and antiviral agents.", [["intravenous", "ANATOMY", 65, 76], ["prednisolone", "CHEMICAL", 94, 106], ["prednisolone", "CHEMICAL", 94, 106], ["patient", "ORGANISM", 5, 12], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 65, 76], ["immunoglobulins", "SIMPLE_CHEMICAL", 77, 92], ["prednisolone", "SIMPLE_CHEMICAL", 94, 106], ["patient", "SPECIES", 5, 12], ["empiric multiple treatments", "TREATMENT", 27, 54], ["intravenous immunoglobulins", "TREATMENT", 65, 92], ["prednisolone", "TREATMENT", 94, 106], ["antiviral agents", "TREATMENT", 112, 128]]], ["Our case shows that improvement might also occur with moderate steroid treatment, avoiding high doses because of uncertain effects on the immunogenic elimination of SARS-CoV2.DiscussionIt remains unclear at present whether post-infectious myelitis after COVID-19 behaves differently from other virus infections.", [["steroid", "CHEMICAL", 63, 70], ["SARS", "DISEASE", 165, 169], ["myelitis", "DISEASE", 239, 247], ["COVID-19", "CHEMICAL", 254, 262], ["infections", "DISEASE", 300, 310], ["steroid", "CHEMICAL", 63, 70], ["COVID-19", "CHEMICAL", 254, 262], ["steroid", "SIMPLE_CHEMICAL", 63, 70], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 165, 174], ["moderate steroid treatment", "TREATMENT", 54, 80], ["SARS", "PROBLEM", 165, 169], ["infectious myelitis", "PROBLEM", 228, 247], ["COVID", "TEST", 254, 259], ["other virus infections", "PROBLEM", 288, 310]]], ["Increased awareness of spinal symptoms following COVID-19 is recommended.Compliance with ethical standardsConflicts of interest None.Statement of ethicsWritten informed consent was obtained from the patient.Disclosure statementThe authors have no relevant financial or nonfinancial relationships to disclose.", [["spinal", "ANATOMY", 23, 29], ["COVID-19", "CHEMICAL", 49, 57], ["COVID-19", "CHEMICAL", 49, 57], ["spinal", "ORGAN", 23, 29], ["patient", "ORGANISM", 199, 206], ["patient", "SPECIES", 199, 206], ["spinal symptoms", "PROBLEM", 23, 38], ["COVID", "TEST", 49, 54], ["ethical standards", "TREATMENT", 89, 106], ["spinal", "ANATOMY", 23, 29], ["no", "UNCERTAINTY", 244, 246]]]], "8b4e7b82e7a3eb242d32d2619ddf4067d9869360": [["Thus the synthesis of glycans resembling human glycan structure and its huge complexity remain a major challenge in glycoengineering of plant cells [6] .", [["cells", "ANATOMY", 142, 147], ["human", "ORGANISM", 41, 46], ["plant cells", "CELL", 136, 147], ["plant cells", "CELL_TYPE", 136, 147], ["human", "SPECIES", 41, 46], ["human", "SPECIES", 41, 46], ["the synthesis of glycans resembling human glycan structure", "PROBLEM", 5, 63], ["glycan structure", "OBSERVATION", 47, 63], ["huge", "OBSERVATION_MODIFIER", 72, 76], ["plant cells", "OBSERVATION", 136, 147]]], ["This is all more challenging due to the complexity and diversity of the glycans in different therapeutic recombinant proteins.", [["therapeutic recombinant proteins", "PROTEIN", 93, 125], ["the glycans", "PROBLEM", 68, 79], ["different therapeutic recombinant proteins", "TREATMENT", 83, 125]]]], "007478d4c47546bf932eff1db15754e0b7bb1617": [["INTRODUCTIONChronic kidney disease (CKD) affects nearly 10% of adults in the United States, and the incidence and prevalence of this disease are increasing worldwide [1] .", [["kidney", "ANATOMY", 20, 26], ["INTRODUCTIONChronic kidney disease", "DISEASE", 0, 34], ["CKD", "DISEASE", 36, 39], ["kidney", "ORGAN", 20, 26], ["INTRODUCTIONChronic kidney disease", "PROBLEM", 0, 34], ["CKD)", "PROBLEM", 36, 40], ["this disease", "PROBLEM", 128, 140], ["kidney", "ANATOMY", 20, 26], ["disease", "OBSERVATION", 27, 34], ["CKD", "OBSERVATION", 36, 39]]], ["CKD progresses to end-stage renal disease as renal function declines gradually when a critical number of functional nephrons are lost.", [["renal", "ANATOMY", 28, 33], ["renal", "ANATOMY", 45, 50], ["nephrons", "ANATOMY", 116, 124], ["CKD", "DISEASE", 0, 3], ["end-stage renal disease", "DISEASE", 18, 41], ["renal", "ORGAN", 28, 33], ["renal", "ORGAN", 45, 50], ["nephrons", "MULTI-TISSUE_STRUCTURE", 116, 124], ["CKD", "PROBLEM", 0, 3], ["end-stage renal disease", "PROBLEM", 18, 41], ["renal function declines", "PROBLEM", 45, 68], ["end", "OBSERVATION_MODIFIER", 18, 21], ["-stage", "OBSERVATION_MODIFIER", 21, 27], ["renal", "ANATOMY", 28, 33], ["disease", "OBSERVATION", 34, 41], ["renal", "ANATOMY", 45, 50], ["function", "OBSERVATION", 51, 59], ["declines", "OBSERVATION_MODIFIER", 60, 68], ["functional nephrons", "OBSERVATION", 105, 124]]], ["Treatment options for CKD are limited and only offer partial protection against CKD progression [2, 3] .", [["CKD", "DISEASE", 22, 25], ["CKD", "DISEASE", 80, 83], ["Treatment options", "TREATMENT", 0, 17], ["CKD", "PROBLEM", 22, 25], ["CKD progression", "PROBLEM", 80, 95]]], ["The development of more effective drugs to halt CKD progression is therefore a critical challenge for public health.INTRODUCTIONNatural small molecules remain promising drug sources.", [["CKD", "DISEASE", 48, 51], ["halt CKD progression", "PROBLEM", 43, 63], ["INTRODUCTIONNatural small molecules", "PROBLEM", 116, 151], ["more effective", "OBSERVATION_MODIFIER", 19, 33], ["small molecules", "OBSERVATION", 136, 151]]], ["Asiatic acid (AA), a triterpenoid compound, is isolated from Centella asiatica, which is a traditional Chinese medicine.", [["Asiatic acid", "CHEMICAL", 0, 12], ["AA", "CHEMICAL", 14, 16], ["Centella asiatica", "CHEMICAL", 61, 78], ["Asiatic acid", "CHEMICAL", 0, 12], ["triterpenoid", "CHEMICAL", 21, 33], ["Asiatic acid", "SIMPLE_CHEMICAL", 0, 12], ["AA", "SIMPLE_CHEMICAL", 14, 16], ["Centella asiatica", "ORGANISM", 61, 78], ["Centella asiatica", "SPECIES", 61, 78], ["Centella asiatica", "SPECIES", 61, 78], ["Asiatic acid (AA)", "PROBLEM", 0, 17], ["a triterpenoid compound", "PROBLEM", 19, 42], ["Centella asiatica", "PROBLEM", 61, 78], ["a traditional Chinese medicine", "TREATMENT", 89, 119], ["triterpenoid compound", "OBSERVATION", 21, 42], ["Centella asiatica", "OBSERVATION", 61, 78]]], ["Previous studies have shown that AA has a variety of pharmacological effects, including anti-inflammation [4] , antioxidation [5] , and antitumor effects [6, 7] .", [["antitumor", "ANATOMY", 136, 145], ["AA", "CHEMICAL", 33, 35], ["AA", "SIMPLE_CHEMICAL", 33, 35], ["antitumor", "CANCER", 136, 145], ["Previous studies", "TEST", 0, 16], ["antioxidation", "TREATMENT", 112, 125]]], ["Few studies have evaluated the mechanism of AA for the treatment of renal fibrosis.", [["renal", "ANATOMY", 68, 73], ["AA", "CHEMICAL", 44, 46], ["renal fibrosis", "DISEASE", 68, 82], ["AA", "SIMPLE_CHEMICAL", 44, 46], ["renal", "ORGAN", 68, 73], ["Few studies", "TEST", 0, 11], ["renal fibrosis", "PROBLEM", 68, 82], ["renal", "ANATOMY", 68, 73], ["fibrosis", "OBSERVATION", 74, 82]]], ["Although previous studies have demonstrated that AA produces a significant effect on the inhibition of renal fibrosis by regulating TGF-\u03b2/Smad signaling [8, 9] , the details remain elusive.", [["renal", "ANATOMY", 103, 108], ["AA", "CHEMICAL", 49, 51], ["fibrosis", "DISEASE", 109, 117], ["AA", "SIMPLE_CHEMICAL", 49, 51], ["renal", "ORGAN", 103, 108], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 132, 137], ["Smad", "GENE_OR_GENE_PRODUCT", 138, 142], ["TGF-\u03b2", "PROTEIN", 132, 137], ["Smad", "PROTEIN", 138, 142], ["previous studies", "TEST", 9, 25], ["AA", "PROBLEM", 49, 51], ["renal fibrosis", "PROBLEM", 103, 117], ["TGF", "TEST", 132, 135], ["Smad signaling", "TEST", 138, 152], ["significant", "OBSERVATION_MODIFIER", 63, 74], ["effect", "OBSERVATION_MODIFIER", 75, 81], ["renal", "ANATOMY", 103, 108], ["fibrosis", "OBSERVATION", 109, 117]]], ["It is unclear whether AA regulates key proteins in the TGF-\u03b2/Smad signaling pathway by direct binding or through other mediators.", [["AA", "CHEMICAL", 22, 24], ["AA", "SIMPLE_CHEMICAL", 22, 24], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 55, 60], ["Smad", "GENE_OR_GENE_PRODUCT", 61, 65], ["TGF", "PROTEIN", 55, 58], ["Smad", "PROTEIN", 61, 65], ["the TGF", "TEST", 51, 58], ["direct binding", "PROBLEM", 87, 101], ["unclear", "UNCERTAINTY", 6, 13]]], ["It has been reported that thiazolidinediones, peroxisome proliferator-activated receptor-\u03b3 (PPAR-\u03b3) agonists, attenuate renal interstitial fibrosis, and inflammation through a reduction in TGF-\u03b2 [10] .", [["renal interstitial", "ANATOMY", 120, 138], ["fibrosis", "DISEASE", 139, 147], ["inflammation", "DISEASE", 153, 165], ["thiazolidinediones", "CHEMICAL", 26, 44], ["thiazolidinediones", "SIMPLE_CHEMICAL", 26, 44], ["peroxisome proliferator-activated receptor-\u03b3", "GENE_OR_GENE_PRODUCT", 46, 90], ["PPAR-\u03b3", "GENE_OR_GENE_PRODUCT", 92, 98], ["renal interstitial", "MULTI-TISSUE_STRUCTURE", 120, 138], ["TGF-\u03b2 [10]", "GENE_OR_GENE_PRODUCT", 189, 199], ["PPAR", "PROTEIN", 92, 96], ["TGF", "PROTEIN", 189, 192], ["thiazolidinediones", "TREATMENT", 26, 44], ["peroxisome proliferator", "TEST", 46, 69], ["activated receptor", "TREATMENT", 70, 88], ["agonists", "TREATMENT", 100, 108], ["renal interstitial fibrosis", "PROBLEM", 120, 147], ["inflammation", "PROBLEM", 153, 165], ["a reduction in TGF", "TREATMENT", 174, 192], ["renal", "ANATOMY", 120, 125], ["interstitial", "ANATOMY_MODIFIER", 126, 138], ["fibrosis", "OBSERVATION", 139, 147], ["inflammation", "OBSERVATION", 153, 165], ["reduction", "OBSERVATION_MODIFIER", 176, 185]]], ["We hypothesize that AA attenuates renal injury and fibrosis by activating PPAR-\u03b3.", [["renal", "ANATOMY", 34, 39], ["AA", "CHEMICAL", 20, 22], ["renal injury", "DISEASE", 34, 46], ["fibrosis", "DISEASE", 51, 59], ["AA", "SIMPLE_CHEMICAL", 20, 22], ["renal", "ORGAN", 34, 39], ["PPAR-\u03b3.", "GENE_OR_GENE_PRODUCT", 74, 81], ["PPAR", "PROTEIN", 74, 78], ["AA attenuates renal injury", "PROBLEM", 20, 46], ["fibrosis", "PROBLEM", 51, 59], ["activating PPAR", "TEST", 63, 78], ["renal", "ANATOMY", 34, 39], ["injury", "OBSERVATION", 40, 46], ["fibrosis", "OBSERVATION", 51, 59]]], ["To test this hypothesis, we investigated whether the selective and irreversible PPAR-\u03b3 antagonist GW9662 counteracts the protective effects against renal injury and fibrosis afforded by AA treatment in animals.", [["renal", "ANATOMY", 148, 153], ["GW9662", "CHEMICAL", 98, 104], ["renal injury", "DISEASE", 148, 160], ["fibrosis", "DISEASE", 165, 173], ["AA", "CHEMICAL", 186, 188], ["GW9662", "CHEMICAL", 98, 104], ["PPAR-\u03b3", "GENE_OR_GENE_PRODUCT", 80, 86], ["GW9662", "SIMPLE_CHEMICAL", 98, 104], ["renal", "ORGAN", 148, 153], ["AA", "SIMPLE_CHEMICAL", 186, 188], ["the selective and irreversible PPAR", "PROBLEM", 49, 84], ["\u03b3 antagonist GW9662", "TREATMENT", 85, 104], ["renal injury", "PROBLEM", 148, 160], ["fibrosis", "PROBLEM", 165, 173], ["AA treatment", "TREATMENT", 186, 198], ["renal", "ANATOMY", 148, 153], ["injury", "OBSERVATION", 154, 160], ["fibrosis", "OBSERVATION", 165, 173]]], ["Our results showed that AA upregulated the expression of nuclear-localized sterol regulatory element-binding proteins-1 (nSREBP-1), enhanced 15d-PGJ2, activated PPAR-\u03b3, and consequentially attenuated renal damage in unilateral ureteral occlusion (UUO) models.MATERIALS AND METHODSChemicals and reagents LC-grade methanol and chloroform were purchased from Merck (Darmstadt, Germany).", [["nuclear", "ANATOMY", 57, 64], ["renal", "ANATOMY", 200, 205], ["ureteral", "ANATOMY", 227, 235], ["AA", "CHEMICAL", 24, 26], ["renal damage", "DISEASE", 200, 212], ["unilateral ureteral occlusion", "DISEASE", 216, 245], ["LC-grade methanol", "CHEMICAL", 303, 320], ["chloroform", "CHEMICAL", 325, 335], ["sterol", "CHEMICAL", 75, 81], ["15d-PGJ2", "CHEMICAL", 141, 149], ["methanol", "CHEMICAL", 312, 320], ["chloroform", "CHEMICAL", 325, 335], ["AA", "SIMPLE_CHEMICAL", 24, 26], ["sterol regulatory element-binding proteins-1", "GENE_OR_GENE_PRODUCT", 75, 119], ["nSREBP-1", "GENE_OR_GENE_PRODUCT", 121, 129], ["15d-PGJ2", "SIMPLE_CHEMICAL", 141, 149], ["PPAR-\u03b3", "GENE_OR_GENE_PRODUCT", 161, 167], ["renal", "ORGAN", 200, 205], ["ureteral", "ORGAN", 227, 235], ["LC-grade methanol", "SIMPLE_CHEMICAL", 303, 320], ["chloroform", "SIMPLE_CHEMICAL", 325, 335], ["nuclear-localized sterol regulatory element-binding proteins-1 (nSREBP-1", "PROTEIN", 57, 129], ["PGJ2", "PROTEIN", 145, 149], ["PPAR-\u03b3", "PROTEIN", 161, 167], ["binding proteins", "TEST", 101, 117], ["nSREBP", "TEST", 121, 127], ["activated PPAR", "TEST", 151, 165], ["consequentially attenuated renal damage in unilateral ureteral occlusion", "PROBLEM", 173, 245], ["METHODSChemicals", "TEST", 273, 289], ["reagents LC", "TEST", 294, 305], ["grade methanol and chloroform", "TREATMENT", 306, 335], ["sterol regulatory element", "OBSERVATION", 75, 100], ["renal", "ANATOMY", 200, 205], ["damage", "OBSERVATION", 206, 212], ["unilateral", "ANATOMY_MODIFIER", 216, 226], ["ureteral", "ANATOMY", 227, 235], ["occlusion", "OBSERVATION", 236, 245]]], ["Internal standards (myristic acid), N, O-bis (trimethylsilyl) trifluoroacetamide (BSTFA), methoxyamine hydrochloride, and pyridine were supplied by Sigma-Aldrich (St. Louis, MO, USA).", [["myristic acid", "CHEMICAL", 20, 33], ["N, O-bis (trimethylsilyl) trifluoroacetamide", "CHEMICAL", 36, 80], ["BSTFA", "CHEMICAL", 82, 87], ["methoxyamine hydrochloride", "CHEMICAL", 90, 116], ["pyridine", "CHEMICAL", 122, 130], ["myristic acid", "CHEMICAL", 20, 33], ["N, O-bis (trimethylsilyl) trifluoroacetamide", "CHEMICAL", 36, 80], ["BSTFA", "CHEMICAL", 82, 87], ["methoxyamine hydrochloride", "CHEMICAL", 90, 116], ["pyridine", "CHEMICAL", 122, 130], ["myristic acid", "SIMPLE_CHEMICAL", 20, 33], ["N, O-bis (trimethylsilyl) trifluoroacetamide", "SIMPLE_CHEMICAL", 36, 80], ["BSTFA", "SIMPLE_CHEMICAL", 82, 87], ["methoxyamine hydrochloride", "SIMPLE_CHEMICAL", 90, 116], ["pyridine", "SIMPLE_CHEMICAL", 122, 130], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 148, 161], ["St. Louis", "ORGANISM", 163, 172], ["Internal standards (myristic acid)", "TREATMENT", 0, 34], ["N, O-bis (trimethylsilyl) trifluoroacetamide (BSTFA)", "TREATMENT", 36, 88], ["methoxyamine hydrochloride", "TREATMENT", 90, 116], ["pyridine", "TREATMENT", 122, 130]]], ["15-Deoxy-\u039412, 14-prostaglandin J2 (15d-PGJ2) was supplied by Cayman Chemical (Ann Arbor, MI, USA).", [["15-Deoxy-\u039412", "CHEMICAL", 0, 12], ["14-prostaglandin J2", "CHEMICAL", 14, 33], ["15d-PGJ2", "CHEMICAL", 35, 43], ["15-Deoxy-\u039412, 14-prostaglandin J2", "CHEMICAL", 0, 33], ["15d-PGJ2", "CHEMICAL", 35, 43], ["15-Deoxy-\u039412", "SIMPLE_CHEMICAL", 0, 12], ["14-prostaglandin J2", "SIMPLE_CHEMICAL", 14, 33], ["15d-PGJ2", "SIMPLE_CHEMICAL", 35, 43], ["Cayman Chemical", "SIMPLE_CHEMICAL", 61, 76], ["Deoxy", "TEST", 3, 8], ["14-prostaglandin J2", "TREATMENT", 14, 33]]], ["AA was obtained from FeiYu Biotech Ltd Co (Nantong, China), and GW9662 was purchased from AbMol BioScience (Houston, TX, USA).", [["AA", "CHEMICAL", 0, 2], ["GW9662", "CHEMICAL", 64, 70], ["GW9662", "CHEMICAL", 64, 70], ["AA", "SIMPLE_CHEMICAL", 0, 2], ["GW9662", "SIMPLE_CHEMICAL", 64, 70]]], ["Fatostatin was supplied by TargetMol (Shanghai, China).", [["Fatostatin", "CHEMICAL", 0, 10], ["Fatostatin", "CHEMICAL", 0, 10], ["Fatostatin", "SIMPLE_CHEMICAL", 0, 10], ["Fatostatin", "TREATMENT", 0, 10]]], ["The chemicals used in this study were of analytical grade, and their purity was above 99.5%.Animal modelsAll animal experiments were approved by the Ethics Committee for Animal Experiments of China Pharmaceutical University.", [["this study", "TEST", 22, 32], ["analytical grade", "TEST", 41, 57], ["their purity", "TEST", 63, 75]]], ["After acclimatization for 1 week, rats and mice were used in the experiments.", [["rats", "ORGANISM", 34, 38], ["mice", "ORGANISM", 43, 47], ["rats", "SPECIES", 34, 38], ["mice", "SPECIES", 43, 47], ["mice", "SPECIES", 43, 47], ["rats and mice", "TREATMENT", 34, 47]]], ["Male Sprague-Dawley rats (weight 180-200 g) and male ICR mice (weight 18-20 g) were given free access to water and regular chow.", [["Male Sprague-Dawley rats", "ORGANISM", 0, 24], ["ICR mice", "ORGANISM", 53, 61], ["Sprague-Dawley rats", "SPECIES", 5, 24], ["mice", "SPECIES", 57, 61], ["mice", "SPECIES", 57, 61], ["weight", "TEST", 26, 32], ["weight", "TEST", 63, 69]]], ["An animal model of UUO was established as described previously [11] .", [["UUO", "OBSERVATION", 19, 22]]], ["In brief, under chloral hydrate anesthesia, the left ureter was double-ligated with a 4-0 silk suture following a midline abdominal incision.", [["left ureter", "ANATOMY", 48, 59], ["abdominal", "ANATOMY", 122, 131], ["chloral hydrate", "CHEMICAL", 16, 31], ["chloral hydrate", "CHEMICAL", 16, 31], ["chloral hydrate", "SIMPLE_CHEMICAL", 16, 31], ["ureter", "ORGAN", 53, 59], ["abdominal", "ORGANISM_SUBDIVISION", 122, 131], ["chloral hydrate anesthesia", "TREATMENT", 16, 42], ["the left ureter", "TREATMENT", 44, 59], ["a 4-0 silk suture", "TREATMENT", 84, 101], ["a midline abdominal incision", "TREATMENT", 112, 140], ["left", "ANATOMY_MODIFIER", 48, 52], ["ureter", "ANATOMY", 53, 59], ["midline", "ANATOMY_MODIFIER", 114, 121], ["abdominal", "ANATOMY", 122, 131], ["incision", "OBSERVATION", 132, 140]]], ["Sham-operated animals underwent the same surgical intervention except for ureteral ligation.Animal modelsTo investigate the effect of AA, the rats were randomly separated into the following four groups: the UUO group (n = 6), the sham-operated group (control group, n = 6), the UUO + AA group (n = 6) (rats that were orally administered AA (10 mg\u00b7kg \u22121 per day, once a day continuously for 7 days) 12 h prior to UUO surgery), and the UUO + AA + GW9662 group (n = 6) (rats that were administered GW9662 (1 mg\u00b7kg \u22121 per day, ip, once a day continuously for 7 days) a half hour prior to the oral administration of AA).", [["ureteral", "ANATOMY", 74, 82], ["oral", "ANATOMY", 588, 592], ["AA", "CHEMICAL", 134, 136], ["AA", "CHEMICAL", 284, 286], ["AA", "CHEMICAL", 337, 339], ["AA", "CHEMICAL", 440, 442], ["GW9662", "CHEMICAL", 445, 451], ["GW9662", "CHEMICAL", 495, 501], ["AA", "CHEMICAL", 611, 613], ["GW9662", "CHEMICAL", 445, 451], ["GW9662", "CHEMICAL", 495, 501], ["animals", "ORGANISM", 14, 21], ["ureteral", "ORGAN", 74, 82], ["AA", "SIMPLE_CHEMICAL", 134, 136], ["rats", "ORGANISM", 142, 146], ["rats", "ORGANISM", 302, 306], ["rats", "ORGANISM", 467, 471], ["GW9662", "SIMPLE_CHEMICAL", 495, 501], ["oral", "ORGANISM_SUBDIVISION", 588, 592], ["rats", "SPECIES", 142, 146], ["rats", "SPECIES", 302, 306], ["rats", "SPECIES", 467, 471], ["the same surgical intervention", "TREATMENT", 32, 62], ["ureteral ligation", "TREATMENT", 74, 91], ["the sham-operated group (control group", "TREATMENT", 226, 264], ["the UUO + AA group (n = 6) (rats", "PROBLEM", 274, 306], ["UUO surgery", "TREATMENT", 412, 423], ["AA", "TEST", 440, 442], ["the oral administration of AA)", "TREATMENT", 584, 614], ["ureteral", "ANATOMY", 74, 82], ["ligation", "OBSERVATION", 83, 91], ["UUO", "ANATOMY", 278, 281], ["UUO", "ANATOMY", 434, 437]]], ["All rats were operated in the morning and sacrificed at 9:00 A.M. 7 days later.", [["rats", "ORGANISM", 4, 8], ["rats", "SPECIES", 4, 8]]], ["For the verification test, male ICR mice were used and randomly separated into the following four groups: the UUO group (n = 3), the control group (n = 3), the UUO + AA group (n = 3) (UUO mice that were given AA (15 mg\u00b7kg \u22121 per day, once a day continuously for 3 days)), and the control + AA group (n = 3) (sham-operated mice that were given AA (15 mg\u00b7kg \u22121 per day, once a day continuously for 3 days)).", [["AA", "CHEMICAL", 166, 168], ["AA", "CHEMICAL", 209, 211], ["AA", "CHEMICAL", 290, 292], ["AA", "CHEMICAL", 343, 345], ["ICR mice", "ORGANISM", 32, 40], ["mice", "ORGANISM", 188, 192], ["mice", "ORGANISM", 322, 326], ["mice", "SPECIES", 36, 40], ["mice", "SPECIES", 188, 192], ["mice", "SPECIES", 322, 326], ["mice", "SPECIES", 36, 40], ["mice", "SPECIES", 188, 192], ["mice", "SPECIES", 322, 326], ["the verification test", "TEST", 4, 25], ["male ICR mice", "TREATMENT", 27, 40], ["AA", "TREATMENT", 209, 211], ["AA", "TREATMENT", 343, 345], ["UUO", "OBSERVATION", 110, 113], ["UUO", "ANATOMY", 160, 163]]], ["All mice were operated on in the morning and sacrificed at 9:00 A.M. 3 days later.", [["mice", "ORGANISM", 4, 8], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 4, 8]]], ["To verify the role of the alterative metabolite 15d-PGJ2 in renal injury, we also used a mouse model, and mice were randomly separated into the UUO group (n = 3), the control group (n = 3), the UUO + 15d-PGJ2 group (n = 3) (mice that were administered 15d-PGJ2 (24 \u03bcg\u00b7kg \u22121 per day, ip, once a day continuously for 7 days)), and the UUO + 15d-PGJ2 + GW9662 group (n = 3) (mice were administered GW9662 (2 mg\u00b7kg \u22121 per day, ip, once a day continuously for 7 days) a half hour prior to the administration of 15d-PGJ2).", [["renal", "ANATOMY", 60, 65], ["15d-PGJ2", "CHEMICAL", 48, 56], ["renal injury", "DISEASE", 60, 72], ["15d-PGJ2", "CHEMICAL", 200, 208], ["15d-PGJ2", "CHEMICAL", 252, 260], ["PGJ2", "CHEMICAL", 343, 347], ["GW9662", "CHEMICAL", 350, 356], ["GW9662", "CHEMICAL", 395, 401], ["15d-PGJ2", "CHEMICAL", 506, 514], ["15d-PGJ2", "CHEMICAL", 48, 56], ["15d-PGJ2", "CHEMICAL", 252, 260], ["GW9662", "CHEMICAL", 350, 356], ["GW9662", "CHEMICAL", 395, 401], ["15d-PGJ2", "CHEMICAL", 506, 514], ["15d-PGJ2", "SIMPLE_CHEMICAL", 48, 56], ["renal", "ORGAN", 60, 65], ["mouse", "ORGANISM", 89, 94], ["mice", "ORGANISM", 106, 110], ["15d-PGJ2", "SIMPLE_CHEMICAL", 200, 208], ["mice", "ORGANISM", 224, 228], ["15d-PGJ2", "SIMPLE_CHEMICAL", 252, 260], ["GW9662", "SIMPLE_CHEMICAL", 350, 356], ["mice", "ORGANISM", 372, 376], ["GW9662", "SIMPLE_CHEMICAL", 395, 401], ["15d-PGJ2", "SIMPLE_CHEMICAL", 506, 514], ["mouse", "SPECIES", 89, 94], ["mice", "SPECIES", 106, 110], ["mice", "SPECIES", 224, 228], ["mice", "SPECIES", 372, 376], ["mouse", "SPECIES", 89, 94], ["mice", "SPECIES", 106, 110], ["mice", "SPECIES", 224, 228], ["mice", "SPECIES", 372, 376], ["the alterative metabolite", "TEST", 22, 47], ["renal injury", "PROBLEM", 60, 72], ["a mouse model", "TREATMENT", 87, 100], ["the UUO", "TEST", 190, 197], ["PGJ2", "TREATMENT", 256, 260], ["renal", "ANATOMY", 60, 65], ["injury", "OBSERVATION", 66, 72], ["UUO", "ANATOMY", 144, 147], ["UUO", "ANATOMY", 194, 197], ["UUO", "ANATOMY", 333, 336]]], ["All mice were operated on in the morning and sacrificed at 9:00 A.M. 7 days later.", [["mice", "ORGANISM", 4, 8], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 4, 8]]], ["To investigate the relationship between AA and the generation of 15d-PGJ2, a mouse model was used, and male ICR mice were randomly separated into the UUO group (n = 3), the control group (n = 3), the UUO + AA group (n = 3) (mice that were given AA (15 mg\u00b7kg \u22121 per day, once a day continuously for 3 days)), and the UUO + AA + fatostatin group (n = 3) (mice that were given fatostatin (30 mg\u00b7kg \u22121 per day, ip, once a day continuously for 3 days) a half hour prior to the administration of AA).", [["AA", "CHEMICAL", 40, 42], ["15d-PGJ2", "CHEMICAL", 65, 73], ["AA", "CHEMICAL", 206, 208], ["AA", "CHEMICAL", 245, 247], ["AA", "CHEMICAL", 322, 324], ["fatostatin", "CHEMICAL", 327, 337], ["fatostatin", "CHEMICAL", 374, 384], ["AA", "CHEMICAL", 490, 492], ["15d-PGJ2", "CHEMICAL", 65, 73], ["fatostatin", "CHEMICAL", 327, 337], ["fatostatin", "CHEMICAL", 374, 384], ["AA", "SIMPLE_CHEMICAL", 40, 42], ["15d-PGJ2", "SIMPLE_CHEMICAL", 65, 73], ["mouse", "ORGANISM", 77, 82], ["ICR mice", "ORGANISM", 108, 116], ["mice", "ORGANISM", 224, 228], ["UUO", "SIMPLE_CHEMICAL", 316, 319], ["AA + fatostatin", "SIMPLE_CHEMICAL", 322, 337], ["mice", "ORGANISM", 353, 357], ["fatostatin", "SIMPLE_CHEMICAL", 374, 384], ["PGJ2", "PROTEIN", 69, 73], ["mouse", "SPECIES", 77, 82], ["mice", "SPECIES", 112, 116], ["mice", "SPECIES", 224, 228], ["mice", "SPECIES", 353, 357], ["mouse", "SPECIES", 77, 82], ["mice", "SPECIES", 112, 116], ["mice", "SPECIES", 224, 228], ["mice", "SPECIES", 353, 357], ["a mouse model", "TREATMENT", 75, 88], ["AA", "TREATMENT", 245, 247], ["AA + fatostatin group", "TREATMENT", 322, 343], ["fatostatin", "TREATMENT", 374, 384], ["AA)", "TREATMENT", 490, 493], ["UUO", "ANATOMY", 150, 153], ["UUO", "ANATOMY", 200, 203], ["UUO", "ANATOMY", 316, 319]]], ["All mice were operated on in the morning and sacrificed at 9:00 A.M. 3 days later.", [["mice", "ORGANISM", 4, 8], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 4, 8]]], ["Under chloral hydrate anesthesia, plasma was collected for biochemical detection or GC/MS analysis, and the left kidney was harvested and stored at \u221280\u00b0C until analysis.Animal modelsBlood parameters, histology, and Western blotting Blood analyses were performed on an Olympus AU640 automatic analyzer.", [["plasma", "ANATOMY", 34, 40], ["left kidney", "ANATOMY", 108, 119], ["Blood", "ANATOMY", 182, 187], ["chloral hydrate", "CHEMICAL", 6, 21], ["chloral hydrate", "CHEMICAL", 6, 21], ["chloral hydrate", "SIMPLE_CHEMICAL", 6, 21], ["plasma", "ORGANISM_SUBSTANCE", 34, 40], ["kidney", "ORGAN", 113, 119], ["Blood", "ORGANISM_SUBSTANCE", 182, 187], ["chloral hydrate anesthesia", "TREATMENT", 6, 32], ["biochemical detection", "TEST", 59, 80], ["GC/MS analysis", "TEST", 84, 98], ["analysis", "TEST", 160, 168], ["Blood parameters", "TEST", 182, 198], ["histology", "TEST", 200, 209], ["Blood analyses", "TEST", 232, 246], ["an Olympus", "TEST", 265, 275], ["left", "ANATOMY_MODIFIER", 108, 112], ["kidney", "ANATOMY", 113, 119], ["harvested", "OBSERVATION", 124, 133]]], ["The histological protocol was described in detail previously [12] .", [["The histological protocol", "TEST", 0, 25]]], ["The Western blot protocol was described previously [13] .", [["The Western blot protocol", "TREATMENT", 0, 25]]], ["The following primary antibodies were used: anti-collagen I (ab34710, Abcam, Cambridge, UK), anti-fibronectin GC-MS sample preparation Internal standard solutions (10 \u00b5L of myristic acid in methanol, 1 mg/mL) were added to 100 \u03bcL of plasma.", [["plasma", "ANATOMY", 233, 239], ["myristic acid", "CHEMICAL", 173, 186], ["myristic acid", "CHEMICAL", 173, 186], ["methanol", "CHEMICAL", 190, 198], ["anti-collagen I", "GENE_OR_GENE_PRODUCT", 44, 59], ["Abcam", "GENE_OR_GENE_PRODUCT", 70, 75], ["UK", "GENE_OR_GENE_PRODUCT", 88, 90], ["anti-fibronectin", "SIMPLE_CHEMICAL", 93, 109], ["myristic acid", "SIMPLE_CHEMICAL", 173, 186], ["methanol", "SIMPLE_CHEMICAL", 190, 198], ["plasma", "ORGANISM_SUBSTANCE", 233, 239], ["primary antibodies", "PROTEIN", 14, 32], ["anti-collagen I", "PROTEIN", 44, 59], ["anti-collagen I", "TEST", 44, 59], ["Abcam", "TEST", 70, 75], ["anti-fibronectin GC", "TREATMENT", 93, 112], ["Internal standard solutions", "TREATMENT", 135, 162], ["myristic acid in methanol", "TREATMENT", 173, 198], ["plasma", "TREATMENT", 233, 239]]], ["The mixed solution was extracted with 300 \u00b5L of methanol and chloroform (3:1, v/v) and vortexed for 30 s.", [["methanol", "CHEMICAL", 48, 56], ["chloroform", "CHEMICAL", 61, 71], ["methanol", "CHEMICAL", 48, 56], ["chloroform", "CHEMICAL", 61, 71], ["methanol", "SIMPLE_CHEMICAL", 48, 56], ["chloroform", "SIMPLE_CHEMICAL", 61, 71], ["The mixed solution", "TREATMENT", 0, 18], ["methanol", "TREATMENT", 48, 56], ["chloroform", "TREATMENT", 61, 71], ["vortexed", "TREATMENT", 87, 95], ["mixed", "OBSERVATION_MODIFIER", 4, 9]]], ["The mixture was stored at room temperature for 10 min and centrifuged at 15 000 \u00d7 g for 10 min at 4\u00b0C. The resulting 300 \u03bcL of supernatant was transferred to a sample vial for vacuum drying at room temperature.", [["supernatant", "ANATOMY", 127, 138], ["vacuum drying", "TREATMENT", 176, 189]]], ["The residue was redissolved in 80 \u03bcL of a methoxyamine solution (15 mg/mL in pyridine) and vortexed for 1 min.", [["methoxyamine", "CHEMICAL", 42, 54], ["pyridine", "CHEMICAL", 77, 85], ["methoxyamine", "CHEMICAL", 42, 54], ["pyridine", "CHEMICAL", 77, 85], ["methoxyamine", "SIMPLE_CHEMICAL", 42, 54], ["pyridine", "SIMPLE_CHEMICAL", 77, 85], ["The residue", "PROBLEM", 0, 11], ["a methoxyamine solution", "TREATMENT", 40, 63], ["redissolved", "OBSERVATION_MODIFIER", 16, 27]]], ["An oximation reaction was performed at 37\u00b0C for 1.5 h.", [["An oximation reaction", "PROBLEM", 0, 21]]], ["Then, 80 \u03bcL of BSTFA (containing 1% TMCS) was added to the solution, and the solution was vortexed for 30 s.", [["BSTFA", "CHEMICAL", 15, 20], ["TMCS", "CHEMICAL", 36, 40], ["BSTFA", "CHEMICAL", 15, 20], ["BSTFA", "SIMPLE_CHEMICAL", 15, 20], ["BSTFA", "TREATMENT", 15, 20], ["1% TMCS)", "TREATMENT", 33, 41], ["the solution", "TREATMENT", 73, 85]]], ["The sample was kept at 70\u00b0C for 1 h and vortexed for 10 s.", [["sample", "ANATOMY", 4, 10], ["The sample", "TEST", 0, 10]]], ["The supernatant was transferred to a sample vial for GC-MS analysis.", [["supernatant", "ANATOMY", 4, 15], ["GC-MS analysis", "TEST", 53, 67]]], ["The samples were analyzed using an Agilent 7890 chromatograph coupled with a 5977B MS system (Agilent Technologies, Santa Clara, CA, USA).", [["samples", "ANATOMY", 4, 11], ["The samples", "TEST", 0, 11], ["an Agilent 7890 chromatograph", "TEST", 32, 61]]], ["Separation was achieved on a DB-5 ms capillary column coated with 95% dimethyl 5% diphenyl polysiloxane (30 m \u00d7 0.25 mm i.d., 0.25-\u00b5m film).", [["dimethyl 5% diphenyl polysiloxane", "CHEMICAL", 70, 103], ["dimethyl", "CHEMICAL", 70, 78], ["diphenyl polysiloxane", "CHEMICAL", 82, 103], ["dimethyl 5% diphenyl polysiloxane", "SIMPLE_CHEMICAL", 70, 103], ["a DB-5 ms capillary column coated", "TREATMENT", 27, 60], ["95% dimethyl 5% diphenyl polysiloxane", "TREATMENT", 66, 103]]], ["The initial GC oven temperature was set at 60\u00b0C for 1 min, followed by a 10\u00b0C/ min oven temperature ramp to 325\u00b0C, which was maintained for 10 min.", [["The initial GC oven temperature", "TEST", 0, 31]]], ["The injection volume was 1 \u03bcL with a split ratio of 1:10.", [["The injection volume", "TEST", 0, 20], ["a split ratio", "TEST", 35, 48]]], ["Helium was used as the carrier gas with a constant flow rate of 0.87 mL/min.", [["Helium", "CHEMICAL", 0, 6], ["Helium", "CHEMICAL", 0, 6], ["Helium", "TREATMENT", 0, 6], ["the carrier gas", "TEST", 19, 34], ["a constant flow rate", "TEST", 40, 60]]], ["Measurements were made with electron impact ionization (70 eV) in full scan mode (m/z 50\u2212650).Data analysisThe raw GC-MS data were converted and prepared for multivariate analysis according to the previously published methods [14] .", [["electron impact ionization", "TREATMENT", 28, 54], ["full scan mode", "TEST", 66, 80], ["Data analysis", "TEST", 94, 107], ["The raw GC", "TEST", 107, 117], ["MS data", "TEST", 118, 125], ["multivariate analysis", "TEST", 158, 179]]], ["The peak area was normalized to the internal standard.", [["The peak area", "TEST", 0, 13], ["peak", "OBSERVATION_MODIFIER", 4, 8], ["area", "OBSERVATION_MODIFIER", 9, 13], ["normalized", "OBSERVATION", 18, 28], ["internal", "ANATOMY_MODIFIER", 36, 44]]], ["PCA analysis was used to visualize general clustering, trends and outliers among the observations.", [["PCA analysis", "TEST", 0, 12]]], ["OPLS-DA was used to validate the PCA model and identify the differential metabolites.", [["DA", "CHEMICAL", 5, 7], ["the PCA model", "TEST", 29, 42]]], ["Fold changes of the arithmetic mean values (each group/the control group) were calculated.", [["Fold changes", "PROBLEM", 0, 12], ["the arithmetic mean values", "TEST", 16, 42]]], ["Student's t test was used to analyze the statistical significance of the results.", [["Student's t test", "TEST", 0, 16]]], ["The P values obtained from Student's t test were further adjusted by a false discovery rate method based on the Hochberg-Benjamini method.", [["P", "DNA", 4, 5], ["The P values", "TEST", 0, 12], ["Student's t test", "TEST", 27, 43]]], ["Differential metabolites were identified by a library search (NIST and Fiehn) and confirmed by available references.GW9662 abolished the protective effects of AA in UUO ratsRepresentative photographs of the left kidneys of the rats are shown in Fig. 1a .", [["left kidneys", "ANATOMY", 207, 219], ["GW9662", "CHEMICAL", 116, 122], ["AA", "CHEMICAL", 159, 161], ["GW9662", "CHEMICAL", 116, 122], ["GW9662", "SIMPLE_CHEMICAL", 116, 122], ["AA", "SIMPLE_CHEMICAL", 159, 161], ["rats", "ORGANISM", 169, 173], ["kidneys", "ORGAN", 212, 219], ["rats", "ORGANISM", 227, 231], ["rats", "SPECIES", 169, 173], ["rats", "SPECIES", 227, 231], ["Differential metabolites", "TEST", 0, 24], ["AA in UUO rats", "TREATMENT", 159, 173], ["UUO", "OBSERVATION", 165, 168], ["left", "ANATOMY_MODIFIER", 207, 211], ["kidneys", "ANATOMY", 212, 219]]], ["As shown in Fig. 1b , the UUO rats exhibited significant increases in serum creatinine (Scr), blood urea nitrogen Asiatic acid ameliorates renal fibrosis via PPAR-\u03b3 ZH Zhang et al. ).", [["serum", "ANATOMY", 70, 75], ["blood", "ANATOMY", 94, 99], ["renal", "ANATOMY", 139, 144], ["creatinine", "CHEMICAL", 76, 86], ["blood urea nitrogen", "CHEMICAL", 94, 113], ["Asiatic acid", "CHEMICAL", 114, 126], ["fibrosis", "DISEASE", 145, 153], ["creatinine", "CHEMICAL", 76, 86], ["urea nitrogen", "CHEMICAL", 100, 113], ["Asiatic acid", "CHEMICAL", 114, 126], ["UUO rats", "ORGANISM", 26, 34], ["serum", "ORGANISM_SUBSTANCE", 70, 75], ["creatinine", "SIMPLE_CHEMICAL", 76, 86], ["Scr", "SIMPLE_CHEMICAL", 88, 91], ["blood", "ORGANISM_SUBSTANCE", 94, 99], ["urea", "SIMPLE_CHEMICAL", 100, 104], ["Asiatic acid", "SIMPLE_CHEMICAL", 114, 126], ["renal", "ORGAN", 139, 144], ["PPAR", "GENE_OR_GENE_PRODUCT", 158, 162], ["PPAR", "PROTEIN", 158, 162], ["rats", "SPECIES", 30, 34], ["significant increases", "PROBLEM", 45, 66], ["serum creatinine", "TEST", 70, 86], ["Scr", "TEST", 88, 91], ["blood urea nitrogen", "TEST", 94, 113], ["Asiatic acid ameliorates", "PROBLEM", 114, 138], ["renal fibrosis", "PROBLEM", 139, 153], ["significant", "OBSERVATION_MODIFIER", 45, 56], ["increases", "OBSERVATION_MODIFIER", 57, 66], ["renal", "ANATOMY", 139, 144], ["fibrosis", "OBSERVATION", 145, 153]]], ["P < 0.001 (compared with control group); # P < 0.05, ## P < 0.01 (compared with UUO group) (BUN), and triglyceride (TG) levels, suggesting a significant degree of renal dysfunction.", [["renal", "ANATOMY", 163, 168], ["triglyceride", "CHEMICAL", 102, 114], ["renal dysfunction", "DISEASE", 163, 180], ["triglyceride", "CHEMICAL", 102, 114], ["UUO", "SIMPLE_CHEMICAL", 80, 83], ["BUN", "SIMPLE_CHEMICAL", 92, 95], ["triglyceride", "SIMPLE_CHEMICAL", 102, 114], ["TG", "SIMPLE_CHEMICAL", 116, 118], ["renal", "ORGAN", 163, 168], ["BUN", "TEST", 92, 95], ["triglyceride (TG) levels", "TEST", 102, 126], ["renal dysfunction", "PROBLEM", 163, 180], ["significant", "OBSERVATION_MODIFIER", 141, 152], ["degree", "OBSERVATION_MODIFIER", 153, 159], ["renal", "ANATOMY", 163, 168], ["dysfunction", "OBSERVATION", 169, 180]]], ["Treatment with AA group significantly attenuated the increase in BUN and Scr levels.", [["AA", "CHEMICAL", 15, 17], ["AA", "SIMPLE_CHEMICAL", 15, 17], ["BUN", "SIMPLE_CHEMICAL", 65, 68], ["Scr", "GENE_OR_GENE_PRODUCT", 73, 76], ["BUN", "PROTEIN", 65, 68], ["Scr", "PROTEIN", 73, 76], ["AA group", "TREATMENT", 15, 23], ["BUN", "TEST", 65, 68], ["Scr levels", "TEST", 73, 83], ["increase", "OBSERVATION_MODIFIER", 53, 61]]], ["However, the attenuation of BUN and Scr levels observed after AA treatment was reversed by the administration of GW9662, an antagonist of PPAR-\u03b3 (Fig. 1b) .", [["AA", "CHEMICAL", 62, 64], ["GW9662", "CHEMICAL", 113, 119], ["GW9662", "CHEMICAL", 113, 119], ["BUN", "GENE_OR_GENE_PRODUCT", 28, 31], ["Scr", "GENE_OR_GENE_PRODUCT", 36, 39], ["AA", "SIMPLE_CHEMICAL", 62, 64], ["GW9662", "SIMPLE_CHEMICAL", 113, 119], ["PPAR-\u03b3", "GENE_OR_GENE_PRODUCT", 138, 144], ["Fig. 1b", "GENE_OR_GENE_PRODUCT", 146, 153], ["BUN", "PROTEIN", 28, 31], ["Scr", "PROTEIN", 36, 39], ["PPAR-\u03b3", "PROTEIN", 138, 144], ["BUN", "TEST", 28, 31], ["Scr levels", "TEST", 36, 46], ["AA treatment", "TREATMENT", 62, 74], ["GW9662", "TREATMENT", 113, 119], ["an antagonist of PPAR", "TREATMENT", 121, 142], ["attenuation", "OBSERVATION_MODIFIER", 13, 24]]], ["Histological analysis suggested that kidney tissues from the UUO rats exhibited severe tubular dilatation, tubular atrophy, and widened interstitial space with severe inflammatory cell infiltration (Fig. 1c) .", [["kidney tissues", "ANATOMY", 37, 51], ["tubular", "ANATOMY", 87, 94], ["tubular", "ANATOMY", 107, 114], ["interstitial space", "ANATOMY", 136, 154], ["inflammatory cell", "ANATOMY", 167, 184], ["tubular atrophy", "DISEASE", 107, 122], ["kidney tissues", "TISSUE", 37, 51], ["UUO rats", "ORGANISM", 61, 69], ["tubular", "TISSUE", 87, 94], ["tubular", "TISSUE", 107, 114], ["inflammatory cell", "CELL", 167, 184], ["rats", "SPECIES", 65, 69], ["Histological analysis", "TEST", 0, 21], ["kidney tissues", "PROBLEM", 37, 51], ["severe tubular dilatation", "PROBLEM", 80, 105], ["tubular atrophy", "PROBLEM", 107, 122], ["widened interstitial space", "PROBLEM", 128, 154], ["severe inflammatory cell infiltration", "PROBLEM", 160, 197], ["kidney tissues", "ANATOMY", 37, 51], ["UUO", "OBSERVATION", 61, 64], ["severe", "OBSERVATION_MODIFIER", 80, 86], ["tubular", "ANATOMY_MODIFIER", 87, 94], ["dilatation", "OBSERVATION", 95, 105], ["tubular", "ANATOMY_MODIFIER", 107, 114], ["atrophy", "OBSERVATION", 115, 122], ["widened", "OBSERVATION_MODIFIER", 128, 135], ["interstitial", "ANATOMY_MODIFIER", 136, 148], ["severe", "OBSERVATION_MODIFIER", 160, 166], ["inflammatory cell infiltration", "OBSERVATION", 167, 197]]], ["The oral administration of AA attenuated the interstitial injury, whereas the attenuation of interstitial damage was reversed by GW9662 (Fig. 1d, e) .", [["oral", "ANATOMY", 4, 8], ["interstitial", "ANATOMY", 45, 57], ["interstitial", "ANATOMY", 93, 105], ["AA", "CHEMICAL", 27, 29], ["interstitial injury", "DISEASE", 45, 64], ["interstitial damage", "DISEASE", 93, 112], ["GW9662", "CHEMICAL", 129, 135], ["GW9662", "CHEMICAL", 129, 135], ["oral", "ORGANISM_SUBDIVISION", 4, 8], ["AA", "SIMPLE_CHEMICAL", 27, 29], ["interstitial", "MULTI-TISSUE_STRUCTURE", 45, 57], ["interstitial", "MULTI-TISSUE_STRUCTURE", 93, 105], ["GW9662", "SIMPLE_CHEMICAL", 129, 135], ["the interstitial injury", "PROBLEM", 41, 64], ["interstitial damage", "PROBLEM", 93, 112], ["interstitial", "ANATOMY_MODIFIER", 45, 57], ["injury", "OBSERVATION", 58, 64], ["attenuation", "OBSERVATION_MODIFIER", 78, 89], ["interstitial", "ANATOMY_MODIFIER", 93, 105], ["damage", "OBSERVATION", 106, 112]]], ["UUO resulted in a significant increase in Collagen I (Col I), fibronectin (FN), and alpha-smooth muscle actin (\u03b1-SMA) levels, as well as Collagen III levels, suggesting interstitial fibrosis (Fig. 2a, b) .", [["interstitial", "ANATOMY", 169, 181], ["fibrosis", "DISEASE", 182, 190], ["Collagen I", "GENE_OR_GENE_PRODUCT", 42, 52], ["Col I", "GENE_OR_GENE_PRODUCT", 54, 59], ["fibronectin", "GENE_OR_GENE_PRODUCT", 62, 73], ["FN", "GENE_OR_GENE_PRODUCT", 75, 77], ["alpha-smooth muscle actin", "GENE_OR_GENE_PRODUCT", 84, 109], ["\u03b1-SMA", "GENE_OR_GENE_PRODUCT", 111, 116], ["Collagen III", "GENE_OR_GENE_PRODUCT", 137, 149], ["interstitial", "MULTI-TISSUE_STRUCTURE", 169, 181], ["Collagen I", "PROTEIN", 42, 52], ["Col I", "PROTEIN", 54, 59], ["fibronectin", "PROTEIN", 62, 73], ["FN", "PROTEIN", 75, 77], ["alpha-smooth muscle actin", "PROTEIN", 84, 109], ["\u03b1", "PROTEIN", 111, 112], ["SMA", "PROTEIN", 113, 116], ["Collagen III", "PROTEIN", 137, 149], ["UUO", "PROBLEM", 0, 3], ["Collagen I (Col I), fibronectin (FN)", "TEST", 42, 78], ["alpha-smooth muscle actin", "TEST", 84, 109], ["Collagen III levels", "TEST", 137, 156], ["interstitial fibrosis", "PROBLEM", 169, 190], ["significant", "OBSERVATION_MODIFIER", 18, 29], ["increase", "OBSERVATION_MODIFIER", 30, 38], ["alpha-smooth muscle", "ANATOMY", 84, 103], ["SMA", "ANATOMY", 113, 116], ["suggesting", "UNCERTAINTY", 158, 168], ["interstitial", "ANATOMY_MODIFIER", 169, 181], ["fibrosis", "OBSERVATION", 182, 190]]], ["The treatment of rats with AA produced a significant attenuation of the UUO-mediated increase in Col I, FN, and \u03b1-SMA levels, indicating improvement in interstitial fibrosis (Fig. 2b) .", [["interstitial", "ANATOMY", 152, 164], ["AA", "CHEMICAL", 27, 29], ["fibrosis", "DISEASE", 165, 173], ["rats", "ORGANISM", 17, 21], ["AA", "SIMPLE_CHEMICAL", 27, 29], ["UUO", "GENE_OR_GENE_PRODUCT", 72, 75], ["Col I", "GENE_OR_GENE_PRODUCT", 97, 102], ["FN", "GENE_OR_GENE_PRODUCT", 104, 106], ["\u03b1-SMA", "GENE_OR_GENE_PRODUCT", 112, 117], ["interstitial", "MULTI-TISSUE_STRUCTURE", 152, 164], ["Col I", "PROTEIN", 97, 102], ["FN", "PROTEIN", 104, 106], ["SMA", "PROTEIN", 114, 117], ["rats", "SPECIES", 17, 21], ["The treatment of rats", "TREATMENT", 0, 21], ["the UUO", "PROBLEM", 68, 75], ["mediated increase in Col I, FN, and \u03b1-SMA levels", "PROBLEM", 76, 124], ["interstitial fibrosis", "PROBLEM", 152, 173], ["significant", "OBSERVATION_MODIFIER", 41, 52], ["attenuation", "OBSERVATION_MODIFIER", 53, 64], ["UUO", "OBSERVATION", 72, 75], ["increase", "OBSERVATION_MODIFIER", 85, 93], ["Col I", "OBSERVATION_MODIFIER", 97, 102], ["SMA", "ANATOMY", 114, 117], ["improvement", "OBSERVATION_MODIFIER", 137, 148], ["interstitial", "ANATOMY_MODIFIER", 152, 164], ["fibrosis", "OBSERVATION", 165, 173]]], ["The administration of GW9662 in AA-treated rats produced an increase in the expression of the abovementioned proteins similar to that in UUO rats and thus abolished the protective effect mediated by AA (Fig. 2a, b) .GW9662 abolished the protective effects of AA in UUO ratsWnt/\u03b2-catenin signaling is closely associated with renal fibrosis [15] as well as the classic TGF-\u03b2/Smad signaling axis.", [["renal", "ANATOMY", 324, 329], ["GW9662", "CHEMICAL", 22, 28], ["AA", "CHEMICAL", 32, 34], ["AA", "CHEMICAL", 199, 201], ["GW9662", "CHEMICAL", 216, 222], ["AA", "CHEMICAL", 259, 261], ["fibrosis", "DISEASE", 330, 338], ["GW9662", "CHEMICAL", 22, 28], ["GW9662", "CHEMICAL", 216, 222], ["GW9662", "SIMPLE_CHEMICAL", 22, 28], ["AA", "SIMPLE_CHEMICAL", 32, 34], ["rats", "ORGANISM", 43, 47], ["UUO rats", "ORGANISM", 137, 145], ["AA", "SIMPLE_CHEMICAL", 199, 201], ["GW9662", "SIMPLE_CHEMICAL", 216, 222], ["AA", "SIMPLE_CHEMICAL", 259, 261], ["UUO rats", "ORGANISM", 265, 273], ["Wnt/\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 273, 286], ["renal", "ORGAN", 324, 329], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 367, 372], ["Smad", "GENE_OR_GENE_PRODUCT", 373, 377], ["\u03b2-catenin", "PROTEIN", 277, 286], ["TGF-\u03b2", "PROTEIN", 367, 372], ["Smad", "PROTEIN", 373, 377], ["rats", "SPECIES", 43, 47], ["rats", "SPECIES", 141, 145], ["rats", "SPECIES", 269, 273], ["GW9662 in AA", "TREATMENT", 22, 34], ["the abovementioned proteins", "PROBLEM", 90, 117], ["AA in UUO rats", "TREATMENT", 259, 273], ["catenin signaling", "PROBLEM", 279, 296], ["renal fibrosis", "PROBLEM", 324, 338], ["the classic TGF", "TEST", 355, 370], ["Smad signaling axis", "PROBLEM", 373, 392], ["increase", "OBSERVATION_MODIFIER", 60, 68], ["renal", "ANATOMY", 324, 329], ["fibrosis", "OBSERVATION", 330, 338], ["signaling axis", "OBSERVATION", 378, 392]]], ["We next examined the effects of GW9662 on the Wnt/\u03b2-catenin and TGF-\u03b2/ Smad signaling pathways in UUO rats treated with AA.", [["GW9662", "CHEMICAL", 32, 38], ["AA", "CHEMICAL", 120, 122], ["GW9662", "CHEMICAL", 32, 38], ["GW9662", "SIMPLE_CHEMICAL", 32, 38], ["Wnt", "GENE_OR_GENE_PRODUCT", 46, 49], ["\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 50, 59], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 64, 69], ["Smad", "GENE_OR_GENE_PRODUCT", 71, 75], ["UUO rats", "ORGANISM", 98, 106], ["TGF", "PROTEIN", 64, 67], ["Smad", "PROTEIN", 71, 75], ["rats", "SPECIES", 102, 106], ["catenin", "TEST", 52, 59], ["TGF", "TEST", 64, 67], ["AA", "TREATMENT", 120, 122], ["UUO", "OBSERVATION", 98, 101]]], ["UUO caused a significant increase in Dvl2, Dvl3, and \u03b2-catenin expression, which indicated the activation of Wnt/\u03b2-catenin signaling.", [["Dvl2", "GENE_OR_GENE_PRODUCT", 37, 41], ["Dvl3", "GENE_OR_GENE_PRODUCT", 43, 47], ["\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 53, 62], ["Wnt", "GENE_OR_GENE_PRODUCT", 109, 112], ["\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 113, 122], ["Dvl2", "PROTEIN", 37, 41], ["Dvl3", "PROTEIN", 43, 47], ["\u03b2-catenin", "PROTEIN", 53, 62], ["\u03b2-catenin", "PROTEIN", 113, 122], ["UUO", "PROBLEM", 0, 3], ["a significant increase in Dvl2", "PROBLEM", 11, 41], ["Dvl3", "TREATMENT", 43, 47], ["catenin signaling", "PROBLEM", 115, 132], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["increase", "OBSERVATION_MODIFIER", 25, 33]]], ["Treatment with AA mediated a significant attenuation of the UUO-induced increase in Dvl2, Dvl3, and \u03b2-catenin expression, while the administration of GW9662 abolished the protective effect of AA (Fig. 2c) .", [["AA", "CHEMICAL", 15, 17], ["GW9662", "CHEMICAL", 150, 156], ["AA", "CHEMICAL", 192, 194], ["GW9662", "CHEMICAL", 150, 156], ["AA", "SIMPLE_CHEMICAL", 15, 17], ["UUO", "SIMPLE_CHEMICAL", 60, 63], ["Dvl2", "GENE_OR_GENE_PRODUCT", 84, 88], ["Dvl3", "GENE_OR_GENE_PRODUCT", 90, 94], ["\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 100, 109], ["GW9662", "SIMPLE_CHEMICAL", 150, 156], ["AA", "SIMPLE_CHEMICAL", 192, 194], ["Dvl2", "PROTEIN", 84, 88], ["\u03b2-catenin", "PROTEIN", 100, 109], ["AA", "TREATMENT", 15, 17], ["the UUO", "PROBLEM", 56, 63], ["Dvl2", "TREATMENT", 84, 88], ["Dvl3", "TREATMENT", 90, 94], ["AA (Fig. 2c", "TREATMENT", 192, 203], ["UUO", "OBSERVATION", 60, 63], ["increase", "OBSERVATION_MODIFIER", 72, 80]]], ["Meanwhile, we found that UUO caused a significant increase in TGF-\u03b21, Smad2, and Smad3 expression and a decrease in Smad7 expression, which indicated the activation of TGF-\u03b2/Smad signaling (Fig. 2d ).", [["UUO", "SIMPLE_CHEMICAL", 25, 28], ["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 62, 68], ["Smad2", "GENE_OR_GENE_PRODUCT", 70, 75], ["Smad3", "GENE_OR_GENE_PRODUCT", 81, 86], ["Smad7", "GENE_OR_GENE_PRODUCT", 116, 121], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 168, 173], ["Smad", "GENE_OR_GENE_PRODUCT", 174, 178], ["TGF-\u03b21", "PROTEIN", 62, 68], ["Smad3", "PROTEIN", 81, 86], ["Smad7", "PROTEIN", 116, 121], ["TGF-\u03b2", "PROTEIN", 168, 173], ["Smad", "PROTEIN", 174, 178], ["UUO", "PROBLEM", 25, 28], ["TGF", "TEST", 62, 65], ["Smad3 expression", "PROBLEM", 81, 97], ["a decrease in Smad7 expression", "PROBLEM", 102, 132], ["TGF", "TEST", 168, 171], ["UUO", "OBSERVATION", 25, 28], ["significant", "OBSERVATION_MODIFIER", 38, 49], ["increase", "OBSERVATION_MODIFIER", 50, 58], ["Smad3 expression", "OBSERVATION", 81, 97], ["decrease", "OBSERVATION_MODIFIER", 104, 112], ["Smad7 expression", "OBSERVATION", 116, 132]]], ["After treatment with AA, the upregulation of TGF-\u03b21, Smad2, and Smad3 expression was significantly reduced; the downregulation of Smad7 expression was significantly increased (Fig. 2d) .", [["AA", "CHEMICAL", 21, 23], ["AA", "SIMPLE_CHEMICAL", 21, 23], ["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 45, 51], ["Smad2", "GENE_OR_GENE_PRODUCT", 53, 58], ["Smad3", "GENE_OR_GENE_PRODUCT", 64, 69], ["Smad7", "GENE_OR_GENE_PRODUCT", 130, 135], ["TGF-\u03b21", "PROTEIN", 45, 51], ["Smad2", "PROTEIN", 53, 58], ["Smad3", "PROTEIN", 64, 69], ["Smad7", "PROTEIN", 130, 135], ["treatment", "TREATMENT", 6, 15], ["AA", "TREATMENT", 21, 23], ["TGF", "TEST", 45, 48], ["Smad3 expression", "PROBLEM", 64, 80], ["the downregulation of Smad7 expression", "TREATMENT", 108, 146], ["significantly", "OBSERVATION_MODIFIER", 85, 98], ["reduced", "OBSERVATION_MODIFIER", 99, 106], ["significantly", "OBSERVATION_MODIFIER", 151, 164], ["increased", "OBSERVATION_MODIFIER", 165, 174]]], ["The administration of GW9662 in AA-treated rats produced a marked increase in TGF-\u03b21, Smad2, and Smad3 expression as well as a marked decrease in Smad7 expression, suggesting that it abolished the improvement in the expression of these proteins mediated by AA (Fig. 2d) .GW9662 abolished the protective effects of AA in UUO ratsIn addition to fibrosis-related proteins and pathways, AA also affected oxidative stress in UUO rats.", [["GW9662", "CHEMICAL", 22, 28], ["AA", "CHEMICAL", 32, 34], ["AA", "CHEMICAL", 257, 259], ["GW9662", "CHEMICAL", 271, 277], ["AA", "CHEMICAL", 314, 316], ["fibrosis", "DISEASE", 343, 351], ["AA", "CHEMICAL", 383, 385], ["GW9662", "CHEMICAL", 22, 28], ["GW9662", "CHEMICAL", 271, 277], ["GW9662", "SIMPLE_CHEMICAL", 22, 28], ["AA", "SIMPLE_CHEMICAL", 32, 34], ["rats", "ORGANISM", 43, 47], ["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 78, 84], ["Smad2", "GENE_OR_GENE_PRODUCT", 86, 91], ["Smad3", "GENE_OR_GENE_PRODUCT", 97, 102], ["Smad7", "GENE_OR_GENE_PRODUCT", 146, 151], ["AA", "SIMPLE_CHEMICAL", 257, 259], ["GW9662", "SIMPLE_CHEMICAL", 271, 277], ["AA", "SIMPLE_CHEMICAL", 314, 316], ["AA", "SIMPLE_CHEMICAL", 383, 385], ["UUO rats", "ORGANISM", 420, 428], ["TGF-\u03b21", "PROTEIN", 78, 84], ["Smad3", "PROTEIN", 97, 102], ["Smad7", "PROTEIN", 146, 151], ["rats", "SPECIES", 43, 47], ["rats", "SPECIES", 424, 428], ["GW9662 in AA", "TREATMENT", 22, 34], ["TGF", "TEST", 78, 81], ["a marked decrease in Smad7 expression", "PROBLEM", 125, 162], ["AA in UUO", "TREATMENT", 314, 323], ["fibrosis", "PROBLEM", 343, 351], ["affected oxidative stress in UUO rats", "PROBLEM", 391, 428], ["marked", "OBSERVATION_MODIFIER", 59, 65], ["increase", "OBSERVATION_MODIFIER", 66, 74], ["marked", "OBSERVATION_MODIFIER", 127, 133], ["decrease", "OBSERVATION_MODIFIER", 134, 142], ["Smad7 expression", "OBSERVATION", 146, 162], ["improvement", "OBSERVATION_MODIFIER", 197, 208], ["fibrosis", "OBSERVATION", 343, 351], ["oxidative stress", "OBSERVATION", 400, 416], ["UUO", "OBSERVATION", 420, 423]]], ["As shown in Fig. 2f , the expression levels of reactive oxygen species (ROS)-generating molecules including NOX4, Rac1, and 12-LOX were significantly increased in UUO rats.", [["oxygen", "CHEMICAL", 56, 62], ["ROS", "CHEMICAL", 72, 75], ["oxygen", "CHEMICAL", 56, 62], ["reactive oxygen species", "SIMPLE_CHEMICAL", 47, 70], ["ROS", "SIMPLE_CHEMICAL", 72, 75], ["NOX4", "GENE_OR_GENE_PRODUCT", 108, 112], ["Rac1", "GENE_OR_GENE_PRODUCT", 114, 118], ["12-LOX", "GENE_OR_GENE_PRODUCT", 124, 130], ["UUO rats", "ORGANISM", 163, 171], ["NOX4", "PROTEIN", 108, 112], ["Rac1", "PROTEIN", 114, 118], ["LOX", "PROTEIN", 127, 130], ["rats", "SPECIES", 167, 171], ["reactive oxygen species", "PROBLEM", 47, 70], ["NOX4", "TEST", 108, 112], ["Rac1", "TEST", 114, 118], ["reactive", "OBSERVATION_MODIFIER", 47, 55], ["oxygen species", "OBSERVATION", 56, 70], ["increased", "OBSERVATION_MODIFIER", 150, 159], ["UUO", "OBSERVATION", 163, 166]]], ["Treatment with AA produced a significant attenuation of the UUO-mediated increase in NOX4, Rac1, and 12-LOX expression, and the administration of GW9662 abolished the antioxidant effect mediated by AA (Fig. 2f) .Expression of PPAR-\u03b3 in rat kidneysSince an antagonist of PPAR-\u03b3, GW9662, can reverse the renal protective effects of AA, we hypothesized that AA may ameliorate renal fibrosis via activating PPAR-\u03b3.", [["kidneys", "ANATOMY", 240, 247], ["renal", "ANATOMY", 302, 307], ["renal", "ANATOMY", 373, 378], ["AA", "CHEMICAL", 15, 17], ["GW9662", "CHEMICAL", 146, 152], ["AA", "CHEMICAL", 198, 200], ["GW9662", "CHEMICAL", 278, 284], ["AA", "CHEMICAL", 330, 332], ["AA", "CHEMICAL", 355, 357], ["fibrosis", "DISEASE", 379, 387], ["GW9662", "CHEMICAL", 146, 152], ["GW9662", "CHEMICAL", 278, 284], ["AA", "SIMPLE_CHEMICAL", 15, 17], ["UUO", "GENE_OR_GENE_PRODUCT", 60, 63], ["NOX4", "GENE_OR_GENE_PRODUCT", 85, 89], ["Rac1", "GENE_OR_GENE_PRODUCT", 91, 95], ["12-LOX", "GENE_OR_GENE_PRODUCT", 101, 107], ["GW9662", "SIMPLE_CHEMICAL", 146, 152], ["AA", "SIMPLE_CHEMICAL", 198, 200], ["PPAR-\u03b3", "GENE_OR_GENE_PRODUCT", 226, 232], ["rat", "ORGANISM", 236, 239], ["kidneys", "ORGAN", 240, 247], ["PPAR-\u03b3", "GENE_OR_GENE_PRODUCT", 270, 276], ["GW9662", "SIMPLE_CHEMICAL", 278, 284], ["renal", "CANCER", 302, 307], ["AA", "SIMPLE_CHEMICAL", 330, 332], ["AA", "SIMPLE_CHEMICAL", 355, 357], ["renal", "ORGAN", 373, 378], ["PPAR-\u03b3.", "GENE_OR_GENE_PRODUCT", 403, 410], ["NOX4", "PROTEIN", 85, 89], ["Rac1", "PROTEIN", 91, 95], ["LOX", "PROTEIN", 104, 107], ["PPAR-\u03b3", "PROTEIN", 226, 232], ["PPAR", "PROTEIN", 270, 274], ["PPAR", "PROTEIN", 403, 407], ["rat", "SPECIES", 236, 239], ["rat", "SPECIES", 236, 239], ["AA", "TREATMENT", 15, 17], ["the UUO", "PROBLEM", 56, 63], ["NOX4", "TEST", 85, 89], ["Rac1", "TEST", 91, 95], ["the antioxidant effect", "TREATMENT", 163, 185], ["PPAR", "TEST", 226, 230], ["renal fibrosis", "PROBLEM", 373, 387], ["activating PPAR", "TEST", 392, 407], ["significant", "OBSERVATION_MODIFIER", 29, 40], ["attenuation", "OBSERVATION_MODIFIER", 41, 52], ["UUO", "OBSERVATION", 60, 63], ["increase", "OBSERVATION_MODIFIER", 73, 81], ["NOX4", "OBSERVATION", 85, 89], ["PPAR", "ANATOMY", 226, 230], ["kidneys", "ANATOMY", 240, 247], ["renal", "ANATOMY", 302, 307], ["protective", "OBSERVATION", 308, 318], ["renal", "ANATOMY", 373, 378], ["fibrosis", "OBSERVATION", 379, 387]]], ["Therefore, we investigated the expression of PPAR-\u03b3 in kidneys from different group of rats.", [["kidneys", "ANATOMY", 55, 62], ["PPAR-\u03b3", "GENE_OR_GENE_PRODUCT", 45, 51], ["kidneys", "ORGAN", 55, 62], ["rats", "ORGANISM", 87, 91], ["PPAR-\u03b3", "PROTEIN", 45, 51], ["rats", "SPECIES", 87, 91], ["PPAR", "TEST", 45, 49], ["PPAR", "ANATOMY", 45, 49], ["kidneys", "ANATOMY", 55, 62]]], ["UUO rats induced a significant increase in the expression of PPAR-\u03b3 compared with that in sham-operated rats (Fig. 2e) .", [["UUO rats", "ORGANISM", 0, 8], ["PPAR-\u03b3", "GENE_OR_GENE_PRODUCT", 61, 67], ["rats", "ORGANISM", 104, 108], ["PPAR-\u03b3", "PROTEIN", 61, 67], ["rats", "SPECIES", 4, 8], ["rats", "SPECIES", 104, 108], ["UUO rats", "PROBLEM", 0, 8], ["significant", "OBSERVATION_MODIFIER", 19, 30], ["increase", "OBSERVATION_MODIFIER", 31, 39]]], ["When compared with that in UUO rats, the expression of PPAR-\u03b3 did not significantly change in rat kidneys after treatment with AA or GW9662 (Fig. 2e) , which indicates that AA activates PPAR-\u03b3 through other processes instead of directly increasing its protein expression.Expression of PPAR-\u03b3 in rat kidneysUntargeted GC-MS-based metabolomics identified important differential plasma metabolites Typical total ion chromatograms of the representative samples obtained are presented in Supplementary Fig. S1 .", [["kidneys", "ANATOMY", 98, 105], ["kidneys", "ANATOMY", 299, 306], ["plasma", "ANATOMY", 376, 382], ["samples", "ANATOMY", 449, 456], ["AA", "CHEMICAL", 127, 129], ["GW9662", "CHEMICAL", 133, 139], ["AA", "CHEMICAL", 173, 175], ["GW9662", "CHEMICAL", 133, 139], ["UUO rats", "ORGANISM", 27, 35], ["PPAR-\u03b3", "GENE_OR_GENE_PRODUCT", 55, 61], ["rat", "ORGANISM", 94, 97], ["kidneys", "ORGAN", 98, 105], ["AA", "SIMPLE_CHEMICAL", 127, 129], ["GW9662", "SIMPLE_CHEMICAL", 133, 139], ["AA", "SIMPLE_CHEMICAL", 173, 175], ["PPAR-\u03b3", "GENE_OR_GENE_PRODUCT", 186, 192], ["PPAR-\u03b3", "GENE_OR_GENE_PRODUCT", 285, 291], ["rat", "ORGANISM", 295, 298], ["kidneys", "ORGAN", 299, 306], ["plasma", "ORGANISM_SUBSTANCE", 376, 382], ["S1", "GENE_OR_GENE_PRODUCT", 502, 504], ["PPAR", "PROTEIN", 55, 59], ["\u03b3", "PROTEIN", 60, 61], ["PPAR", "PROTEIN", 186, 190], ["\u03b3", "PROTEIN", 191, 192], ["PPAR-\u03b3", "PROTEIN", 285, 291], ["S1", "PROTEIN", 502, 504], ["rats", "SPECIES", 31, 35], ["rat", "SPECIES", 94, 97], ["rat", "SPECIES", 295, 298], ["rat", "SPECIES", 94, 97], ["rat", "SPECIES", 295, 298], ["PPAR", "TEST", 55, 59], ["AA", "TREATMENT", 127, 129], ["AA activates PPAR", "TEST", 173, 190], ["PPAR", "TEST", 285, 289], ["Untargeted GC", "TEST", 306, 319], ["plasma metabolites", "TEST", 376, 394], ["total ion chromatograms", "TEST", 403, 426], ["kidneys", "ANATOMY", 98, 105], ["PPAR", "ANATOMY", 285, 289], ["kidneys", "ANATOMY", 299, 306]]], ["A PCA score plot of the plasma metabolites from the control and UUO groups is shown in Fig. 3a .", [["plasma", "ANATOMY", 24, 30], ["plasma", "ORGANISM_SUBSTANCE", 24, 30], ["A PCA score plot", "TEST", 0, 16], ["the plasma metabolites", "TEST", 20, 42], ["UUO", "OBSERVATION", 64, 67]]], ["There was a clear separation observed in the plot of the plasma samples from the control and UUO groups, and a supervised method, OPLS-DA, was also used to show the metabolic distinction between the two groups (Fig. 3b) .", [["plasma samples", "ANATOMY", 57, 71], ["DA", "CHEMICAL", 135, 137], ["plasma samples", "ORGANISM_SUBSTANCE", 57, 71], ["a clear separation", "PROBLEM", 10, 28], ["the plasma samples", "TEST", 53, 71], ["clear", "OBSERVATION_MODIFIER", 12, 17], ["separation", "OBSERVATION", 18, 28], ["UUO", "OBSERVATION", 93, 96], ["metabolic distinction", "OBSERVATION", 165, 186]]], ["The OPLS-DA model parameters R 2 Y and Q 2 (cum) were 0.885 and 0.701, suggesting good fitness and predictive ability of the OPLS-DA model.", [["DA", "CHEMICAL", 130, 132], ["The OPLS", "TEST", 0, 8]]], ["PCA and OPLS-DA score plots of plasma metabolites in the control, UUO and UUO + AA groups are shown in Fig. 3c , d.", [["plasma", "ANATOMY", 31, 37], ["DA", "CHEMICAL", 13, 15], ["AA", "CHEMICAL", 80, 82], ["plasma", "ORGANISM_SUBSTANCE", 31, 37], ["PCA", "TREATMENT", 0, 3], ["plasma metabolites", "TEST", 31, 49], ["UUO", "OBSERVATION", 74, 77]]], ["The UUO + AA group was more similar to the control groups than the UUO group was.Expression of PPAR-\u03b3 in rat kidneysTwenty-two plasma metabolites were identified ( Table 1 ).", [["kidneys", "ANATOMY", 109, 116], ["plasma", "ANATOMY", 127, 133], ["AA", "CHEMICAL", 10, 12], ["UUO", "SIMPLE_CHEMICAL", 4, 7], ["PPAR-\u03b3", "GENE_OR_GENE_PRODUCT", 95, 101], ["rat", "ORGANISM", 105, 108], ["kidneys", "ORGAN", 109, 116], ["plasma", "ORGANISM_SUBSTANCE", 127, 133], ["PPAR-\u03b3", "PROTEIN", 95, 101], ["rat", "SPECIES", 105, 108], ["rat", "SPECIES", 105, 108], ["PPAR", "TEST", 95, 99], ["two plasma metabolites", "TEST", 123, 145], ["UUO", "OBSERVATION", 4, 7], ["AA group", "OBSERVATION_MODIFIER", 10, 18], ["UUO", "OBSERVATION", 67, 70], ["PPAR", "ANATOMY", 95, 99], ["kidneys", "ANATOMY", 109, 116]]], ["Out of the 22 metabolites, 15 were differentially expressed in UUO rats.", [["UUO rats", "ORGANISM", 63, 71], ["rats", "SPECIES", 67, 71], ["UUO", "OBSERVATION", 63, 66]]], ["Then, a heatmap was created to visualize the relative levels of the 22 differential metabolites in each group (Supplementary Fig. S2) .", [["S2", "PROTEIN", 130, 132], ["a heatmap", "TREATMENT", 6, 15], ["Supplementary Fig", "TREATMENT", 111, 128]]], ["Notably, of these 22 identified metabolites, there were two PPAR-\u03b3 ligands, namely, 15d-PGJ2 and linoleic acid.", [["15d-PGJ2", "CHEMICAL", 84, 92], ["linoleic acid", "CHEMICAL", 97, 110], ["15d-PGJ2", "CHEMICAL", 84, 92], ["linoleic acid", "CHEMICAL", 97, 110], ["PPAR-\u03b3", "GENE_OR_GENE_PRODUCT", 60, 66], ["15d-PGJ2", "SIMPLE_CHEMICAL", 84, 92], ["linoleic acid", "SIMPLE_CHEMICAL", 97, 110], ["PPAR", "PROTEIN", 60, 64], ["PPAR", "TEST", 60, 64], ["ligands", "TEST", 67, 74], ["linoleic acid", "TREATMENT", 97, 110]]], ["Both of them were significantly increased in AA-treated rats compared with UUO rats (Fig. 3e) .Expression of PPAR-\u03b3 in rat kidneysTargeted GC-MS-based metabolomics validated the production of 15d-PGJ2 To validate whether AA can enhance the production of 15d-PGJ2, the plasma level of 15d-PGJ2 in mice was measured by GC-MS.", [["kidneys", "ANATOMY", 123, 130], ["plasma", "ANATOMY", 268, 274], ["AA", "CHEMICAL", 45, 47], ["15d-PGJ2", "CHEMICAL", 192, 200], ["AA", "CHEMICAL", 221, 223], ["15d-PGJ2", "CHEMICAL", 254, 262], ["15d-PGJ2", "CHEMICAL", 284, 292], ["PGJ2", "CHEMICAL", 196, 200], ["15d-PGJ2", "CHEMICAL", 254, 262], ["15d-PGJ2", "CHEMICAL", 284, 292], ["AA", "SIMPLE_CHEMICAL", 45, 47], ["rats", "ORGANISM", 56, 60], ["UUO rats", "ORGANISM", 75, 83], ["PPAR-\u03b3", "GENE_OR_GENE_PRODUCT", 109, 115], ["rat", "ORGANISM", 119, 122], ["kidneys", "ORGAN", 123, 130], ["AA", "SIMPLE_CHEMICAL", 221, 223], ["15d-PGJ2", "SIMPLE_CHEMICAL", 254, 262], ["plasma", "ORGANISM_SUBSTANCE", 268, 274], ["15d-PGJ2", "SIMPLE_CHEMICAL", 284, 292], ["mice", "ORGANISM", 296, 300], ["PPAR-\u03b3", "PROTEIN", 109, 115], ["rats", "SPECIES", 56, 60], ["rats", "SPECIES", 79, 83], ["rat", "SPECIES", 119, 122], ["mice", "SPECIES", 296, 300], ["rat", "SPECIES", 119, 122], ["mice", "SPECIES", 296, 300], ["PPAR", "TEST", 109, 113], ["Targeted GC", "TEST", 130, 141], ["the plasma level", "TEST", 264, 280], ["significantly", "OBSERVATION_MODIFIER", 18, 31], ["increased", "OBSERVATION_MODIFIER", 32, 41], ["PPAR", "ANATOMY", 109, 113], ["kidneys", "ANATOMY", 123, 130]]], ["Mice treated with AA showed a higher level of 15d-PGJ2 than that exhibited by controls.", [["AA", "CHEMICAL", 18, 20], ["15d-PGJ2", "CHEMICAL", 46, 54], ["15d-PGJ2", "CHEMICAL", 46, 54], ["Mice", "ORGANISM", 0, 4], ["AA", "SIMPLE_CHEMICAL", 18, 20], ["15d-PGJ2", "GENE_OR_GENE_PRODUCT", 46, 54], ["PGJ2", "PROTEIN", 50, 54], ["Mice", "SPECIES", 0, 4], ["AA", "TREATMENT", 18, 20]]], ["In addition, UUO mice treated with AA showed an enhanced level of 15d-PGJ2 compared with that shown by UUO mice (Fig. 3f) .", [["AA", "CHEMICAL", 35, 37], ["15d-PGJ2", "CHEMICAL", 66, 74], ["15d-PGJ2", "CHEMICAL", 66, 74], ["UUO mice", "ORGANISM", 13, 21], ["AA", "SIMPLE_CHEMICAL", 35, 37], ["15d-PGJ2", "GENE_OR_GENE_PRODUCT", 66, 74], ["UUO mice", "ORGANISM", 103, 111], ["PGJ2", "PROTEIN", 70, 74], ["mice", "SPECIES", 17, 21], ["mice", "SPECIES", 107, 111], ["mice", "SPECIES", 17, 21], ["mice", "SPECIES", 107, 111], ["an enhanced level", "TEST", 45, 62], ["UUO", "OBSERVATION", 13, 16], ["UUO", "OBSERVATION", 103, 106]]], ["These results demonstrate that AA indeed increases the plasma level of 15d-PGJ2.Expression of PPAR-\u03b3 in rat kidneys15d-PGJ2 mediated similar therapeutic effects as those of AA in UUO mice To prove our hypothesis that AA ameliorates renal fibrosis via enhanced formation of 15d-PGJ2, we administered 15d-PGJ2 to UUO mice to test whether 15d-PGJ2 shows similar therapeutic effect as those of AA.", [["plasma", "ANATOMY", 55, 61], ["kidneys", "ANATOMY", 108, 115], ["renal", "ANATOMY", 232, 237], ["AA", "CHEMICAL", 31, 33], ["15d-PGJ2", "CHEMICAL", 71, 79], ["15d-PGJ2", "CHEMICAL", 115, 123], ["AA", "CHEMICAL", 173, 175], ["AA", "CHEMICAL", 217, 219], ["fibrosis", "DISEASE", 238, 246], ["15d-PGJ2", "CHEMICAL", 273, 281], ["15d-PGJ2", "CHEMICAL", 299, 307], ["15d-PGJ2", "CHEMICAL", 336, 344], ["AA", "CHEMICAL", 390, 392], ["15d-PGJ2", "CHEMICAL", 71, 79], ["15d-PGJ2", "CHEMICAL", 115, 123], ["15d-PGJ2", "CHEMICAL", 273, 281], ["15d-PGJ2", "CHEMICAL", 299, 307], ["15d-PGJ2", "CHEMICAL", 336, 344], ["AA", "SIMPLE_CHEMICAL", 31, 33], ["plasma", "ORGANISM_SUBSTANCE", 55, 61], ["15d-PGJ2", "GENE_OR_GENE_PRODUCT", 71, 79], ["PPAR-\u03b3", "GENE_OR_GENE_PRODUCT", 94, 100], ["rat", "ORGANISM", 104, 107], ["kidneys", "ORGAN", 108, 115], ["15d-PGJ2", "SIMPLE_CHEMICAL", 115, 123], ["AA", "SIMPLE_CHEMICAL", 173, 175], ["UUO mice", "ORGANISM", 179, 187], ["AA", "SIMPLE_CHEMICAL", 217, 219], ["renal", "ORGAN", 232, 237], ["15d-PGJ2", "SIMPLE_CHEMICAL", 273, 281], ["15d-PGJ2", "SIMPLE_CHEMICAL", 299, 307], ["UUO mice", "ORGANISM", 311, 319], ["15d-PGJ2", "SIMPLE_CHEMICAL", 336, 344], ["AA", "SIMPLE_CHEMICAL", 390, 392], ["PGJ2", "PROTEIN", 75, 79], ["PPAR-\u03b3", "PROTEIN", 94, 100], ["rat", "SPECIES", 104, 107], ["mice", "SPECIES", 183, 187], ["mice", "SPECIES", 315, 319], ["rat", "SPECIES", 104, 107], ["mice", "SPECIES", 183, 187], ["mice", "SPECIES", 315, 319], ["the plasma level", "TEST", 51, 67], ["PPAR", "TEST", 94, 98], ["AA in UUO mice", "TREATMENT", 173, 187], ["AA ameliorates renal fibrosis", "PROBLEM", 217, 246], ["PGJ2", "TREATMENT", 340, 344], ["increases", "OBSERVATION_MODIFIER", 41, 50], ["PPAR", "ANATOMY", 94, 98], ["kidneys", "ANATOMY", 108, 115], ["renal", "ANATOMY", 232, 237], ["fibrosis", "OBSERVATION", 238, 246], ["therapeutic effect", "OBSERVATION", 359, 377]]], ["UUO mice exhibited significant increases in BUN and Scr levels, suggesting a significant reduction in renal function.", [["renal", "ANATOMY", 102, 107], ["UUO mice", "ORGANISM", 0, 8], ["BUN", "SIMPLE_CHEMICAL", 44, 47], ["Scr", "GENE_OR_GENE_PRODUCT", 52, 55], ["renal", "ORGAN", 102, 107], ["BUN", "PROTEIN", 44, 47], ["Scr", "PROTEIN", 52, 55], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 4, 8], ["significant increases in BUN and Scr levels", "PROBLEM", 19, 62], ["a significant reduction in renal function", "PROBLEM", 75, 116], ["significant", "OBSERVATION_MODIFIER", 19, 30], ["increases", "OBSERVATION_MODIFIER", 31, 40], ["significant", "OBSERVATION_MODIFIER", 77, 88], ["reduction", "OBSERVATION_MODIFIER", 89, 98], ["renal", "ANATOMY", 102, 107], ["function", "OBSERVATION", 108, 116]]], ["Treatment with 15d-PGJ2 significantly attenuated the increase in BUN and Scr levels.", [["15d-PGJ2", "CHEMICAL", 15, 23], ["15d-PGJ2", "CHEMICAL", 15, 23], ["15d-PGJ2", "SIMPLE_CHEMICAL", 15, 23], ["BUN", "SIMPLE_CHEMICAL", 65, 68], ["Scr", "GENE_OR_GENE_PRODUCT", 73, 76], ["BUN", "PROTEIN", 65, 68], ["Scr", "PROTEIN", 73, 76], ["Treatment", "TREATMENT", 0, 9], ["PGJ2", "TREATMENT", 19, 23], ["BUN", "TEST", 65, 68], ["Scr levels", "TEST", 73, 83], ["increase", "OBSERVATION_MODIFIER", 53, 61]]], ["However, the attenuation of BUN and Scr levels observed after 15d-PGJ2 treatment was reversed by the administration of GW9662 (Fig. 4a, b) .", [["15d-PGJ2", "CHEMICAL", 62, 70], ["GW9662", "CHEMICAL", 119, 125], ["15d-PGJ2", "CHEMICAL", 62, 70], ["GW9662", "CHEMICAL", 119, 125], ["BUN", "GENE_OR_GENE_PRODUCT", 28, 31], ["Scr", "GENE_OR_GENE_PRODUCT", 36, 39], ["15d-PGJ2", "SIMPLE_CHEMICAL", 62, 70], ["GW9662", "SIMPLE_CHEMICAL", 119, 125], ["BUN", "PROTEIN", 28, 31], ["Scr", "PROTEIN", 36, 39], ["BUN", "TEST", 28, 31], ["Scr levels", "TEST", 36, 46], ["PGJ2 treatment", "TREATMENT", 66, 80], ["attenuation", "OBSERVATION_MODIFIER", 13, 24]]], ["Kidney tissues from UUO mice showed severe interstitial fibrosis and inflammatory cell infiltration.", [["Kidney tissues", "ANATOMY", 0, 14], ["interstitial", "ANATOMY", 43, 55], ["inflammatory cell", "ANATOMY", 69, 86], ["fibrosis", "DISEASE", 56, 64], ["Kidney tissues", "TISSUE", 0, 14], ["mice", "ORGANISM", 24, 28], ["interstitial", "IMMATERIAL_ANATOMICAL_ENTITY", 43, 55], ["inflammatory cell", "CELL", 69, 86], ["mice", "SPECIES", 24, 28], ["mice", "SPECIES", 24, 28], ["Kidney tissues", "TEST", 0, 14], ["severe interstitial fibrosis", "PROBLEM", 36, 64], ["inflammatory cell infiltration", "PROBLEM", 69, 99], ["UUO", "OBSERVATION", 20, 23], ["severe", "OBSERVATION_MODIFIER", 36, 42], ["interstitial", "ANATOMY_MODIFIER", 43, 55], ["fibrosis", "OBSERVATION", 56, 64], ["inflammatory cell infiltration", "OBSERVATION", 69, 99]]], ["The administration of 15d-PGJ2 significantly attenuated the interstitial damage, whereas the attenuation was reversed by GW9662 ( Figs.", [["interstitial", "ANATOMY", 60, 72], ["15d-PGJ2", "CHEMICAL", 22, 30], ["interstitial damage", "DISEASE", 60, 79], ["GW9662", "CHEMICAL", 121, 127], ["15d-PGJ2", "CHEMICAL", 22, 30], ["GW9662", "CHEMICAL", 121, 127], ["15d-PGJ2", "SIMPLE_CHEMICAL", 22, 30], ["interstitial", "TISSUE", 60, 72], ["GW9662", "SIMPLE_CHEMICAL", 121, 127], ["PGJ2", "TREATMENT", 26, 30], ["the interstitial damage", "PROBLEM", 56, 79], ["interstitial", "ANATOMY_MODIFIER", 60, 72], ["damage", "OBSERVATION", 73, 79], ["attenuation", "OBSERVATION_MODIFIER", 93, 104]]], ["In addition, UUO mediated a significant increase in the expression of type I collagen (Col I), FN, and \u03b1-SMA, which are marker proteins in fibrosis (Fig. 5b) .", [["fibrosis", "DISEASE", 139, 147], ["UUO", "SIMPLE_CHEMICAL", 13, 16], ["type I collagen", "GENE_OR_GENE_PRODUCT", 70, 85], ["Col I", "GENE_OR_GENE_PRODUCT", 87, 92], ["FN", "GENE_OR_GENE_PRODUCT", 95, 97], ["\u03b1-SMA", "GENE_OR_GENE_PRODUCT", 103, 108], ["type I collagen", "PROTEIN", 70, 85], ["Col I", "PROTEIN", 87, 92], ["FN", "PROTEIN", 95, 97], ["\u03b1-SMA", "PROTEIN", 103, 108], ["UUO", "PROBLEM", 13, 16], ["a significant increase", "PROBLEM", 26, 48], ["type I collagen (Col I), FN, and \u03b1-SMA", "PROBLEM", 70, 108], ["fibrosis", "PROBLEM", 139, 147], ["UUO", "OBSERVATION", 13, 16], ["significant", "OBSERVATION_MODIFIER", 28, 39], ["increase", "OBSERVATION_MODIFIER", 40, 48], ["SMA", "ANATOMY", 105, 108], ["fibrosis", "OBSERVATION", 139, 147]]], ["The treatment of mice with 15d-PGJ2 produced a significant attenuation of the UUO-induced increase in Col I, FN, and \u03b1-SMA expression, indicating an improvement in interstitial fibrosis, while the administration of GW9662 abolished the protective effect mediated by 15d-PGJ2 (Fig. 5b) .", [["interstitial", "ANATOMY", 164, 176], ["15d-PGJ2", "CHEMICAL", 27, 35], ["fibrosis", "DISEASE", 177, 185], ["GW9662", "CHEMICAL", 215, 221], ["15d-PGJ2", "CHEMICAL", 266, 274], ["15d-PGJ2", "CHEMICAL", 27, 35], ["GW9662", "CHEMICAL", 215, 221], ["15d-PGJ2", "CHEMICAL", 266, 274], ["mice", "ORGANISM", 17, 21], ["15d-PGJ2", "SIMPLE_CHEMICAL", 27, 35], ["UUO", "SIMPLE_CHEMICAL", 78, 81], ["Col I", "GENE_OR_GENE_PRODUCT", 102, 107], ["FN", "GENE_OR_GENE_PRODUCT", 109, 111], ["\u03b1-SMA", "GENE_OR_GENE_PRODUCT", 117, 122], ["interstitial", "MULTI-TISSUE_STRUCTURE", 164, 176], ["GW9662", "SIMPLE_CHEMICAL", 215, 221], ["15d-PGJ2", "SIMPLE_CHEMICAL", 266, 274], ["Col I", "PROTEIN", 102, 107], ["FN", "PROTEIN", 109, 111], ["SMA", "PROTEIN", 119, 122], ["mice", "SPECIES", 17, 21], ["mice", "SPECIES", 17, 21], ["The treatment of mice", "TREATMENT", 0, 21], ["PGJ2", "TREATMENT", 31, 35], ["the UUO", "PROBLEM", 74, 81], ["interstitial fibrosis", "PROBLEM", 164, 185], ["the protective effect", "TREATMENT", 232, 253], ["significant", "OBSERVATION_MODIFIER", 47, 58], ["attenuation", "OBSERVATION_MODIFIER", 59, 70], ["UUO", "OBSERVATION", 78, 81], ["increase", "OBSERVATION_MODIFIER", 90, 98], ["Col I", "OBSERVATION_MODIFIER", 102, 107], ["SMA", "ANATOMY", 119, 122], ["improvement", "OBSERVATION_MODIFIER", 149, 160], ["interstitial", "ANATOMY_MODIFIER", 164, 176], ["fibrosis", "OBSERVATION", 177, 185]]], ["Similar to AA, 15d-PGJ2 inhibited the activation of Wnt/\u03b2catenin and TGF-\u03b2/Smad signaling pathways, and the effect was blocked by GW9662 (Fig. 5c, d) .", [["AA", "CHEMICAL", 11, 13], ["15d-PGJ2", "CHEMICAL", 15, 23], ["GW9662", "CHEMICAL", 130, 136], ["15d-PGJ2", "CHEMICAL", 15, 23], ["GW9662", "CHEMICAL", 130, 136], ["AA", "SIMPLE_CHEMICAL", 11, 13], ["15d-PGJ2", "SIMPLE_CHEMICAL", 15, 23], ["Wnt", "GENE_OR_GENE_PRODUCT", 52, 55], ["\u03b2catenin", "GENE_OR_GENE_PRODUCT", 56, 64], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 69, 74], ["Smad", "GENE_OR_GENE_PRODUCT", 75, 79], ["GW9662", "SIMPLE_CHEMICAL", 130, 136], ["\u03b2catenin", "PROTEIN", 56, 64], ["TGF", "PROTEIN", 69, 72], ["Smad", "PROTEIN", 75, 79], ["Wnt/\u03b2catenin", "TREATMENT", 52, 64], ["TGF", "TEST", 69, 72]]], ["Taken together, these data suggest that 15d-PGJ2 shows similar therapeutic effects as those of AA in the UUO animal model and that the renoprotective effects of 15d-PGJ2 can be abolished by GW9662.Expression of PPAR-\u03b3 in rat kidneysAA regulated the formation of endogenous 15d-PGJ2 through SREBP-1 It was demonstrated that AA activates PPAR-\u03b3 by promoting the production of endogenous 15d-PGJ2, the natural ligand of PPAR-\u03b3.", [["kidneys", "ANATOMY", 225, 232], ["15d-PGJ2", "CHEMICAL", 40, 48], ["AA", "CHEMICAL", 95, 97], ["15d-PGJ2", "CHEMICAL", 161, 169], ["GW9662", "CHEMICAL", 190, 196], ["AA", "CHEMICAL", 232, 234], ["15d-PGJ2", "CHEMICAL", 273, 281], ["AA", "CHEMICAL", 323, 325], ["15d-PGJ2", "CHEMICAL", 385, 393], ["15d-PGJ2", "CHEMICAL", 40, 48], ["15d-PGJ2", "CHEMICAL", 161, 169], ["GW9662", "CHEMICAL", 190, 196], ["15d-PGJ2", "CHEMICAL", 385, 393], ["15d-PGJ2", "SIMPLE_CHEMICAL", 40, 48], ["AA", "SIMPLE_CHEMICAL", 95, 97], ["15d-PGJ2", "SIMPLE_CHEMICAL", 161, 169], ["GW9662", "SIMPLE_CHEMICAL", 190, 196], ["PPAR-\u03b3", "GENE_OR_GENE_PRODUCT", 211, 217], ["rat", "ORGANISM", 221, 224], ["kidneys", "ORGAN", 225, 232], ["AA", "SIMPLE_CHEMICAL", 232, 234], ["15d-PGJ2", "GENE_OR_GENE_PRODUCT", 273, 281], ["SREBP-1", "GENE_OR_GENE_PRODUCT", 290, 297], ["AA", "SIMPLE_CHEMICAL", 323, 325], ["PPAR-\u03b3", "GENE_OR_GENE_PRODUCT", 336, 342], ["15d-PGJ2", "GENE_OR_GENE_PRODUCT", 385, 393], ["PPAR-\u03b3.", "GENE_OR_GENE_PRODUCT", 417, 424], ["PPAR-\u03b3", "PROTEIN", 211, 217], ["PGJ2", "PROTEIN", 277, 281], ["SREBP-1", "PROTEIN", 290, 297], ["PPAR-\u03b3", "PROTEIN", 336, 342], ["PPAR", "PROTEIN", 417, 421], ["rat", "SPECIES", 221, 224], ["rat", "SPECIES", 221, 224], ["these data", "TEST", 16, 26], ["15d-PGJ2", "TREATMENT", 161, 169], ["PPAR", "TEST", 211, 215], ["SREBP", "TEST", 290, 295], ["AA activates PPAR", "TEST", 323, 340], ["UUO", "OBSERVATION", 105, 108], ["PPAR", "ANATOMY", 211, 215], ["kidneys", "ANATOMY", 225, 232]]], ["To investigate how AA regulates 15d-PGJ2, we measured the expression of SREBP-1, which is of importance in the synthesis of fatty acids since 15d-PGJ2 contains a long-chain fatty acid structure.", [["AA", "CHEMICAL", 19, 21], ["15d-PGJ2", "CHEMICAL", 32, 40], ["fatty acids", "CHEMICAL", 124, 135], ["15d-PGJ2", "CHEMICAL", 142, 150], ["15d-PGJ2", "CHEMICAL", 32, 40], ["fatty acids", "CHEMICAL", 124, 135], ["15d-PGJ2", "CHEMICAL", 142, 150], ["fatty acid", "CHEMICAL", 173, 183], ["AA", "SIMPLE_CHEMICAL", 19, 21], ["15d-PGJ2", "GENE_OR_GENE_PRODUCT", 32, 40], ["SREBP-1", "GENE_OR_GENE_PRODUCT", 72, 79], ["fatty acids", "SIMPLE_CHEMICAL", 124, 135], ["15d-PGJ2", "SIMPLE_CHEMICAL", 142, 150], ["fatty acid", "SIMPLE_CHEMICAL", 173, 183], ["15d-PGJ2", "PROTEIN", 32, 40], ["SREBP-1", "PROTEIN", 72, 79], ["PGJ2", "PROTEIN", 146, 150], ["SREBP", "TEST", 72, 77], ["fatty acids", "TEST", 124, 135], ["a long-chain fatty acid structure", "PROBLEM", 160, 193], ["long", "OBSERVATION_MODIFIER", 162, 166], ["fatty acid structure", "OBSERVATION", 173, 193]]], ["We found that the expression of active nSREBP-1 was significantly increased in UUO rats treated with AA compared with model rats, while the expression of full-length SREBP-1 was slightly decreased (Fig. 6a) , and total SREBP-1 mRNA levels Quantitative measurements of protein expression in kidneys from each group as indicated.", [["kidneys", "ANATOMY", 290, 297], ["AA", "CHEMICAL", 101, 103], ["nSREBP-1", "GENE_OR_GENE_PRODUCT", 39, 47], ["UUO rats", "ORGANISM", 79, 87], ["AA", "SIMPLE_CHEMICAL", 101, 103], ["rats", "ORGANISM", 124, 128], ["SREBP-1", "GENE_OR_GENE_PRODUCT", 166, 173], ["SREBP-1", "GENE_OR_GENE_PRODUCT", 219, 226], ["kidneys", "ORGAN", 290, 297], ["nSREBP-1", "PROTEIN", 39, 47], ["SREBP-1", "PROTEIN", 166, 173], ["SREBP", "PROTEIN", 219, 224], ["rats", "SPECIES", 83, 87], ["rats", "SPECIES", 124, 128], ["active nSREBP", "TEST", 32, 45], ["AA", "TREATMENT", 101, 103], ["model rats", "TREATMENT", 118, 128], ["full-length SREBP", "TEST", 154, 171], ["total SREBP", "TEST", 213, 224], ["mRNA levels", "TEST", 227, 238], ["protein expression in kidneys", "PROBLEM", 268, 297], ["active", "OBSERVATION_MODIFIER", 32, 38], ["increased", "OBSERVATION_MODIFIER", 66, 75], ["UUO", "OBSERVATION", 79, 82], ["kidneys", "ANATOMY", 290, 297]]], ["P < 0.001 remained unchanged between the two groups (Fig. 6b) , suggesting that AA mediated SREBP-1 activity at the posttranscriptional level.", [["AA", "CHEMICAL", 80, 82], ["AA", "SIMPLE_CHEMICAL", 80, 82], ["SREBP-1", "GENE_OR_GENE_PRODUCT", 92, 99], ["SREBP-1", "PROTEIN", 92, 99], ["AA mediated SREBP", "TEST", 80, 97], ["unchanged", "OBSERVATION_MODIFIER", 19, 28]]], ["To validate whether SREBP-1 regulates the formation of 15d-PGJ2, we gave UUO + AA mice fatostatin to test whether the level of 15d-PGJ2 was decreased.", [["15d-PGJ2", "CHEMICAL", 55, 63], ["fatostatin", "CHEMICAL", 87, 97], ["15d-PGJ2", "CHEMICAL", 127, 135], ["15d-PGJ2", "CHEMICAL", 55, 63], ["fatostatin", "CHEMICAL", 87, 97], ["15d-PGJ2", "CHEMICAL", 127, 135], ["SREBP-1", "GENE_OR_GENE_PRODUCT", 20, 27], ["15d-PGJ2", "SIMPLE_CHEMICAL", 55, 63], ["UUO", "SIMPLE_CHEMICAL", 73, 76], ["mice", "ORGANISM", 82, 86], ["fatostatin", "SIMPLE_CHEMICAL", 87, 97], ["15d-PGJ2", "GENE_OR_GENE_PRODUCT", 127, 135], ["SREBP-1", "PROTEIN", 20, 27], ["PGJ2", "PROTEIN", 131, 135], ["mice", "SPECIES", 82, 86], ["SREBP", "TEST", 20, 25], ["UUO", "TREATMENT", 73, 76], ["AA mice fatostatin", "TREATMENT", 79, 97], ["the level", "TEST", 114, 123], ["PGJ2", "TREATMENT", 131, 135]]], ["The treatment of mice with AA significantly increased the expression of nSREBP-1 compared with that in UUO mice, while the administration of fatostatin, which is an inhibitor of SREBP-1, in AA-treated mice produced a decrease in the expression of nSREBP-1 (Figs.", [["AA", "CHEMICAL", 27, 29], ["fatostatin", "CHEMICAL", 141, 151], ["AA", "CHEMICAL", 190, 192], ["fatostatin", "CHEMICAL", 141, 151], ["mice", "ORGANISM", 17, 21], ["AA", "SIMPLE_CHEMICAL", 27, 29], ["nSREBP-1", "GENE_OR_GENE_PRODUCT", 72, 80], ["UUO mice", "ORGANISM", 103, 111], ["fatostatin", "SIMPLE_CHEMICAL", 141, 151], ["SREBP-1", "GENE_OR_GENE_PRODUCT", 178, 185], ["AA", "SIMPLE_CHEMICAL", 190, 192], ["mice", "ORGANISM", 201, 205], ["nSREBP-1", "GENE_OR_GENE_PRODUCT", 247, 255], ["nSREBP-1", "PROTEIN", 72, 80], ["SREBP-1", "PROTEIN", 178, 185], ["nSREBP", "PROTEIN", 247, 253], ["mice", "SPECIES", 17, 21], ["mice", "SPECIES", 107, 111], ["mice", "SPECIES", 201, 205], ["mice", "SPECIES", 17, 21], ["mice", "SPECIES", 107, 111], ["The treatment of mice with AA", "TREATMENT", 0, 29], ["nSREBP", "TEST", 72, 78], ["fatostatin", "TREATMENT", 141, 151], ["SREBP", "TEST", 178, 183], ["nSREBP", "TEST", 247, 253], ["decrease", "OBSERVATION_MODIFIER", 217, 225]]], ["The plasma level of 15d-PGJ2 in the mice was measured by GC-MS.", [["plasma", "ANATOMY", 4, 10], ["15d-PGJ2", "CHEMICAL", 20, 28], ["15d-PGJ2", "CHEMICAL", 20, 28], ["plasma", "ORGANISM_SUBSTANCE", 4, 10], ["15d-PGJ2", "SIMPLE_CHEMICAL", 20, 28], ["mice", "ORGANISM", 36, 40], ["mice", "SPECIES", 36, 40], ["mice", "SPECIES", 36, 40], ["The plasma level", "TEST", 0, 16]]], ["UUO mice treated with AA showed a higher level of 15d-PGJ2 compared with that in the UUO group, while fatostatin significantly decreased the level of 15d-PGJ2 compared with that in UUO mice treated with AA (Fig. 6d) , which was consistent with the expression of nSREBP-1.Expression of PPAR-\u03b3 in rat kidneysMoreover, the expression of fibrotic proteins was decreased in AA-treated mice and upregulated after the administration of fatostatin (Supplementary Fig. S4 ).", [["kidneys", "ANATOMY", 299, 306], ["AA", "CHEMICAL", 22, 24], ["15d-PGJ2", "CHEMICAL", 50, 58], ["fatostatin", "CHEMICAL", 102, 112], ["15d-PGJ2", "CHEMICAL", 150, 158], ["AA", "CHEMICAL", 203, 205], ["AA", "CHEMICAL", 369, 371], ["fatostatin", "CHEMICAL", 429, 439], ["15d-PGJ2", "CHEMICAL", 50, 58], ["fatostatin", "CHEMICAL", 102, 112], ["15d-PGJ2", "CHEMICAL", 150, 158], ["fatostatin", "CHEMICAL", 429, 439], ["UUO mice", "ORGANISM", 0, 8], ["15d-PGJ2", "SIMPLE_CHEMICAL", 50, 58], ["UUO", "SIMPLE_CHEMICAL", 85, 88], ["fatostatin", "SIMPLE_CHEMICAL", 102, 112], ["15d-PGJ2", "SIMPLE_CHEMICAL", 150, 158], ["UUO mice", "ORGANISM", 181, 189], ["nSREBP-1", "GENE_OR_GENE_PRODUCT", 262, 270], ["PPAR-\u03b3", "GENE_OR_GENE_PRODUCT", 285, 291], ["rat", "ORGANISM", 295, 298], ["kidneys", "ORGAN", 299, 306], ["AA", "SIMPLE_CHEMICAL", 369, 371], ["mice", "ORGANISM", 380, 384], ["fatostatin", "SIMPLE_CHEMICAL", 429, 439], ["nSREBP-1", "PROTEIN", 262, 270], ["PPAR-\u03b3", "PROTEIN", 285, 291], ["fibrotic proteins", "PROTEIN", 334, 351], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 185, 189], ["rat", "SPECIES", 295, 298], ["mice", "SPECIES", 380, 384], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 185, 189], ["rat", "SPECIES", 295, 298], ["mice", "SPECIES", 380, 384], ["AA", "TEST", 22, 24], ["AA (Fig. 6d)", "TEST", 203, 215], ["nSREBP", "TEST", 262, 268], ["PPAR", "TEST", 285, 289], ["fibrotic proteins", "PROBLEM", 334, 351], ["fatostatin", "TREATMENT", 429, 439], ["Supplementary Fig", "TREATMENT", 441, 458], ["UUO", "OBSERVATION", 85, 88], ["consistent with", "UNCERTAINTY", 228, 243], ["PPAR", "ANATOMY", 285, 289], ["kidneys", "ANATOMY", 299, 306], ["fibrotic", "OBSERVATION_MODIFIER", 334, 342], ["decreased", "OBSERVATION_MODIFIER", 356, 365]]], ["These results demonstrated that AA might regulate the level of endogenous 15d-PGJ2 in mice through SREBP-1 and play an antifibrotic role.DISCUSSIONIn this study, we demonstrated that the upregulation of nSREBP-1 mediated by AA enhances the level of endogenous 15d-PGJ2, which activates PPAR-\u03b3 and protects against renal damage and renal fibrosis (Fig. 6e) .", [["renal", "ANATOMY", 314, 319], ["renal", "ANATOMY", 331, 336], ["AA", "CHEMICAL", 32, 34], ["15d-PGJ2", "CHEMICAL", 74, 82], ["AA", "CHEMICAL", 224, 226], ["15d-PGJ2", "CHEMICAL", 260, 268], ["renal damage", "DISEASE", 314, 326], ["fibrosis", "DISEASE", 337, 345], ["15d-PGJ2", "CHEMICAL", 74, 82], ["15d-PGJ2", "CHEMICAL", 260, 268], ["AA", "SIMPLE_CHEMICAL", 32, 34], ["15d-PGJ2", "GENE_OR_GENE_PRODUCT", 74, 82], ["mice", "ORGANISM", 86, 90], ["SREBP-1", "GENE_OR_GENE_PRODUCT", 99, 106], ["nSREBP-1", "GENE_OR_GENE_PRODUCT", 203, 211], ["AA", "SIMPLE_CHEMICAL", 224, 226], ["15d-PGJ2", "GENE_OR_GENE_PRODUCT", 260, 268], ["PPAR-\u03b3", "GENE_OR_GENE_PRODUCT", 286, 292], ["renal", "ORGAN", 314, 319], ["renal", "ORGAN", 331, 336], ["endogenous 15d-PGJ2", "PROTEIN", 63, 82], ["SREBP-1", "PROTEIN", 99, 106], ["nSREBP-1", "PROTEIN", 203, 211], ["PGJ2", "PROTEIN", 264, 268], ["PPAR-\u03b3", "PROTEIN", 286, 292], ["mice", "SPECIES", 86, 90], ["mice", "SPECIES", 86, 90], ["SREBP", "TEST", 99, 104], ["this study", "TEST", 150, 160], ["nSREBP", "TEST", 203, 209], ["PPAR", "TEST", 286, 290], ["renal damage", "PROBLEM", 314, 326], ["renal fibrosis", "PROBLEM", 331, 345], ["antifibrotic", "OBSERVATION", 119, 131], ["renal", "ANATOMY", 314, 319], ["damage", "OBSERVATION", 320, 326], ["renal", "ANATOMY", 331, 336], ["fibrosis", "OBSERVATION", 337, 345]]], ["Our major novel findings include the following: (1) AA attenuates renal injury, oxidative stress, and fibrosis induced by the activation of PPAR-\u03b3 through increasing its Fig. 3 a PCA scores plot from control and UUO groups. b OPLS-DA scores plot from control and UUO groups. c PCA scores plot from control, UUO, and UUO + AA groups. d OPLS-DA scores plot from control, UUO, and UUO + AA groups. e Alteration of the level of 15d-PGJ2 and linoleic acid in plasma samples of rats using GC-MS.", [["renal", "ANATOMY", 66, 71], ["plasma samples", "ANATOMY", 454, 468], ["AA", "CHEMICAL", 52, 54], ["renal injury", "DISEASE", 66, 78], ["fibrosis", "DISEASE", 102, 110], ["DA", "CHEMICAL", 231, 233], ["DA", "CHEMICAL", 340, 342], ["15d-PGJ2", "CHEMICAL", 424, 432], ["linoleic acid", "CHEMICAL", 437, 450], ["(1) AA", "CHEMICAL", 48, 54], ["15d-PGJ2", "CHEMICAL", 424, 432], ["linoleic acid", "CHEMICAL", 437, 450], ["(1) AA", "SIMPLE_CHEMICAL", 48, 54], ["renal", "ORGAN", 66, 71], ["PPAR-\u03b3", "GENE_OR_GENE_PRODUCT", 140, 146], ["15d-PGJ2", "SIMPLE_CHEMICAL", 424, 432], ["linoleic acid", "SIMPLE_CHEMICAL", 437, 450], ["plasma samples", "ORGANISM_SUBSTANCE", 454, 468], ["rats", "ORGANISM", 472, 476], ["PPAR", "PROTEIN", 140, 144], ["\u03b3", "PROTEIN", 145, 146], ["rats", "SPECIES", 472, 476], ["AA attenuates renal injury", "PROBLEM", 52, 78], ["oxidative stress", "PROBLEM", 80, 96], ["fibrosis", "PROBLEM", 102, 110], ["PPAR", "TEST", 140, 144], ["PCA scores plot", "TEST", 277, 292], ["d OPLS", "TEST", 333, 339], ["UUO", "PROBLEM", 369, 372], ["PGJ2", "TREATMENT", 428, 432], ["linoleic acid in plasma samples", "TEST", 437, 468], ["renal", "ANATOMY", 66, 71], ["injury", "OBSERVATION", 72, 78], ["oxidative stress", "OBSERVATION", 80, 96], ["fibrosis", "OBSERVATION", 102, 110], ["UUO", "OBSERVATION", 212, 215], ["UUO", "OBSERVATION", 307, 310], ["UUO", "ANATOMY", 316, 319], ["UUO", "ANATOMY", 378, 381]]], ["Asterisk denotes UUO + AA vs UUO, **P < 0.01. f The plasma level of 15d-PGJ2 in mice treated with AA. *P < 0.05, **P < 0.01 natural ligand 15d-PGJ2 in UUO rats; (2) 15d-PGJ2 attenuates interstitial fibrosis in UUO mice; and (3) AA regulates the production of endogenous 15d-PGJ2, which may be through SREBP-1.", [["plasma", "ANATOMY", 52, 58], ["interstitial", "ANATOMY", 185, 197], ["15d-PGJ2", "CHEMICAL", 68, 76], ["AA", "CHEMICAL", 98, 100], ["15d-PGJ2", "CHEMICAL", 139, 147], ["15d-PGJ2", "CHEMICAL", 165, 173], ["fibrosis", "DISEASE", 198, 206], ["AA", "CHEMICAL", 228, 230], ["15d-PGJ2", "CHEMICAL", 270, 278], ["15d-PGJ2", "CHEMICAL", 68, 76], ["15d-PGJ2", "CHEMICAL", 139, 147], ["15d-PGJ2", "CHEMICAL", 165, 173], ["15d-PGJ2", "CHEMICAL", 270, 278], ["plasma", "ORGANISM_SUBSTANCE", 52, 58], ["15d-PGJ2", "SIMPLE_CHEMICAL", 68, 76], ["mice", "ORGANISM", 80, 84], ["15d-PGJ2", "SIMPLE_CHEMICAL", 139, 147], ["UUO rats", "ORGANISM", 151, 159], ["15d-PGJ2", "SIMPLE_CHEMICAL", 165, 173], ["interstitial", "MULTI-TISSUE_STRUCTURE", 185, 197], ["mice", "ORGANISM", 214, 218], ["AA", "SIMPLE_CHEMICAL", 228, 230], ["15d-PGJ2", "GENE_OR_GENE_PRODUCT", 270, 278], ["SREBP-1", "GENE_OR_GENE_PRODUCT", 301, 308], ["PGJ2", "PROTEIN", 72, 76], ["SREBP-1", "PROTEIN", 301, 308], ["mice", "SPECIES", 80, 84], ["rats", "SPECIES", 155, 159], ["mice", "SPECIES", 214, 218], ["mice", "SPECIES", 80, 84], ["mice", "SPECIES", 214, 218], ["UUO", "PROBLEM", 17, 20], ["UUO", "TEST", 29, 32], ["The plasma level", "TEST", 48, 64], ["AA", "TREATMENT", 98, 100], ["natural ligand", "TEST", 124, 138], ["interstitial fibrosis", "PROBLEM", 185, 206], ["UUO", "OBSERVATION", 17, 20], ["UUO", "ANATOMY", 29, 32], ["interstitial", "ANATOMY_MODIFIER", 185, 197], ["fibrosis", "OBSERVATION", 198, 206], ["UUO", "ANATOMY", 210, 213]]], ["This study demonstrates for the first time that the administration of the selective PPAR-\u03b3 antagonist GW9662 abolishes the renoprotective effects observed upon treatment with AA in rats.", [["GW9662", "CHEMICAL", 102, 108], ["AA", "CHEMICAL", 175, 177], ["GW9662", "CHEMICAL", 102, 108], ["PPAR-\u03b3", "GENE_OR_GENE_PRODUCT", 84, 90], ["GW9662", "SIMPLE_CHEMICAL", 102, 108], ["AA", "SIMPLE_CHEMICAL", 175, 177], ["rats", "ORGANISM", 181, 185], ["PPAR", "PROTEIN", 84, 88], ["rats", "SPECIES", 181, 185], ["This study", "TEST", 0, 10], ["the selective PPAR", "TREATMENT", 70, 88], ["\u03b3 antagonist GW9662", "TREATMENT", 89, 108], ["the renoprotective effects", "TREATMENT", 119, 145], ["AA in rats", "TREATMENT", 175, 185]]], ["This result indicates that the renoprotective effects of AA are closely associated with PPAR-\u03b3.DISCUSSIONPPAR-\u03b3, which is expressed in many organs, including the kidney [16] , is a member of the ligand-activated transcription factor superfamily.", [["organs", "ANATOMY", 140, 146], ["kidney", "ANATOMY", 162, 168], ["AA", "CHEMICAL", 57, 59], ["AA", "SIMPLE_CHEMICAL", 57, 59], ["PPAR-\u03b3.", "GENE_OR_GENE_PRODUCT", 88, 95], ["DISCUSSIONPPAR-\u03b3", "GENE_OR_GENE_PRODUCT", 95, 111], ["organs", "ORGAN", 140, 146], ["kidney", "ORGAN", 162, 168], ["PPAR", "PROTEIN", 88, 92], ["DISCUSSIONPPAR", "PROTEIN", 95, 109], ["\u03b3", "PROTEIN", 110, 111], ["ligand-activated transcription factor superfamily", "PROTEIN", 195, 244], ["kidney", "ANATOMY", 162, 168]]], ["PPAR-\u03b3 is involved in the expression of many genes and regulates glucose metabolism, insulin sensitivity, lipid metabolism, fibrosis, inflammation, and oxidative stress [17, 18] .", [["glucose", "CHEMICAL", 65, 72], ["fibrosis", "DISEASE", 124, 132], ["inflammation", "DISEASE", 134, 146], ["glucose", "CHEMICAL", 65, 72], ["PPAR-\u03b3", "GENE_OR_GENE_PRODUCT", 0, 6], ["glucose", "SIMPLE_CHEMICAL", 65, 72], ["insulin", "GENE_OR_GENE_PRODUCT", 85, 92], ["lipid", "SIMPLE_CHEMICAL", 106, 111], ["PPAR-\u03b3", "PROTEIN", 0, 6], ["glucose metabolism", "TEST", 65, 83], ["insulin sensitivity", "TEST", 85, 104], ["lipid metabolism", "PROBLEM", 106, 122], ["fibrosis", "PROBLEM", 124, 132], ["inflammation", "PROBLEM", 134, 146], ["oxidative stress", "PROBLEM", 152, 168], ["fibrosis", "OBSERVATION", 124, 132], ["inflammation", "OBSERVATION", 134, 146]]], ["It has been reported that the PPAR-\u03b3 agonist pioglitazone reduces proteinuria and preserves renal structure and function in passive Heymann nephritis rats [19] .", [["renal", "ANATOMY", 92, 97], ["pioglitazone", "CHEMICAL", 45, 57], ["proteinuria", "DISEASE", 66, 77], ["nephritis", "DISEASE", 140, 149], ["pioglitazone", "CHEMICAL", 45, 57], ["PPAR-\u03b3", "GENE_OR_GENE_PRODUCT", 30, 36], ["pioglitazone", "SIMPLE_CHEMICAL", 45, 57], ["renal", "ORGAN", 92, 97], ["Heymann nephritis rats", "ORGANISM", 132, 154], ["PPAR", "PROTEIN", 30, 34], ["rats", "SPECIES", 150, 154], ["the PPAR-\u03b3 agonist pioglitazone", "TREATMENT", 26, 57], ["proteinuria", "PROBLEM", 66, 77], ["passive Heymann nephritis rats", "PROBLEM", 124, 154], ["proteinuria", "OBSERVATION", 66, 77], ["renal", "ANATOMY", 92, 97], ["passive", "OBSERVATION_MODIFIER", 124, 131], ["Heymann nephritis", "OBSERVATION", 132, 149]]], ["In addition, a PPAR-\u03b3 agonist can inhibit the generation of ROS and the oxidative stress response [20, 21] , and oxidative stress plays an important role in the pathogenesis of CKD and its complications [22, 23] .", [["ROS", "CHEMICAL", 60, 63], ["CKD", "DISEASE", 177, 180], ["PPAR-\u03b3", "GENE_OR_GENE_PRODUCT", 15, 21], ["ROS", "SIMPLE_CHEMICAL", 60, 63], ["PPAR", "PROTEIN", 15, 19], ["a PPAR-\u03b3 agonist", "TREATMENT", 13, 29], ["the oxidative stress response", "TEST", 68, 97], ["oxidative stress plays", "PROBLEM", 113, 135], ["CKD", "PROBLEM", 177, 180], ["its complications", "PROBLEM", 185, 202], ["CKD", "OBSERVATION", 177, 180]]], ["In our study, AA attenuated oxidative stress and fibrosis via the activation of PPAR-\u03b3 in UUO rats.", [["AA", "CHEMICAL", 14, 16], ["fibrosis", "DISEASE", 49, 57], ["AA", "SIMPLE_CHEMICAL", 14, 16], ["PPAR-\u03b3", "GENE_OR_GENE_PRODUCT", 80, 86], ["UUO rats", "ORGANISM", 90, 98], ["PPAR-\u03b3", "PROTEIN", 80, 86], ["rats", "SPECIES", 94, 98], ["our study", "TEST", 3, 12], ["AA attenuated oxidative stress", "PROBLEM", 14, 44], ["fibrosis", "PROBLEM", 49, 57], ["PPAR", "TEST", 80, 84], ["attenuated", "OBSERVATION_MODIFIER", 17, 27], ["oxidative stress", "OBSERVATION", 28, 44], ["fibrosis", "OBSERVATION", 49, 57], ["UUO", "ANATOMY", 90, 93]]], ["PPAR-\u03b3 expression was upregulated in UUO rats compared to control rats, which is consistent with previous studies of a renal ischemia reperfusion injury model [24, 25] .", [["renal", "ANATOMY", 119, 124], ["renal ischemia", "DISEASE", 119, 133], ["PPAR-\u03b3", "GENE_OR_GENE_PRODUCT", 0, 6], ["UUO rats", "ORGANISM", 37, 45], ["rats", "ORGANISM", 66, 70], ["renal", "ORGAN", 119, 124], ["PPAR", "PROTEIN", 0, 4], ["\u03b3", "PROTEIN", 5, 6], ["rats", "SPECIES", 41, 45], ["rats", "SPECIES", 66, 70], ["PPAR", "TEST", 0, 4], ["a renal ischemia reperfusion injury model", "PROBLEM", 117, 158], ["UUO", "OBSERVATION", 37, 40], ["consistent with", "UNCERTAINTY", 81, 96], ["renal", "ANATOMY", 119, 124], ["ischemia", "OBSERVATION", 125, 133]]], ["Compared with that in UUO rats, the expression of PPAR-\u03b3 did not change upon treatment with AA, implying that the renoprotective effects afforded by AA may be due to the overproduction of endogenous PPAR-\u03b3 agonists instead of the upregulation of the protein expression of PPAR-\u03b3.DISCUSSIONTo verify whether endogenous PPAR-\u03b3 ligands are overproduced, we applied untargeted GC-MS-based metabolomics to investigate plasma samples from the control, UUO, and UUO + AA groups.", [["plasma samples", "ANATOMY", 413, 427], ["AA", "CHEMICAL", 92, 94], ["AA", "CHEMICAL", 149, 151], ["AA", "CHEMICAL", 461, 463], ["UUO rats", "ORGANISM", 22, 30], ["PPAR-\u03b3", "GENE_OR_GENE_PRODUCT", 50, 56], ["AA", "SIMPLE_CHEMICAL", 92, 94], ["AA", "SIMPLE_CHEMICAL", 149, 151], ["PPAR-\u03b3", "GENE_OR_GENE_PRODUCT", 199, 205], ["PPAR-\u03b3.", "GENE_OR_GENE_PRODUCT", 272, 279], ["PPAR-\u03b3", "GENE_OR_GENE_PRODUCT", 318, 324], ["plasma samples", "ORGANISM_SUBSTANCE", 413, 427], ["PPAR", "PROTEIN", 50, 54], ["\u03b3", "PROTEIN", 55, 56], ["PPAR", "PROTEIN", 199, 203], ["PPAR", "PROTEIN", 272, 276], ["PPAR", "PROTEIN", 318, 322], ["rats", "SPECIES", 26, 30], ["AA", "TREATMENT", 92, 94], ["endogenous PPAR", "TREATMENT", 188, 203], ["agonists", "TREATMENT", 206, 214], ["endogenous PPAR", "TEST", 307, 322], ["plasma samples", "TEST", 413, 427], ["UUO", "OBSERVATION", 455, 458]]], ["Twenty-two plasma metabolites were identified and are shown in Table 1 ; we found two ligands of PPAR-\u03b3, namely, 15d-PGJ2, and linoleic acid.", [["plasma", "ANATOMY", 11, 17], ["15d-PGJ2", "CHEMICAL", 113, 121], ["linoleic acid", "CHEMICAL", 127, 140], ["15d-PGJ2", "CHEMICAL", 113, 121], ["linoleic acid", "CHEMICAL", 127, 140], ["plasma", "ORGANISM_SUBSTANCE", 11, 17], ["PPAR-\u03b3", "GENE_OR_GENE_PRODUCT", 97, 103], ["15d-PGJ2", "SIMPLE_CHEMICAL", 113, 121], ["linoleic acid", "SIMPLE_CHEMICAL", 127, 140], ["PPAR", "PROTEIN", 97, 101], ["two plasma metabolites", "TEST", 7, 29], ["PPAR", "TEST", 97, 101], ["PGJ2", "TREATMENT", 117, 121], ["linoleic acid", "TREATMENT", 127, 140], ["linoleic acid", "OBSERVATION", 127, 140]]], ["They were significantly increased in AAtreated rats compared with UUO rats (Fig. 3e) .", [["rats", "ORGANISM", 47, 51], ["UUO rats", "ORGANISM", 66, 74], ["rats", "SPECIES", 47, 51], ["rats", "SPECIES", 70, 74], ["significantly", "OBSERVATION_MODIFIER", 10, 23], ["increased", "OBSERVATION_MODIFIER", 24, 33]]], ["Endogenous 15d-PGJ2 produced by the nonenzymatic dehydration of PGD2 has an affinity for PPAR-\u03b3 of approximately 2 \u03bcM [26] .", [["15d-PGJ2", "CHEMICAL", 11, 19], ["dehydration", "DISEASE", 49, 60], ["PGD2", "CHEMICAL", 64, 68], ["15d-PGJ2", "CHEMICAL", 11, 19], ["PGD2", "CHEMICAL", 64, 68], ["15d-PGJ2", "SIMPLE_CHEMICAL", 11, 19], ["PGD2", "SIMPLE_CHEMICAL", 64, 68], ["PPAR-\u03b3", "GENE_OR_GENE_PRODUCT", 89, 95], ["15d-PGJ2", "PROTEIN", 11, 19], ["PPAR", "PROTEIN", 89, 93], ["the nonenzymatic dehydration of PGD2", "PROBLEM", 32, 68], ["PPAR", "TEST", 89, 93]]], ["This metabolite is the most potent natural ligand of PPAR-\u03b3.", [["PPAR-\u03b3.", "GENE_OR_GENE_PRODUCT", 53, 60], ["PPAR", "PROTEIN", 53, 57]]], ["PPAR-\u03b3 is also activated by a variety of long-chain polyunsaturated fatty acids.", [["fatty acids", "CHEMICAL", 68, 79], ["polyunsaturated fatty acids", "CHEMICAL", 52, 79], ["PPAR-\u03b3", "GENE_OR_GENE_PRODUCT", 0, 6], ["long-chain polyunsaturated fatty acids", "SIMPLE_CHEMICAL", 41, 79], ["PPAR-\u03b3", "PROTEIN", 0, 6], ["PPAR", "TEST", 0, 4], ["long-chain polyunsaturated fatty acids", "TREATMENT", 41, 79]]], ["Linoleic acid has been reported to bind to and activate PPAR-\u03b3 with relatively scale bar, 100 \u00b5m; magnification, \u00d7200).", [["Linoleic acid", "CHEMICAL", 0, 13], ["Linoleic acid", "CHEMICAL", 0, 13], ["Linoleic acid", "SIMPLE_CHEMICAL", 0, 13], ["PPAR-\u03b3", "GENE_OR_GENE_PRODUCT", 56, 62], ["PPAR", "PROTEIN", 56, 60], ["\u03b3", "PROTEIN", 61, 62], ["Linoleic acid", "TREATMENT", 0, 13], ["PPAR", "TEST", 56, 60]]], ["P < 0.001 (compared with control group); # P < 0.05, ## P < 0.01 (compared with UUO group) low affinity (K d = 10-100 \u03bcM) [27] .", [["low affinity", "PROBLEM", 91, 103], ["K d", "TEST", 105, 108]]], ["Then, we further validated that AA indeed enhances the plasma level of 15d-PGJ2 in mice using targeted GC-MS-based metabolomics (Fig. 3f) .", [["plasma", "ANATOMY", 55, 61], ["AA", "CHEMICAL", 32, 34], ["15d-PGJ2", "CHEMICAL", 71, 79], ["15d-PGJ2", "CHEMICAL", 71, 79], ["AA", "SIMPLE_CHEMICAL", 32, 34], ["plasma", "ORGANISM_SUBSTANCE", 55, 61], ["15d-PGJ2", "SIMPLE_CHEMICAL", 71, 79], ["mice", "ORGANISM", 83, 87], ["mice", "SPECIES", 83, 87], ["mice", "SPECIES", 83, 87], ["the plasma level", "TEST", 51, 67]]], ["Moreover, the administration of 15d-PGJ2 attenuated (1) renal dysfunction (reduced the increase in Scr and BUN levels, Fig. 4a, b) ; (2) interstitial damage (H&E staining, Fig. 4c); (3) the expression of fibrotic proteins (Fig. 5a, b) ; and (4) the disorder of TGF-\u03b2/Smad and Wnt/\u03b2-catenin signaling pathways (Fig. 5c, d) .", [["renal", "ANATOMY", 56, 61], ["interstitial", "ANATOMY", 137, 149], ["15d-PGJ2", "CHEMICAL", 32, 40], ["renal dysfunction", "DISEASE", 56, 73], ["interstitial damage", "DISEASE", 137, 156], ["disorder", "DISEASE", 249, 257], ["15d-PGJ2", "CHEMICAL", 32, 40], ["15d-PGJ2", "SIMPLE_CHEMICAL", 32, 40], ["renal", "ORGAN", 56, 61], ["Scr", "GENE_OR_GENE_PRODUCT", 99, 102], ["BUN", "SIMPLE_CHEMICAL", 107, 110], ["interstitial", "TISSUE", 137, 149], ["Fig. 5a", "GENE_OR_GENE_PRODUCT", 223, 230], ["b", "GENE_OR_GENE_PRODUCT", 232, 233], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 261, 266], ["Smad", "GENE_OR_GENE_PRODUCT", 267, 271], ["Wnt/\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 276, 289], ["Scr", "PROTEIN", 99, 102], ["BUN", "PROTEIN", 107, 110], ["fibrotic proteins", "PROTEIN", 204, 221], ["Fig. 5a, b", "PROTEIN", 223, 233], ["TGF-\u03b2", "PROTEIN", 261, 266], ["Smad", "PROTEIN", 267, 271], ["\u03b2-catenin", "PROTEIN", 280, 289], ["renal dysfunction", "PROBLEM", 56, 73], ["Scr", "TEST", 99, 102], ["BUN levels", "TEST", 107, 117], ["interstitial damage (H&E staining", "PROBLEM", 137, 170], ["fibrotic proteins", "PROBLEM", 204, 221], ["the disorder", "PROBLEM", 245, 257], ["TGF", "TEST", 261, 264], ["catenin signaling pathways", "PROBLEM", 282, 308], ["renal", "ANATOMY", 56, 61], ["dysfunction", "OBSERVATION", 62, 73], ["increase", "OBSERVATION_MODIFIER", 87, 95], ["interstitial", "ANATOMY_MODIFIER", 137, 149], ["damage", "OBSERVATION", 150, 156], ["fibrotic", "OBSERVATION", 204, 212]]], ["Overall, 15d-PGJ2 showed similar therapeutic effects as those of AA in UUO animal model, and their renoprotective effects were abolished by GW9662.", [["15d-PGJ2", "CHEMICAL", 9, 17], ["AA", "CHEMICAL", 65, 67], ["GW9662", "CHEMICAL", 140, 146], ["15d-PGJ2", "CHEMICAL", 9, 17], ["GW9662", "CHEMICAL", 140, 146], ["15d-PGJ2", "SIMPLE_CHEMICAL", 9, 17], ["AA", "SIMPLE_CHEMICAL", 65, 67], ["GW9662", "SIMPLE_CHEMICAL", 140, 146], ["UUO", "OBSERVATION", 71, 74]]], ["These data indicate that AA ameliorates renal fibrosis, at least in part via enhanced formation of endogenous 15d-PGJ2 in a UUO animal model.", [["renal", "ANATOMY", 40, 45], ["AA", "CHEMICAL", 25, 27], ["fibrosis", "DISEASE", 46, 54], ["15d-PGJ2", "CHEMICAL", 110, 118], ["15d-PGJ2", "CHEMICAL", 110, 118], ["AA", "SIMPLE_CHEMICAL", 25, 27], ["renal", "ORGAN", 40, 45], ["15d-PGJ2", "GENE_OR_GENE_PRODUCT", 110, 118], ["endogenous 15d-PGJ2", "PROTEIN", 99, 118], ["These data", "TEST", 0, 10], ["AA ameliorates renal fibrosis", "PROBLEM", 25, 54], ["a UUO animal model", "TREATMENT", 122, 140], ["renal", "ANATOMY", 40, 45], ["fibrosis", "OBSERVATION", 46, 54], ["UUO", "OBSERVATION", 124, 127]]], ["SREBPs play a central role in cell metabolism by controlling the synthesis of fatty acids, TGs, and cholesterol [28] .", [["cell", "ANATOMY", 30, 34], ["fatty acids", "CHEMICAL", 78, 89], ["cholesterol", "CHEMICAL", 100, 111], ["fatty acids", "CHEMICAL", 78, 89], ["TGs", "CHEMICAL", 91, 94], ["cholesterol", "CHEMICAL", 100, 111], ["SREBPs", "GENE_OR_GENE_PRODUCT", 0, 6], ["cell", "CELL", 30, 34], ["fatty acids", "SIMPLE_CHEMICAL", 78, 89], ["TGs", "SIMPLE_CHEMICAL", 91, 94], ["cholesterol", "SIMPLE_CHEMICAL", 100, 111], ["SREBPs", "PROTEIN", 0, 6], ["fatty acids", "TEST", 78, 89], ["TGs", "TEST", 91, 94], ["central", "OBSERVATION_MODIFIER", 14, 21], ["cell metabolism", "OBSERVATION", 30, 45]]], ["SREBP-1 is one of the most important SREBPs, which are synthesized as inactive precursors bound to the ER [28, 29] .", [["SREBP-1", "GENE_OR_GENE_PRODUCT", 0, 7], ["SREBPs", "GENE_OR_GENE_PRODUCT", 37, 43], ["ER", "GENE_OR_GENE_PRODUCT", 103, 105], ["SREBP-1", "PROTEIN", 0, 7], ["SREBPs", "PROTEIN", 37, 43], ["ER", "PROTEIN", 103, 105], ["SREBP", "TEST", 0, 5]]], ["When sterols are depleted in the ER membrane, SREBP-1 is transported to the Golgi, proteolytically released by two proteases and then shuttled to the nucleus to induce the expression of genes involved in fatty d Western blots showing protein expression in the TGF-\u03b2/Smad signaling pathway in kidneys from all groups.", [["ER membrane", "ANATOMY", 33, 44], ["Golgi", "ANATOMY", 76, 81], ["nucleus", "ANATOMY", 150, 157], ["kidneys", "ANATOMY", 292, 299], ["sterols", "CHEMICAL", 5, 12], ["sterols", "CHEMICAL", 5, 12], ["sterols", "SIMPLE_CHEMICAL", 5, 12], ["ER membrane", "CELLULAR_COMPONENT", 33, 44], ["SREBP-1", "GENE_OR_GENE_PRODUCT", 46, 53], ["Golgi", "CELLULAR_COMPONENT", 76, 81], ["nucleus", "CELLULAR_COMPONENT", 150, 157], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 260, 265], ["Smad", "GENE_OR_GENE_PRODUCT", 266, 270], ["kidneys", "ORGAN", 292, 299], ["ER", "PROTEIN", 33, 35], ["SREBP-1", "PROTEIN", 46, 53], ["proteases", "PROTEIN", 115, 124], ["TGF-\u03b2", "PROTEIN", 260, 265], ["Smad", "PROTEIN", 266, 270], ["fatty d Western blots", "TEST", 204, 225], ["protein expression", "PROBLEM", 234, 252], ["the TGF", "TEST", 256, 263], ["depleted", "OBSERVATION", 17, 25], ["kidneys", "ANATOMY", 292, 299]]], ["Quantitative measurements of protein expression in kidneys from each group as indicated.", [["kidneys", "ANATOMY", 51, 58], ["kidneys", "ORGAN", 51, 58], ["protein expression in kidneys", "PROBLEM", 29, 58], ["protein expression", "OBSERVATION", 29, 47], ["kidneys", "ANATOMY", 51, 58]]], ["P < 0.001 acid synthesis.", [["acid synthesis", "TEST", 10, 24]]], ["A previous study reported that the expression of an activated form of SREBP-1 causes cells to produce ligand(s) of PPAR-\u03b3 [30] .", [["cells", "ANATOMY", 85, 90], ["SREBP-1", "GENE_OR_GENE_PRODUCT", 70, 77], ["cells", "CELL", 85, 90], ["PPAR-\u03b3", "GENE_OR_GENE_PRODUCT", 115, 121], ["SREBP-1", "PROTEIN", 70, 77], ["PPAR", "PROTEIN", 115, 119], ["A previous study", "TEST", 0, 16], ["SREBP", "TEST", 70, 75], ["PPAR", "TEST", 115, 119]]], ["Our results show that UUO animals treated with AA exhibit significant increases in the levels of activated SREBP-1 and 15d-PGJ2 compared to those in the UUO group (Figs.", [["AA", "CHEMICAL", 47, 49], ["15d-PGJ2", "CHEMICAL", 119, 127], ["AA", "SIMPLE_CHEMICAL", 47, 49], ["SREBP-1", "GENE_OR_GENE_PRODUCT", 107, 114], ["15d-PGJ2", "GENE_OR_GENE_PRODUCT", 119, 127], ["SREBP-1", "PROTEIN", 107, 114], ["15d", "PROTEIN", 119, 122], ["PGJ2", "PROTEIN", 123, 127], ["AA", "TREATMENT", 47, 49], ["significant increases", "PROBLEM", 58, 79], ["activated SREBP", "TEST", 97, 112], ["PGJ2", "TREATMENT", 123, 127], ["UUO", "OBSERVATION", 22, 25], ["significant", "OBSERVATION_MODIFIER", 58, 69], ["increases", "OBSERVATION_MODIFIER", 70, 79]]], ["3e and 6a) , while the administration of fatostatin in AA-treated mice produces a decrease in nSREBP-1 and 15d-PGJ2 levels (Fig. 6c, d) .", [["fatostatin", "CHEMICAL", 41, 51], ["AA", "CHEMICAL", 55, 57], ["fatostatin", "CHEMICAL", 41, 51], ["15d-PGJ2", "CHEMICAL", 107, 115], ["fatostatin", "SIMPLE_CHEMICAL", 41, 51], ["AA", "SIMPLE_CHEMICAL", 55, 57], ["mice", "ORGANISM", 66, 70], ["nSREBP-1", "GENE_OR_GENE_PRODUCT", 94, 102], ["15d-PGJ2", "SIMPLE_CHEMICAL", 107, 115], ["nSREBP", "PROTEIN", 94, 100], ["PGJ2", "PROTEIN", 111, 115], ["mice", "SPECIES", 66, 70], ["mice", "SPECIES", 66, 70], ["fatostatin in AA", "TREATMENT", 41, 57], ["nSREBP", "TEST", 94, 100], ["PGJ2 levels", "TEST", 111, 122], ["decrease", "OBSERVATION_MODIFIER", 82, 90]]], ["The data presented here indicate clearly that nSREBP-1 triggers the generation of endogenous 15d-PGJ2.DISCUSSIONIn summary, we demonstrated that AA increases the expression of activated SREBP-1, upregulates nSREBP-1, enhances the level of endogenous 15d-PGJ2, which activates PPAR-\u03b3, attenuates oxidative stress, rebalances the disorder of the TGF-\u03b2/Smad and Wnt/\u03b2-catenin signaling pathways, and ameliorates renal fibrosis (Fig. 6e) .", [["renal", "ANATOMY", 409, 414], ["AA", "CHEMICAL", 145, 147], ["15d-PGJ2", "CHEMICAL", 250, 258], ["disorder", "DISEASE", 328, 336], ["fibrosis", "DISEASE", 415, 423], ["15d-PGJ2", "CHEMICAL", 250, 258], ["nSREBP-1", "GENE_OR_GENE_PRODUCT", 46, 54], ["AA", "SIMPLE_CHEMICAL", 145, 147], ["SREBP-1", "GENE_OR_GENE_PRODUCT", 186, 193], ["nSREBP-1", "GENE_OR_GENE_PRODUCT", 207, 215], ["15d-PGJ2", "GENE_OR_GENE_PRODUCT", 250, 258], ["PPAR-\u03b3", "GENE_OR_GENE_PRODUCT", 276, 282], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 344, 349], ["Smad", "GENE_OR_GENE_PRODUCT", 350, 354], ["Wnt/\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 359, 372], ["renal", "ORGAN", 409, 414], ["nSREBP-1", "PROTEIN", 46, 54], ["SREBP-1", "PROTEIN", 186, 193], ["nSREBP-1", "PROTEIN", 207, 215], ["PGJ2", "PROTEIN", 254, 258], ["PPAR-\u03b3", "PROTEIN", 276, 282], ["TGF-\u03b2", "PROTEIN", 344, 349], ["Smad", "PROTEIN", 350, 354], ["\u03b2-catenin", "PROTEIN", 363, 372], ["nSREBP", "TEST", 46, 52], ["activated SREBP", "TEST", 176, 191], ["upregulates nSREBP", "TEST", 195, 213], ["PPAR", "TEST", 276, 280], ["attenuates oxidative stress", "PROBLEM", 284, 311], ["the disorder", "PROBLEM", 324, 336], ["the TGF", "TEST", 340, 347], ["catenin signaling pathways", "PROBLEM", 365, 391], ["renal fibrosis", "PROBLEM", 409, 423], ["oxidative stress", "OBSERVATION", 295, 311], ["renal", "ANATOMY", 409, 414], ["fibrosis", "OBSERVATION", 415, 423]]], ["Our study, for the first time, reveals, in part, the mechanism by which AA can treat renal fibrosis through regulating endogenous metabolites.", [["renal", "ANATOMY", 85, 90], ["AA", "CHEMICAL", 72, 74], ["fibrosis", "DISEASE", 91, 99], ["AA", "SIMPLE_CHEMICAL", 72, 74], ["renal", "ORGAN", 85, 90], ["Our study", "TEST", 0, 9], ["renal fibrosis", "PROBLEM", 85, 99], ["renal", "ANATOMY", 85, 90], ["fibrosis", "OBSERVATION", 91, 99], ["endogenous metabolites", "OBSERVATION", 119, 141]]], ["This study also provides a paradigm for mechanistic studies of molecules with similar characteristics as those of AA.", [["AA", "CHEMICAL", 114, 116], ["AA", "SIMPLE_CHEMICAL", 114, 116], ["This study", "TEST", 0, 10], ["mechanistic studies", "TEST", 40, 59]]], ["Fig. 6 The protein (a) and mRNA expression (b) of SREBP-1 in kidneys from control, UUO, and UUO + AA rats. c Western blots showing nSREBP-1 expressions in kidneys from Control, UUO, UUO + AA, and UUO + AA + fatostatin mice.", [["kidneys", "ANATOMY", 61, 68], ["kidneys", "ANATOMY", 155, 162], ["AA", "CHEMICAL", 188, 190], ["AA", "CHEMICAL", 202, 204], ["fatostatin", "CHEMICAL", 207, 217], ["SREBP-1", "GENE_OR_GENE_PRODUCT", 50, 57], ["kidneys", "ORGAN", 61, 68], ["UUO + AA rats", "ORGANISM", 92, 105], ["nSREBP-1", "GENE_OR_GENE_PRODUCT", 131, 139], ["kidneys", "ORGAN", 155, 162], ["UUO + AA", "SIMPLE_CHEMICAL", 196, 204], ["mice", "ORGANISM", 218, 222], ["SREBP-1", "PROTEIN", 50, 57], ["nSREBP", "PROTEIN", 131, 137], ["rats", "SPECIES", 101, 105], ["mice", "SPECIES", 218, 222], ["mice", "SPECIES", 218, 222], ["mRNA expression", "TEST", 27, 42], ["SREBP", "TEST", 50, 55], ["Western blots", "TEST", 109, 122], ["nSREBP", "TEST", 131, 137], ["AA", "PROBLEM", 188, 190], ["UUO", "PROBLEM", 196, 199], ["AA", "PROBLEM", 202, 204], ["fatostatin mice", "TREATMENT", 207, 222], ["kidneys", "ANATOMY", 61, 68], ["UUO", "OBSERVATION", 83, 86], ["UUO", "OBSERVATION", 92, 95], ["kidneys", "ANATOMY", 155, 162], ["UUO", "OBSERVATION", 177, 180], ["UUO", "OBSERVATION", 182, 185], ["UUO", "ANATOMY", 196, 199]]], ["Quantitative measurements of protein expression in kidneys from each group as indicated. *P < 0.05, **P < 0.01. d Alteration of the plasma level of 15d-PGJ2 in mice using GC-MS. *P < 0.05, **P < 0.01. e Suggested antifibrotic mechanism of asiatic acid Team.", [["kidneys", "ANATOMY", 51, 58], ["plasma", "ANATOMY", 132, 138], ["15d-PGJ2", "CHEMICAL", 148, 156], ["asiatic acid", "CHEMICAL", 239, 251], ["15d-PGJ2", "CHEMICAL", 148, 156], ["asiatic acid", "CHEMICAL", 239, 251], ["kidneys", "ORGAN", 51, 58], ["plasma", "ORGANISM_SUBSTANCE", 132, 138], ["15d-PGJ2", "SIMPLE_CHEMICAL", 148, 156], ["mice", "ORGANISM", 160, 164], ["asiatic acid", "SIMPLE_CHEMICAL", 239, 251], ["mice", "SPECIES", 160, 164], ["mice", "SPECIES", 160, 164], ["protein expression in kidneys", "PROBLEM", 29, 58], ["the plasma level", "TEST", 128, 144], ["protein expression", "OBSERVATION", 29, 47], ["kidneys", "ANATOMY", 51, 58]]], ["The authors would like to thank Zhe Wang for the discussion of the manuscript.AUTHOR CONTRIBUTIONSZHZ, HCC and NHT designed the experiments.", [["HCC", "ANATOMY", 103, 106], ["HCC", "DISEASE", 103, 106], ["HCC", "CANCER", 103, 106], ["HCC", "PROBLEM", 103, 106], ["HCC", "OBSERVATION", 103, 106]]], ["ZHZ and JQH collected and analyzed the data.", [["ZHZ", "PROTEIN", 0, 3], ["ZHZ", "TEST", 0, 3], ["JQH", "TREATMENT", 8, 11], ["the data", "TEST", 35, 43]]], ["YYZ and NHT contributed analytical tools.", [["YYZ", "CHEMICAL", 0, 3], ["YYZ", "SIMPLE_CHEMICAL", 0, 3], ["NHT", "SIMPLE_CHEMICAL", 8, 11]]]], "8eb4a136e3f250475537f682f6bdb6448eabb1e9": [["The clinical manifestations associated with colds and influenza overshadow the equally important mood and performance impairments.", [["colds", "DISEASE", 44, 49], ["influenza", "DISEASE", 54, 63], ["mood and performance impairments", "DISEASE", 97, 129], ["The clinical manifestations", "PROBLEM", 0, 27], ["colds", "PROBLEM", 44, 49], ["influenza", "PROBLEM", 54, 63], ["performance impairments", "PROBLEM", 106, 129]]], ["While decreased alertness and increased anxiety can be considered side effects of symptomatology, symptoms alone may not be responsible for the psychomotor and attention deficits of colds and influenza, respectively.", [["decreased alertness", "DISEASE", 6, 25], ["anxiety", "DISEASE", 40, 47], ["psychomotor and attention deficits", "DISEASE", 144, 178], ["colds", "DISEASE", 182, 187], ["influenza", "DISEASE", 192, 201], ["decreased alertness", "PROBLEM", 6, 25], ["increased anxiety", "PROBLEM", 30, 47], ["symptomatology", "PROBLEM", 82, 96], ["symptoms", "PROBLEM", 98, 106], ["the psychomotor and attention deficits", "PROBLEM", 140, 178], ["colds", "PROBLEM", 182, 187], ["influenza", "PROBLEM", 192, 201]]], ["An alternative hypothesis, as proposed in this review, suggests that the immune response, in the form of a cytokine cascade, may be responsible for both the physical and psychological symptoms.", [["cytokine", "PROTEIN", 107, 115], ["a cytokine cascade", "TREATMENT", 105, 123], ["the physical and psychological symptoms", "PROBLEM", 153, 192], ["hypothesis", "OBSERVATION", 15, 25]]], ["In particular, patterns of cytokine production for each infection will dictate the symptoms and performance deficits both within and between viruses.", [["infection", "DISEASE", 56, 65], ["cytokine", "PROTEIN", 27, 35], ["cytokine production", "PROBLEM", 27, 46], ["each infection", "PROBLEM", 51, 65], ["the symptoms", "PROBLEM", 79, 91], ["performance deficits", "PROBLEM", 96, 116], ["cytokine production", "OBSERVATION", 27, 46]]], ["This hypothesis can be extended to incorporate infectious mononucleosis, as well as colds and influenza.", [["infectious mononucleosis", "DISEASE", 47, 71], ["colds", "DISEASE", 84, 89], ["influenza", "DISEASE", 94, 103], ["infectious mononucleosis", "PROBLEM", 47, 71], ["colds", "PROBLEM", 84, 89], ["influenza", "PROBLEM", 94, 103], ["infectious", "OBSERVATION_MODIFIER", 47, 57], ["influenza", "OBSERVATION", 94, 103]]], ["The efficacy of symptom-based overthe-counter medications is then called into question.", [["symptom", "PROBLEM", 16, 23], ["overthe-counter medications", "TREATMENT", 30, 57]]]], "9da5e8215398edd77d8192eccab19e7bb2afffe9": [["1 Liposuctie, ook wel lipoplastiek of 'liposculpture' genaamd, is een chirurgische contourtechniek waarbij met een vacu\u00fcmzuigsysteem (traditionele liposuctie) of met ultrasone energie (ultrageluidliposuctie) ongewenste vetophopingen verwijderd kunnen worden.", [["een vacu\u00fcmzuigsysteem", "TREATMENT", 111, 132]]], ["2 Naast bekende cosmetische toepassingen als liposuctie van heup, billen en buik en als aanvullende behandeling bij abdominoplastiek, mammareductie en gynaecomastiecorrectie, wordt liposuctie ook functioneel gebruikt.", [["Naast", "TREATMENT", 2, 7]]], ["Bijvoorbeeld voor het uitdunnen ('debulking') van transpositie-of vrije gerevasculariseerde huidlappen en als behandeling bij subcutane extravasatie van (agressieve) infusievloeistoffen.", [["vrije gerevasculariseerde huidlappen", "TREATMENT", 66, 102], ["infusievloeistoffen", "TREATMENT", 166, 185]]]], "PMC7486585": [["IntroductionWithout ambitious energy efficiency targets and a significant increase in energy efficiency investments, the EU will most likely miss even its current 2030 climate target of reducing greenhouse gas (GHG) emissions by 40% based on 1990 levels, let alone deliver on the commitments made in Paris (Rosenow et al. 2018).1 On a global scale, the International Energy Agency (IEA) recently concluded that improvements in end-use energy efficiency could deliver at least 35% of the total emission reductions needed by 2050 to avoid drastic global climate disruption (IEA 2018).", [["GHG", "CHEMICAL", 211, 214], ["a significant increase in energy efficiency investments", "PROBLEM", 60, 115], ["reducing greenhouse gas", "TREATMENT", 186, 209], ["the total emission reductions", "TREATMENT", 483, 512], ["drastic global climate disruption", "PROBLEM", 537, 570], ["significant", "OBSERVATION_MODIFIER", 62, 73], ["increase", "OBSERVATION_MODIFIER", 74, 82], ["energy efficiency", "OBSERVATION", 86, 103], ["climate disruption", "OBSERVATION", 552, 570]]], ["However, the EU ETS, Europe\u2019s key tool to reduce GHG emissions, is not able to overcome the various non-price barriers to energy efficiency because a carbon pricing instrument alone does not address lack of information, behavioural failures and liquidity constraints (e.g. Cowart 2011).", [["carbon", "CHEMICAL", 150, 156], ["a carbon pricing instrument", "TREATMENT", 148, 175], ["behavioural failures and liquidity constraints", "PROBLEM", 220, 266]]], ["The EU ETS has the ability to reinforce EU energy efficiency policy and cost-effective energy efficiency improvements by making use of both the carbon price and the opportunity to recycle auctioning revenues strategically.IntroductionThe ongoing political discussion on the EU ETS, however, still puts a larger emphasis on the carbon price and its potential to incentivise low-carbon investments.", [["carbon", "CHEMICAL", 144, 150], ["carbon", "CHEMICAL", 327, 333], ["carbon", "CHEMICAL", 377, 383], ["the carbon price", "TREATMENT", 140, 156], ["the carbon price", "TREATMENT", 323, 339], ["incentivise low-carbon investments", "TREATMENT", 361, 395], ["energy efficiency", "OBSERVATION", 87, 104]]], ["Considering that auctioning revenues are an increasing source of income for EU Member States, we propose that it is time to assess the potential contribution of strategic revenue investments to accelerate decarbonisation efforts.IntroductionTotal auctioning revenues have increased by around 46% from 2016 to 2017.2 The volume of auctioning revenues that EU Member States receive is a function of the number of allowances available for auction and the EU carbon price paid for these allowances (Ecologic Institute and WWF 2016).", [["carbon", "CHEMICAL", 455, 461], ["strategic revenue investments", "TREATMENT", 161, 190], ["decarbonisation efforts", "TREATMENT", 205, 228], ["Total auctioning revenues", "TREATMENT", 241, 266], ["the EU carbon price", "TREATMENT", 448, 467], ["increased", "OBSERVATION_MODIFIER", 272, 281], ["volume", "OBSERVATION_MODIFIER", 320, 326]]], ["The EU carbon price has increased from under 5 euros per tonne at the end of 2016 to around 7.5 euros per tonne at the end of 2017 to as high as 25 euros per tonne at the end of 2019.3 This price increase can be attributed to recent changes within the ETS framework and the revision of the EU ETS Directive4: The Market Stability Reserve (MSR) started operating in January 2019 and the linear reduction factor (LRF) will increase from 1.74 to 2.2% annually from 2021.", [["carbon", "CHEMICAL", 7, 13], ["carbon", "CHEMICAL", 7, 13], ["The EU carbon price", "TREATMENT", 0, 19], ["recent changes within the ETS framework", "PROBLEM", 226, 265], ["the linear reduction factor", "TREATMENT", 382, 409], ["carbon price", "OBSERVATION", 7, 19], ["increased", "OBSERVATION_MODIFIER", 24, 33], ["linear", "OBSERVATION_MODIFIER", 386, 392], ["reduction", "OBSERVATION_MODIFIER", 393, 402]]], ["Addressing the surplus of emission allowances in the EU carbon market and reducing the cap, respectively, both the MSR and the LRF, are expected to have an increasing effect on the EU carbon price and consequently auctioning revenues.", [["carbon", "CHEMICAL", 56, 62], ["carbon", "CHEMICAL", 184, 190], ["MSR", "PROTEIN", 115, 118], ["the EU carbon price", "TREATMENT", 177, 196], ["cap", "OBSERVATION_MODIFIER", 87, 90], ["increasing", "OBSERVATION_MODIFIER", 156, 166], ["effect", "OBSERVATION_MODIFIER", 167, 173]]], ["The lasting price effect will depend on various additional factors that appear to drive the EU carbon price such as regulatory and political events and investor behaviour (Friedrich and Pahle 2019).", [["carbon", "CHEMICAL", 95, 101], ["the EU carbon price", "TREATMENT", 88, 107]]], ["The recent changes within the ETS framework and the revision of the EU ETS Directive also affect the number of allowances available for auction.", [["The recent changes within the ETS framework", "PROBLEM", 0, 43], ["the revision", "TREATMENT", 48, 60], ["the EU ETS Directive", "TREATMENT", 64, 84]]], ["While both the MSR and the LRF reduce the number of allowances available, will the share of free allocations reduce to 30% until 2026 and reduce to 0% by 2030 (for sectors not at risk for carbon leakage).", [["carbon", "CHEMICAL", 188, 194], ["MSR", "PROTEIN", 15, 18], ["LRF", "PROTEIN", 27, 30], ["carbon leakage", "PROBLEM", 188, 202], ["carbon leakage", "OBSERVATION", 188, 202]]], ["A reduction in the number of allowances allocated for free increases the number being auctioned and, thus, will have a positive effect on revenues generated through auctioning.IntroductionAll of the above affects the volume of auctioning revenues that EU Member States receive.", [["A reduction", "TREATMENT", 0, 11], ["reduction", "OBSERVATION_MODIFIER", 2, 11]]], ["The effect finally depends on the price effect opposed to the volume effect, i.e., the number of allowances available for auction.", [["auction", "TEST", 122, 129], ["volume effect", "OBSERVATION", 62, 75]]], ["Yet, projected auctioning revenues show a future increase up to 20 billion euros per year before 2030 (Ecologic Institute and WWF 2016), which also the most recent trends of prices and revenues confirm.IntroductionWe argue in this paper that strategically investing this growing opportunity into energy efficiency programmes would reinforce the ETS and deliver multiple benefits5:Additional emission reductions from sectors both covered by and outside the ETS.Lower economic and societal decarbonisation costs by capturing a larger fraction of cost-effective emission reduction potential, which would possibly remain untapped if no additional funding for energy efficiency is made available, and reducing energy bills for end-users.A wide range of non-energy benefits from energy efficiency improvements and the resulting demand reduction.", [["Additional emission reductions from sectors", "TREATMENT", 380, 423], ["societal decarbonisation costs", "TREATMENT", 479, 509], ["energy efficiency", "PROBLEM", 655, 672], ["energy efficiency improvements", "PROBLEM", 773, 803], ["the resulting demand reduction", "TREATMENT", 808, 838], ["economic", "OBSERVATION_MODIFIER", 466, 474], ["wide", "OBSERVATION_MODIFIER", 734, 738], ["energy efficiency", "OBSERVATION", 773, 790], ["demand reduction", "OBSERVATION", 822, 838]]], ["Among those benefits are improvements in health, comfort, air quality, job creation and economic growth.Support for the political process to further tighten the EU ETS cap.", [["economic growth", "PROBLEM", 88, 103], ["the EU ETS cap", "TREATMENT", 157, 171], ["cap", "OBSERVATION_MODIFIER", 168, 171]]], ["An increase in the political will and social acceptance, as a result of the previous benefits, can enable more ambitious long-term decarbonisation targets.IntroductionThe aim of this paper is to present detailed data on the current status in Europe regarding carbon revenue recycling and to demonstrate why increasing the share of carbon revenues that are recycled for energy efficiency investments is desirable from a carbon perspective.", [["carbon", "CHEMICAL", 259, 265], ["carbon", "CHEMICAL", 331, 337], ["carbon", "CHEMICAL", 419, 425], ["ambitious long-term decarbonisation targets", "TREATMENT", 111, 154], ["carbon revenue recycling", "TREATMENT", 259, 283], ["carbon revenues", "TREATMENT", 331, 346], ["energy efficiency investments", "TREATMENT", 369, 398], ["a carbon perspective", "TREATMENT", 417, 437], ["increase", "OBSERVATION_MODIFIER", 3, 11]]], ["The assessment includes additional information on auctioning revenue use in Germany and the Czech Republic, which we identify as exceptional cases.", [["The assessment", "TEST", 0, 14]]], ["(Wiese et al. 2019).Background: the economic case for investing auctioning revenues in energy efficiencyStrategically investing auctioning revenues in energy efficiency measures can make a relevant contribution to achieve emission reductions at the lowest economic and societal costs.", [["energy efficiency measures", "TREATMENT", 151, 177], ["emission reductions", "TREATMENT", 222, 241], ["energy efficiency", "OBSERVATION", 87, 104]]], ["Some economists would strictly disagree with this proposition, defining external costs of GHG emissions as the only market failure to address.", [["GHG emissions", "TREATMENT", 90, 103]]], ["In a first-best setting, a single carbon pricing instrument as the EU ETS would, in theory, internalise the externality and effectively incentivise emission reductions, while any policy on top would distort market forces (e.g. Barranzini et al. 2017).Background: the economic case for investing auctioning revenues in energy efficiencyHowever, others acknowledge the existence of second-best problems, e.g. market failures and/or exogenous real-world constraints, which rationalise the use of multiple policies with a common policy target (e.g. Bennear and Stavins 2007).", [["carbon", "CHEMICAL", 34, 40], ["a single carbon pricing instrument", "TREATMENT", 25, 59], ["effectively incentivise emission reductions", "TREATMENT", 124, 167], ["energy efficiency", "OBSERVATION", 318, 335]]], ["Investing auctioning revenues to further strengthen EU energy efficiency policy could reinforce the EU ETS and reduce the economic and societal costs of GHG emission reductions, because:Investing auctioning revenues in energy efficiency can help to realise a larger fraction of cost-effective emissions reduction potential.", [["GHG emission reductions", "TREATMENT", 153, 176]]], ["Recent evidence shows that there exists a large and untapped potential for cost-effective energy efficiency improvements in EU Member States (Thema et al. 2019).", [["cost-effective energy efficiency", "PROBLEM", 75, 107], ["large", "OBSERVATION_MODIFIER", 42, 47], ["energy efficiency", "OBSERVATION", 90, 107]]], ["Realising this potential would accelerate GHG emission reductions and, because it is cost-effective and would save more than it would cost in many instances, reduce the economic cost of reaching decarbonisation targets.", [["GHG emission reductions", "TREATMENT", 42, 65], ["GHG emission", "OBSERVATION", 42, 54]]], ["The potential remains untapped due to various barriers to energy efficiency, which includes imperfect and asymmetric information, principal agent problems, behavioural failures and limited access to capital.", [["principal agent problems", "PROBLEM", 130, 154], ["behavioural failures", "PROBLEM", 156, 176], ["energy efficiency", "OBSERVATION", 58, 75], ["asymmetric", "OBSERVATION_MODIFIER", 106, 116]]], ["It is well established that in the markets for energy efficiency, market failures and barriers beyond the negative externality of energy production and consumption exist.", [["energy efficiency", "PROBLEM", 47, 64], ["market failures", "PROBLEM", 66, 81]]], ["These barriers keep energy end-users from investing in cost-effective energy efficiency improvements and are a major justification for public policy interventions that implement multiple policies (Jaffe and Stavins 1994; Gillingham et al. 2009).", [["public policy interventions", "TREATMENT", 135, 162]]], ["By definition, non-price barriers to energy efficiency cannot be overcome by a pricing policy alone; i.e., due to other real-world constraints, a carbon price cannot unlock all long-term, cost-effective energy saving and thus GHG emissions reduction potential.", [["carbon", "CHEMICAL", 146, 152], ["a carbon price", "TREATMENT", 144, 158], ["cost-effective energy saving", "TREATMENT", 188, 216], ["GHG emissions reduction", "TREATMENT", 226, 249]]], ["Therefore, energy efficiency programmes that address the behavioural, financial and legal barriers to energy efficiency are needed in order to make use of a greater fraction of the cost-effective emissions reduction potential.Investing auctioning revenues in energy efficiency would reduce the energy bill impacts of carbon pricing on energy end-users.", [["carbon", "CHEMICAL", 317, 323], ["carbon", "SIMPLE_CHEMICAL", 317, 323], ["energy efficiency programmes", "TREATMENT", 11, 39], ["carbon pricing", "TREATMENT", 317, 331]]], ["A calculation of the consumer cost per tonne of abatement in competitive power markets shows that the cost to consumers per tonne of carbon reduced can be several times larger than the market price of carbon allowances (Cowart 2011).", [["carbon", "CHEMICAL", 133, 139], ["carbon", "CHEMICAL", 133, 139], ["carbon", "CHEMICAL", 201, 207], ["carbon reduced", "OBSERVATION", 133, 147]]], ["According to a study from Cambridge Econometrics and the Energy Centre of the Netherlands (2013), a carbon price of 20 euros per tonne impacts the merit order of dispatch in wholesale power markets in such a way that it yields a cost to power consumers amounting to 248 euros per tonne avoided, assuming nil price elasticity.7 The study furthermore shows that greater support for investments in end-use energy efficiency would reduce energy demand, which a pricing instrument alone would only achieve to a limited degree considering low energy price elasticities, specifically in the short run.", [["carbon", "CHEMICAL", 100, 106], ["a study", "TEST", 13, 20], ["a carbon price", "TREATMENT", 98, 112], ["The study", "TEST", 327, 336], ["energy demand", "PROBLEM", 434, 447], ["a pricing instrument", "TREATMENT", 455, 475], ["energy demand", "OBSERVATION", 434, 447]]], ["The reduction in energy demand due to greater support for investments in end-use energy efficiency would reduce GHG emissions and consumer energy bills due to lower prices on wholesale power markets.8 Particularly if energy efficiency investments are geared towards low-income households, this would potentially increase the public acceptability of carbon pricing, an issue that is often underappreciated by theoretical economic analysis (Rabe 2016, 2018).", [["carbon", "CHEMICAL", 349, 355], ["The reduction in energy demand", "TREATMENT", 0, 30], ["energy efficiency investments", "PROBLEM", 217, 246], ["carbon pricing", "TREATMENT", 349, 363], ["reduction", "OBSERVATION_MODIFIER", 4, 13], ["energy demand", "OBSERVATION", 17, 30], ["carbon pricing", "OBSERVATION", 349, 363]]], ["Analyses of real-world examples of carbon pricing (and revenue recycling) regimes demonstrate that public acceptability is of high importance for the long-term success of carbon pricing policies (Klenert et al. 2018).", [["carbon", "CHEMICAL", 35, 41], ["carbon", "CHEMICAL", 171, 177], ["carbon pricing", "TREATMENT", 35, 49], ["revenue recycling) regimes", "TREATMENT", 55, 81], ["carbon pricing policies", "TREATMENT", 171, 194]]], ["If targeted effectively, earmarked revenues can deliver significant benefits to specific communities or demographics.", [["communities", "ANATOMY", 89, 100]]], ["Revenues can be used, for example, to directly compensate for the cost of the tax or to support programmes that reduce energy costs for low-income households, (through energy efficiency or renewable energy), expand public infrastructure (e.g. transport), create economic stimulus in transition regions or reduce local pollution in disadvantaged communities.", [["tax", "PROTEIN", 78, 81], ["the tax", "TREATMENT", 74, 81], ["transition regions", "PROBLEM", 283, 301], ["local", "OBSERVATION_MODIFIER", 312, 317], ["pollution", "OBSERVATION", 318, 327]]], ["Among mechanisms to offset the impact of a carbon price on consumers, the most frequently used are those that directly compensate for additional costs associated with the carbon price.", [["carbon", "CHEMICAL", 43, 49], ["carbon", "CHEMICAL", 171, 177], ["a carbon price", "TREATMENT", 41, 55], ["the carbon price", "TREATMENT", 167, 183]]], ["Consumers are compensated through the return of carbon revenue through a variety of means such as a lump-sum cashback or the reduction of income, employment or capital taxes.", [["carbon", "CHEMICAL", 48, 54], ["carbon revenue", "TREATMENT", 48, 62], ["a lump", "PROBLEM", 98, 104], ["compensated", "OBSERVATION_MODIFIER", 14, 25]]], ["Cashback to all consumers is generally evaluated to be more progressive (benefiting proportionally more households on low incomes) than redistribution through tax adjustments (Cunha Montenegro et al. 2019).", [["Cashback", "CHEMICAL", 0, 8], ["tax", "PROTEIN", 159, 162]]], ["Returning revenues to energy-poor households and vulnerable communities is an important and equitable means to offset the cost burden imposed by a carbon price in the short term.", [["carbon", "CHEMICAL", 147, 153], ["a carbon price", "TREATMENT", 145, 159]]], ["However, returning the majority of revenues back to all consumers is an ineffective strategy to meet overall carbon goals.", [["carbon", "CHEMICAL", 109, 115], ["an ineffective strategy", "TREATMENT", 69, 92]]], ["Returning all revenues to consumers relies solely on the price impact to drive down emissions; as has been illustrated, carbon prices would have to be unrealistically high to drive deep change.", [["carbon", "CHEMICAL", 120, 126], ["carbon prices", "TREATMENT", 120, 133]]], ["Together with targeted cashback or bill support for low-income households, recycling of revenues into efficiency and renewable energy programmes targeted to low-income households or communities reduces bills significantly in the long term.", [["bill support", "TREATMENT", 35, 47], ["renewable energy programmes", "TREATMENT", 117, 144]]], ["This investment can tackle the significant challenges of reducing energy poverty and accelerating decarbonisation in hard-to-change sectors such as housing and transport.", [["reducing energy poverty", "TREATMENT", 57, 80], ["accelerating decarbonisation", "TREATMENT", 85, 113], ["significant", "OBSERVATION_MODIFIER", 31, 42]]], ["There is evidence that this rationale may be gaining ground with new taxes that have been recently announced coupled with ring-fenced support for low-income and energy-poor households and earmarking for clean energy transition programmes (e.g. in 2019 in Ireland (Press Association 2019) and Luxembourg (Euractiv 2019)).Background: the economic case for investing auctioning revenues in energy efficiencyBoth rationales make clear why using auctioning revenues to support energy efficiency measures complementary to the EU ETS would reduce the economic and societal costs of decarbonisation.", [["ring-fenced support", "TREATMENT", 122, 141], ["auctioning revenues", "TREATMENT", 441, 460], ["energy efficiency measures", "TREATMENT", 472, 498], ["decarbonisation", "TREATMENT", 575, 590], ["energy efficiency", "OBSERVATION", 387, 404]]], ["Energy efficiency is a key to capturing cost-effective energy and emission reduction potentials, while minimising rate and cost impacts.9Assessment of the Member States\u2019 reporting on the use of 2017 auctioning revenues ::: Status quo of auctioning revenue use at the EU Member State levelIn 2017, EU Member States received 5.09 billion euros through the auctioning of emission allowances in the EU ETS.14 Altogether, the reporting shows that Member States used or planned to use 4.07 billion euros (80.0%) of the total amount of 2017 revenues or the equivalent in financial value for energy- and climate-related purposes.", [["Energy efficiency", "PROBLEM", 0, 17], ["emission reduction potentials", "TEST", 66, 95], ["efficiency", "OBSERVATION", 7, 17], ["EU ETS", "ANATOMY", 395, 401]]], ["This relatively high share is consistent with the findings of reports on the use of auctioning revenues from previous years (Ecologic Institute and WWF 2016; Le Den et al. 2017; Wiese et al. 2018).", [["high", "OBSERVATION", 16, 20], ["consistent with", "UNCERTAINTY", 30, 45]]], ["The further assessment of Member States\u2019 auctioning revenue use therefore considers only the use of earmarked revenues and excludes Member States that do not earmark.", [["The further assessment", "TEST", 0, 22]]], ["We therefore continue focusing on Member States\u2019 domestic use of auctioning revenues.", [["auctioning revenues", "TREATMENT", 65, 84]]], ["The assessment of domestically used revenues reveals the challenge of heterogeneity among Member States\u2019 way of reporting: Germany indicates to use 100% of its total 2017 revenues for energy- and climate-related purposes (1.15 billion euros).", [["The assessment", "TEST", 0, 14]]], ["In order to present an accurate figure for the domestic use of auctioning revenues, we have removed Germany\u2019s non-ETS funds from the analysis.", [["auctioning revenues", "TREATMENT", 63, 82], ["the analysis", "TEST", 129, 141]]], ["We have adjusted its domestic use, setting it equal to 100% total revenue in 2017, and applied the ratios of domestic types of use to this amount.16Assessment of the Member States\u2019 reporting on the use of 2017 auctioning revenues ::: Status quo of auctioning revenue use at the EU Member State levelFigure 1 shows how Member States use their earmarked auctioning revenues domestically as a share of total earmarked and domestically reinvested revenues, distinguishing different types of use.Assessment of the Member States\u2019 reporting on the use of 2017 auctioning revenues ::: Status quo of auctioning revenue use at the EU Member State levelThe largest share of domestically used auctioning revenues (40.8% = 1.09 billion euros) finances energy efficiency measures, followed by the promotion of renewable energy (31.9% = 0.85 billion euros), other domestic/EU uses (9.4% = 0.25 billion euros) and the shift to low emission and public forms of transport (8.1% = 0.22 billion euros).17Assessment of the Member States\u2019 reporting on the use of 2017 auctioning revenues ::: Status quo of auctioning revenue use at the EU Member State levelA total of 59.2% of the total domestic use for energy efficiency in the EU as a whole comes from German auctioning revenues (with adjustment).", [["renewable energy", "TEST", 796, 812], ["transport", "TEST", 944, 953], ["German auctioning revenues", "TREATMENT", 1232, 1258], ["largest", "OBSERVATION_MODIFIER", 646, 653]]], ["Yet, also Belgium, Czech Republic, Croatia, Hungary, Italy and Latvia report to strategically invest between 50 and 100% of their domestic use of auctioning revenues in energy efficiency.", [["energy efficiency", "OBSERVATION", 169, 186]]], ["We identified two exceptional cases: Germany reports the highest 2017 auctioning revenues of all EU Member States and thus with a high share supporting energy efficiency measures, it contributes significantly to the total reported use for energy efficiency.", [["energy efficiency", "PROBLEM", 239, 256], ["energy efficiency", "OBSERVATION", 152, 169]]], ["The Czech New Green Savings Programme has been funded by auctioning revenues since its programme launch in 2013, and auctioning revenues are considered a major source for energy efficiency finance.", [["Green Savings", "OBSERVATION", 14, 27]]], ["Furthermore, the programmes partially funded by auctioning revenues in these countries have been shown to deliver energy savings and GHG emissions reductions, cost savings to consumers, tax revenue to the national budgets, employment and economic growth (Department of Communications, Climate Action, and Environment 2017; Diefenbach et al. 2018; Z\u00e1me\u010dn\u00edk and Lhot\u00e1k 2012; Ministry of Industry and Trade 2017).", [["GHG emissions reductions", "TREATMENT", 133, 157]]], ["Table 1 provides further information on the supported programmes in Germany and Czech Republic.Critical review of Member States\u2019 revenue data ::: Status quo of auctioning revenue use at the EU Member State levelOur assessment uses the Member States\u2019 official reporting on the use of 2017 auctioning revenues.", [["Our assessment", "TEST", 211, 225]]], ["Thus, the assessment requires some degree of reliance on the states\u2019 submissions.", [["the assessment", "TEST", 6, 20]]], ["Thus, there is a need for more transparent and granular reporting, which should ideally also include a requirement for independent monitoring and verification of the reported uses.The reporting does not allow to draw conclusions whether the use of auctioning revenues for energy efficiency in some Member States has led to additional programme support, as it would require a counterfactual without the revenue income stream.", [["independent monitoring", "TEST", 119, 141], ["auctioning revenues", "TREATMENT", 248, 267], ["additional programme support", "TREATMENT", 323, 351]]], ["Future research could estimate the additional impact of auctioning revenues on efficiency programmes by comparing trends in funding levels before and after the revenues were assigned to certain programmes and by studying their political and administrative histories.Slovakia, Belgium, Greece and Germany report to use a share of their total domestically reinvested revenues for electricity price compensation to energy-intensive industry at risk for carbon leakage.", [["carbon", "CHEMICAL", 450, 456], ["carbon", "SIMPLE_CHEMICAL", 450, 456], ["efficiency programmes", "TREATMENT", 79, 100], ["carbon leakage", "PROBLEM", 450, 464], ["carbon leakage", "OBSERVATION", 450, 464]]], ["This list includes all Member States that report to strategically reinvest auctioning revenues and to use a certain share of their revenues for compensation payments.", [["compensation payments", "TREATMENT", 144, 165]]], ["The list, however, is not a complete list of all Member States that provide compensation payments financed through some national budget.18 Although the use of auctioning revenues for compensation payments is permitted to count as an energy- and climate-related purpose under EU rules, it certainly decreases the beneficiaries\u2019 motivation to reduce their energy consumption.", [["auctioning revenues", "TREATMENT", 159, 178], ["compensation payments", "TREATMENT", 183, 204], ["an energy", "TEST", 230, 239]]], ["Instead, using revenues to improve energy efficiency at such industries could improve their competitiveness while also reducing emissions.The economic report of Germany\u2019s energy and climate fund (for 2017) shows that a large fraction of money (approximately 40%) committed to support energy and climate programmes was not disbursed for actual use (Zeitung f\u00fcr Kommunale Wirtschaft 2018).", [["large", "OBSERVATION_MODIFIER", 219, 224], ["fraction", "OBSERVATION_MODIFIER", 225, 233]]], ["This case shows that the provision of financial resources is one important step; however, it does not solve the challenge to overcome all other barriers to energy efficiency.Discussion: interactions among the EU ETS, auctioning revenue use and energy efficiency improvementsThe recent changes within the ETS framework are intended to address the current surplus of emission allowances and reduce the overall cap (MSR and LRF, respectively).", [["MSR", "PROTEIN", 413, 416], ["LRF", "PROTEIN", 421, 424], ["cap", "OBSERVATION_MODIFIER", 408, 411]]], ["On the other hand, a tighter market increases the carbon price, and the gradual elimination of free allocations also tends to drive up total auctioning revenues.", [["carbon", "CHEMICAL", 50, 56], ["the carbon price", "TREATMENT", 46, 62], ["total auctioning revenues", "TREATMENT", 135, 160], ["carbon price", "OBSERVATION", 50, 62]]], ["As mentioned before, projections indicate that total auctioning revenues across the EU might increase up to 20 billion euros per year before 2030 (Ecologic Institute and WWF 2016).", [["total auctioning revenues", "TREATMENT", 47, 72], ["increase", "OBSERVATION_MODIFIER", 93, 101]]], ["If Member States continue to devote the same fraction of auctioning revenues to efficiency programmes as reported in 2017, higher revenues would increase the amount of revenues used for energy- and climate-related purposes and increase the income stream available for energy efficiency programme support.Discussion: interactions among the EU ETS, auctioning revenue use and energy efficiency improvementsThe interaction between the EU ETS and improved energy efficiency, expecting higher (and ideally incremental) support for complementary energy efficiency measures, is more complex and often debated among researchers and policy advisers.19 If energy efficiency programmes have the effect of lowering demand for allowances by reducing energy consumption and generation (covered by the ETS, i.e. electricity), the carbon price would reduce.", [["carbon", "CHEMICAL", 815, 821], ["carbon", "SIMPLE_CHEMICAL", 815, 821], ["EU ETS", "PROTEIN", 432, 438], ["energy efficiency programme support", "TREATMENT", 268, 303], ["incremental) support", "TREATMENT", 501, 521], ["complementary energy efficiency measures", "TREATMENT", 526, 566], ["energy efficiency programmes", "PROBLEM", 646, 674], ["lowering demand", "TREATMENT", 694, 709], ["the carbon price", "TREATMENT", 811, 827], ["improved", "OBSERVATION_MODIFIER", 443, 451], ["energy efficiency", "OBSERVATION", 452, 469], ["energy efficiency", "OBSERVATION", 540, 557]]], ["Freed-up allowances would be banked for later use or would be sold to other emitters, meaning that the efficiency programmes would not achieve emission reductions under the cap-and-trade system but only reduce the price and thus the cost to businesses and consumers of complying with the cap.", [["the efficiency programmes", "TREATMENT", 99, 124], ["the cap", "TEST", 169, 176], ["the cap", "TREATMENT", 284, 291]]], ["The carbon price reduction would furthermore hamper the capacity of the EU ETS to incentivise low-carbon investments.Discussion: interactions among the EU ETS, auctioning revenue use and energy efficiency improvementsWhile critics have frequently used this \u2018waterbed effect\u2019 to argue against the implementation of measures that would reduce emissions additional to the EU ETS, we start with the argument that the overriding rationale of carbon cap-and-trade systems is, indeed, to uncover the lowest-cost opportunities to reduce emissions and therefore to reduce the price of carbon.", [["carbon", "CHEMICAL", 4, 10], ["carbon", "CHEMICAL", 576, 582], ["carbon", "CHEMICAL", 4, 10], ["carbon", "CHEMICAL", 98, 104], ["carbon", "CHEMICAL", 437, 443], ["carbon", "CHEMICAL", 576, 582], ["carbon", "SIMPLE_CHEMICAL", 4, 10], ["carbon", "SIMPLE_CHEMICAL", 576, 582], ["The carbon price reduction", "TREATMENT", 0, 26], ["low-carbon investments", "TREATMENT", 94, 116], ["carbon cap", "TREATMENT", 437, 447], ["the price of carbon", "TREATMENT", 563, 582]]], ["Thus, any action to reduce emissions within a cap-and-trade system will intentionally release emissions allowances into the market and reduce pressure on the carbon price without directly reducing the cap.", [["carbon", "CHEMICAL", 158, 164], ["a cap", "TEST", 44, 49], ["pressure on the carbon price", "TREATMENT", 142, 170], ["pressure", "OBSERVATION_MODIFIER", 142, 150], ["cap", "OBSERVATION_MODIFIER", 201, 204]]], ["It is therefore inconsistent with cap-and-trade theory to criticise additional policies, such as efficiency programmes, merely because they may reduce carbon prices under a cap.Discussion: interactions among the EU ETS, auctioning revenue use and energy efficiency improvementsWe emphasise three further interactions between energy efficiency improvements and the EU ETS, taking into account where revenues are currently invested, why the revised ETS framework \u2018punctures the waterbed\u2019 and how future revisions could further reinforce the major objective of the EU ETS to reduce emissions cost effectively:Some Member States use their auctioning revenues to improve the thermal efficiency in buildings and add insulation to homes, reducing energy consumption of natural gas, fuel oil or district heat systems that are largely outside the ETS.", [["carbon", "CHEMICAL", 151, 157], ["oil", "ORGANISM_SUBSTANCE", 780, 783], ["cap", "TEST", 34, 37], ["carbon prices", "TREATMENT", 151, 164], ["a cap", "TREATMENT", 171, 176], ["future revisions", "TREATMENT", 494, 510], ["their auctioning revenues", "TREATMENT", 629, 654], ["natural gas", "TREATMENT", 762, 773], ["district heat systems", "TREATMENT", 787, 808], ["carbon prices", "OBSERVATION", 151, 164], ["cap", "OBSERVATION_MODIFIER", 173, 176]]], ["In this way, the cap-and-trade scheme can drive reductions outside, and in addition to, the reductions mandated by the cap.", [["the cap", "TEST", 13, 20], ["cap", "OBSERVATION_MODIFIER", 17, 20], ["cap", "OBSERVATION_MODIFIER", 119, 122]]], ["This approach is especially useful when it would be impracticable or politically infeasible to bring those sectors into the cap regime.Considering the large amount of surplus allowances built-up in the EU ETS and the introduction of the MSR, the argued \u2018waterbed effect\u2019 is punctured (Sandbag 2017; Perino 2018).", [["MSR", "PROTEIN", 237, 240], ["the cap regime", "TREATMENT", 120, 134], ["cap regime", "OBSERVATION", 124, 134], ["large", "OBSERVATION_MODIFIER", 151, 156], ["amount", "OBSERVATION_MODIFIER", 157, 163], ["surplus", "OBSERVATION", 167, 174]]], ["From 2019 to 2028, the MSR is expected to take in approximately 1.8 billion allowances (additional to the initial transfer of unallocated and back-loaded allowances from phase 3).", [["MSR", "PROTEIN", 23, 26]]], ["Moreover, allowances in the MSR are limited in their validity.", [["MSR", "PROTEIN", 28, 31]]], ["Therefore, a substantial number, up to 2.4 billion, is expected to be cancelled in 2023 (Marcu et al. 2018).", [["substantial", "OBSERVATION_MODIFIER", 13, 24], ["number", "OBSERVATION_MODIFIER", 25, 31]]], ["With the MSR in operation, complementary measures that reduce the demand for allowances increase the surplus, of which a large proportion will eventually be cancelled.", [["MSR", "PROTEIN", 9, 12], ["the MSR in operation", "TREATMENT", 5, 25], ["complementary measures", "TREATMENT", 27, 49], ["the surplus", "TREATMENT", 97, 108]]], ["Thus, freed-up allowances and finally emissions are not simply shifted in space and time, as supposed by the \u2018waterbed effect\u2019 argument, but added to the existing surplus on the EU carbon market.20With respect to future revisions of the ETS framework, success in the strategic use of auctioning revenues for energy efficiency, which lowers energy bills along with emissions, could be used to support the political process to tighten the cap (Cowart et al. 2015).", [["carbon", "CHEMICAL", 181, 187], ["the ETS framework", "TREATMENT", 233, 250], ["auctioning revenues", "TREATMENT", 284, 303], ["energy efficiency", "PROBLEM", 308, 325], ["energy efficiency", "OBSERVATION", 308, 325]]], ["There is ample evidence from multiple jurisdictions that carbon pricing enjoys a much higher level of support among economists than it does across the general public, and many observers doubt that carbon pricing can, by itself, attract sufficient public support to drive down emissions enough to meet global carbon targets (Rabe 2016, 2018).", [["carbon", "CHEMICAL", 197, 203], ["carbon", "CHEMICAL", 57, 63], ["carbon", "CHEMICAL", 197, 203], ["carbon", "CHEMICAL", 308, 314], ["carbon", "SIMPLE_CHEMICAL", 197, 203], ["carbon pricing", "TREATMENT", 57, 71], ["carbon pricing", "TREATMENT", 197, 211], ["multiple", "OBSERVATION_MODIFIER", 29, 37], ["jurisdictions", "OBSERVATION", 38, 51]]], ["However, the public\u2019s willingness to support carbon pricing is greatly enhanced where the revenue would be directed towards programs to reduce emissions, especially renewable energy (Fowlie 2019).", [["carbon", "CHEMICAL", 45, 51], ["carbon", "CHEMICAL", 45, 51], ["carbon pricing", "TREATMENT", 45, 59]]], ["The nine states comprising the RGGI cap-and-trade scheme in the north-eastern USA advanced this idea further, using most of the auction revenues to support energy efficiency programs among end-users\u2014not just reducing emissions but directly lowering many consumers\u2019 bills as well as the cost of electricity generally.21 As a result, while several nations, states and provinces from Australia to Ontario have reversed course and abandoned carbon pricing, the RGGI states have twice renewed the RGGI programme and significantly lowered the regional cap.", [["carbon", "CHEMICAL", 437, 443], ["the RGGI cap", "TEST", 27, 39], ["the auction revenues", "TREATMENT", 124, 144], ["energy efficiency programs", "TREATMENT", 156, 182], ["abandoned carbon pricing", "TREATMENT", 427, 451], ["regional cap", "OBSERVATION", 537, 549]]], ["By turning the carbon price \u2018penalty\u2019 into a tool to support public benefits, RGGI demonstrates the political value of carbon revenue recycling to sustaining carbon pricing as a climate mitigation tool (Raymond 2016).ConclusionStrategically investing auctioning revenues in end-use energy efficiency provides an increasing opportunity for Member States to reinforce the EU ETS.", [["carbon", "CHEMICAL", 15, 21], ["carbon", "CHEMICAL", 119, 125], ["carbon", "CHEMICAL", 158, 164], ["carbon revenue recycling", "TREATMENT", 119, 143], ["carbon pricing", "TREATMENT", 158, 172]]], ["Support for complementary energy efficiency programmes can yield multiple benefits because energy efficiency improvements help to deliver cost savings and emissions reductions, reduce the upward pressure on consumer energy bills and realise the energy and non-energy benefits of end-use energy efficiency.", [["complementary energy efficiency programmes", "TREATMENT", 12, 54], ["energy efficiency", "PROBLEM", 91, 108], ["cost savings", "TREATMENT", 138, 150], ["emissions reductions", "TREATMENT", 155, 175], ["the upward pressure", "TREATMENT", 184, 203]]], ["Furthermore, in practical political terms, the multiple benefits from strategic investments can be substantial.", [["strategic investments", "TREATMENT", 70, 91], ["multiple", "OBSERVATION_MODIFIER", 47, 55], ["substantial", "OBSERVATION_MODIFIER", 99, 110]]], ["To achieve the targets of the Paris agreement and avoid drastic global climate disruption, climate policies must deliver GHG emission reductions sustainably over decades of progress, which, in modern democratic societies, requires sustained political support.", [["drastic global climate disruption", "PROBLEM", 56, 89], ["sustained political support", "TREATMENT", 231, 258], ["climate disruption", "OBSERVATION", 71, 89]]], ["Public support for climate policies will be easier to maintain when the consumer costs of carbon pricing are moderate and the policy is seen to deliver cost savings to end-users, not primarily higher prices across the board.ConclusionIn the EU ETS, the potential to use these benefits is to a large extend still untapped.", [["carbon", "CHEMICAL", 90, 96], ["Public support", "TREATMENT", 0, 14], ["carbon pricing", "TREATMENT", 90, 104], ["large", "OBSERVATION_MODIFIER", 293, 298]]], ["The fundamental understanding that both the carbon price and the strategic use of revenues can help to achieve the EU\u2019s decarbonisation targets cost-effectively is, however, limited.", [["carbon", "CHEMICAL", 44, 50], ["the carbon price", "TREATMENT", 40, 56]]], ["Our assessment of the Member States\u2019 use of auctioning revenues shows that in 2017, 44.7% of total revenues are strategically invested for energy- and climate-related purposes, no more than 21.4% in energy efficiency programmes.ConclusionA recent assessment of Member States\u2019 National Energy and Climate Plans by the European Commission revealed that a majority of Member States needs to increase energy efficiency efforts in order to achieve the EU\u2019s energy and climate targets (European Commission 2019b).", [["Our assessment", "TEST", 0, 14]]], ["Further establishing the strategic use auctioning revenues requires a broader political and scientific debate on the EU ETS and its ability to reduce greenhouse gas emissions cost-effectively, including both the carbon price and carbon revenues.", [["carbon", "CHEMICAL", 212, 218], ["carbon", "CHEMICAL", 229, 235], ["carbon", "SIMPLE_CHEMICAL", 229, 235], ["greenhouse gas emissions", "PROBLEM", 150, 174], ["the carbon price", "TREATMENT", 208, 224], ["carbon revenues", "TREATMENT", 229, 244]]]], "d8af2e829ede411d11c015c64e252201be6f1c5a": [["IntroductionCoronaviruses have a large, positive-sense, RNA genome of about 28 kb.", [["Coronaviruses", "GENE_OR_GENE_PRODUCT", 12, 25], ["Coronaviruses", "PROTEIN", 12, 25], ["RNA genome", "DNA", 56, 66], ["large", "OBSERVATION_MODIFIER", 33, 38]]], ["Full-length and multiple subgenomic mRNAs are expressed within infected cells, and these encode the structural and non-structural proteins of the virus (see Brian and Baric, 2005) .", [["cells", "ANATOMY", 72, 77], ["cells", "CELL", 72, 77], ["subgenomic mRNAs", "RNA", 25, 41], ["infected cells", "CELL_TYPE", 63, 77], ["structural and non-structural proteins", "PROTEIN", 100, 138], ["multiple subgenomic mRNAs", "PROBLEM", 16, 41], ["multiple", "OBSERVATION_MODIFIER", 16, 24], ["subgenomic mRNAs", "OBSERVATION", 25, 41], ["infected cells", "OBSERVATION", 63, 77], ["non-structural proteins", "OBSERVATION", 115, 138]]], ["The virus particles include the spike (S) protein, the envelope (E) protein, the membrane (M) protein and the nucleocapsid (N) protein.", [["membrane", "ANATOMY", 81, 89], ["envelope (E)", "GENE_OR_GENE_PRODUCT", 55, 67], ["membrane", "CELLULAR_COMPONENT", 81, 89], ["nucleocapsid (N)", "GENE_OR_GENE_PRODUCT", 110, 126], ["spike (S) protein", "PROTEIN", 32, 49], ["envelope (E) protein", "PROTEIN", 55, 75], ["membrane (M) protein", "PROTEIN", 81, 101], ["nucleocapsid (N) protein", "PROTEIN", 110, 134], ["The virus particles", "PROBLEM", 0, 19], ["the envelope (E) protein", "TEST", 51, 75], ["protein", "TEST", 94, 101], ["the nucleocapsid (N) protein", "TEST", 106, 134], ["virus particles", "OBSERVATION", 4, 19], ["spike", "OBSERVATION_MODIFIER", 32, 37]]], ["The spike protein is exposed on the virus surface and gives the virus particles their characteristic morphology, and it is also important for inducing neutralizing antibodies (Song and Park, 2012) .IntroductionSeveral different porcine coronaviruses have been characterized including transmissible gastroenteritis virus (TGEV) and porcine epidemic diarrhoea virus (PEDV).", [["surface", "ANATOMY", 42, 49], ["transmissible gastroenteritis virus", "DISEASE", 284, 319], ["porcine epidemic diarrhoea virus", "DISEASE", 331, 363], ["porcine", "ORGANISM", 228, 235], ["coronaviruses", "ORGANISM", 236, 249], ["transmissible gastroenteritis virus", "ORGANISM", 284, 319], ["TGEV", "ORGANISM", 321, 325], ["porcine epidemic diarrhoea virus", "ORGANISM", 331, 363], ["PEDV", "CANCER", 365, 369], ["spike protein", "PROTEIN", 4, 17], ["neutralizing antibodies", "PROTEIN", 151, 174], ["transmissible gastroenteritis virus", "SPECIES", 284, 319], ["TGEV", "SPECIES", 321, 325], ["porcine epidemic diarrhoea virus", "SPECIES", 331, 363], ["porcine coronaviruses", "SPECIES", 228, 249], ["transmissible gastroenteritis virus", "SPECIES", 284, 319], ["TGEV", "SPECIES", 321, 325], ["porcine epidemic diarrhoea virus", "SPECIES", 331, 363], ["PEDV", "SPECIES", 365, 369], ["The spike protein", "PROBLEM", 0, 17], ["the virus surface", "TREATMENT", 32, 49], ["the virus", "PROBLEM", 60, 69], ["Several different porcine coronaviruses", "PROBLEM", 210, 249], ["transmissible gastroenteritis virus (TGEV", "PROBLEM", 284, 325], ["porcine epidemic diarrhoea virus", "PROBLEM", 331, 363], ["virus", "OBSERVATION", 64, 69], ["morphology", "OBSERVATION_MODIFIER", 101, 111], ["porcine coronaviruses", "OBSERVATION", 228, 249], ["transmissible", "OBSERVATION_MODIFIER", 284, 297], ["gastroenteritis", "OBSERVATION", 298, 313], ["porcine", "OBSERVATION_MODIFIER", 331, 338], ["epidemic", "OBSERVATION_MODIFIER", 339, 347]]], ["These viruses each replicate within the intestine and cause clinical disease, including diarrhoea and vomiting, that can lead to severe dehydration in young piglets and consequently high levels of mortality (Stevenson et al., 2013) .IntroductionInfections by PEDV were first recognized in Europe in the 1970s, and then, the virus spread widely within Europe and to Asia (Jung and Saif, 2015; Lee, 2015) .", [["intestine", "ANATOMY", 40, 49], ["diarrhoea", "DISEASE", 88, 97], ["vomiting", "DISEASE", 102, 110], ["dehydration", "DISEASE", 136, 147], ["Infections", "DISEASE", 245, 255], ["intestine", "ORGAN", 40, 49], ["piglets", "ORGANISM", 157, 164], ["PEDV", "GENE_OR_GENE_PRODUCT", 259, 263], ["piglets", "SPECIES", 157, 164], ["PEDV", "SPECIES", 259, 263], ["These viruses", "PROBLEM", 0, 13], ["clinical disease", "PROBLEM", 60, 76], ["diarrhoea", "PROBLEM", 88, 97], ["vomiting", "PROBLEM", 102, 110], ["severe dehydration in young piglets", "PROBLEM", 129, 164], ["IntroductionInfections", "PROBLEM", 233, 255], ["PEDV", "PROBLEM", 259, 263], ["the virus spread", "PROBLEM", 320, 336], ["viruses", "OBSERVATION", 6, 13], ["intestine", "ANATOMY", 40, 49], ["severe", "OBSERVATION_MODIFIER", 129, 135], ["dehydration", "OBSERVATION", 136, 147], ["high levels", "OBSERVATION_MODIFIER", 182, 193], ["Infections", "OBSERVATION", 245, 255]]], ["The incidence of the disease declined in Europe in the late 1980s and 1990s but persisted within Asia.", [["the disease", "PROBLEM", 17, 28], ["disease", "OBSERVATION", 21, 28]]], ["The occurrence of disease attributed to TGEV infection within Europe also declined; this was coincident with the spread of another porcine coronavirus, porcine respiratory coronavirus (PRCV), which is closely related to TGEV (but does not cause apparent disease) and acted like a vaccine against it (Saif et al., 2012) .IntroductionNew strains of PEDV appeared in Asia from 2010 onwards, and in 2013, for the first time, PEDV infections occurred in the USA and spread to other countries in North, Central and Southern America.", [["TGEV infection", "DISEASE", 40, 54], ["porcine coronavirus", "DISEASE", 131, 150], ["porcine respiratory coronavirus", "DISEASE", 152, 183], ["PEDV", "CHEMICAL", 347, 351], ["infections", "DISEASE", 426, 436], ["TGEV", "ORGANISM", 40, 44], ["porcine coronavirus", "ORGANISM", 131, 150], ["porcine respiratory coronavirus", "ORGANISM", 152, 183], ["PRCV", "CANCER", 185, 189], ["TGEV", "ORGANISM", 220, 224], ["PEDV", "ORGANISM", 347, 351], ["porcine coronavirus", "SPECIES", 131, 150], ["porcine respiratory coronavirus", "SPECIES", 152, 183], ["TGEV", "SPECIES", 40, 44], ["porcine coronavirus", "SPECIES", 131, 150], ["porcine respiratory coronavirus", "SPECIES", 152, 183], ["PRCV", "SPECIES", 185, 189], ["TGEV", "SPECIES", 220, 224], ["PEDV", "SPECIES", 347, 351], ["PEDV", "SPECIES", 421, 425], ["disease", "PROBLEM", 18, 25], ["TGEV infection", "PROBLEM", 40, 54], ["another porcine coronavirus", "PROBLEM", 123, 150], ["porcine respiratory coronavirus", "PROBLEM", 152, 183], ["TGEV", "PROBLEM", 220, 224], ["apparent disease)", "PROBLEM", 245, 262], ["PEDV", "PROBLEM", 347, 351], ["PEDV infections", "PROBLEM", 421, 436], ["disease", "OBSERVATION", 18, 25], ["attributed to", "UNCERTAINTY", 26, 39], ["TGEV", "OBSERVATION_MODIFIER", 40, 44], ["infection", "OBSERVATION", 45, 54], ["respiratory coronavirus", "OBSERVATION", 160, 183], ["infections", "OBSERVATION", 426, 436], ["Central", "ANATOMY_MODIFIER", 497, 504]]], ["About 7 million piglets died as a result of the PEDV infections in the USA in a single year (Jung and Saif, 2015) .", [["infections", "DISEASE", 53, 63], ["piglets", "ORGANISM", 16, 23], ["piglets", "SPECIES", 16, 23], ["PEDV", "SPECIES", 48, 52], ["the PEDV infections", "PROBLEM", 44, 63], ["infections", "OBSERVATION", 53, 63]]], ["Infections by two distinct genogroups of PEDV (termed 1b and 2b, based on the Sgene sequences) have occurred in the USA, while the initial outbreaks of disease in Europe were caused by genogroup 1a (the CV777 strain is the prototype).", [["Infections", "DISEASE", 0, 10], ["PEDV", "GENE_OR_GENE_PRODUCT", 41, 45], ["genogroup 1a", "ORGANISM", 185, 197], ["PEDV", "DNA", 41, 45], ["Sgene sequences", "DNA", 78, 93], ["Infections", "PROBLEM", 0, 10], ["PEDV", "PROBLEM", 41, 45], ["the Sgene sequences", "TEST", 74, 93], ["disease", "PROBLEM", 152, 159], ["distinct", "OBSERVATION_MODIFIER", 18, 26], ["genogroups", "OBSERVATION", 27, 37], ["PEDV", "OBSERVATION", 41, 45], ["disease", "OBSERVATION", 152, 159]]], ["It seems that the genogroup 1b viruses, also referred to as 'INDEL' strains, are less virulent than the genogroup 2b viruses (Wang et al., 2014) , but the relationship between virus genotype and clinical disease is still not fully understood and probably dependent on a number of factors (EFSA, 2014) .", [["genogroup 1b viruses", "ORGANISM", 18, 38], ["genogroup 2b viruses", "ORGANISM", 104, 124], ["genogroup 1b viruses", "SPECIES", 18, 38], ["genogroup 2b viruses", "SPECIES", 104, 124], ["the genogroup 1b viruses", "PROBLEM", 14, 38], ["'INDEL' strains", "PROBLEM", 60, 75], ["virus genotype", "PROBLEM", 176, 190], ["clinical disease", "PROBLEM", 195, 211], ["genogroup 1b viruses", "OBSERVATION", 18, 38], ["less", "OBSERVATION_MODIFIER", 81, 85], ["virulent", "OBSERVATION_MODIFIER", 86, 94]]], ["Recently, new cases of PEDV infection have occurred in multiple European countries including Germany, Italy, France, Portugal, Austria and Slovenia (see Grasland et al., 2015; Hanke et al., 2015; Mesquita et al., 2015; Steinrigl et al., 2015; Boniotti et al., 2016; Toplak et al., 2016; ) .", [["PEDV infection", "DISEASE", 23, 37], ["PEDV", "ORGANISM", 23, 27], ["PEDV", "SPECIES", 23, 27], ["PEDV infection", "PROBLEM", 23, 37], ["PEDV", "OBSERVATION_MODIFIER", 23, 27], ["infection", "OBSERVATION", 28, 37]]], ["These new cases have all been caused by viruses within genogroup 1b.", [["genogroup 1b", "ORGANISM", 55, 67], ["viruses", "PROBLEM", 40, 47], ["viruses", "OBSERVATION", 40, 47]]], ["It should be noted that no vaccination against PEDV is used within Europe and thus no vaccine strains of PEDV are in circulation.IntroductionThe re-emergence of PEDV infections in Europe (since 2014) has encouraged the search for these viruses in archived faecal and intestinal samples collected previously from pigs.", [["faecal", "ANATOMY", 256, 262], ["intestinal samples", "ANATOMY", 267, 285], ["PEDV", "CHEMICAL", 47, 51], ["PEDV", "CHEMICAL", 105, 109], ["PEDV infections", "DISEASE", 161, 176], ["PEDV", "ORGANISM", 47, 51], ["PEDV", "SIMPLE_CHEMICAL", 105, 109], ["PEDV", "ORGANISM", 161, 165], ["faecal", "ORGANISM_SUBSTANCE", 256, 262], ["intestinal samples", "CANCER", 267, 285], ["pigs", "ORGANISM", 312, 316], ["pigs", "SPECIES", 312, 316], ["PEDV", "SPECIES", 47, 51], ["PEDV", "SPECIES", 105, 109], ["PEDV", "SPECIES", 161, 165], ["pigs", "SPECIES", 312, 316], ["vaccination", "TREATMENT", 27, 38], ["PEDV", "PROBLEM", 47, 51], ["vaccine strains", "TREATMENT", 86, 101], ["PEDV", "PROBLEM", 105, 109], ["PEDV infections", "PROBLEM", 161, 176], ["these viruses", "PROBLEM", 230, 243], ["intestinal samples", "TEST", 267, 285], ["PEDV", "OBSERVATION_MODIFIER", 161, 165], ["infections", "OBSERVATION", 166, 176], ["intestinal", "ANATOMY", 267, 277]]], ["From such analyses, Boniotti et al. (2016) identified a novel chimeric (recombinant) porcine coronavirus that was termed a swine enteric coronavirus (SeCoV), which circulated in Italy from 2009 until 2012 and then apparently disappeared.", [["enteric coronavirus", "DISEASE", 129, 148], ["porcine coronavirus", "ORGANISM", 85, 104], ["swine enteric coronavirus", "ORGANISM", 123, 148], ["SeCoV", "ORGANISM", 150, 155], ["porcine coronavirus", "SPECIES", 85, 104], ["swine enteric coronavirus", "SPECIES", 123, 148], ["porcine coronavirus", "SPECIES", 85, 104], ["swine enteric coronavirus", "SPECIES", 123, 148], ["SeCoV", "SPECIES", 150, 155], ["a novel chimeric (recombinant) porcine coronavirus", "PROBLEM", 54, 104], ["a swine enteric coronavirus", "PROBLEM", 121, 148]]], ["Most of the genome of this virus is derived from TGEV, but the S-gene, encoding the spike protein, is derived from PEDV.", [["genome", "CELLULAR_COMPONENT", 12, 18], ["TGEV", "ORGANISM", 49, 53], ["PEDV", "GENE_OR_GENE_PRODUCT", 115, 119], ["S-gene", "DNA", 63, 69], ["spike protein", "PROTEIN", 84, 97], ["PEDV", "PROTEIN", 115, 119], ["TGEV", "SPECIES", 49, 53], ["this virus", "PROBLEM", 22, 32], ["TGEV", "PROBLEM", 49, 53], ["PEDV", "PROBLEM", 115, 119]]], ["Similarly, in Germany, stored faecal samples from herds showing typical symptoms of PEDV infection were also analysed and a sample from 2012 was shown to contain coronavirus RNA with a genomic sequence that is 99.5% identical to the chimeric SeCoV described from Italy (Akimkin et al., 2016) .", [["faecal samples", "ANATOMY", 30, 44], ["PEDV infection", "DISEASE", 84, 98], ["faecal samples", "MULTI-TISSUE_STRUCTURE", 30, 44], ["coronavirus", "ORGANISM", 162, 173], ["SeCoV", "GENE_OR_GENE_PRODUCT", 242, 247], ["coronavirus RNA", "RNA", 162, 177], ["chimeric SeCoV", "PROTEIN", 233, 247], ["PEDV", "SPECIES", 84, 88], ["faecal samples", "TEST", 30, 44], ["herds", "PROBLEM", 50, 55], ["typical symptoms", "PROBLEM", 64, 80], ["PEDV infection", "PROBLEM", 84, 98], ["a sample", "TEST", 122, 130], ["coronavirus RNA", "PROBLEM", 162, 177], ["a genomic sequence", "TEST", 183, 201], ["PEDV infection", "OBSERVATION", 84, 98], ["coronavirus RNA", "OBSERVATION", 162, 177]]], ["The recombination junction on the 3 0 -side of the S-gene appears to be slightly different in these two virus strains, but the upstream junction is identical.", [["upstream junction", "ANATOMY", 127, 144], ["3 0 -side", "DNA", 34, 43], ["S-gene", "DNA", 51, 57], ["The recombination junction", "TREATMENT", 0, 26], ["slightly different", "PROBLEM", 72, 90], ["these two virus strains", "PROBLEM", 94, 117], ["recombination junction", "OBSERVATION", 4, 26], ["appears to be", "UNCERTAINTY", 58, 71], ["slightly", "OBSERVATION_MODIFIER", 72, 80], ["different", "OBSERVATION_MODIFIER", 81, 90], ["two", "OBSERVATION_MODIFIER", 100, 103], ["virus strains", "OBSERVATION", 104, 117]]], ["No isolation of the SeCoV has been reported, so far, and no serological analysis has been performed on the infected herds in Italy and Germany as the SeCoV has been detected retrospectively.", [["SeCoV", "CHEMICAL", 20, 25], ["SeCoV", "GENE_OR_GENE_PRODUCT", 20, 25], ["SeCoV", "DNA", 20, 25], ["serological analysis", "TEST", 60, 80], ["isolation", "OBSERVATION", 3, 12]]], ["As both the S protein and the N protein are immunogenic, then it is clear that serological assays for the presence of antibodies to PEDV and TGEV could give apparently discordant results if an infection by SeCoV is present.", [["infection", "DISEASE", 193, 202], ["PEDV", "GENE_OR_GENE_PRODUCT", 132, 136], ["TGEV", "ORGANISM", 141, 145], ["SeCoV", "GENE_OR_GENE_PRODUCT", 206, 211], ["S protein", "PROTEIN", 12, 21], ["N protein", "PROTEIN", 30, 39], ["antibodies", "PROTEIN", 118, 128], ["SeCoV", "PROTEIN", 206, 211], ["PEDV", "SPECIES", 132, 136], ["TGEV", "SPECIES", 141, 145], ["the S protein", "TEST", 8, 21], ["serological assays", "TEST", 79, 97], ["antibodies", "PROBLEM", 118, 128], ["PEDV", "PROBLEM", 132, 136], ["TGEV", "PROBLEM", 141, 145], ["an infection", "PROBLEM", 190, 202], ["infection", "OBSERVATION", 193, 202]]], ["We describe here the characterization of a new chimeric SeCoV identified in samples from clinically diseased pigs in Central Eastern Europe and have, for the first time, performed a serological analysis of a SeCoV-infected herd.Material and MethodsDetection of viral RNA by RT-qPCR and sequence determination The presence of viral RNA in samples was determined by RT-qPCR.", [["samples", "ANATOMY", 76, 83], ["samples", "ANATOMY", 338, 345], ["SeCoV", "CHEMICAL", 208, 213], ["SeCoV", "GENE_OR_GENE_PRODUCT", 56, 61], ["samples", "CANCER", 76, 83], ["pigs", "ORGANISM", 109, 113], ["SeCoV", "GENE_OR_GENE_PRODUCT", 208, 213], ["herd", "ORGANISM", 223, 227], ["samples", "CANCER", 338, 345], ["chimeric SeCoV", "PROTEIN", 47, 61], ["viral RNA", "RNA", 261, 270], ["viral RNA", "RNA", 325, 334], ["pigs", "SPECIES", 109, 113], ["SeCoV", "SPECIES", 208, 213], ["a new chimeric SeCoV", "PROBLEM", 41, 61], ["a serological analysis", "TEST", 180, 202], ["viral RNA", "PROBLEM", 261, 270], ["qPCR", "TEST", 277, 281], ["sequence determination", "TEST", 286, 308], ["viral RNA in samples", "PROBLEM", 325, 345], ["qPCR", "TEST", 367, 371], ["viral RNA", "OBSERVATION", 261, 270], ["viral RNA", "OBSERVATION", 325, 334]]], ["Briefly, RNA was extracted from faecal samples using a ZR soil/faecal RNA MicroPrep kit (Zymo Research, Irvine, CA, USA).", [["faecal samples", "ANATOMY", 32, 46], ["faecal samples", "ORGANISM_SUBSTANCE", 32, 46], ["faecal", "ORGANISM_SUBSTANCE", 63, 69], ["faecal samples", "TEST", 32, 46], ["a ZR soil", "TREATMENT", 53, 62], ["faecal RNA", "TREATMENT", 63, 73]]], ["Samples were initially analysed using a multiplexed PEDV/TGEV virotype RT-qPCR assay (Qiagen, Hilden, Germany) that separately detects the S-gene of PEDV and TGEV.", [["Samples", "ANATOMY", 0, 7], ["TGEV", "ORGANISM", 57, 61], ["PEDV", "GENE_OR_GENE_PRODUCT", 149, 153], ["TGEV", "ORGANISM", 158, 162], ["S-gene", "DNA", 139, 145], ["TGEV", "SPECIES", 158, 162], ["TGEV", "SPECIES", 57, 61], ["PEDV", "SPECIES", 149, 153], ["TGEV", "SPECIES", 158, 162], ["Samples", "TEST", 0, 7], ["a multiplexed PEDV/TGEV virotype RT", "TREATMENT", 38, 73], ["PEDV", "PROBLEM", 149, 153], ["TGEV", "PROBLEM", 158, 162]]], ["Subsequently, two samples (42845 and 42848), that scored positive in the PEDV assay, were tested using individual assays specific for the PEDV N-gene (as described by Lohse et al., 2016) , the TGEV/PRCV N-gene and the TGEV S-gene (Kim et al., 2007) using a one-step RT-PCR kit (Qiagen).", [["samples", "ANATOMY", 18, 25], ["PEDV N", "GENE_OR_GENE_PRODUCT", 138, 144], ["TGEV", "ORGANISM", 193, 197], ["PRCV N", "GENE_OR_GENE_PRODUCT", 198, 204], ["TGEV", "ORGANISM", 218, 222], ["PEDV N-gene", "DNA", 138, 149], ["TGEV/PRCV N-gene", "DNA", 193, 209], ["TGEV S-gene", "DNA", 218, 229], ["TGEV", "SPECIES", 193, 197], ["TGEV", "SPECIES", 193, 197], ["TGEV", "SPECIES", 218, 222], ["two samples", "TEST", 14, 25], ["the PEDV assay", "TEST", 69, 83], ["individual assays", "TEST", 103, 120], ["the TGEV/PRCV N", "TREATMENT", 189, 204], ["the TGEV S", "TEST", 214, 224], ["a one-step RT-PCR kit", "TREATMENT", 255, 276]]], ["The assays were run for 40 cycles.Material and MethodsIn conventional RT-PCRs (initially targeting the S-gene and then adjacent sequences), primers (see Table 1 ) were used to produce amplicons that were gel-purified and sequenced with a BigDye Terminator v. 3.1 Cycle Sequencing Kit and an ABI PRISM 3500 DNA Analyzer (Applied Biosystems, Foster City, CA, USA).", [["DNA", "CELLULAR_COMPONENT", 306, 309], ["S-gene", "DNA", 103, 109], ["The assays", "TEST", 0, 10], ["Material", "TEST", 34, 42], ["MethodsIn conventional RT-PCRs", "TREATMENT", 47, 77], ["amplicons", "TREATMENT", 184, 193], ["a BigDye Terminator v.", "TREATMENT", 236, 258], ["Sequencing Kit", "TEST", 269, 283], ["an ABI PRISM", "TEST", 288, 300], ["DNA Analyzer", "TEST", 306, 318]]], ["Sequences from overlapping amplicons were assembled using Seq Man Pro and analysed using Geneious \u00e2 6.1.7 and MUSCLE (using http://www.ebi.ac.uk/Tools).", [["overlapping amplicons", "TEST", 15, 36], ["Geneious", "TEST", 89, 97], ["MUSCLE", "ANATOMY", 110, 116]]], ["Alignments generated were edited manually.Detection of anti-coronavirus antibodies in field seraAn 'in-house' blocking ELISA, using PEDV-infected cell harvest as antigen, as described previously (Lohse et al., 2016) , and a commercial PEDV N protein-specific indirect ELISA (Biovet, Quebec, Canada) were used to detect anti-PEDV antibodies in pig sera.", [["cell", "ANATOMY", 146, 150], ["sera", "ANATOMY", 347, 351], ["PEDV", "CHEMICAL", 132, 136], ["anti-coronavirus antibodies", "GENE_OR_GENE_PRODUCT", 55, 82], ["cell", "CELL", 146, 150], ["anti-PEDV antibodies", "GENE_OR_GENE_PRODUCT", 319, 339], ["pig", "ORGANISM", 343, 346], ["sera", "ORGANISM_SUBSTANCE", 347, 351], ["anti-coronavirus antibodies", "PROTEIN", 55, 82], ["PEDV", "PROTEIN", 132, 136], ["PEDV N protein", "PROTEIN", 235, 249], ["anti-PEDV antibodies", "PROTEIN", 319, 339], ["pig", "SPECIES", 343, 346], ["PEDV", "SPECIES", 235, 239], ["anti-PEDV", "SPECIES", 319, 328], ["pig", "SPECIES", 343, 346], ["anti-coronavirus antibodies", "PROBLEM", 55, 82], ["PEDV", "PROBLEM", 132, 136], ["infected cell harvest", "TREATMENT", 137, 158], ["a commercial PEDV N protein", "TEST", 222, 249], ["infected cell harvest", "OBSERVATION", 137, 158]]], ["Antibodies to TGEV and PRCV were detected using a commercial blocking ELISA (Svanovir TGEV/PRCV-Ab assay; Svanova, Uppsala, Sweden).Results and DiscussionVery recently, in late 2015, outbreaks of PED have been described in Slovenia (Toplak et al., 2016) .", [["PED", "DISEASE", 196, 199], ["TGEV", "ORGANISM", 14, 18], ["PRCV", "GENE_OR_GENE_PRODUCT", 23, 27], ["TGEV", "ORGANISM", 86, 90], ["PRCV", "PROTEIN", 23, 27], ["TGEV", "SPECIES", 14, 18], ["TGEV", "SPECIES", 14, 18], ["PRCV", "SPECIES", 23, 27], ["TGEV", "SPECIES", 86, 90], ["Antibodies", "TEST", 0, 10], ["PRCV", "TREATMENT", 23, 27], ["a commercial blocking ELISA", "TREATMENT", 48, 75], ["Svanovir TGEV", "TREATMENT", 77, 90], ["Ab assay", "TREATMENT", 96, 104], ["Svanova", "TREATMENT", 106, 113]]], ["In February 2016, a large pig herd (30-130 kg pigs), also within Central Eastern Europe (CEE), experienced severe clinical disease in all age groups, including diarrhoea and vomiting with poor growth performance and about 10% mortality; hence, the occurrence of PEDV infection was suspected.", [["diarrhoea", "DISEASE", 160, 169], ["vomiting", "DISEASE", 174, 182], ["PEDV", "CHEMICAL", 262, 266], ["infection", "DISEASE", 267, 276], ["pig", "ORGANISM", 26, 29], ["herd", "ORGANISM_SUBDIVISION", 30, 34], ["pigs", "ORGANISM", 46, 50], ["PEDV", "ORGANISM", 262, 266], ["pig", "SPECIES", 26, 29], ["pigs", "SPECIES", 46, 50], ["pig", "SPECIES", 26, 29], ["PEDV", "SPECIES", 262, 266], ["a large pig herd", "TREATMENT", 18, 34], ["severe clinical disease in all age groups", "PROBLEM", 107, 148], ["diarrhoea", "PROBLEM", 160, 169], ["vomiting", "PROBLEM", 174, 182], ["poor growth performance", "PROBLEM", 188, 211], ["PEDV infection", "PROBLEM", 262, 276], ["large", "OBSERVATION_MODIFIER", 20, 25], ["Central", "ANATOMY_MODIFIER", 65, 72], ["severe", "OBSERVATION_MODIFIER", 107, 113], ["disease", "OBSERVATION", 123, 130], ["PEDV", "OBSERVATION_MODIFIER", 262, 266], ["infection", "OBSERVATION", 267, 276]]], ["Indeed, initial testing of the faecal samples from the diseased pigs using a commercial PEDV/TGEV RT-qPCR assay (targeting the S-genes) identified two samples (42845 ad 42848) as PEDV positive but TGEV negative (see Table 2 ).", [["faecal samples", "ANATOMY", 31, 45], ["samples", "ANATOMY", 151, 158], ["PEDV", "CHEMICAL", 88, 92], ["faecal samples", "ORGANISM_SUBSTANCE", 31, 45], ["pigs", "ORGANISM", 64, 68], ["TGEV", "ORGANISM", 93, 97], ["TGEV", "ORGANISM", 197, 201], ["S-genes", "DNA", 127, 134], ["pigs", "SPECIES", 64, 68], ["pigs", "SPECIES", 64, 68], ["PEDV", "SPECIES", 88, 92], ["TGEV", "SPECIES", 93, 97], ["TGEV", "SPECIES", 197, 201], ["the faecal samples", "TEST", 27, 45], ["the diseased pigs", "TREATMENT", 51, 68], ["a commercial PEDV/TGEV RT-qPCR assay", "TEST", 75, 111], ["PEDV", "PROBLEM", 179, 183], ["TGEV", "TEST", 197, 201]]], ["As part of a process to characterize further the presumed PEDV, the extracted RNA from these two samples was then analysed using a collection of other RT-qPCR assays (see Table 2 ).", [["samples", "ANATOMY", 97, 104], ["PEDV", "CANCER", 58, 62], ["PEDV", "DNA", 58, 62], ["PEDV", "PROBLEM", 58, 62], ["the extracted RNA", "PROBLEM", 64, 81], ["other RT-qPCR assays", "TEST", 145, 165], ["PEDV", "OBSERVATION", 58, 62]]], ["Unexpectedly, using an assay specific for the N-gene of PEDV (that recognizes genogroups 1 and 2, as described by Lohse et al., 2016) , the samples were scored as negative for PEDV.", [["samples", "ANATOMY", 140, 147], ["PEDV", "GENE_OR_GENE_PRODUCT", 56, 60], ["N-gene", "DNA", 46, 52], ["PEDV", "DNA", 56, 60], ["PEDV", "PROTEIN", 176, 180], ["PEDV", "SPECIES", 56, 60], ["PEDV", "SPECIES", 176, 180], ["an assay", "TEST", 20, 28], ["PEDV", "PROBLEM", 56, 60], ["the samples", "TEST", 136, 147], ["PEDV", "PROBLEM", 176, 180]]], ["In contrast, in another assay that detects both TGEV and PRCV (targeted at the N-gene, Kim et al., 2007) , the samples scored positive but they scored negative in a TGEV-specific assay (targeted at the TGEV S-gene, Kim et al., 2007) .", [["samples", "ANATOMY", 111, 118], ["TGEV", "ORGANISM", 48, 52], ["PRCV", "GENE_OR_GENE_PRODUCT", 57, 61], ["TGEV", "ORGANISM", 165, 169], ["N-gene", "DNA", 79, 85], ["TGEV S-gene", "DNA", 202, 213], ["TGEV", "SPECIES", 48, 52], ["PRCV", "SPECIES", 57, 61], ["TGEV", "SPECIES", 165, 169], ["another assay", "TEST", 16, 29], ["PRCV", "TEST", 57, 61], ["the samples", "TEST", 107, 118], ["both TGEV", "OBSERVATION", 43, 52]]], ["Thus, the results (Table 2) were not consistent with the presence of either PEDV or TGEV and therefore did not provide an explanation for the clinical disease.Results and DiscussionIn a conventional RT-PCR, using primers that are specific for the PEDV S-gene (see Table 1 ), an amplicon was produced (ca.", [["TGEV", "ORGANISM", 84, 88], ["PEDV S", "GENE_OR_GENE_PRODUCT", 247, 253], ["PEDV S-gene", "DNA", 247, 258], ["PEDV", "SPECIES", 76, 80], ["TGEV", "SPECIES", 84, 88], ["PEDV", "PROBLEM", 76, 80], ["TGEV", "PROBLEM", 84, 88], ["the clinical disease", "PROBLEM", 138, 158], ["a conventional RT-PCR", "TREATMENT", 184, 205], ["primers", "TREATMENT", 213, 220], ["the PEDV S", "TEST", 243, 253], ["an amplicon", "TREATMENT", 275, 286], ["not consistent with", "UNCERTAINTY", 33, 52], ["PEDV", "OBSERVATION", 76, 80]]], ["1600 bp) from sample 42845 (which had the lowest Ct for PEDV in the S-gene-specific assay) and then sequenced.", [["sample 42845", "ANATOMY", 14, 26], ["PEDV", "DNA", 56, 60], ["S-gene", "DNA", 68, 74], ["bp", "TEST", 5, 7], ["sample", "TEST", 14, 20], ["the lowest Ct", "TEST", 38, 51], ["PEDV", "PROBLEM", 56, 60]]], ["The sequence generated was found (using BLAST) to be most closely related to the S-gene from the recently described SeCoV (SeCoV/Italy/213306/2009, Acc.", [["SeCoV", "GENE_OR_GENE_PRODUCT", 116, 121], ["S-gene", "DNA", 81, 87], ["Acc", "DNA", 148, 151]]], ["Using additional primers (Table 1) , designed from known porcine coronavirus sequences, in further RT-PCRs, some nine, overlapping, amplicons were produced.", [["porcine coronavirus", "ORGANISM", 57, 76], ["porcine coronavirus sequences", "DNA", 57, 86], ["RT-PCRs", "DNA", 99, 106], ["porcine coronavirus", "SPECIES", 57, 76], ["porcine coronavirus", "SPECIES", 57, 76], ["known porcine coronavirus sequences", "PROBLEM", 51, 86], ["further RT-PCRs", "TEST", 91, 106], ["amplicons", "TREATMENT", 132, 141]]], ["Using Sanger sequencing, a total of ca.", [["Sanger sequencing", "TEST", 6, 23]]], ["9050 nt of contiguous sequence, upstream from the poly(A) tail, was determined (GenBank, Acc.", [["poly(A) tail", "GENE_OR_GENE_PRODUCT", 50, 62], ["9050 nt of contiguous sequence", "DNA", 0, 30], ["poly(A) tail", "DNA", 50, 62], ["Acc", "DNA", 89, 92], ["tail", "ANATOMY", 58, 62]]], ["KX689261).", [["KX689261", "CHEMICAL", 0, 8], ["KX689261", "CHEMICAL", 0, 8], ["KX689261", "SIMPLE_CHEMICAL", 0, 8]]], ["Using BLAST, the consensus sequence of this 'contig' proved to be very closely related (99% identical, across 9016 nt) to the equivalent portion of the sequence of the chimeric SeCoV from Italy (Boniotti et al., 2016) and 98% identical (across 8957 nt) to the closely related, but distinct, virus from Germany (Akimkin et al., 2016; Acc.", [["consensus sequence", "DNA", 17, 35], ["9016 nt", "DNA", 110, 117], ["chimeric SeCoV", "PROTEIN", 168, 182], ["this 'contig'", "PROBLEM", 39, 52]]], ["LT545990) .", [["LT545990", "CHEMICAL", 0, 8], ["LT545990", "CHEMICAL", 0, 8], ["LT545990", "SIMPLE_CHEMICAL", 0, 8]]], ["Thus, on this basis, a third SeCoV has been identified, from CEE, and is termed here the SeCoV/CEE/42845/2016 (but abbreviated to SeCoV/CEE/16 subsequently).", [["SeCoV", "CHEMICAL", 29, 34], ["CEE", "CHEMICAL", 61, 64], ["CEE", "CHEMICAL", 95, 98], ["SeCoV", "GENE_OR_GENE_PRODUCT", 29, 34], ["CEE", "SIMPLE_CHEMICAL", 61, 64], ["SeCoV", "DNA", 29, 34], ["SeCoV", "PROTEIN", 130, 135], ["SeCoV/CEE", "TREATMENT", 130, 139]]], ["For comparison, this SeCoV/CEE/16 sequence was 92% identical (across the 4234 nt including the S-gene and putative 3a coding sequence) to the corresponding region of the prototypic CV777 strain of PEDV (genogroup 1a, Acc.", [["SeCoV", "GENE_OR_GENE_PRODUCT", 21, 26], ["CV777 strain", "ORGANISM", 181, 193], ["PEDV (genogroup 1a", "ORGANISM", 197, 215], ["SeCoV/CEE/16 sequence", "DNA", 21, 42], ["4234 nt", "DNA", 73, 80], ["S-gene", "DNA", 95, 101], ["Acc", "DNA", 217, 220], ["PEDV", "SPECIES", 197, 201], ["this SeCoV/CEE/16 sequence", "TEST", 16, 42], ["PEDV", "PROBLEM", 197, 201]]], ["AF353511) and 91% identical in the same region to genogroup 1b PED viruses (e.g. OH851, Acc.", [["AF353511", "CHEMICAL", 0, 8], ["genogroup 1b", "OBSERVATION", 50, 62], ["viruses", "OBSERVATION", 67, 74]]], ["KJ399978 that is 99.5% identical to recent European strains of PEDV, see Hanke et al., 2015) .", [["KJ399978", "CHEMICAL", 0, 8], ["KJ399978", "CHEMICAL", 0, 8], ["PEDV", "PROBLEM", 63, 67]]], ["This partial SeCoV/CEE/16 sequence contains a region that is 96% identical (across some 3551nt) to the TGEV TS strain (Acc.", [["CEE", "CHEMICAL", 19, 22], ["SeCoV", "GENE_OR_GENE_PRODUCT", 13, 18], ["TGEV TS strain", "ORGANISM", 103, 117], ["SeCoV/CEE/16 sequence", "DNA", 13, 34], ["TGEV TS strain", "SPECIES", 103, 117], ["This partial SeCoV/CEE/16 sequence", "TREATMENT", 0, 34], ["the TGEV TS strain", "PROBLEM", 99, 117]]], ["DQ201447), but this match is to the region downstream of the S and 3a sequences but includes the M-and N-genes (see Fig. 1a ).", [["DQ201447", "CHEMICAL", 0, 8], ["S and 3a sequences", "DNA", 61, 79], ["M-and N-genes", "DNA", 97, 110], ["the S and 3a sequences", "TEST", 57, 79], ["the M", "TEST", 93, 98]]], ["The level of sequence identity within the S-gene to PEDV is clearly high (\u226591%), but the sequences are significantly diverged from both the genogroup 1a and genogroup 1b sequences known to have been in Europe, and thus, the actual parental PEDV responsible for donating the S-gene portion of the SeCoVs is not yet apparent.", [["PEDV", "CHEMICAL", 240, 244], ["PEDV", "GENE_OR_GENE_PRODUCT", 52, 56], ["PEDV", "GENE_OR_GENE_PRODUCT", 240, 244], ["SeCoVs", "GENE_OR_GENE_PRODUCT", 296, 302], ["S-gene", "DNA", 42, 48], ["PEDV", "DNA", 52, 56], ["genogroup 1a and genogroup 1b sequences", "DNA", 140, 179], ["PEDV", "DNA", 240, 244], ["S-gene portion", "DNA", 274, 288], ["SeCoVs", "DNA", 296, 302], ["PEDV", "PROBLEM", 52, 56], ["the sequences", "TEST", 85, 98], ["high", "OBSERVATION_MODIFIER", 68, 72], ["not yet apparent", "UNCERTAINTY", 306, 322]]], ["Furthermore, there are numerous sequence differences between the three different SeCoVs (Fig. 1b) .", [["SeCoVs", "PROTEIN", 81, 87], ["numerous sequence differences", "PROBLEM", 23, 52], ["numerous", "OBSERVATION_MODIFIER", 23, 31]]], ["The sequence data (see Figures S1 and S2) showed that the recombination junctions in the SeCoV/ CEE/16 sequence match those reported for the SeCoV/ Italy/213306/2009 by Boniotti et al. (2016) .", [["SeCoV", "GENE_OR_GENE_PRODUCT", 89, 94], ["SeCoV/ CEE/16 sequence", "DNA", 89, 111], ["The sequence data", "TEST", 0, 17], ["the recombination junctions", "PROBLEM", 54, 81]]], ["The recombination event has resulted in the presence of the complete Sgene and a short putative 3a coding sequence mainly derived from the PEDV sequence within a TGEV backbone (it should be noted, however, that PEDV does not encode a separate 3a protein but does have a functional ORF 3).", [["Sgene", "GENE_OR_GENE_PRODUCT", 69, 74], ["PEDV", "GENE_OR_GENE_PRODUCT", 139, 143], ["TGEV", "ORGANISM", 162, 166], ["Sgene", "DNA", 69, 74], ["short putative 3a coding sequence", "DNA", 81, 114], ["PEDV sequence", "DNA", 139, 152], ["PEDV", "PROTEIN", 211, 215], ["ORF 3", "DNA", 281, 286], ["TGEV", "SPECIES", 162, 166], ["a short putative 3a coding sequence", "PROBLEM", 79, 114], ["the PEDV sequence", "TEST", 135, 152], ["a TGEV backbone", "TREATMENT", 160, 175], ["PEDV", "PROBLEM", 211, 215]]], ["In all three SeCoV sequences known, the 5 0 -recombination junction, upstream of the S-gene, appears to be the same [note the high level of sequence identity between TGEV(d)Putative 3a amino acid sequences The complete polyadenylated genome sequences of the SeCoV/ITL and SeCoV/GER are known (Akimkin et al., 2016; Boniotti et al., 2016) and about 9 kb from the 3 0 -terminus of the SeCoV/CEE genome has been determined.", [["amino acid", "CHEMICAL", 185, 195], ["CEE", "CHEMICAL", 389, 392], ["amino acid", "CHEMICAL", 185, 195], ["amino acid", "AMINO_ACID", 185, 195], ["SeCoV", "GENE_OR_GENE_PRODUCT", 258, 263], ["ITL", "GENE_OR_GENE_PRODUCT", 264, 267], ["SeCoV", "GENE_OR_GENE_PRODUCT", 272, 277], ["SeCoV", "GENE_OR_GENE_PRODUCT", 383, 388], ["SeCoV sequences", "DNA", 13, 28], ["5 0 -recombination junction", "DNA", 40, 67], ["S-gene", "DNA", 85, 91], ["amino acid sequences", "PROTEIN", 185, 205], ["polyadenylated genome sequences", "DNA", 219, 250], ["SeCoV", "DNA", 258, 263], ["ITL", "DNA", 264, 267], ["SeCoV", "DNA", 272, 277], ["GER", "DNA", 278, 281], ["3 0 -terminus", "DNA", 362, 375], ["SeCoV/CEE genome", "DNA", 383, 399], ["the 5 0 -recombination junction", "TREATMENT", 36, 67], ["a amino acid sequences", "TEST", 183, 205], ["SeCoV/GER", "TREATMENT", 272, 281], ["the SeCoV/CEE genome", "TREATMENT", 379, 399], ["polyadenylated genome", "OBSERVATION", 219, 240], ["CEE genome", "OBSERVATION", 389, 399]]], ["This region includes the coding regions for the S (spike) protein from PEDV (indicated in black) and the TGEV E (envelope), M (membrane) and N (nucleoprotein) ORFs indicated by open rectangles.", [["S (spike)", "GENE_OR_GENE_PRODUCT", 48, 57], ["PEDV", "GENE_OR_GENE_PRODUCT", 71, 75], ["TGEV E", "ORGANISM", 105, 111], ["coding regions", "DNA", 25, 39], ["S (spike) protein", "PROTEIN", 48, 65], ["PEDV", "PROTEIN", 71, 75], ["TGEV E (envelope), M (membrane) and N (nucleoprotein) ORFs", "DNA", 105, 163], ["TGEV", "SPECIES", 105, 109], ["TGEV", "SPECIES", 105, 109], ["the S (spike) protein", "PROBLEM", 44, 65], ["PEDV", "PROBLEM", 71, 75], ["the TGEV E", "TEST", 101, 111], ["M (membrane) and N (nucleoprotein) ORFs", "PROBLEM", 124, 163]]], ["Panel (b).", [["Panel", "TEST", 0, 5]]], ["Sequence differences within this 9 kb fragment between the three SeCoVs are indicated by black lines.", [["SeCoVs", "GENE_OR_GENE_PRODUCT", 65, 71], ["black lines", "CELL", 89, 100], ["9 kb fragment", "DNA", 33, 46], ["SeCoVs", "DNA", 65, 71], ["black lines", "CELL_LINE", 89, 100], ["Sequence differences", "PROBLEM", 0, 20], ["this 9 kb fragment", "PROBLEM", 28, 46], ["black lines", "PROBLEM", 89, 100], ["black lines", "OBSERVATION", 89, 100]]], ["The three sequences are >98% identical throughout this region.", [["The three sequences", "TEST", 0, 19]]], ["A short putative 3a protein coding region is present in each SeCoV, but the ORF is truncated by 9 nt in the SeCoV/GER sequence; this results in the predicted loss of the C-terminal 3 amino acids.", [["amino acids", "CHEMICAL", 183, 194], ["C", "CHEMICAL", 170, 171], ["amino acids", "CHEMICAL", 183, 194], ["SeCoV", "GENE_OR_GENE_PRODUCT", 61, 66], ["SeCoV", "GENE_OR_GENE_PRODUCT", 108, 113], ["amino acids", "AMINO_ACID", 183, 194], ["short putative 3a protein coding region", "DNA", 2, 41], ["SeCoV", "DNA", 61, 66], ["ORF", "DNA", 76, 79], ["SeCoV/GER sequence", "DNA", 108, 126], ["C-terminal 3 amino acids", "PROTEIN", 170, 194], ["A short putative 3a protein coding region", "PROBLEM", 0, 41], ["the ORF", "TEST", 72, 79], ["the C-terminal 3 amino acids", "TREATMENT", 166, 194]]], ["A deletion of 3 nt within the spike protein coding region of the SeCoV/ITL modifies the N-terminal region of that protein.", [["N", "CHEMICAL", 88, 89], ["SeCoV", "GENE_OR_GENE_PRODUCT", 65, 70], ["ITL", "GENE_OR_GENE_PRODUCT", 71, 74], ["spike protein coding region", "DNA", 30, 57], ["SeCoV", "PROTEIN", 65, 70], ["ITL", "DNA", 71, 74], ["N-terminal region", "DNA", 88, 105], ["A deletion of 3 nt", "PROBLEM", 0, 18], ["the SeCoV/ITL", "TREATMENT", 61, 74], ["terminal", "ANATOMY_MODIFIER", 90, 98]]], ["Individual amino acid differences between the SeCoV proteins are highlighted (in panels c and d) in black, while a short variable region of the S protein (panel d) that lacks a single amino acid in the SeCoV/ITL sequence is highlighted in grey. and the SeCoV sequences upstream of the S protein initiation codon ( Figure S1B ) and the high sequence similarity between PEDV and SeCoV sequence downstream of this point ( Figure S1A) ].", [["amino acid", "CHEMICAL", 11, 21], ["amino acid", "CHEMICAL", 184, 194], ["amino acid", "CHEMICAL", 11, 21], ["amino acid", "CHEMICAL", 184, 194], ["amino acid", "AMINO_ACID", 11, 21], ["SeCoV", "GENE_OR_GENE_PRODUCT", 46, 51], ["amino acid", "AMINO_ACID", 184, 194], ["SeCoV", "GENE_OR_GENE_PRODUCT", 202, 207], ["SeCoV proteins", "PROTEIN", 46, 60], ["short variable region", "PROTEIN", 115, 136], ["S protein", "PROTEIN", 144, 153], ["SeCoV/ITL sequence", "DNA", 202, 220], ["SeCoV sequences", "DNA", 253, 268], ["S protein initiation codon", "DNA", 285, 311], ["Figure S1B", "DNA", 314, 324], ["PEDV", "DNA", 368, 372], ["SeCoV sequence", "DNA", 377, 391], ["Individual amino acid differences", "PROBLEM", 0, 33], ["the SeCoV proteins", "TEST", 42, 60], ["the S protein", "TEST", 140, 153], ["a single amino acid", "TEST", 175, 194], ["the SeCoV/ITL sequence", "TREATMENT", 198, 220], ["the SeCoV sequences", "TEST", 249, 268], ["the high sequence similarity", "PROBLEM", 331, 359], ["PEDV", "PROBLEM", 368, 372], ["amino acid", "OBSERVATION", 11, 21]]], ["In contrast, the sequences of the SeCoVs differ around the location of the 3 0 -recombination junction, downstream of the S-gene.", [["SeCoVs", "GENE_OR_GENE_PRODUCT", 34, 40], ["SeCoVs", "DNA", 34, 40], ["3 0 -recombination junction", "DNA", 75, 102], ["S-gene", "DNA", 122, 128], ["the 3 0 -recombination junction", "TREATMENT", 71, 102]]], ["The sequences of the SeCoV/ITL and the SeCoV/CEE are identical in this region.", [["SeCoV", "GENE_OR_GENE_PRODUCT", 21, 26], ["ITL", "GENE_OR_GENE_PRODUCT", 27, 30], ["SeCoV", "GENE_OR_GENE_PRODUCT", 39, 44], ["SeCoV", "DNA", 21, 26], ["ITL", "DNA", 27, 30], ["SeCoV", "DNA", 39, 44], ["CEE", "DNA", 45, 48], ["the SeCoV/CEE", "TREATMENT", 35, 48]]], ["However, in the German strain (SeCoV/GER/L00930/ 2012), there is an absence of 10 nt relative to the SeCoV/ ITL and SeCoV/CEE strains around this point.", [["CEE", "CHEMICAL", 122, 125], ["SeCoV", "GENE_OR_GENE_PRODUCT", 101, 106], ["ITL", "GENE_OR_GENE_PRODUCT", 108, 111], ["SeCoV", "GENE_OR_GENE_PRODUCT", 116, 121], ["the SeCoV/ ITL", "TREATMENT", 97, 111], ["SeCoV/CEE strains", "TREATMENT", 116, 133]]], ["The lack of 9 nt truncates the coding region (only 90 nt in length) for a putative SeCoV 3a protein by three codons and, if translated, would result in the loss of the C-terminal amino acid residues, LKN (Fig. 1c) .", [["amino acid", "CHEMICAL", 179, 189], ["C", "CHEMICAL", 168, 169], ["amino acid", "CHEMICAL", 179, 189], ["SeCoV 3", "GENE_OR_GENE_PRODUCT", 83, 90], ["amino acid", "AMINO_ACID", 179, 189], ["coding region", "DNA", 31, 44], ["SeCoV 3", "DNA", 83, 90], ["C-terminal amino acid residues", "PROTEIN", 168, 198], ["LKN", "PROTEIN", 200, 203], ["The lack of 9 nt truncates the coding region", "PROBLEM", 0, 44], ["the loss of the C-terminal amino acid residues", "PROBLEM", 152, 198], ["acid residues", "OBSERVATION", 185, 198]]], ["A single nt deletion is located downstream of the 3a termination codon (see Figure S2B ).", [["nt deletion", "DNA", 9, 20], ["3a termination codon", "DNA", 50, 70], ["A single nt deletion", "PROBLEM", 0, 20]]], ["The putative SeCoV 3a sequence contains part of the PEDV ORF 3 ( Figure S2A ) but has the termination codon (and in the case of the SeCoV/ITL and SeCoV/CEE sequences, some coding sequence) derived from TGEV ORF 3a (see Figure S2B ).", [["SeCoV 3a", "GENE_OR_GENE_PRODUCT", 13, 21], ["PEDV ORF 3", "GENE_OR_GENE_PRODUCT", 52, 62], ["Figure S2A", "GENE_OR_GENE_PRODUCT", 65, 75], ["SeCoV", "GENE_OR_GENE_PRODUCT", 132, 137], ["ITL", "GENE_OR_GENE_PRODUCT", 138, 141], ["SeCoV", "GENE_OR_GENE_PRODUCT", 146, 151], ["SeCoV 3a sequence", "DNA", 13, 30], ["PEDV ORF 3", "DNA", 52, 62], ["Figure S2A", "DNA", 65, 75], ["termination codon", "DNA", 90, 107], ["SeCoV", "DNA", 132, 137], ["ITL", "DNA", 138, 141], ["SeCoV", "DNA", 146, 151], ["CEE sequences", "DNA", 152, 165], ["coding sequence", "DNA", 172, 187], ["TGEV ORF 3", "DNA", 202, 212], ["TGEV", "SPECIES", 202, 206], ["the PEDV ORF", "TREATMENT", 48, 60], ["the SeCoV/ITL and SeCoV/CEE sequences", "TREATMENT", 128, 165]]], ["The function of the coronavirus 3a protein is not well defined and is highly variable among different coronaviruses; thus, the significance of the differences in the ORF3a is not yet clear.", [["coronavirus 3", "ORGANISM", 20, 33], ["coronaviruses", "ORGANISM", 102, 115], ["ORF3a", "GENE_OR_GENE_PRODUCT", 166, 171], ["coronavirus 3a protein", "PROTEIN", 20, 42], ["ORF3a", "PROTEIN", 166, 171], ["different coronaviruses", "PROBLEM", 92, 115], ["coronavirus", "OBSERVATION", 20, 31], ["not", "UNCERTAINTY", 46, 49], ["well defined", "OBSERVATION_MODIFIER", 50, 62], ["highly", "OBSERVATION_MODIFIER", 70, 76], ["variable", "OBSERVATION_MODIFIER", 77, 85], ["different", "OBSERVATION_MODIFIER", 92, 101], ["coronaviruses", "OBSERVATION", 102, 115], ["clear", "OBSERVATION", 183, 188]]], ["Each of the three SeCoVs contains an open reading frame (only 81-90 nt) that could encode for a short 3a protein, whereas this sequence within PEDV (which is highly similar to that within the SeCoVs, see Figure S2A ) is part of the larger ORF3.", [["SeCoVs", "GENE_OR_GENE_PRODUCT", 18, 24], ["PEDV", "GENE_OR_GENE_PRODUCT", 143, 147], ["see Figure S2A", "GENE_OR_GENE_PRODUCT", 200, 214], ["ORF3", "GENE_OR_GENE_PRODUCT", 239, 243], ["SeCoVs", "DNA", 18, 24], ["open reading frame", "DNA", 37, 55], ["PEDV", "PROTEIN", 143, 147], ["SeCoVs", "DNA", 192, 198], ["ORF3", "DNA", 239, 243], ["a short 3a protein", "PROBLEM", 94, 112], ["PEDV", "PROBLEM", 143, 147], ["open", "OBSERVATION", 37, 41], ["larger", "OBSERVATION_MODIFIER", 232, 238], ["ORF3", "OBSERVATION", 239, 243]]], ["It is currently unknown whether this sequence within SeCoV is translated and detailed analysis of the expression of the various SeCoV subgenomic mRNAs and the encoded proteins will probably require the isolation of a SeCoV and characterization in cell culture.", [["cell culture", "ANATOMY", 247, 259], ["SeCoV", "GENE_OR_GENE_PRODUCT", 53, 58], ["SeCoV", "GENE_OR_GENE_PRODUCT", 128, 133], ["SeCoV", "GENE_OR_GENE_PRODUCT", 217, 222], ["cell culture", "CELL", 247, 259], ["SeCoV", "DNA", 53, 58], ["SeCoV subgenomic mRNAs", "RNA", 128, 150], ["SeCoV", "PROTEIN", 217, 222], ["the various SeCoV subgenomic mRNAs", "PROBLEM", 116, 150], ["a SeCoV", "TREATMENT", 215, 222], ["cell culture", "TEST", 247, 259], ["subgenomic mRNAs", "OBSERVATION", 134, 150]]], ["In TGEV, the 3a ORF is 219 nt in length and is extended at both termini compared to the 3a ORF in the SeCoVs ( Figure S2B ).", [["TGEV", "ORGANISM", 3, 7], ["3a ORF", "DNA", 13, 19], ["3a ORF", "DNA", 88, 94], ["SeCoVs", "DNA", 102, 108], ["TGEV", "SPECIES", 3, 7], ["the 3a ORF", "TEST", 9, 19]]], ["The exact 3 0recombination junction cannot be determined, but it is clearly very close to the termination codon of the SeCoV 3a ORF.", [["SeCoV 3a", "GENE_OR_GENE_PRODUCT", 119, 127], ["SeCoV 3a ORF", "DNA", 119, 131], ["The exact 3 0recombination junction", "TREATMENT", 0, 35]]], ["It is apparent that upstream of this point, there is a very close sequence similarity between the SeCoV sequences and PEDV (see Figure S2A ), whereas downstream of this point, the SeCOVs are much closer to the TGEV (see Figure S2B ).", [["SeCoV", "GENE_OR_GENE_PRODUCT", 98, 103], ["see Figure S2A", "GENE_OR_GENE_PRODUCT", 124, 138], ["SeCOVs", "GENE_OR_GENE_PRODUCT", 180, 186], ["TGEV", "ORGANISM", 210, 214], ["SeCoV sequences", "DNA", 98, 113], ["PEDV", "DNA", 118, 122], ["SeCOVs", "DNA", 180, 186], ["TGEV", "SPECIES", 210, 214], ["the SeCoV sequences", "TEST", 94, 113], ["PEDV", "PROBLEM", 118, 122]]], ["The TGEV 3b protein (the homologue of the PEDV ORF 3 protein) should be expressed by each of the SeCoVs.", [["TGEV 3b", "GENE_OR_GENE_PRODUCT", 4, 11], ["PEDV ORF 3", "GENE_OR_GENE_PRODUCT", 42, 52], ["SeCoVs", "GENE_OR_GENE_PRODUCT", 97, 103], ["TGEV 3b protein", "PROTEIN", 4, 19], ["PEDV ORF 3 protein", "PROTEIN", 42, 60], ["SeCoVs", "PROTEIN", 97, 103], ["The TGEV 3b protein", "TEST", 0, 19], ["the PEDV ORF", "TREATMENT", 38, 50]]], ["A deletion of 3 nt (one codon) was observed in the Sgene of the Italian strain relative to both the German and CEE SeCoV strains (Fig. 1d) .", [["CEE", "CHEMICAL", 111, 114], ["A deletion of 3 nt (one codon", "PROBLEM", 0, 29], ["CEE SeCoV strains", "TREATMENT", 111, 128]]], ["This resulted in the spike protein amino acid sequence including -LYKDNGNT-in the Italian sequence, while it is -LYKNTNGNT-in the German strain and -LHKATDGNI-in the CEE strain; this is a variable region within the S1 domain close to the N-terminus of the PEDV spike protein.", [["amino acid", "CHEMICAL", 35, 45], ["amino acid", "CHEMICAL", 35, 45], ["N", "CHEMICAL", 238, 239], ["amino acid", "AMINO_ACID", 35, 45], ["-LYKDNGNT", "GENE_OR_GENE_PRODUCT", 65, 74], ["-LYKNTNGNT", "GENE_OR_GENE_PRODUCT", 112, 122], ["-LHKATDGNI", "GENE_OR_GENE_PRODUCT", 148, 158], ["PEDV spike protein", "GENE_OR_GENE_PRODUCT", 256, 274], ["spike protein amino acid sequence", "PROTEIN", 21, 54], ["-LYKDNGNT", "PROTEIN", 65, 74], ["-LYKNTNGNT", "PROTEIN", 112, 122], ["S1 domain", "PROTEIN", 215, 224], ["N-terminus", "PROTEIN", 238, 248], ["PEDV spike protein", "PROTEIN", 256, 274], ["the spike protein amino acid sequence", "PROBLEM", 17, 54], ["-LYKDNGNT", "TEST", 65, 74], ["-LYKNTNGNT", "TEST", 112, 122], ["-LHKATDGNI", "TEST", 148, 158], ["the CEE strain", "PROBLEM", 162, 176], ["the PEDV spike protein", "PROBLEM", 252, 274], ["CEE strain", "ANATOMY", 166, 176], ["S1", "ANATOMY", 215, 217], ["PEDV", "OBSERVATION", 256, 260]]], ["In addition, there are many single nucleotide differences between these strains of SeCoV strain (see Fig. 1b ) and thus these viruses are clearly distinct.", [["nucleotide", "CHEMICAL", 35, 45], ["SeCoV strain", "ORGANISM", 83, 95], ["Fig. 1b", "GENE_OR_GENE_PRODUCT", 101, 108], ["many single nucleotide differences", "PROBLEM", 23, 57], ["SeCoV strain", "PROBLEM", 83, 95], ["viruses", "OBSERVATION", 126, 133]]], ["It is currently unknown whether the different SeCoVs have been generated independently or whether they have been produced from a single recombination event and then diverged.", [["SeCoVs", "GENE_OR_GENE_PRODUCT", 46, 52], ["SeCoVs", "DNA", 46, 52]]], ["It is noteworthy that the S-gene sequence in each SeCoV is very closely related (>98% identity) in each case but significantly different (only 91-92% identity) from the S-gene of known PEDVs.", [["SeCoV", "GENE_OR_GENE_PRODUCT", 50, 55], ["PEDVs", "PATHOLOGICAL_FORMATION", 185, 190], ["S-gene sequence", "DNA", 26, 41], ["SeCoV", "DNA", 50, 55], ["S-gene", "DNA", 169, 175], ["PEDVs", "DNA", 185, 190], ["known PEDVs", "PROBLEM", 179, 190]]], ["It should be noted that detection of the SeCoV RNA was achieved in six of 11 faecal/intestinal samples tested from this herd early on the outbreak.SeCoV/GER M K F L I H C W L F L P L L S A F S L T Q D V T R C G V N T N F R R F F S K F N V Q A P A T V V L G G Y L P S M N S S S W Y C G V G I E T A S G V H G I F L S Y I D S G Q G F E I G I A Q E P F D P S G Y Q L Y L Y K N T N G N T G A T A R L R I C Q FSera were collected in March 2016 from 39 pigs from the herd experiencing the outbreak of diarrhoea (Farm 1).", [["intestinal samples", "ANATOMY", 84, 102], ["diarrhoea", "DISEASE", 494, 503], ["SeCoV", "GENE_OR_GENE_PRODUCT", 41, 46], ["intestinal samples", "CANCER", 84, 102], ["pigs", "ORGANISM", 446, 450], ["SeCoV RNA", "RNA", 41, 50], ["pigs", "SPECIES", 446, 450], ["SeCoV", "SPECIES", 41, 46], ["the SeCoV RNA", "PROBLEM", 37, 50], ["faecal/intestinal samples", "TEST", 77, 102], ["SeCoV", "TEST", 147, 152], ["GER", "TEST", 153, 156], ["A F S", "TEST", 187, 192], ["T", "TEST", 203, 204], ["C", "TEST", 207, 208], ["G", "TEST", 209, 210], ["V", "TEST", 211, 212], ["K F", "TEST", 231, 234], ["V", "TEST", 237, 238], ["V", "TEST", 251, 252], ["S M", "TEST", 265, 268], ["S S", "TEST", 271, 274], ["T", "TEST", 293, 294], ["G V", "TEST", 299, 302], ["G", "TEST", 305, 306], ["G", "TEST", 323, 324], ["D", "TEST", 349, 350], ["S G", "TEST", 353, 356], ["Y", "TEST", 357, 358], ["K", "TEST", 369, 370], ["T", "TEST", 373, 374], ["N", "TEST", 375, 376], ["G", "TEST", 377, 378], ["T", "TEST", 381, 382], ["G", "TEST", 383, 384], ["A", "TEST", 385, 386], ["A R L R I C Q FSera", "TEST", 389, 408], ["diarrhoea", "PROBLEM", 494, 503], ["intestinal", "ANATOMY", 84, 94]]], ["The herd had been suspected of being infected with PEDV but was identified here as being infected with a chimeric SeCoV (see above).", [["PEDV", "CHEMICAL", 51, 55], ["SeCoV", "GENE_OR_GENE_PRODUCT", 114, 119], ["chimeric SeCoV", "PROTEIN", 105, 119], ["PEDV", "SPECIES", 51, 55], ["SeCoV", "SPECIES", 114, 119], ["PEDV", "PROBLEM", 51, 55], ["a chimeric SeCoV", "TREATMENT", 103, 119], ["suspected of", "UNCERTAINTY", 18, 30], ["infected", "OBSERVATION", 37, 45], ["PEDV", "OBSERVATION", 51, 55]]], ["The sera were analysed for the presence of antibodies to PEDV, TGEV and PRCV.", [["sera", "ANATOMY", 4, 8], ["sera", "ORGANISM_SUBSTANCE", 4, 8], ["PEDV", "GENE_OR_GENE_PRODUCT", 57, 61], ["TGEV", "ORGANISM", 63, 67], ["PRCV", "CANCER", 72, 76], ["antibodies", "PROTEIN", 43, 53], ["PEDV", "PROTEIN", 57, 61], ["PEDV", "SPECIES", 57, 61], ["TGEV", "SPECIES", 63, 67], ["PRCV", "SPECIES", 72, 76], ["The sera", "TEST", 0, 8], ["antibodies", "TREATMENT", 43, 53], ["PEDV", "PROBLEM", 57, 61], ["PRCV", "TREATMENT", 72, 76]]], ["In total, 14 of these 39 sera were clearly positive (>40% blocking) for anti-PEDV antibodies in the 'in-house' ELISA while five gave inconclusive results (>35% but <40% blocking) and the rest were negative (Table 3) .", [["sera", "ANATOMY", 25, 29], ["sera", "ORGANISM_SUBSTANCE", 25, 29], ["anti-PEDV antibodies", "PROTEIN", 72, 92], ["anti-PEDV", "SPECIES", 72, 81], ["these 39 sera", "TEST", 16, 29], ["anti-PEDV antibodies", "PROBLEM", 72, 92]]], ["Furthermore, 33 of these sera were positive for antibodies to PRCV but none of these sera scored positive in the commercial TGEV-specific ELISA assays.", [["sera", "ANATOMY", 25, 29], ["sera", "ANATOMY", 85, 89], ["sera", "ORGANISM_SUBSTANCE", 25, 29], ["PRCV", "CANCER", 62, 66], ["sera", "ORGANISM_SUBSTANCE", 85, 89], ["TGEV", "ORGANISM", 124, 128], ["antibodies", "PROTEIN", 48, 58], ["PRCV", "SPECIES", 62, 66], ["TGEV", "SPECIES", 124, 128], ["these sera", "TEST", 19, 29], ["antibodies", "PROBLEM", 48, 58], ["PRCV", "TEST", 62, 66], ["these sera", "TEST", 79, 89], ["specific ELISA assays", "TEST", 129, 150]]], ["From a second farm (Farm 2), within the same area but without clinical disease, 36 of the 40 sera tested were positive for anti-PRCV antibodies (plus two inconclusive results) but were each negative in the TGEV-and PEDVspecific assays.", [["sera", "ANATOMY", 93, 97], ["sera", "ORGANISM_SUBSTANCE", 93, 97], ["anti-PRCV", "GENE_OR_GENE_PRODUCT", 123, 132], ["TGEV", "ORGANISM", 206, 210], ["anti-PRCV antibodies", "PROTEIN", 123, 143], ["anti-PRCV", "SPECIES", 123, 132], ["TGEV", "SPECIES", 206, 210], ["clinical disease", "PROBLEM", 62, 78], ["the 40 sera", "TEST", 86, 97], ["anti-PRCV antibodies", "PROBLEM", 123, 143], ["the TGEV", "TEST", 202, 210], ["without", "UNCERTAINTY", 54, 61]]], ["On Farm 3, also in the same area and without clinical disease, just two sera (from 40 tested) scored positive in the PRCV assay and all 40 were negative in the assays for antibodies against TGEV and PEDV (see Table 3 ).", [["sera", "ANATOMY", 72, 76], ["sera", "ORGANISM_SUBSTANCE", 72, 76], ["TGEV", "ORGANISM", 190, 194], ["antibodies", "PROTEIN", 171, 181], ["PRCV", "SPECIES", 117, 121], ["TGEV", "SPECIES", 190, 194], ["PEDV", "SPECIES", 199, 203], ["clinical disease", "PROBLEM", 45, 61], ["two sera", "TEST", 68, 76], ["the PRCV assay", "TEST", 113, 127], ["antibodies", "TEST", 171, 181], ["TGEV", "PROBLEM", 190, 194], ["PEDV", "PROBLEM", 199, 203], ["without", "UNCERTAINTY", 37, 44]]], ["Almost 1 month later, a further 20 sera were collected from Farm 1 and tested in the same assays.", [["sera", "ANATOMY", 35, 39], ["sera", "ORGANISM_SUBSTANCE", 35, 39], ["a further 20 sera", "TEST", 22, 39]]], ["A similar prevalence of anti-PEDV antibodies (40% positive) was observed, as seen initially (Table 3) .", [["anti-PEDV antibodies", "GENE_OR_GENE_PRODUCT", 24, 44], ["anti-PEDV antibodies", "PROTEIN", 24, 44], ["anti-PEDV", "SPECIES", 24, 33], ["anti-PEDV antibodies", "TEST", 24, 44]]], ["Using the Biovet ELISA (that detects antibodies to the PEDV N protein), just one sample of these 20 sera tested positive, and this is a similar frequency as the detection rate in this test from uninfected animals (Strandbygaard et al., in preparation) .", [["sera", "ANATOMY", 100, 104], ["PEDV N protein", "GENE_OR_GENE_PRODUCT", 55, 69], ["sera", "ORGANISM_SUBSTANCE", 100, 104], ["antibodies", "PROTEIN", 37, 47], ["PEDV N protein", "PROTEIN", 55, 69], ["the Biovet ELISA", "TEST", 6, 22], ["the PEDV N protein", "TEST", 51, 69], ["these 20 sera", "TEST", 91, 104], ["the detection rate", "TEST", 157, 175], ["this test", "TEST", 179, 188]]], ["Analysis of faecal samples collected at this time showed three positive samples of 10 tested, judged by the combined results of TGEV/PRCV and PEDV RT-qPCRs (data not shown).", [["faecal samples", "ANATOMY", 12, 26], ["faecal samples", "ORGANISM_SUBSTANCE", 12, 26], ["TGEV", "ORGANISM", 128, 132], ["TGEV", "SPECIES", 128, 132], ["PRCV", "SPECIES", 133, 137], ["PEDV", "SPECIES", 142, 146], ["Analysis of faecal samples", "TEST", 0, 26], ["TGEV/PRCV", "TREATMENT", 128, 137], ["PEDV RT", "TREATMENT", 142, 149], ["faecal", "ANATOMY", 12, 18]]], ["The three different SeCoVs described so far are distinct but each have the PEDV S-gene (encoding the spike protein) together with adjacent sequences potentially encoding a short 3a protein (<30 amino acids) recombined into a TGEV genome.", [["amino acids", "CHEMICAL", 194, 205], ["amino acids", "CHEMICAL", 194, 205], ["SeCoVs", "GENE_OR_GENE_PRODUCT", 20, 26], ["PEDV S", "GENE_OR_GENE_PRODUCT", 75, 81], ["amino acids", "AMINO_ACID", 194, 205], ["TGEV", "ORGANISM", 225, 229], ["SeCoVs", "DNA", 20, 26], ["PEDV S-gene", "DNA", 75, 86], ["spike protein", "PROTEIN", 101, 114], ["short 3a protein", "PROTEIN", 172, 188], ["TGEV genome", "DNA", 225, 236], ["TGEV", "SPECIES", 225, 229], ["the PEDV S", "TEST", 71, 81], ["a short 3a protein", "PROBLEM", 170, 188], ["amino acids", "TEST", 194, 205], ["a TGEV genome", "PROBLEM", 223, 236], ["TGEV genome", "OBSERVATION", 225, 236]]], ["The spike protein is important for the immunogenicity of PEDV (Song and Park, 2012) .", [["spike protein", "PROTEIN", 4, 17], ["PEDV", "SPECIES", 57, 61], ["The spike protein", "TEST", 0, 17], ["PEDV", "PROBLEM", 57, 61]]], ["Many sera from the farm in CEE with SeCoV-infected pigs scored positive in tests for antibodies to PEDV (Table 3) , although not with the Biovet assay as this only detects antibodies to the PEDV N protein.", [["sera", "ANATOMY", 5, 9], ["CEE", "CHEMICAL", 27, 30], ["SeCoV", "CHEMICAL", 36, 41], ["sera", "ORGANISM_SUBSTANCE", 5, 9], ["CEE", "SIMPLE_CHEMICAL", 27, 30], ["SeCoV", "GENE_OR_GENE_PRODUCT", 36, 41], ["pigs", "ORGANISM", 51, 55], ["PEDV N protein", "GENE_OR_GENE_PRODUCT", 190, 204], ["antibodies", "PROTEIN", 85, 95], ["PEDV", "PROTEIN", 99, 103], ["antibodies", "PROTEIN", 172, 182], ["PEDV N protein", "PROTEIN", 190, 204], ["pigs", "SPECIES", 51, 55], ["pigs", "SPECIES", 51, 55], ["PEDV", "SPECIES", 99, 103], ["PEDV", "SPECIES", 190, 194], ["Many sera", "PROBLEM", 0, 9], ["SeCoV", "TREATMENT", 36, 41], ["infected pigs", "PROBLEM", 42, 55], ["antibodies", "PROBLEM", 85, 95], ["PEDV", "TEST", 99, 103], ["the Biovet assay", "TEST", 134, 150]]], ["Furthermore, these sera were scored negative in assays for TGEV antibodies as these tests determine antibodies specifically against the TGEV spike protein.", [["sera", "ANATOMY", 19, 23], ["sera", "ORGANISM_SUBSTANCE", 19, 23], ["TGEV", "ORGANISM", 59, 63], ["TGEV", "ORGANISM", 136, 140], ["TGEV antibodies", "PROTEIN", 59, 74], ["antibodies", "PROTEIN", 100, 110], ["TGEV spike protein", "PROTEIN", 136, 154], ["TGEV", "SPECIES", 59, 63], ["TGEV", "SPECIES", 136, 140], ["these sera", "TEST", 13, 23], ["TGEV antibodies", "TEST", 59, 74], ["these tests", "TEST", 78, 89], ["antibodies", "TEST", 100, 110], ["the TGEV spike protein", "PROBLEM", 132, 154]]], ["Many of the animals were also seropositive against PRCV, a widely spread respiratory virus, that does not induce diarrhoea, and indeed has acted like a vaccine against TGEV (Saif et al., 2012) .", [["PRCV", "CHEMICAL", 51, 55], ["respiratory virus", "DISEASE", 73, 90], ["diarrhoea", "DISEASE", 113, 122], ["TGEV", "DISEASE", 168, 172], ["animals", "ORGANISM", 12, 19], ["PRCV", "ORGANISM", 51, 55], ["TGEV", "ORGANISM", 168, 172], ["PRCV", "SPECIES", 51, 55], ["TGEV", "SPECIES", 168, 172], ["PRCV", "PROBLEM", 51, 55], ["a widely spread respiratory virus", "PROBLEM", 57, 90], ["diarrhoea", "PROBLEM", 113, 122], ["widely", "OBSERVATION_MODIFIER", 59, 65], ["spread", "OBSERVATION_MODIFIER", 66, 72], ["respiratory virus", "OBSERVATION", 73, 90]]], ["As many pig samples scored positive for anti-PRCV antibodies in pigs from Farm 2 but all pigs scored negative for anti-PEDV antibodies, it is clear that the positive PEDV reaction in pigs from Farm 1 is not due to a cross-reaction to PRCV in the PEDV ELISA.", [["samples", "ANATOMY", 12, 19], ["pig", "ORGANISM", 8, 11], ["pigs", "ORGANISM", 64, 68], ["pigs", "ORGANISM", 89, 93], ["PEDV", "GENE_OR_GENE_PRODUCT", 166, 170], ["pigs", "ORGANISM", 183, 187], ["Farm 1", "ORGANISM", 193, 199], ["PRCV", "SIMPLE_CHEMICAL", 234, 238], ["anti-PRCV antibodies", "PROTEIN", 40, 60], ["anti-PEDV antibodies", "PROTEIN", 114, 134], ["pig", "SPECIES", 8, 11], ["pigs", "SPECIES", 64, 68], ["pigs", "SPECIES", 89, 93], ["pigs", "SPECIES", 183, 187], ["pig", "SPECIES", 8, 11], ["anti-PRCV", "SPECIES", 40, 49], ["pigs", "SPECIES", 64, 68], ["pigs", "SPECIES", 89, 93], ["anti-PEDV", "SPECIES", 114, 123], ["pigs", "SPECIES", 183, 187], ["PRCV", "SPECIES", 234, 238], ["PEDV", "SPECIES", 246, 250], ["many pig samples", "TEST", 3, 19], ["anti-PRCV antibodies", "PROBLEM", 40, 60], ["anti-PEDV antibodies", "PROBLEM", 114, 134], ["the positive PEDV reaction", "PROBLEM", 153, 179], ["a cross-reaction to PRCV", "PROBLEM", 214, 238], ["positive", "OBSERVATION_MODIFIER", 157, 165], ["PEDV", "OBSERVATION", 166, 170]]], ["Thus, it is apparent that the presence of antibodies in pigs against PRCV does not prevent SeCoV infection.ConclusionsThe results presented here clearly shows the presence of a chimeric SeCoV in pigs on a farm in Central Eastern Europe, during early 2016, where marked clinical signs suggestive of PEDV infection, including diarrhoea and vomiting, were apparent.", [["PRCV", "CHEMICAL", 69, 73], ["SeCoV", "CHEMICAL", 91, 96], ["infection", "DISEASE", 97, 106], ["SeCoV", "CHEMICAL", 186, 191], ["infection", "DISEASE", 303, 312], ["diarrhoea", "DISEASE", 324, 333], ["vomiting", "DISEASE", 338, 346], ["pigs", "ORGANISM", 56, 60], ["PRCV", "ORGANISM", 69, 73], ["SeCoV", "GENE_OR_GENE_PRODUCT", 91, 96], ["SeCoV", "GENE_OR_GENE_PRODUCT", 186, 191], ["pigs", "ORGANISM", 195, 199], ["antibodies", "PROTEIN", 42, 52], ["chimeric SeCoV", "PROTEIN", 177, 191], ["pigs", "SPECIES", 56, 60], ["pigs", "SPECIES", 195, 199], ["pigs", "SPECIES", 56, 60], ["PRCV", "SPECIES", 69, 73], ["SeCoV", "SPECIES", 91, 96], ["pigs", "SPECIES", 195, 199], ["PEDV", "SPECIES", 298, 302], ["antibodies in pigs", "TREATMENT", 42, 60], ["PRCV", "TREATMENT", 69, 73], ["SeCoV infection", "PROBLEM", 91, 106], ["PEDV infection", "PROBLEM", 298, 312], ["diarrhoea", "PROBLEM", 324, 333], ["vomiting", "PROBLEM", 338, 346], ["infection", "OBSERVATION", 97, 106], ["Central", "ANATOMY_MODIFIER", 213, 220], ["suggestive of", "UNCERTAINTY", 284, 297], ["PEDV", "OBSERVATION_MODIFIER", 298, 302], ["infection", "OBSERVATION", 303, 312]]], ["This recombinant virus is closely related to, but distinct from, the chimeric SeCoV viruses previously identified in samples from Italy (within 2009-2012) and Germany (2012) by Boniotti et al. (2016) and Akimkin et al. (2016) respectively.", [["samples", "ANATOMY", 117, 124], ["SeCoV", "GENE_OR_GENE_PRODUCT", 78, 83], ["This recombinant virus", "PROBLEM", 0, 22], ["the chimeric SeCoV viruses", "PROBLEM", 65, 91], ["virus", "OBSERVATION", 17, 22]]], ["It is demonstrated, for the first time, that pigs that were infected with the SeCoV/CEE/16 seroconverted against PEDV (when tested using an appropriate test) but they do not seroconvert against TGEV, as determined using a spike protein-specific assay, consistent with the chimeric structure of the recombinant SeCoV.ConclusionsClearly, the specific target sequences used in diagnostic RT-qPCR assays determine the recognition of the chimeric SeCoV in such assays.", [["CEE", "CHEMICAL", 84, 87], ["PEDV", "CHEMICAL", 113, 117], ["pigs", "ORGANISM", 45, 49], ["SeCoV", "GENE_OR_GENE_PRODUCT", 78, 83], ["CEE/16", "ORGANISM", 84, 90], ["PEDV", "ORGANISM", 113, 117], ["TGEV", "ORGANISM", 194, 198], ["SeCoV", "GENE_OR_GENE_PRODUCT", 310, 315], ["SeCoV", "GENE_OR_GENE_PRODUCT", 442, 447], ["spike protein", "PROTEIN", 222, 235], ["recombinant SeCoV", "PROTEIN", 298, 315], ["chimeric SeCoV", "PROTEIN", 433, 447], ["pigs", "SPECIES", 45, 49], ["pigs", "SPECIES", 45, 49], ["SeCoV/CEE/16", "SPECIES", 78, 90], ["PEDV", "SPECIES", 113, 117], ["TGEV", "SPECIES", 194, 198], ["the SeCoV/CEE", "TREATMENT", 74, 87], ["PEDV", "PROBLEM", 113, 117], ["an appropriate test", "TEST", 137, 156], ["TGEV", "PROBLEM", 194, 198], ["a spike protein", "TEST", 220, 235], ["diagnostic RT-qPCR assays", "TEST", 374, 399], ["the chimeric SeCoV", "TREATMENT", 429, 447], ["consistent with", "UNCERTAINTY", 252, 267]]], ["It is necessary to use either a PEDV S-gene-specific assay in conjunction with an assay for some other region of the TGEV genome (e.g. the N-gene) to identify the SeCoV RNA (see Table 2 ) or to develop a new SeCoV RT-qPCR-specific assay.", [["TGEV", "ORGANISM", 117, 121], ["PEDV S-gene", "DNA", 32, 43], ["TGEV genome", "DNA", 117, 128], ["N-gene", "DNA", 139, 145], ["SeCoV RNA", "RNA", 163, 172], ["TGEV", "SPECIES", 117, 121], ["a PEDV S", "TREATMENT", 30, 38], ["an assay", "TEST", 79, 87], ["the TGEV genome", "PROBLEM", 113, 128], ["a new SeCoV RT", "TEST", 202, 216], ["qPCR", "TEST", 217, 221]]], ["Currently, SeCoV has not yet been isolated and it will be necessary to achieve this to prove that this virus alone is sufficient to induce the clinical disease that has been observed in pigs.", [["SeCoV", "CHEMICAL", 11, 16], ["SeCoV", "GENE_OR_GENE_PRODUCT", 11, 16], ["pigs", "ORGANISM", 186, 190], ["SeCoV", "PROTEIN", 11, 16], ["pigs", "SPECIES", 186, 190], ["pigs", "SPECIES", 186, 190], ["this virus", "PROBLEM", 98, 108], ["the clinical disease", "PROBLEM", 139, 159]]]], "PMC7480397": [["Case 1 ::: Case Presentations ::: IntroductionA 66-year-old Caucasian male healthcare worker with a medical history of diabetes mellitus and hypertension presented to our hospital on March 26, 2020 from home with 1 week complaints of progressive shortness of breath, cough with minimal expectoration, fevers, and watery diarrhea.", [["diabetes mellitus", "DISEASE", 119, 136], ["hypertension", "DISEASE", 141, 153], ["shortness of breath", "DISEASE", 246, 265], ["cough", "DISEASE", 267, 272], ["expectoration", "DISEASE", 286, 299], ["fevers", "DISEASE", 301, 307], ["watery diarrhea", "DISEASE", 313, 328], ["diabetes mellitus", "PROBLEM", 119, 136], ["hypertension", "PROBLEM", 141, 153], ["progressive shortness of breath", "PROBLEM", 234, 265], ["cough", "PROBLEM", 267, 272], ["minimal expectoration", "PROBLEM", 278, 299], ["fevers", "PROBLEM", 301, 307], ["watery diarrhea", "PROBLEM", 313, 328], ["diabetes mellitus", "OBSERVATION", 119, 136], ["hypertension", "OBSERVATION", 141, 153], ["progressive", "OBSERVATION_MODIFIER", 234, 245], ["minimal", "OBSERVATION_MODIFIER", 278, 285], ["expectoration", "OBSERVATION", 286, 299], ["fevers", "OBSERVATION", 301, 307], ["watery", "OBSERVATION_MODIFIER", 313, 319], ["diarrhea", "OBSERVATION", 320, 328]]], ["On presentation, he had a temperature of 99.7 \u00b0F, heart rate of 92 beats/minute, respiratory rate of 24 breaths/minute, blood pressure of 120/85 mmHg, and oxygen saturation of 96% on room air.", [["heart", "ANATOMY", 50, 55], ["respiratory", "ANATOMY", 81, 92], ["blood", "ANATOMY", 120, 125], ["oxygen", "CHEMICAL", 155, 161], ["oxygen", "CHEMICAL", 155, 161], ["heart", "ORGAN", 50, 55], ["blood", "ORGANISM_SUBSTANCE", 120, 125], ["oxygen", "SIMPLE_CHEMICAL", 155, 161], ["a temperature", "TEST", 24, 37], ["heart rate", "TEST", 50, 60], ["respiratory rate", "TEST", 81, 97], ["blood pressure", "TEST", 120, 134], ["oxygen saturation", "TEST", 155, 172]]], ["Physical exam was significant for tachypnea without accessory muscle use and decreased breath sounds at the bilateral lung bases.", [["muscle", "ANATOMY", 62, 68], ["lung", "ANATOMY", 118, 122], ["tachypnea", "DISEASE", 34, 43], ["muscle", "ORGAN", 62, 68], ["lung", "ORGAN", 118, 122], ["Physical exam", "TEST", 0, 13], ["tachypnea", "PROBLEM", 34, 43], ["accessory muscle use", "PROBLEM", 52, 72], ["decreased breath sounds at the bilateral lung bases", "PROBLEM", 77, 128], ["muscle", "ANATOMY", 62, 68], ["decreased", "OBSERVATION_MODIFIER", 77, 86], ["breath sounds", "OBSERVATION", 87, 100], ["bilateral", "ANATOMY_MODIFIER", 108, 117], ["lung", "ANATOMY", 118, 122], ["bases", "ANATOMY_MODIFIER", 123, 128]]], ["Admission laboratory studies revealed an acute kidney injury, a normal WBC with lymphopenia, mildly elevated aspartate aminotransferase (AST), and elevations in several inflammatory markers (Table 1, Table 2).", [["kidney", "ANATOMY", 47, 53], ["WBC", "ANATOMY", 71, 74], ["acute kidney injury", "DISEASE", 41, 60], ["lymphopenia", "DISEASE", 80, 91], ["aspartate", "CHEMICAL", 109, 118], ["aspartate", "CHEMICAL", 109, 118], ["kidney", "ORGAN", 47, 53], ["aspartate aminotransferase", "GENE_OR_GENE_PRODUCT", 109, 135], ["AST", "SIMPLE_CHEMICAL", 137, 140], ["aspartate aminotransferase", "PROTEIN", 109, 135], ["AST", "PROTEIN", 137, 140], ["inflammatory markers", "PROTEIN", 169, 189], ["Admission laboratory studies", "TEST", 0, 28], ["an acute kidney injury", "PROBLEM", 38, 60], ["lymphopenia", "PROBLEM", 80, 91], ["mildly elevated aspartate aminotransferase (AST)", "PROBLEM", 93, 141], ["elevations in several inflammatory markers", "PROBLEM", 147, 189], ["acute", "OBSERVATION_MODIFIER", 41, 46], ["kidney", "ANATOMY", 47, 53], ["injury", "OBSERVATION", 54, 60], ["normal", "OBSERVATION_MODIFIER", 64, 70], ["WBC", "OBSERVATION_MODIFIER", 71, 74], ["lymphopenia", "OBSERVATION", 80, 91], ["mildly", "OBSERVATION_MODIFIER", 93, 99], ["elevated", "OBSERVATION_MODIFIER", 100, 108], ["aspartate aminotransferase", "OBSERVATION", 109, 135], ["elevations", "OBSERVATION_MODIFIER", 147, 157], ["several", "OBSERVATION_MODIFIER", 161, 168], ["inflammatory", "OBSERVATION_MODIFIER", 169, 181]]], ["He was also found to have an abnormal troponin of 0.535 ng/mL with a normal electrocardiogram.", [["He", "ORGANISM", 0, 2], ["troponin", "GENE_OR_GENE_PRODUCT", 38, 46], ["troponin", "PROTEIN", 38, 46], ["an abnormal troponin", "PROBLEM", 26, 46], ["abnormal", "OBSERVATION", 29, 37]]], ["Chest radiograph showed an infiltrate in the left lower lobe with mild vascular congestion (Figure 1).", [["left lower lobe", "ANATOMY", 45, 60], ["vascular", "ANATOMY", 71, 79], ["vascular congestion", "DISEASE", 71, 90], ["lower lobe", "ORGANISM_SUBDIVISION", 50, 60], ["vascular", "MULTI-TISSUE_STRUCTURE", 71, 79], ["Chest radiograph", "TEST", 0, 16], ["an infiltrate in the left lower lobe", "PROBLEM", 24, 60], ["mild vascular congestion", "PROBLEM", 66, 90], ["infiltrate", "OBSERVATION", 27, 37], ["left lower lobe", "ANATOMY", 45, 60], ["mild", "OBSERVATION_MODIFIER", 66, 70], ["vascular", "ANATOMY", 71, 79], ["congestion", "OBSERVATION", 80, 90]]], ["The rapid influenza diagnostic test (RIDT) returned positive for influenza B infection via nasopharyngeal swab.", [["nasopharyngeal swab", "ANATOMY", 91, 110], ["influenza B infection", "DISEASE", 65, 86], ["influenza B", "ORGANISM", 65, 76], ["nasopharyngeal swab", "ORGANISM_SUBSTANCE", 91, 110], ["The rapid influenza diagnostic test", "TEST", 0, 35], ["influenza B infection via nasopharyngeal swab", "PROBLEM", 65, 110], ["infection", "OBSERVATION", 77, 86], ["nasopharyngeal", "ANATOMY", 91, 105]]], ["The patient also tested positive for SARS-CoV-2 via reverse\u2013transcriptase\u2013polymerase-chain\u2013reaction (RT\u2013PCR) of a nasopharyngeal swab.", [["nasopharyngeal swab", "ANATOMY", 114, 133], ["patient", "ORGANISM", 4, 11], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 37, 47], ["nasopharyngeal swab", "CANCER", 114, 133], ["patient", "SPECIES", 4, 11], ["SARS-CoV", "SPECIES", 37, 45], ["SARS", "PROBLEM", 37, 41], ["CoV", "TEST", 42, 45], ["reverse\u2013transcriptase\u2013polymerase", "TEST", 52, 84], ["chain\u2013reaction", "TREATMENT", 85, 99], ["RT\u2013PCR", "TREATMENT", 101, 107], ["a nasopharyngeal swab", "PROBLEM", 112, 133], ["nasopharyngeal", "ANATOMY", 114, 128], ["swab", "OBSERVATION", 129, 133]]], ["He was treated with 5 days of azithromycin oral 250 mg/day.", [["oral", "ANATOMY", 43, 47], ["azithromycin", "CHEMICAL", 30, 42], ["azithromycin", "CHEMICAL", 30, 42], ["He", "ORGANISM", 0, 2], ["azithromycin", "SIMPLE_CHEMICAL", 30, 42], ["oral", "ORGANISM_SUBDIVISION", 43, 47], ["azithromycin oral", "TREATMENT", 30, 47]]], ["The patient remained febrile for the first 3 days of hospitalization and then remained afebrile for the remainder of his hospitalization.", [["febrile", "DISEASE", 21, 28], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["febrile", "PROBLEM", 21, 28], ["afebrile", "PROBLEM", 87, 95], ["febrile", "OBSERVATION", 21, 28], ["afebrile", "OBSERVATION", 87, 95]]], ["The patient was discharged home on day 6 and did not require supplemental oxygen during his hospitalization.Case 1 ::: Case Presentations ::: IntroductionCase 1 (A): infiltrate in the left lower lobe with mild vascular congestion; Case 2 (B): patchy diffuse bilateral pulmonary infiltrates; Case 3 (C): infiltrates of the right lung base and right perihilar region; Case 4 (D): streaky opacities within the lower lungs fields bilaterally.Case 2 ::: Case Presentations ::: IntroductionA 60-year-old African American female healthcare worker with a medical history of diabetes mellitus and hypertension presented to our hospital on April 4, 2020 with a 2 week history of fevers, cough, malaise, myalgias, and progressive shortness of breath.", [["left lower lobe", "ANATOMY", 184, 199], ["vascular", "ANATOMY", 210, 218], ["pulmonary", "ANATOMY", 268, 277], ["right lung base", "ANATOMY", 322, 337], ["right perihilar region", "ANATOMY", 342, 364], ["lower lungs", "ANATOMY", 407, 418], ["oxygen", "CHEMICAL", 74, 80], ["vascular congestion", "DISEASE", 210, 229], ["diabetes mellitus", "DISEASE", 566, 583], ["hypertension", "DISEASE", 588, 600], ["fevers", "DISEASE", 669, 675], ["cough", "DISEASE", 677, 682], ["myalgias", "DISEASE", 693, 701], ["shortness of breath", "DISEASE", 719, 738], ["oxygen", "CHEMICAL", 74, 80], ["patient", "ORGANISM", 4, 11], ["oxygen", "SIMPLE_CHEMICAL", 74, 80], ["A", "CANCER", 162, 163], ["lobe", "ORGAN", 195, 199], ["vascular", "MULTI-TISSUE_STRUCTURE", 210, 218], ["lung", "ORGAN", 328, 332], ["lungs", "ORGAN", 413, 418], ["American", "ORGANISM", 506, 514], ["female", "ORGANISM", 515, 521], ["patient", "SPECIES", 4, 11], ["supplemental oxygen", "TREATMENT", 61, 80], ["infiltrate in the left lower lobe", "PROBLEM", 166, 199], ["mild vascular congestion", "PROBLEM", 205, 229], ["patchy diffuse bilateral pulmonary infiltrates", "PROBLEM", 243, 289], ["infiltrates of the right lung base and right perihilar region", "PROBLEM", 303, 364], ["streaky opacities within the lower lungs fields bilaterally", "PROBLEM", 378, 437], ["diabetes mellitus", "PROBLEM", 566, 583], ["hypertension", "PROBLEM", 588, 600], ["fevers", "PROBLEM", 669, 675], ["cough", "PROBLEM", 677, 682], ["malaise", "PROBLEM", 684, 691], ["myalgias", "PROBLEM", 693, 701], ["progressive shortness of breath", "PROBLEM", 707, 738], ["infiltrate", "OBSERVATION", 166, 176], ["left lower lobe", "ANATOMY", 184, 199], ["mild", "OBSERVATION_MODIFIER", 205, 209], ["vascular", "ANATOMY", 210, 218], ["congestion", "OBSERVATION", 219, 229], ["patchy", "OBSERVATION_MODIFIER", 243, 249], ["diffuse", "OBSERVATION_MODIFIER", 250, 257], ["bilateral", "ANATOMY_MODIFIER", 258, 267], ["pulmonary", "ANATOMY", 268, 277], ["infiltrates", "OBSERVATION", 278, 289], ["infiltrates", "OBSERVATION", 303, 314], ["right", "ANATOMY_MODIFIER", 322, 327], ["lung", "ANATOMY", 328, 332], ["base", "ANATOMY_MODIFIER", 333, 337], ["right", "ANATOMY_MODIFIER", 342, 347], ["perihilar", "ANATOMY_MODIFIER", 348, 357], ["streaky", "OBSERVATION_MODIFIER", 378, 385], ["opacities", "OBSERVATION", 386, 395], ["lower", "ANATOMY_MODIFIER", 407, 412], ["lungs", "ANATOMY", 413, 418], ["fields", "ANATOMY_MODIFIER", 419, 425], ["bilaterally", "ANATOMY_MODIFIER", 426, 437], ["diabetes", "OBSERVATION", 566, 574], ["hypertension", "OBSERVATION", 588, 600], ["fevers", "OBSERVATION", 669, 675], ["cough", "OBSERVATION", 677, 682], ["malaise", "OBSERVATION", 684, 691], ["myalgias", "OBSERVATION", 693, 701], ["progressive", "OBSERVATION_MODIFIER", 707, 718]]], ["On presentation, she had a temperature of 99.1\u00b0F, heart rate of.Case 2 ::: Case Presentations ::: Introduction106 beats/minute, respiratory rate of 21 breaths/minute, blood pressure of 110/51 mmHg, and oxygen saturation of 76% on room air.", [["heart", "ANATOMY", 50, 55], ["blood", "ANATOMY", 167, 172], ["oxygen", "CHEMICAL", 202, 208], ["oxygen", "CHEMICAL", 202, 208], ["heart", "ORGAN", 50, 55], ["blood", "ORGANISM_SUBSTANCE", 167, 172], ["oxygen", "SIMPLE_CHEMICAL", 202, 208], ["a temperature", "TEST", 25, 38], ["heart rate", "TEST", 50, 60], ["respiratory rate", "TEST", 128, 144], ["blood pressure", "TEST", 167, 181], ["oxygen saturation", "TEST", 202, 219]]], ["She was placed on 20 L high-flow nasal cannula with improvement in her saturations to 96%.", [["nasal", "ANATOMY", 33, 38], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 33, 46], ["20 L high-flow nasal cannula", "TREATMENT", 18, 46], ["her saturations", "TEST", 67, 82]]], ["Physical exam was significant for bilateral coarse breath sounds.", [["Physical exam", "TEST", 0, 13], ["bilateral coarse breath sounds", "PROBLEM", 34, 64], ["bilateral", "ANATOMY_MODIFIER", 34, 43], ["coarse", "OBSERVATION_MODIFIER", 44, 50], ["breath sounds", "OBSERVATION", 51, 64]]], ["Initial laboratory testing revealed a normal WBC with mild lymphopenia, and elevations in AST and several inflammatory markers (Table 1, Table 2.).", [["WBC", "ANATOMY", 45, 48], ["lymphopenia", "DISEASE", 59, 70], ["AST", "SIMPLE_CHEMICAL", 90, 93], ["AST", "PROTEIN", 90, 93], ["inflammatory markers", "PROTEIN", 106, 126], ["Initial laboratory testing", "TEST", 0, 26], ["mild lymphopenia", "PROBLEM", 54, 70], ["elevations in AST", "PROBLEM", 76, 93], ["several inflammatory markers", "TEST", 98, 126], ["mild", "OBSERVATION_MODIFIER", 54, 58], ["lymphopenia", "OBSERVATION", 59, 70], ["elevations", "OBSERVATION_MODIFIER", 76, 86], ["inflammatory", "OBSERVATION_MODIFIER", 106, 118]]], ["Chest radiograph revealed patchy diffuse bilateral pulmonary infiltrates (Figure 1).", [["pulmonary", "ANATOMY", 51, 60], ["pulmonary infiltrates", "PATHOLOGICAL_FORMATION", 51, 72], ["Chest radiograph", "TEST", 0, 16], ["patchy diffuse bilateral pulmonary infiltrates", "PROBLEM", 26, 72], ["patchy", "OBSERVATION_MODIFIER", 26, 32], ["diffuse", "OBSERVATION_MODIFIER", 33, 40], ["bilateral", "ANATOMY_MODIFIER", 41, 50], ["pulmonary", "ANATOMY", 51, 60], ["infiltrates", "OBSERVATION", 61, 72]]], ["Her RIDT returned positive for influenza B via nasopharyngeal swab.", [["nasopharyngeal swab", "ANATOMY", 47, 66], ["influenza B", "DISEASE", 31, 42], ["nasopharyngeal swab", "ORGANISM_SUBSTANCE", 47, 66], ["Her RIDT", "TEST", 0, 8], ["influenza B", "PROBLEM", 31, 42], ["nasopharyngeal swab", "TEST", 47, 66], ["nasopharyngeal", "ANATOMY", 47, 61], ["swab", "OBSERVATION", 62, 66]]], ["She also tested positive for SARS-CoV-2 that was obtained via outpatient RT\u2013PCR assay of a nasopharyngeal swab 5 days prior to presentation.", [["nasopharyngeal swab", "ANATOMY", 91, 110], ["She", "ORGANISM", 0, 3], ["SARS-CoV-2", "ORGANISM", 29, 39], ["SARS-CoV", "SPECIES", 29, 37], ["SARS", "PROBLEM", 29, 33], ["CoV", "TEST", 34, 37], ["outpatient RT\u2013PCR", "TEST", 62, 79], ["a nasopharyngeal swab", "PROBLEM", 89, 110], ["nasopharyngeal", "ANATOMY", 91, 105]]], ["The patient was admitted to the intensive care unit (ICU) and initiated on intravenous (IV) levofloxacin 750 mg/day, IV vancomycin 1.25 g/twice daily, oral oseltamivir 75 mg/twice daily, and oral hydroxychloroquine 400 mg/twice daily for one day and 200 mg/twice daily for 4 days.", [["intravenous", "ANATOMY", 75, 86], ["oral", "ANATOMY", 151, 155], ["oral", "ANATOMY", 191, 195], ["levofloxacin", "CHEMICAL", 92, 104], ["vancomycin", "CHEMICAL", 120, 130], ["oseltamivir", "CHEMICAL", 156, 167], ["hydroxychloroquine", "CHEMICAL", 196, 214], ["levofloxacin", "CHEMICAL", 92, 104], ["vancomycin", "CHEMICAL", 120, 130], ["oseltamivir", "CHEMICAL", 156, 167], ["hydroxychloroquine", "CHEMICAL", 196, 214], ["patient", "ORGANISM", 4, 11], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 75, 86], ["levofloxacin", "SIMPLE_CHEMICAL", 92, 104], ["vancomycin", "SIMPLE_CHEMICAL", 120, 130], ["oral", "ORGANISM_SUBDIVISION", 151, 155], ["oseltamivir", "SIMPLE_CHEMICAL", 156, 167], ["oral", "ORGANISM_SUBDIVISION", 191, 195], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 196, 214], ["patient", "SPECIES", 4, 11], ["intravenous (IV)", "TREATMENT", 75, 91], ["levofloxacin", "TREATMENT", 92, 104], ["IV vancomycin", "TREATMENT", 117, 130], ["oral oseltamivir", "TREATMENT", 151, 167], ["oral hydroxychloroquine", "TREATMENT", 191, 214]]], ["She also received a one time dose of IV mehylprednisolone 60 mg and was transitioned to oral prednisone 40 mg/day.", [["oral", "ANATOMY", 88, 92], ["mehylprednisolone", "CHEMICAL", 40, 57], ["prednisone", "CHEMICAL", 93, 103], ["mehylprednisolone", "CHEMICAL", 40, 57], ["prednisone", "CHEMICAL", 93, 103], ["mehylprednisolone", "SIMPLE_CHEMICAL", 40, 57], ["oral", "ORGANISM_SUBDIVISION", 88, 92], ["prednisone", "SIMPLE_CHEMICAL", 93, 103], ["IV mehylprednisolone", "TREATMENT", 37, 57], ["oral prednisone", "TREATMENT", 88, 103]]], ["On day 2 of hospitalization she was transferred to the general medical ward on 4 L nasal cannula.", [["nasal", "ANATOMY", 83, 88], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 83, 96], ["4 L nasal cannula", "TREATMENT", 79, 96]]], ["Levofloxacin and vancomycin were discontinued after 2 days.", [["Levofloxacin", "CHEMICAL", 0, 12], ["vancomycin", "CHEMICAL", 17, 27], ["Levofloxacin", "CHEMICAL", 0, 12], ["vancomycin", "CHEMICAL", 17, 27], ["Levofloxacin", "SIMPLE_CHEMICAL", 0, 12], ["vancomycin", "SIMPLE_CHEMICAL", 17, 27], ["Levofloxacin", "TREATMENT", 0, 12], ["vancomycin", "TREATMENT", 17, 27]]], ["She remained afebrile throughout hospitalization.", [["afebrile", "PROBLEM", 13, 21], ["afebrile", "OBSERVATION", 13, 21]]], ["On day 5 of hospitalization she was maintaining oxygen saturations of 98% on room air and was discharged home with 2 L of supplemental oxygen as needed.", [["oxygen", "CHEMICAL", 48, 54], ["oxygen", "CHEMICAL", 135, 141], ["oxygen", "CHEMICAL", 48, 54], ["oxygen", "CHEMICAL", 135, 141], ["oxygen", "SIMPLE_CHEMICAL", 48, 54], ["oxygen", "SIMPLE_CHEMICAL", 135, 141], ["oxygen saturations", "TEST", 48, 66], ["supplemental oxygen", "TREATMENT", 122, 141]]], ["She completed 5 days of prednisone, hydroxychloroquine, and oseltamivir.Case 3 ::: Case Presentations ::: IntroductionA 62-year-old African American female with a medical history of end-stage renal disease on hemodialysis, anemia of chronic kidney disease, diastolic heart failure, hypothyroidism, diabetes mellitus, and chronic left foot ulcer presented to our hospital on April 17, 2020 from a nursing home with 1 day complaints of cough, dyspnea, and fevers.", [["renal", "ANATOMY", 192, 197], ["kidney", "ANATOMY", 241, 247], ["heart", "ANATOMY", 267, 272], ["left foot ulcer", "ANATOMY", 329, 344], ["prednisone", "CHEMICAL", 24, 34], ["hydroxychloroquine", "CHEMICAL", 36, 54], ["oseltamivir", "CHEMICAL", 60, 71], ["end-stage renal disease", "DISEASE", 182, 205], ["anemia", "DISEASE", 223, 229], ["chronic kidney disease", "DISEASE", 233, 255], ["diastolic heart failure", "DISEASE", 257, 280], ["hypothyroidism", "DISEASE", 282, 296], ["diabetes mellitus", "DISEASE", 298, 315], ["chronic left foot ulcer", "DISEASE", 321, 344], ["cough", "DISEASE", 434, 439], ["dyspnea", "DISEASE", 441, 448], ["fevers", "DISEASE", 454, 460], ["prednisone", "CHEMICAL", 24, 34], ["hydroxychloroquine", "CHEMICAL", 36, 54], ["oseltamivir", "CHEMICAL", 60, 71], ["prednisone", "SIMPLE_CHEMICAL", 24, 34], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 36, 54], ["oseltamivir", "SIMPLE_CHEMICAL", 60, 71], ["American", "ORGANISM", 140, 148], ["female", "ORGANISM", 149, 155], ["renal", "ORGAN", 192, 197], ["kidney", "ORGAN", 241, 247], ["heart", "ORGAN", 267, 272], ["prednisone", "TREATMENT", 24, 34], ["hydroxychloroquine", "TREATMENT", 36, 54], ["oseltamivir", "TREATMENT", 60, 71], ["end-stage renal disease", "PROBLEM", 182, 205], ["hemodialysis", "TREATMENT", 209, 221], ["anemia", "PROBLEM", 223, 229], ["chronic kidney disease", "PROBLEM", 233, 255], ["diastolic heart failure", "PROBLEM", 257, 280], ["hypothyroidism", "PROBLEM", 282, 296], ["diabetes mellitus", "PROBLEM", 298, 315], ["chronic left foot ulcer", "PROBLEM", 321, 344], ["cough", "PROBLEM", 434, 439], ["dyspnea", "PROBLEM", 441, 448], ["fevers", "PROBLEM", 454, 460], ["renal", "ANATOMY", 192, 197], ["disease", "OBSERVATION", 198, 205], ["hemodialysis", "OBSERVATION", 209, 221], ["anemia", "OBSERVATION", 223, 229], ["chronic", "OBSERVATION_MODIFIER", 233, 240], ["kidney", "ANATOMY", 241, 247], ["disease", "OBSERVATION", 248, 255], ["diastolic", "OBSERVATION_MODIFIER", 257, 266], ["heart", "ANATOMY", 267, 272], ["failure", "OBSERVATION", 273, 280], ["hypothyroidism", "OBSERVATION", 282, 296], ["diabetes mellitus", "OBSERVATION", 298, 315], ["chronic", "OBSERVATION_MODIFIER", 321, 328], ["left", "ANATOMY_MODIFIER", 329, 333], ["foot", "ANATOMY", 334, 338], ["ulcer", "OBSERVATION", 339, 344], ["cough", "OBSERVATION", 434, 439], ["dyspnea", "OBSERVATION", 441, 448], ["fevers", "OBSERVATION", 454, 460]]], ["The patient\u2019s roommate was reported to be recently diagnosed with Covid-19 infection.", [["Covid-19 infection", "DISEASE", 66, 84], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["Covid-19", "SPECIES", 66, 74], ["Covid-19 infection", "PROBLEM", 66, 84], ["infection", "OBSERVATION", 75, 84]]], ["The patient was recently initiated on antibiotics with IV vancomycin 1g/daily and oral metronidazole 500 mg/three times daily for a left foot ulcer on April 13, 2020 to complete a total of 10 days.", [["oral", "ANATOMY", 82, 86], ["left foot ulcer", "ANATOMY", 132, 147], ["vancomycin", "CHEMICAL", 58, 68], ["metronidazole", "CHEMICAL", 87, 100], ["ulcer", "DISEASE", 142, 147], ["vancomycin", "CHEMICAL", 58, 68], ["metronidazole", "CHEMICAL", 87, 100], ["patient", "ORGANISM", 4, 11], ["vancomycin", "SIMPLE_CHEMICAL", 58, 68], ["oral", "ORGANISM_SUBDIVISION", 82, 86], ["metronidazole", "SIMPLE_CHEMICAL", 87, 100], ["foot", "ORGANISM_SUBDIVISION", 137, 141], ["patient", "SPECIES", 4, 11], ["antibiotics", "TREATMENT", 38, 49], ["IV vancomycin", "TREATMENT", 55, 68], ["oral metronidazole", "TREATMENT", 82, 100], ["a left foot ulcer", "PROBLEM", 130, 147], ["left", "ANATOMY_MODIFIER", 132, 136], ["foot", "ANATOMY", 137, 141], ["ulcer", "OBSERVATION", 142, 147]]], ["Upon presentation, she had a temperature of 102\u00b0F, heart rate of 83 beats/minute, respiratory rate of 27 breaths/minute, blood pressure of 110/51 mmHg, and oxygen saturation of 87% on room air.", [["heart", "ANATOMY", 51, 56], ["respiratory", "ANATOMY", 82, 93], ["blood", "ANATOMY", 121, 126], ["oxygen", "CHEMICAL", 156, 162], ["oxygen", "CHEMICAL", 156, 162], ["heart", "ORGAN", 51, 56], ["blood", "ORGANISM_SUBSTANCE", 121, 126], ["oxygen", "SIMPLE_CHEMICAL", 156, 162], ["a temperature", "TEST", 27, 40], ["heart rate", "TEST", 51, 61], ["respiratory rate", "TEST", 82, 98], ["blood pressure", "TEST", 121, 135], ["oxygen saturation", "TEST", 156, 173]]], ["She was placed on 2 L of supplemental oxygen with improvement in her oxygen saturations to 95%.", [["oxygen", "CHEMICAL", 38, 44], ["oxygen", "CHEMICAL", 69, 75], ["oxygen", "CHEMICAL", 38, 44], ["oxygen", "CHEMICAL", 69, 75], ["oxygen", "SIMPLE_CHEMICAL", 38, 44], ["oxygen", "SIMPLE_CHEMICAL", 69, 75], ["supplemental oxygen", "TREATMENT", 25, 44], ["her oxygen saturations", "TEST", 65, 87]]], ["Physical exam was significant for tachypnea with accessory muscle use and decreased breath sounds at the bilateral lung bases.Initial laboratory testing revealed a normal WBC with mild lymphopenia and elevations in several inflammatory markers (Table 1, Table 2).", [["muscle", "ANATOMY", 59, 65], ["lung", "ANATOMY", 115, 119], ["WBC", "ANATOMY", 171, 174], ["tachypnea", "DISEASE", 34, 43], ["lymphopenia", "DISEASE", 185, 196], ["muscle", "ORGAN", 59, 65], ["lung", "ORGAN", 115, 119], ["inflammatory markers", "PROTEIN", 223, 243], ["Physical exam", "TEST", 0, 13], ["tachypnea", "PROBLEM", 34, 43], ["accessory muscle use", "PROBLEM", 49, 69], ["decreased breath sounds at the bilateral lung bases", "PROBLEM", 74, 125], ["Initial laboratory testing", "TEST", 126, 152], ["mild lymphopenia", "PROBLEM", 180, 196], ["elevations in several inflammatory markers", "PROBLEM", 201, 243], ["accessory muscle", "ANATOMY", 49, 65], ["decreased", "OBSERVATION_MODIFIER", 74, 83], ["breath sounds", "OBSERVATION", 84, 97], ["bilateral", "ANATOMY_MODIFIER", 105, 114], ["lung", "ANATOMY", 115, 119], ["bases", "ANATOMY_MODIFIER", 120, 125], ["mild", "OBSERVATION_MODIFIER", 180, 184], ["lymphopenia", "OBSERVATION", 185, 196], ["elevations", "OBSERVATION_MODIFIER", 201, 211], ["several", "OBSERVATION_MODIFIER", 215, 222], ["inflammatory", "OBSERVATION_MODIFIER", 223, 235]]], ["Chest radiograph revealed infiltrates of the right lung base and right perihilar region (Figure 1).", [["right lung base", "ANATOMY", 45, 60], ["right perihilar region", "ANATOMY", 65, 87], ["lung", "ORGAN", 51, 55], ["Chest radiograph", "TEST", 0, 16], ["infiltrates of the right lung base", "PROBLEM", 26, 60], ["infiltrates", "OBSERVATION", 26, 37], ["right", "ANATOMY_MODIFIER", 45, 50], ["lung", "ANATOMY", 51, 55], ["base", "ANATOMY_MODIFIER", 56, 60], ["right", "ANATOMY_MODIFIER", 65, 70], ["perihilar", "ANATOMY_MODIFIER", 71, 80]]], ["RIDT via nasopharyngeal swab returned positive for influenza A infection.", [["nasopharyngeal swab", "ANATOMY", 9, 28], ["influenza A infection", "DISEASE", 51, 72], ["nasopharyngeal swab", "ORGANISM_SUBSTANCE", 9, 28], ["influenza A", "SPECIES", 51, 62], ["RIDT via nasopharyngeal swab", "TEST", 0, 28], ["influenza A infection", "PROBLEM", 51, 72], ["nasopharyngeal", "ANATOMY", 9, 23], ["swab", "OBSERVATION", 24, 28], ["positive for", "UNCERTAINTY", 38, 50], ["influenza", "OBSERVATION", 51, 60], ["infection", "OBSERVATION", 63, 72]]], ["The patient also tested positive for SARS-CoV-2 via RT\u2013PCR assay of a nasopharyngeal swab.", [["nasopharyngeal swab", "ANATOMY", 70, 89], ["patient", "ORGANISM", 4, 11], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 37, 47], ["nasopharyngeal swab", "CANCER", 70, 89], ["patient", "SPECIES", 4, 11], ["SARS-CoV", "SPECIES", 37, 45], ["SARS", "PROBLEM", 37, 41], ["CoV", "TEST", 42, 45], ["RT\u2013PCR", "TEST", 52, 58], ["a nasopharyngeal swab", "TEST", 68, 89], ["nasopharyngeal", "ANATOMY", 70, 84], ["swab", "OBSERVATION", 85, 89]]], ["She was initiated on IV levofloxacin 750 mg/day in addition to the continuation of vancomycin and metronidazole antibiotics.", [["levofloxacin", "CHEMICAL", 24, 36], ["vancomycin", "CHEMICAL", 83, 93], ["metronidazole", "CHEMICAL", 98, 111], ["levofloxacin", "CHEMICAL", 24, 36], ["vancomycin", "CHEMICAL", 83, 93], ["metronidazole", "CHEMICAL", 98, 111], ["levofloxacin", "SIMPLE_CHEMICAL", 24, 36], ["vancomycin", "SIMPLE_CHEMICAL", 83, 93], ["metronidazole", "SIMPLE_CHEMICAL", 98, 111], ["IV levofloxacin", "TREATMENT", 21, 36], ["vancomycin", "TREATMENT", 83, 93], ["metronidazole antibiotics", "TREATMENT", 98, 123]]], ["The patient was also started on oral hydroxychloroquine 400 mg/twice daily for one day and 200 mg/twice daily for 4 days and oral oseltamivir 75 mg/twice daily for 5 days.", [["oral", "ANATOMY", 32, 36], ["oral", "ANATOMY", 125, 129], ["hydroxychloroquine", "CHEMICAL", 37, 55], ["oseltamivir", "CHEMICAL", 130, 141], ["hydroxychloroquine", "CHEMICAL", 37, 55], ["oseltamivir", "CHEMICAL", 130, 141], ["patient", "ORGANISM", 4, 11], ["oral", "ORGANISM_SUBDIVISION", 32, 36], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 37, 55], ["oral", "ORGANISM_SUBDIVISION", 125, 129], ["oseltamivir", "SIMPLE_CHEMICAL", 130, 141], ["patient", "SPECIES", 4, 11], ["oral hydroxychloroquine", "TREATMENT", 32, 55], ["oral oseltamivir", "TREATMENT", 125, 141]]], ["Levofloxacin was discontinued on day 2 of hospitalization.", [["Levofloxacin", "CHEMICAL", 0, 12], ["Levofloxacin", "CHEMICAL", 0, 12], ["Levofloxacin", "SIMPLE_CHEMICAL", 0, 12], ["Levofloxacin", "TREATMENT", 0, 12]]], ["The patient improved throughout her hospitalization and was successfully weaned off of supplemental oxygen to room air, and remained afebrile after 3 days of initial hospitalization.", [["oxygen", "CHEMICAL", 100, 106], ["oxygen", "CHEMICAL", 100, 106], ["patient", "ORGANISM", 4, 11], ["oxygen", "SIMPLE_CHEMICAL", 100, 106], ["patient", "SPECIES", 4, 11], ["supplemental oxygen", "TREATMENT", 87, 106], ["afebrile", "PROBLEM", 133, 141], ["initial hospitalization", "TREATMENT", 158, 181], ["improved", "OBSERVATION_MODIFIER", 12, 20]]], ["She completed 5 days of oseltamivir and hydroxychloroquine.", [["oseltamivir", "CHEMICAL", 24, 35], ["hydroxychloroquine", "CHEMICAL", 40, 58], ["oseltamivir", "CHEMICAL", 24, 35], ["hydroxychloroquine", "CHEMICAL", 40, 58], ["oseltamivir", "SIMPLE_CHEMICAL", 24, 35], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 40, 58], ["oseltamivir", "TREATMENT", 24, 35], ["hydroxychloroquine", "TREATMENT", 40, 58]]], ["The patient was discharged to the nursing home after 6 days of hospitalization.Case 4 ::: Case Presentations ::: IntroductionA 58-year-old African American male with no significant past medical history presented to the emergency department on April 13, 2020 with increasing dyspnea, intermittent body aches, and cough for 5 days duration.", [["body", "ANATOMY", 296, 300], ["dyspnea", "DISEASE", 274, 281], ["intermittent body aches", "DISEASE", 283, 306], ["cough", "DISEASE", 312, 317], ["patient", "ORGANISM", 4, 11], ["American", "ORGANISM", 147, 155], ["body", "ORGANISM_SUBDIVISION", 296, 300], ["aches", "ORGANISM_SUBDIVISION", 301, 306], ["patient", "SPECIES", 4, 11], ["increasing dyspnea", "PROBLEM", 263, 281], ["intermittent body aches", "PROBLEM", 283, 306], ["cough", "PROBLEM", 312, 317], ["increasing", "OBSERVATION_MODIFIER", 263, 273], ["dyspnea", "OBSERVATION", 274, 281], ["body", "ANATOMY", 296, 300], ["aches", "OBSERVATION", 301, 306], ["cough", "OBSERVATION", 312, 317]]], ["He initially presented to an urgent care facility 1 day prior where he was diagnosed with influenza A via RIDT of a nasopharyngeal swab.", [["nasopharyngeal swab", "ANATOMY", 116, 135], ["nasopharyngeal swab", "CANCER", 116, 135], ["influenza A", "PROBLEM", 90, 101], ["a nasopharyngeal swab", "PROBLEM", 114, 135], ["influenza", "OBSERVATION", 90, 99], ["nasopharyngeal", "ANATOMY", 116, 130], ["swab", "OBSERVATION", 131, 135]]], ["He was given azithromycin 500 mg/day for one day, 250 mg/day for 4 days, and instructed to self-isolate at his home.", [["azithromycin", "CHEMICAL", 13, 25], ["azithromycin", "CHEMICAL", 13, 25], ["He", "ORGANISM", 0, 2], ["azithromycin", "SIMPLE_CHEMICAL", 13, 25], ["azithromycin", "TREATMENT", 13, 25]]], ["However, the patient\u2019s symptoms worsened, which prompted his presentation to the emergency department.", [["patient", "ORGANISM", 13, 20], ["patient", "SPECIES", 13, 20], ["symptoms", "PROBLEM", 23, 31]]], ["Upon presentation, the patient had a temperature of 99.9 \u00b0F, heart rate of 91 beats/minute, respiratory rate of 17 breaths/minute, blood pressure of 115/61, and oxygen saturation of 94% on room air.", [["heart", "ANATOMY", 61, 66], ["blood", "ANATOMY", 131, 136], ["oxygen", "CHEMICAL", 161, 167], ["oxygen", "CHEMICAL", 161, 167], ["patient", "ORGANISM", 23, 30], ["heart", "ORGAN", 61, 66], ["blood", "ORGANISM_SUBSTANCE", 131, 136], ["oxygen", "SIMPLE_CHEMICAL", 161, 167], ["patient", "SPECIES", 23, 30], ["a temperature", "TEST", 35, 48], ["heart rate", "TEST", 61, 71], ["respiratory rate", "TEST", 92, 108], ["blood pressure", "TEST", 131, 145], ["oxygen saturation", "TEST", 161, 178]]], ["On physical exam, his breathing was non-labored and lung sounds were clear to auscultation bilaterally.", [["lung", "ANATOMY", 52, 56], ["lung", "ORGAN", 52, 56], ["physical exam", "TEST", 3, 16], ["non-labored", "PROBLEM", 36, 47], ["lung sounds", "TEST", 52, 63], ["auscultation", "TEST", 78, 90], ["lung", "ANATOMY", 52, 56], ["clear", "OBSERVATION", 69, 74], ["auscultation", "OBSERVATION", 78, 90], ["bilaterally", "ANATOMY_MODIFIER", 91, 102]]], ["Chest radiograph showed streaky opacities within the lower lungs fields bilaterally.", [["lower lungs", "ANATOMY", 53, 64], ["lungs", "ORGAN", 59, 64], ["Chest radiograph", "TEST", 0, 16], ["streaky opacities within the lower lungs fields bilaterally", "PROBLEM", 24, 83], ["streaky", "OBSERVATION_MODIFIER", 24, 31], ["opacities", "OBSERVATION", 32, 41], ["lower", "ANATOMY_MODIFIER", 53, 58], ["lungs", "ANATOMY", 59, 64], ["fields", "ANATOMY_MODIFIER", 65, 71], ["bilaterally", "ANATOMY_MODIFIER", 72, 83]]], ["Repeat RIDT via nasopharyngeal swab on admission was positive for influenza B and negative for influenza A infection.", [["nasopharyngeal swab", "ANATOMY", 16, 35], ["influenza B", "DISEASE", 66, 77], ["influenza A infection", "DISEASE", 95, 116], ["nasopharyngeal swab", "CANCER", 16, 35], ["influenza A", "ORGANISM", 95, 106], ["influenza A", "SPECIES", 95, 106], ["Repeat RIDT via nasopharyngeal swab", "TEST", 0, 35], ["influenza B", "PROBLEM", 66, 77], ["influenza A infection", "PROBLEM", 95, 116], ["nasopharyngeal", "ANATOMY", 16, 30], ["infection", "OBSERVATION", 107, 116]]], ["The patient was deemed to be clinically stable and was discharged home from the emergency department.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["stable", "OBSERVATION", 40, 46]]], ["He was discharged home with a 7 day course of amoxicillin-clavulanate 875-125mg/day.", [["amoxicillin-clavulanate", "CHEMICAL", 46, 69], ["amoxicillin-clavulanate", "CHEMICAL", 46, 69], ["amoxicillin-clavulanate", "SIMPLE_CHEMICAL", 46, 69], ["amoxicillin", "TREATMENT", 46, 57], ["clavulanate", "TREATMENT", 58, 69]]], ["Subsequent SARS-CoV-2 RT-PCR testing returned positive following discharge.DiscussionSevere acute respiratory syndrome coronavirus\u20132 (SARS-CoV-2) is the novel coronavirus that causes the pandemic known as coronavirus disease 2019 (Covid-19) and is responsible for approximately 3 million cases and 200,000 deaths worldwide.", [["acute respiratory syndrome coronavirus\u20132", "DISEASE", 92, 132], ["coronavirus", "DISEASE", 159, 170], ["coronavirus disease", "DISEASE", 205, 224], ["deaths", "DISEASE", 306, 312], ["DiscussionSevere acute respiratory", "ORGANISM", 75, 109], ["SARS-CoV-2", "ORGANISM", 134, 144], ["coronavirus", "ORGANISM", 159, 170], ["DiscussionSevere acute respiratory syndrome coronavirus\u20132 (SARS-CoV-2", "SPECIES", 75, 144], ["Subsequent SARS", "TEST", 0, 15], ["CoV", "TEST", 16, 19], ["RT-PCR testing", "TEST", 22, 36], ["acute respiratory syndrome coronavirus\u20132", "PROBLEM", 92, 132], ["SARS", "TEST", 134, 138], ["CoV", "TEST", 139, 142], ["the novel coronavirus", "PROBLEM", 149, 170], ["coronavirus disease", "PROBLEM", 205, 224], ["Covid", "TEST", 231, 236], ["acute", "OBSERVATION_MODIFIER", 92, 97], ["respiratory syndrome", "OBSERVATION", 98, 118], ["coronavirus", "OBSERVATION", 159, 170]]], ["Influenza is a common endemic respiratory virus that causes seasonal outbreaks of respiratory illness, particularly during the winter months.", [["respiratory", "ANATOMY", 82, 93], ["Influenza", "DISEASE", 0, 9], ["respiratory virus", "DISEASE", 30, 47], ["respiratory illness", "DISEASE", 82, 101], ["Influenza", "SPECIES", 0, 9], ["Influenza", "PROBLEM", 0, 9], ["a common endemic respiratory virus", "PROBLEM", 13, 47], ["respiratory illness", "PROBLEM", 82, 101], ["common", "OBSERVATION_MODIFIER", 15, 21], ["endemic", "OBSERVATION_MODIFIER", 22, 29], ["respiratory virus", "OBSERVATION", 30, 47], ["respiratory illness", "OBSERVATION", 82, 101]]], ["SARS-CoV-2 and influenza viruses cause varying degrees of disease severity, from mild symptoms to severe respiratory illness requiring mechanical ventilation and even death.", [["respiratory", "ANATOMY", 105, 116], ["SARS", "DISEASE", 0, 4], ["influenza viruses", "DISEASE", 15, 32], ["respiratory illness", "DISEASE", 105, 124], ["death", "DISEASE", 167, 172], ["SARS-CoV-2", "ORGANISM", 0, 10], ["influenza viruses", "ORGANISM", 15, 32], ["SARS-CoV-2", "SPECIES", 0, 10], ["SARS", "TEST", 0, 4], ["CoV", "TEST", 5, 8], ["influenza viruses", "PROBLEM", 15, 32], ["disease severity", "PROBLEM", 58, 74], ["mild symptoms", "PROBLEM", 81, 94], ["severe respiratory illness", "PROBLEM", 98, 124], ["mechanical ventilation", "TREATMENT", 135, 157], ["even death", "PROBLEM", 162, 172], ["varying degrees", "OBSERVATION_MODIFIER", 39, 54], ["disease", "OBSERVATION", 58, 65], ["mild", "OBSERVATION_MODIFIER", 81, 85], ["severe", "OBSERVATION_MODIFIER", 98, 104], ["respiratory illness", "OBSERVATION", 105, 124], ["mechanical ventilation", "OBSERVATION", 135, 157]]], ["There have been few reports in the literature of patients with Covid-19 and influenza coinfection, and the effect on disease severity or outcomes in these patients has yet to be established.DiscussionIn this case series, we identified 4 cases of coinfection with influenza out of the 81 positive Covid-19 patients who presented to our institution, with an incidence rate of 4.9%.", [["influenza coinfection", "DISEASE", 76, 97], ["coinfection", "DISEASE", 246, 257], ["influenza", "DISEASE", 263, 272], ["patients", "ORGANISM", 49, 57], ["Covid-19", "ORGANISM", 63, 71], ["influenza", "ORGANISM", 76, 85], ["patients", "ORGANISM", 155, 163], ["patients", "ORGANISM", 305, 313], ["patients", "SPECIES", 49, 57], ["patients", "SPECIES", 155, 163], ["patients", "SPECIES", 305, 313], ["Covid", "TEST", 63, 68], ["influenza coinfection", "PROBLEM", 76, 97], ["disease severity", "PROBLEM", 117, 133], ["coinfection", "PROBLEM", 246, 257], ["influenza", "PROBLEM", 263, 272], ["an incidence rate", "TEST", 353, 370], ["few", "OBSERVATION_MODIFIER", 16, 19], ["coinfection", "OBSERVATION", 86, 97]]], ["While no official numbers exist as far as rates of influenza coinfection, review of the literature suggests that the rate ranges anywhere from 0.08 to 90%, depending on region.", [["influenza coinfection", "DISEASE", 51, 72], ["influenza coinfection", "PROBLEM", 51, 72], ["the rate", "TEST", 113, 121], ["influenza", "OBSERVATION", 51, 60]]], ["In a retrospective chart review performed by Zhou and Ding at a single hospital center in Wuhan, China, the authors found that nine out of 1,054 (0.9%) patients who tested positive for Covid-19 also tested positive for influenza (5).", [["influenza", "DISEASE", 219, 228], ["patients", "ORGANISM", 152, 160], ["patients", "SPECIES", 152, 160], ["Covid", "TEST", 185, 190], ["influenza", "PROBLEM", 219, 228]]], ["In another cohort of cases from the same region, 5 out of 115 (4.35%) patients who tested positive for Covid-19 also tested positive for influenza (6).", [["influenza", "DISEASE", 137, 146], ["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 70, 78], ["Covid", "TEST", 103, 108], ["influenza", "PROBLEM", 137, 146]]], ["On the contrary, a double-center study conducted by Xing and Li found that rates of coninfection in Qingdao, China were much higher than that in Wuhan, as much as up to 60% for influenza A and 53% of influenza B, although the sample sizes were considerably smaller in this particular study.Discussion(7).", [["coninfection", "DISEASE", 84, 96], ["influenza", "DISEASE", 177, 186], ["influenza B", "DISEASE", 200, 211], ["influenza B", "ORGANISM", 200, 211], ["influenza A", "SPECIES", 177, 188], ["a double-center study", "TEST", 17, 38], ["coninfection", "PROBLEM", 84, 96], ["influenza", "PROBLEM", 177, 186], ["influenza B", "PROBLEM", 200, 211], ["the sample sizes", "TEST", 222, 238], ["this particular study", "TEST", 268, 289], ["sizes", "OBSERVATION_MODIFIER", 233, 238], ["considerably", "OBSERVATION_MODIFIER", 244, 256], ["smaller", "OBSERVATION_MODIFIER", 257, 264]]], ["The authors suggested that localities with more temperate climates (i.e Qingdao) may have higher rates of coinfection with influenza and other respiratory viruses than places in subtropical climates.", [["coinfection", "DISEASE", 106, 117], ["influenza", "DISEASE", 123, 132], ["respiratory viruses", "DISEASE", 143, 162], ["coinfection", "PROBLEM", 106, 117], ["influenza", "PROBLEM", 123, 132], ["other respiratory viruses", "PROBLEM", 137, 162], ["coinfection", "OBSERVATION", 106, 117], ["respiratory viruses", "OBSERVATION", 143, 162]]], ["While a majority of novel coronavirus studies have been performed in China, other places around the globe have also reported simultaneous influenza infection with Covid-19.", [["influenza infection", "DISEASE", 138, 157], ["coronavirus", "ORGANISM", 26, 37], ["novel coronavirus studies", "TEST", 20, 45], ["simultaneous influenza infection", "PROBLEM", 125, 157], ["Covid", "TEST", 163, 168], ["globe", "ANATOMY", 100, 105], ["simultaneous", "OBSERVATION_MODIFIER", 125, 137], ["influenza", "OBSERVATION", 138, 147]]], ["In a sample of 116 specimens from multiple sites in Northern California who were positive for SARS-CoV-2, 1 (0.9%) was found to test positive for influenza A (8).", [["specimens", "ANATOMY", 19, 28], ["influenza", "DISEASE", 146, 155], ["SARS-CoV-2", "ORGANISM", 94, 104], ["SARS-CoV-2", "SPECIES", 94, 104], ["SARS", "PROBLEM", 94, 98], ["CoV", "TEST", 99, 102], ["influenza", "PROBLEM", 146, 155]]], ["In a retrospective study conducted in New York City, investigators found a coinfection rate of only 0.08%, however it is important to note that only 13% of Covid-19 positive samples were tested for influenza (9).", [["samples", "ANATOMY", 174, 181], ["coinfection", "DISEASE", 75, 86], ["influenza", "DISEASE", 198, 207], ["samples", "CANCER", 174, 181], ["a retrospective study", "TEST", 3, 24], ["a coinfection rate", "TEST", 73, 91], ["Covid", "TEST", 156, 161], ["influenza", "PROBLEM", 198, 207], ["coinfection", "OBSERVATION", 75, 86]]], ["Furthermore, a case-series published in Iran reported four cases of coinfection with Covid-19 and influenza A (10).DiscussionThe rapid influenza diagnostic test (RIDT) is an antigen detection assay that can detect influenza viral antigens in 10-15 minutes.", [["coinfection", "DISEASE", 68, 79], ["influenza viral antigens", "PROTEIN", 214, 238], ["Covid-19", "SPECIES", 85, 93], ["coinfection", "PROBLEM", 68, 79], ["Covid", "TEST", 85, 90], ["influenza A", "PROBLEM", 98, 109], ["The rapid influenza diagnostic test", "TEST", 125, 160], ["an antigen detection assay", "TEST", 171, 197], ["influenza viral antigens", "PROBLEM", 214, 238], ["coinfection", "OBSERVATION", 68, 79]]], ["Most rapid influenza diagnostic tests have a sensitivity of 50-79% for detecting influenza virus antigens and greater than 90% specific (11).", [["influenza virus antigens", "PROTEIN", 81, 105], ["influenza virus", "SPECIES", 81, 96], ["influenza virus", "SPECIES", 81, 96], ["Most rapid influenza diagnostic tests", "TEST", 0, 37], ["a sensitivity", "TEST", 43, 56], ["influenza virus antigens", "PROBLEM", 81, 105]]], ["Sensitivity of RIDTs to detect influenza B viral antigens is lower than for detection of influenza A viral antigens.", [["influenza B viral", "ORGANISM", 31, 48], ["RIDTs", "PROTEIN", 15, 20], ["influenza B viral antigens", "PROTEIN", 31, 57], ["influenza A viral antigens", "PROTEIN", 89, 115], ["influenza A", "SPECIES", 89, 100], ["RIDTs", "TEST", 15, 20], ["influenza B viral antigens", "TEST", 31, 57], ["influenza A viral antigens", "PROBLEM", 89, 115]]], ["Tests with low to moderate sensitivity and high specificity have the potential to produce false negative results more commonly than false positive results, especially during peak influenza activity in the community.", [["Tests", "TEST", 0, 5], ["low to moderate sensitivity", "PROBLEM", 11, 38], ["false positive results", "PROBLEM", 132, 154], ["low to moderate", "OBSERVATION_MODIFIER", 11, 26]]], ["In contrast, false-positive RIDT results are less likely, but can occur especially during periods of low influenza activity.", [["influenza", "DISEASE", 105, 114], ["low influenza activity", "PROBLEM", 101, 123], ["positive RIDT", "OBSERVATION_MODIFIER", 19, 32], ["less likely", "UNCERTAINTY", 45, 56], ["low", "OBSERVATION_MODIFIER", 101, 104], ["influenza", "OBSERVATION", 105, 114]]], ["When interpreting RIDT results it is important for clinicians to consider that a positive result means that a influenza viral antigen was detected, but does not necessarily mean a viable influenza virus is present or that the patient is contagious.", [["influenza", "DISEASE", 187, 196], ["influenza virus", "ORGANISM", 187, 202], ["patient", "ORGANISM", 226, 233], ["influenza viral antigen", "PROTEIN", 110, 133], ["patient", "SPECIES", 226, 233], ["a influenza viral antigen", "TEST", 108, 133], ["a viable influenza virus", "PROBLEM", 178, 202], ["influenza", "OBSERVATION", 187, 196]]], ["This may pose diagnostic difficulties considering the similar presentation of Covid-19 and influenza infections.", [["influenza infections", "DISEASE", 91, 111], ["influenza", "ORGANISM", 91, 100], ["Covid-19", "SPECIES", 78, 86], ["Covid", "TEST", 78, 83], ["influenza infections", "PROBLEM", 91, 111]]], ["Interestingly, the patient discussed in case 4 had a positive RIDT for influenza A and negative for influenza B initially, and then on repeat testing returned positive for influenza B and negative for influenza A. In order to further address these potential issues follow up with confirmatory tests such as RT-PCR or viral culture may be beneficial.DiscussionThe ages of the patients identified in this case series ranged from 58 to 66 with the average age being 61.5 years (Table 3).", [["influenza A", "DISEASE", 71, 82], ["influenza B", "DISEASE", 100, 111], ["influenza B", "DISEASE", 172, 183], ["influenza A", "DISEASE", 201, 212], ["patient", "ORGANISM", 19, 26], ["patients", "ORGANISM", 375, 383], ["patient", "SPECIES", 19, 26], ["patients", "SPECIES", 375, 383], ["influenza A", "PROBLEM", 71, 82], ["influenza B", "PROBLEM", 100, 111], ["repeat testing", "TEST", 135, 149], ["influenza B", "PROBLEM", 172, 183], ["influenza", "PROBLEM", 201, 210], ["confirmatory tests", "TEST", 280, 298], ["RT-PCR", "TEST", 307, 313], ["viral culture", "TEST", 317, 330]]], ["The 3 patients who were classified as obese (i.e body mass index (BMI \u2265 30.0)) were admitted to the hospital, as opposed to the patient with a BMI of 26.7 who was discharged home from the emergency department.", [["body", "ANATOMY", 49, 53], ["patients", "ORGANISM", 6, 14], ["body", "ORGANISM_SUBDIVISION", 49, 53], ["patient", "ORGANISM", 128, 135], ["patients", "SPECIES", 6, 14], ["patient", "SPECIES", 128, 135], ["obese (i.e body mass index", "PROBLEM", 38, 64], ["a BMI", "TEST", 141, 146], ["obese", "OBSERVATION", 38, 43]]], ["Furthermore, the 2 patients who met criteria for severe obesity (BMI \u2265 40) required supplemental oxygen, with 1 of them requiring ICU level of care.", [["obesity", "DISEASE", 56, 63], ["oxygen", "CHEMICAL", 97, 103], ["oxygen", "CHEMICAL", 97, 103], ["patients", "ORGANISM", 19, 27], ["oxygen", "SIMPLE_CHEMICAL", 97, 103], ["patients", "SPECIES", 19, 27], ["severe obesity", "PROBLEM", 49, 63], ["supplemental oxygen", "TREATMENT", 84, 103], ["ICU level of care", "TREATMENT", 130, 147], ["severe", "OBSERVATION_MODIFIER", 49, 55], ["obesity", "OBSERVATION", 56, 63]]], ["This is consistent with previous reports linking obesity to more severe illness and complications from Covid-19, which is thought to be due to increased expression of cytokines leading to a dysregulated inflammatory response.", [["obesity", "DISEASE", 49, 56], ["illness", "DISEASE", 72, 79], ["Covid-19", "CHEMICAL", 103, 111], ["cytokines", "PROTEIN", 167, 176], ["linking obesity", "PROBLEM", 41, 56], ["more severe illness", "PROBLEM", 60, 79], ["complications", "PROBLEM", 84, 97], ["Covid", "TEST", 103, 108], ["increased expression of cytokines", "PROBLEM", 143, 176], ["a dysregulated inflammatory response", "PROBLEM", 188, 224], ["consistent with", "UNCERTAINTY", 8, 23], ["obesity", "OBSERVATION", 49, 56], ["severe", "OBSERVATION_MODIFIER", 65, 71], ["illness", "OBSERVATION", 72, 79], ["thought to be due to", "UNCERTAINTY", 122, 142], ["increased", "OBSERVATION_MODIFIER", 143, 152], ["cytokines", "OBSERVATION", 167, 176], ["dysregulated", "OBSERVATION_MODIFIER", 190, 202], ["inflammatory", "OBSERVATION", 203, 215]]], ["It is also reported that obesity can impair the adaptive immune response to both the SARS-CoV-2 virus as well as the influenza virus (12).", [["obesity", "DISEASE", 25, 32], ["influenza virus", "DISEASE", 117, 132], ["SARS-CoV-2 virus", "ORGANISM", 85, 101], ["influenza virus", "ORGANISM", 117, 132], ["CoV-2 virus", "SPECIES", 90, 101], ["influenza virus", "SPECIES", 117, 132], ["SARS-CoV-2 virus", "SPECIES", 85, 101], ["obesity", "PROBLEM", 25, 32], ["the SARS", "TEST", 81, 89], ["CoV-2 virus", "TREATMENT", 90, 101], ["the influenza virus", "PROBLEM", 113, 132], ["obesity", "OBSERVATION", 25, 32]]], ["In regards to co-existing medical conditions, all 3 of our hospitalized patients had multiple comorbidities, with the most common being diabetes mellitus and hypertension.", [["diabetes mellitus", "DISEASE", 136, 153], ["hypertension", "DISEASE", 158, 170], ["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80], ["co-existing medical conditions", "PROBLEM", 14, 44], ["multiple comorbidities", "PROBLEM", 85, 107], ["diabetes mellitus", "PROBLEM", 136, 153], ["hypertension", "PROBLEM", 158, 170], ["diabetes mellitus", "OBSERVATION", 136, 153], ["hypertension", "OBSERVATION", 158, 170]]], ["This is also consistent with studies linking comorbid conditions to disease severity in Covid-19 as well as influenza (13,14).DiscussionPrevious studies have suggested a correlation between severe disease with lymphopenia and elevations in several inflammatory markers (15).", [["influenza", "DISEASE", 108, 117], ["lymphopenia", "DISEASE", 210, 221], ["inflammatory markers", "PROTEIN", 248, 268], ["Covid-19", "SPECIES", 88, 96], ["comorbid conditions", "PROBLEM", 45, 64], ["disease severity", "PROBLEM", 68, 84], ["Covid", "TEST", 88, 93], ["influenza", "PROBLEM", 108, 117], ["DiscussionPrevious studies", "TEST", 126, 152], ["severe disease", "PROBLEM", 190, 204], ["lymphopenia", "PROBLEM", 210, 221], ["elevations", "PROBLEM", 226, 236], ["several inflammatory markers", "TEST", 240, 268], ["consistent with", "UNCERTAINTY", 13, 28], ["severe", "OBSERVATION_MODIFIER", 190, 196], ["disease", "OBSERVATION", 197, 204], ["lymphopenia", "OBSERVATION", 210, 221], ["elevations", "OBSERVATION_MODIFIER", 226, 236], ["several", "OBSERVATION_MODIFIER", 240, 247], ["inflammatory", "OBSERVATION_MODIFIER", 248, 260]]], ["Inflammatory markers were not obtained for 1 patient who was discharged from the emergency department.", [["patient", "ORGANISM", 45, 52], ["patient", "SPECIES", 45, 52], ["Inflammatory markers", "TEST", 0, 20]]], ["The patient described in case 2 who required ICU admission demonstrated higher elevations in their inflammatory markers CK, LDH, and ferritin.", [["patient", "ORGANISM", 4, 11], ["CK", "GENE_OR_GENE_PRODUCT", 120, 122], ["LDH", "GENE_OR_GENE_PRODUCT", 124, 127], ["ferritin", "GENE_OR_GENE_PRODUCT", 133, 141], ["inflammatory markers", "PROTEIN", 99, 119], ["CK", "PROTEIN", 120, 122], ["LDH", "PROTEIN", 124, 127], ["ferritin", "PROTEIN", 133, 141], ["patient", "SPECIES", 4, 11], ["higher elevations", "PROBLEM", 72, 89], ["their inflammatory markers CK", "TEST", 93, 122], ["LDH", "TEST", 124, 127], ["ferritin", "TEST", 133, 141], ["inflammatory", "OBSERVATION_MODIFIER", 99, 111]]], ["The patient in case 3 also demonstrated higher inflammatory markers, although was being treated with IV antibiotics prior to admission for an underlying infection.", [["infection", "DISEASE", 153, 162], ["patient", "ORGANISM", 4, 11], ["inflammatory markers", "PROTEIN", 47, 67], ["patient", "SPECIES", 4, 11], ["higher inflammatory markers", "PROBLEM", 40, 67], ["IV antibiotics", "TREATMENT", 101, 115], ["an underlying infection", "PROBLEM", 139, 162], ["higher", "OBSERVATION_MODIFIER", 40, 46], ["inflammatory", "OBSERVATION_MODIFIER", 47, 59], ["infection", "OBSERVATION", 153, 162]]], ["Lymphopenia was common in our patient population and was seen in all 4 patients.", [["Lymphopenia", "DISEASE", 0, 11], ["patient", "ORGANISM", 30, 37], ["patients", "ORGANISM", 71, 79], ["patient", "SPECIES", 30, 37], ["patients", "SPECIES", 71, 79], ["Lymphopenia", "PROBLEM", 0, 11]]], ["Elevations of AST on admission were also observed in 3 of our patients.", [["AST", "SIMPLE_CHEMICAL", 14, 17], ["patients", "ORGANISM", 62, 70], ["AST", "PROTEIN", 14, 17], ["patients", "SPECIES", 62, 70], ["Elevations of AST", "PROBLEM", 0, 17]]], ["There are currently no reports in the literature discussing the specific significance of inflammatory marker elevations in patients with influenza and Covid-19 coinfection.", [["influenza", "DISEASE", 137, 146], ["patients", "ORGANISM", 123, 131], ["Covid-19", "ORGANISM", 151, 159], ["patients", "SPECIES", 123, 131], ["Covid-19", "SPECIES", 151, 159], ["inflammatory marker elevations", "PROBLEM", 89, 119], ["influenza", "PROBLEM", 137, 146], ["Covid", "TEST", 151, 156], ["coinfection", "PROBLEM", 160, 171], ["inflammatory", "OBSERVATION_MODIFIER", 89, 101]]], ["One retrospective study of 5 patients with Covid-19 and influenzavirus coinfection found that these patients did not appear to show more severe disease based on the laboratory findings, imaging studies, and patient prognosis (6).", [["influenzavirus coinfection", "DISEASE", 56, 82], ["patients", "ORGANISM", 29, 37], ["influenzavirus", "ORGANISM", 56, 70], ["patients", "ORGANISM", 100, 108], ["patient", "ORGANISM", 207, 214], ["patients", "SPECIES", 29, 37], ["patients", "SPECIES", 100, 108], ["patient", "SPECIES", 207, 214], ["One retrospective study", "TEST", 0, 23], ["Covid", "TEST", 43, 48], ["influenzavirus coinfection", "PROBLEM", 56, 82], ["more severe disease", "PROBLEM", 132, 151], ["the laboratory findings", "TEST", 161, 184], ["imaging studies", "TEST", 186, 201], ["severe", "OBSERVATION_MODIFIER", 137, 143], ["disease", "OBSERVATION", 144, 151]]], ["Our patients demonstrated similar clinical outcomes, with all 4 patients being discharged; although, 1 patient required ICU admission, she did not require mechanical ventilation and was transferred out of the ICU after 2 days.", [["patients", "ORGANISM", 4, 12], ["patients", "ORGANISM", 64, 72], ["patient", "ORGANISM", 103, 110], ["patients", "SPECIES", 4, 12], ["patients", "SPECIES", 64, 72], ["patient", "SPECIES", 103, 110], ["mechanical ventilation", "TREATMENT", 155, 177]]], ["The average length of stay was 4\u00b13 days, with 1 patient being discharged from the emergency department.", [["patient", "ORGANISM", 48, 55], ["patient", "SPECIES", 48, 55], ["average", "OBSERVATION_MODIFIER", 4, 11], ["length", "OBSERVATION_MODIFIER", 12, 18]]], ["There is currently very limited data concerning patients with Covid-19 and influenza coinfection; although, our small case series also suggests that the presence of coinfection alone does not appear to result in more severe disease presentations.", [["influenza coinfection", "DISEASE", 75, 96], ["coinfection", "DISEASE", 165, 176], ["patients", "ORGANISM", 48, 56], ["Covid-19", "ORGANISM", 62, 70], ["influenza", "ORGANISM", 75, 84], ["patients", "SPECIES", 48, 56], ["Covid", "TEST", 62, 67], ["influenza coinfection", "PROBLEM", 75, 96], ["coinfection", "PROBLEM", 165, 176], ["more severe disease presentations", "PROBLEM", 212, 245], ["coinfection", "OBSERVATION", 85, 96], ["small", "OBSERVATION_MODIFIER", 112, 117], ["coinfection", "OBSERVATION", 165, 176], ["severe", "OBSERVATION_MODIFIER", 217, 223], ["disease", "OBSERVATION", 224, 231]]], ["This finding may be attributed to the small sample size studied along with failure to accurately identify all hospitalized patients with coinfection.", [["coinfection", "DISEASE", 137, 148], ["patients", "ORGANISM", 123, 131], ["patients", "SPECIES", 123, 131], ["the small sample size", "PROBLEM", 34, 55], ["failure", "PROBLEM", 75, 82], ["coinfection", "PROBLEM", 137, 148], ["may be attributed to", "UNCERTAINTY", 13, 33], ["small", "OBSERVATION_MODIFIER", 38, 43], ["sample", "OBSERVATION_MODIFIER", 44, 50], ["size", "OBSERVATION_MODIFIER", 51, 55], ["coinfection", "OBSERVATION", 137, 148]]], ["Further reports are needed to investigate the impact of coinfection on disease severity and guidance on clinical management.ConclusionThe SARS-CoV-2 and influenza viruses have been known to cause mild to severe respiratory illness.", [["respiratory", "ANATOMY", 211, 222], ["coinfection", "DISEASE", 56, 67], ["influenza viruses", "DISEASE", 153, 170], ["respiratory illness", "DISEASE", 211, 230], ["SARS-CoV-2", "ORGANISM", 138, 148], ["influenza viruses", "ORGANISM", 153, 170], ["SARS-CoV-2", "SPECIES", 138, 148], ["coinfection on disease severity", "PROBLEM", 56, 87], ["clinical management", "TREATMENT", 104, 123], ["The SARS", "TEST", 134, 142], ["CoV", "TEST", 143, 146], ["influenza viruses", "PROBLEM", 153, 170], ["mild to severe respiratory illness", "PROBLEM", 196, 230], ["coinfection", "OBSERVATION", 56, 67], ["severe", "OBSERVATION_MODIFIER", 204, 210], ["respiratory illness", "OBSERVATION", 211, 230]]], ["There is a sparsity in the literature concerning coinfection of these two respiratory viruses and their impact on clinical outcomes.", [["respiratory viruses", "DISEASE", 74, 93], ["these two respiratory viruses", "PROBLEM", 64, 93], ["sparsity", "OBSERVATION_MODIFIER", 11, 19], ["coinfection", "OBSERVATION", 49, 60], ["respiratory viruses", "OBSERVATION", 74, 93]]], ["Here we reported 4 cases of patients with coinfection of Covid-19 and influenza.", [["coinfection", "DISEASE", 42, 53], ["influenza", "DISEASE", 70, 79], ["patients", "ORGANISM", 28, 36], ["Covid-19", "ORGANISM", 57, 65], ["influenza", "ORGANISM", 70, 79], ["patients", "SPECIES", 28, 36], ["Covid-19", "SPECIES", 57, 65], ["Covid", "TEST", 57, 62], ["influenza", "PROBLEM", 70, 79]]], ["Our study did not demonstrate more severe disease with coinfection.", [["coinfection", "DISEASE", 55, 66], ["Our study", "TEST", 0, 9], ["more severe disease", "PROBLEM", 30, 49], ["coinfection", "PROBLEM", 55, 66], ["severe", "OBSERVATION_MODIFIER", 35, 41], ["disease", "OBSERVATION", 42, 49], ["coinfection", "OBSERVATION", 55, 66]]], ["Due to lack of cotesting for both Covid-19 and influenza in everyConclusionpatient, we estimate the incidence of coinfection to be higher in the general population.", [["influenza", "DISEASE", 47, 56], ["coinfection", "DISEASE", 113, 124], ["cotesting", "TEST", 15, 24], ["Covid", "TEST", 34, 39], ["influenza", "PROBLEM", 47, 56], ["coinfection", "PROBLEM", 113, 124], ["coinfection", "OBSERVATION", 113, 124], ["higher", "OBSERVATION_MODIFIER", 131, 137]]], ["This case series highlights the necessity of further clinical reporting and guidance on clinical management.ConsentPatient consents were obtained for this case series.Declaration of Competing InterestThe authors declare that there are no conflicts of interest.", [["clinical management", "TREATMENT", 88, 107], ["this case series", "TEST", 150, 166]]]], "cd0b0291f39cdbb5c7d80273410807e4690b0679": [["INTRODUCTIONOne of the greatest challenges facing clinicians during the COVID-19 pandemic is the overwhelming number of patients requiring ventilatory support.", [["patients", "ORGANISM", 120, 128], ["patients", "SPECIES", 120, 128], ["ventilatory support", "TREATMENT", 139, 158], ["ventilatory support", "OBSERVATION", 139, 158]]], ["Hospitals in some areas have already faced having more patients that require mechanical ventilation than their available supply.INTRODUCTIONOne proposed method to extend the ventilator supply is to share a single ventilator between 2 or more patients.", [["patients", "ORGANISM", 55, 63], ["patients", "ORGANISM", 242, 250], ["patients", "SPECIES", 55, 63], ["patients", "SPECIES", 242, 250], ["mechanical ventilation", "TREATMENT", 77, 99], ["the ventilator supply", "TREATMENT", 170, 191], ["a single ventilator", "TREATMENT", 204, 223]]], ["Following its initial development in 2006 1 , investigations into ventilator splitting were initially limited to simulation 2 and an animal study 3 .", [["ventilator splitting", "TREATMENT", 66, 86], ["an animal study", "TEST", 130, 145]]], ["More recently, experience using shared ventilation in human patients has emerged from New York where a form of the technique was successfully applied to treat multiple patients with COVID-19 in the face of ventilator shortages.INTRODUCTIONVentilator splitting has received crisis approval by Health and Human Services and the Federal Drug Administration during the COVID-19 pandemic 4 .", [["human", "ORGANISM", 54, 59], ["patients", "ORGANISM", 60, 68], ["patients", "ORGANISM", 168, 176], ["Human", "ORGANISM", 303, 308], ["human", "SPECIES", 54, 59], ["patients", "SPECIES", 60, 68], ["patients", "SPECIES", 168, 176], ["Human", "SPECIES", 303, 308], ["human", "SPECIES", 54, 59], ["the technique", "TREATMENT", 111, 124], ["COVID", "TEST", 182, 187], ["ventilator shortages", "TREATMENT", 206, 226], ["the Federal Drug Administration", "TREATMENT", 322, 353], ["the COVID", "TEST", 361, 370], ["ventilator shortages", "OBSERVATION", 206, 226]]], ["However, it has also received criticism and words of caution from several preeminent medical organizations 5 .", [["caution", "TREATMENT", 53, 60]]], ["One of the concerns of these groups is the inability to adjust ventilator settings for patients individually to compensate for changes in patients' clinical status.INTRODUCTIONTo address these concerns, several groups have been working to create modified ventilator circuits which permit individualized settings for patients sharing a ventilator also known as Differential Multi-Ventilation (DVM).", [["patients", "ORGANISM", 87, 95], ["patients", "ORGANISM", 138, 146], ["patients", "ORGANISM", 316, 324], ["patients", "SPECIES", 87, 95], ["patients", "SPECIES", 138, 146], ["patients", "SPECIES", 316, 324], ["ventilator settings", "TREATMENT", 63, 82], ["changes in patients' clinical status", "PROBLEM", 127, 163], ["modified ventilator circuits", "TREATMENT", 246, 274], ["a ventilator", "TREATMENT", 333, 345]]], ["These systems utilize valves, sensors, and restrictors to allow for discrete adjustment and monitoring of ventilation parameters.", [["valves", "MULTI-TISSUE_STRUCTURE", 22, 28], ["valves", "TREATMENT", 22, 28], ["sensors", "TREATMENT", 30, 37], ["restrictors", "TREATMENT", 43, 54], ["discrete adjustment", "TREATMENT", 68, 87], ["monitoring of ventilation parameters", "TEST", 92, 128], ["valves", "OBSERVATION", 22, 28]]], ["A key component of these systems is an inline Positive End Expiratory Pressure (PEEP) valve.", [["an inline Positive End Expiratory Pressure (PEEP) valve", "TREATMENT", 36, 91], ["Expiratory Pressure", "OBSERVATION", 59, 78]]], ["With the ventilator in a pressure control mode, which is recommended for DVM setups 1-4,6 , a pressure relief type valve like an inline PEEP valve allows for adjustment of individual inspiratory and expiratory pressures.", [["the ventilator", "TREATMENT", 5, 19], ["a pressure control mode", "TREATMENT", 23, 46], ["DVM setups", "TEST", 73, 83], ["a pressure relief type valve", "TREATMENT", 92, 120], ["an inline PEEP valve", "TREATMENT", 126, 146], ["individual inspiratory and expiratory pressures", "TEST", 172, 219], ["PEEP valve", "OBSERVATION", 136, 146], ["expiratory pressures", "OBSERVATION", 199, 219]]], ["When placed on the expiratory limb, they allow for increased PEEP above the ventilator.", [["limb", "ANATOMY", 30, 34], ["limb", "ORGANISM_SUBDIVISION", 30, 34], ["increased PEEP", "TREATMENT", 51, 65], ["the ventilator", "TREATMENT", 72, 86], ["expiratory limb", "ANATOMY", 19, 34]]], ["When placed on the inspiratory limb, they remain closed to ventilator pressure until their setpoint is reached, thereby decreasing the inspiratory pressure, and therefore volume, delivered to the patient.INTRODUCTIONAdjustable inline PEEP valves are commercially available, but have been consistently backordered since the start of the pandemic and are not commonly stocked in hospitals.", [["inspiratory limb", "ANATOMY", 19, 35], ["inspiratory limb", "ORGANISM_SUBDIVISION", 19, 35], ["patient", "ORGANISM", 196, 203], ["patient", "SPECIES", 196, 203], ["ventilator pressure", "TREATMENT", 59, 78], ["the inspiratory pressure", "TEST", 131, 155], ["volume", "TREATMENT", 171, 177], ["INTRODUCTIONAdjustable inline PEEP valves", "TREATMENT", 204, 245], ["inspiratory limb", "ANATOMY", 19, 35], ["inspiratory pressure", "OBSERVATION", 135, 155], ["PEEP valves", "OBSERVATION", 234, 245]]], ["Standard adjustable PEEP valves are commonly available and used on bag-valve-masks during resuscitation; however, these models vent exhaled gases to the atmosphere whereas inline valves keep all gas within the circuit.", [["Standard adjustable PEEP valves", "TREATMENT", 0, 31], ["bag-valve", "TREATMENT", 67, 76], ["resuscitation", "TREATMENT", 90, 103], ["vent exhaled gases", "TEST", 127, 145], ["the atmosphere", "TREATMENT", 149, 163], ["inline valves", "TREATMENT", 172, 185], ["PEEP valves", "OBSERVATION", 20, 31], ["valve", "ANATOMY", 71, 76]]], ["The latter is preferable because most ventilators detect leak by comparing the volume of air returning from the expiratory limb to the volume delivered to the inspiratory limb.", [["limb", "ANATOMY", 123, 127], ["inspiratory limb", "ANATOMY", 159, 175], ["expiratory limb", "ORGANISM_SUBDIVISION", 112, 127], ["inspiratory limb", "ORGANISM_SUBDIVISION", 159, 175], ["leak", "PROBLEM", 57, 61], ["leak", "OBSERVATION", 57, 61], ["air", "OBSERVATION", 89, 92], ["expiratory limb", "ANATOMY", 112, 127], ["inspiratory limb", "ANATOMY", 159, 175]]], ["Venting to the atmosphere will result in the ventilator detecting a leak, and has the potential to contaminate providers and other patients.INTRODUCTIONIf a commercial inline PEEP valve is not available, a standard PEEP valve can be converted to an inline version with the addition of a device that collects exhaled gases.", [["patients", "ORGANISM", 131, 139], ["patients", "SPECIES", 131, 139], ["Venting", "TREATMENT", 0, 7], ["the ventilator", "TREATMENT", 41, 55], ["a leak", "PROBLEM", 66, 72], ["a commercial inline PEEP valve", "TREATMENT", 155, 185], ["a standard PEEP valve", "TREATMENT", 204, 225], ["an inline version", "TREATMENT", 246, 263], ["a device", "TREATMENT", 285, 293], ["exhaled gases", "TEST", 308, 321], ["leak", "OBSERVATION", 68, 72], ["PEEP valve", "OBSERVATION", 175, 185]]], ["The authors, in conjunction with the International Differential Multiventilation Working Group (www.differentialmultivent.org), propose a novel 3D printed collar that fits a standard bag-valve-mask (BVM) PEEP valve and converts it to an inline valve.INTRODUCTIONJ o u r n a l P r e -p r o o f METHODS IMAGE 1: A-a standard bag-valve-mask (BVM) PEEP valve (a) adjustment cap, (b) valve stem, (c) exhaust vents; B-a proposed diagram of the valve with the 3D-printed Collar; C-picture of the prototype A standard BVM PEEP valve is an adjustable pressure relief valve (Image 1, A).", [["valve stem", "ANATOMY", 379, 389], ["valve", "ANATOMY", 438, 443], ["valve", "PATHOLOGICAL_FORMATION", 244, 249], ["valve", "MULTI-TISSUE_STRUCTURE", 438, 443], ["a novel 3D printed collar", "TREATMENT", 136, 161], ["a standard bag-valve", "TREATMENT", 172, 192], ["mask (BVM) PEEP valve", "TREATMENT", 193, 214], ["an inline valve", "TREATMENT", 234, 249], ["A-a standard bag", "TREATMENT", 310, 326], ["valve-mask (BVM", "TREATMENT", 327, 342], ["PEEP valve", "TREATMENT", 344, 354], ["a) adjustment cap, (b) valve stem", "TREATMENT", 356, 389], ["the valve", "TREATMENT", 434, 443], ["the 3D-printed Collar", "TREATMENT", 449, 470], ["the prototype", "TREATMENT", 485, 498], ["A standard BVM PEEP valve", "TREATMENT", 499, 524], ["an adjustable pressure relief valve", "TREATMENT", 528, 563], ["valve", "ANATOMY", 187, 192], ["PEEP valve", "OBSERVATION", 204, 214], ["inline valve", "OBSERVATION", 237, 249], ["valve", "ANATOMY", 327, 332], ["PEEP valve", "OBSERVATION", 344, 354], ["valve stem", "ANATOMY", 379, 389], ["valve", "ANATOMY", 438, 443], ["PEEP valve", "OBSERVATION", 514, 524], ["adjustable pressure", "OBSERVATION", 531, 550], ["relief valve", "OBSERVATION", 551, 563]]], ["It has a diaphragm held in place by a spring which separates the pre-and post-valve airflow.", [["diaphragm", "ANATOMY", 9, 18], ["diaphragm", "ORGAN", 9, 18], ["diaphragm", "ANATOMY", 9, 18]]], ["The diaphragm opens to allow air to pass when the pre-valve pressure exceeds the setpoint of the valve.", [["diaphragm", "ANATOMY", 4, 13], ["pre-valve", "ANATOMY", 50, 59], ["valve", "ANATOMY", 97, 102], ["diaphragm", "ORGAN", 4, 13], ["valve", "PATHOLOGICAL_FORMATION", 97, 102], ["the pre-valve pressure", "TEST", 46, 68], ["the valve", "TREATMENT", 93, 102], ["diaphragm", "ANATOMY", 4, 13], ["air", "OBSERVATION", 29, 32], ["valve", "ANATOMY", 97, 102]]], ["The valve setpoint is adjusted by turning a knob on top of the valve, which loads the spring and increases the pressure required to open the diaphragm.", [["valve", "ANATOMY", 4, 9], ["valve", "ANATOMY", 63, 68], ["diaphragm", "ANATOMY", 141, 150], ["valve", "MULTI-TISSUE_STRUCTURE", 4, 9], ["valve", "PATHOLOGICAL_FORMATION", 63, 68], ["diaphragm", "ORGAN", 141, 150], ["The valve setpoint", "TREATMENT", 0, 18], ["the valve", "TREATMENT", 59, 68], ["the pressure", "TREATMENT", 107, 119], ["valve", "OBSERVATION", 4, 9], ["valve", "OBSERVATION", 63, 68], ["pressure", "OBSERVATION_MODIFIER", 111, 119], ["diaphragm", "ANATOMY", 141, 150]]], ["However, a standard PEEP valve vents exhaled air to the atmosphere.", [["a standard PEEP valve vents", "TREATMENT", 9, 36], ["PEEP valve", "OBSERVATION", 20, 30]]], ["To convert this to an inline valve, the authors designed a collar that sits on the exhaust side of the valve and collects exhaled gasses to return them to the ventilator.", [["valve", "ANATOMY", 103, 108], ["valve", "PATHOLOGICAL_FORMATION", 29, 34], ["valve", "PATHOLOGICAL_FORMATION", 103, 108], ["an inline valve", "TREATMENT", 19, 34], ["a collar", "TREATMENT", 57, 65], ["the valve", "TREATMENT", 99, 108], ["exhaled gasses", "TEST", 122, 136], ["the ventilator", "TREATMENT", 155, 169], ["valve", "OBSERVATION", 29, 34], ["valve", "ANATOMY", 103, 108]]], ["The device is printable with professional or hobbyist level 3d printers.", [["The device", "TREATMENT", 0, 10]]], ["Construction after that takes just a few minutes.INTRODUCTIONDesign: measurements were taken of all available PEEP valves.", [["PEEP valves", "TREATMENT", 110, 121], ["PEEP valves", "OBSERVATION", 110, 121]]], ["Using Tinkercad 3D design software (www.tinkercad.com), a collar was designed with one end that slipped over the neck of the PEEP valve to cover the outflow and an outflow tube that connected to standard 22mm ventilator tubing (Image 1, B).Construction:The collar was printed with 1.75mm PETG filament (240\u00b0 C nozzle, 70\u00b0 C bed, 40% infill) on a Creality (Shenzhen, China) Ender 3 printer.", [["neck", "ANATOMY", 113, 117], ["outflow tube", "ANATOMY", 164, 176], ["neck", "ORGANISM_SUBDIVISION", 113, 117], ["outflow tube", "TISSUE", 164, 176], ["a collar", "TREATMENT", 56, 64], ["the PEEP valve", "TREATMENT", 121, 135], ["an outflow tube", "TREATMENT", 161, 176], ["standard 22mm ventilator tubing", "TREATMENT", 195, 226], ["The collar", "TREATMENT", 253, 263], ["C nozzle", "TREATMENT", 308, 316], ["slipped", "OBSERVATION", 96, 103], ["neck", "ANATOMY", 113, 117], ["PEEP valve", "OBSERVATION", 125, 135], ["outflow", "ANATOMY_MODIFIER", 149, 156], ["outflow tube", "OBSERVATION", 164, 176], ["ventilator tubing", "OBSERVATION", 209, 226], ["collar", "ANATOMY", 257, 263]]], ["A standard BVM PEEP valve was obtained (Teleflex Medical-Morrisville, NC).", [["BVM", "ANATOMY", 11, 14], ["A standard BVM PEEP valve", "TREATMENT", 0, 25], ["NC", "TREATMENT", 70, 72], ["PEEP valve", "OBSERVATION", 15, 25]]], ["The valve adjustment cap was unscrewed and removed and the set screw (if present) was removed from the cap.", [["valve", "ANATOMY", 4, 9], ["valve", "MULTI-TISSUE_STRUCTURE", 4, 9], ["The valve adjustment cap", "TREATMENT", 0, 24], ["the set screw", "TREATMENT", 55, 68], ["valve", "ANATOMY", 4, 9], ["cap", "OBSERVATION_MODIFIER", 21, 24], ["screw", "OBSERVATION", 63, 68], ["cap", "OBSERVATION_MODIFIER", 103, 106]]], ["The collar was slid over the PEEP valve and a small amount of sealant (eg epoxy or silicon) was applied over the upper and lower joints of the collar to the valve.", [["valve", "ANATOMY", 157, 162], ["silicon", "CHEMICAL", 83, 90], ["epoxy", "CHEMICAL", 74, 79], ["silicon", "CHEMICAL", 83, 90], ["upper", "ORGANISM_SUBDIVISION", 113, 118], ["lower joints", "ORGANISM_SUBDIVISION", 123, 135], ["valve", "PATHOLOGICAL_FORMATION", 157, 162], ["The collar", "TREATMENT", 0, 10], ["the PEEP valve", "TREATMENT", 25, 39], ["sealant (eg epoxy or silicon)", "TREATMENT", 62, 91], ["collar", "ANATOMY", 4, 10], ["PEEP valve", "OBSERVATION", 29, 39], ["small", "OBSERVATION_MODIFIER", 46, 51], ["amount", "OBSERVATION_MODIFIER", 52, 58], ["sealant", "OBSERVATION_MODIFIER", 62, 69], ["upper", "ANATOMY_MODIFIER", 113, 118], ["lower joints", "ANATOMY", 123, 135], ["collar", "ANATOMY", 143, 149], ["valve", "ANATOMY", 157, 162]]], ["Thread sealing tape (aka plumbers tape) was wrapped around the threads of the PEEP valve prior to screwing the cap back on (Image 1, C).", [["Thread sealing tape", "TREATMENT", 0, 19], ["aka plumbers tape", "TREATMENT", 21, 38], ["the PEEP valve", "TREATMENT", 74, 88], ["sealing", "OBSERVATION_MODIFIER", 7, 14], ["tape", "OBSERVATION_MODIFIER", 15, 19], ["PEEP valve", "OBSERVATION", 78, 88], ["cap", "OBSERVATION_MODIFIER", 111, 114]]], ["Testing: the collared valve (Figure 1, C) was setup in series with another PEEP valve (Figure 1 , E) to simulate it being used with a ventilator.", [["the collared valve", "TREATMENT", 9, 27], ["another PEEP valve", "TREATMENT", 67, 85], ["a ventilator", "TREATMENT", 132, 144], ["collared valve", "ANATOMY", 13, 27]]], ["Simple manometers were constructed to measure the pressure behind Valve C (i.e. the PEEP delivered to a patient) and behind Valve E (i.e. the PEEP set on the ventilator).", [["patient", "ORGANISM", 104, 111], ["patient", "SPECIES", 104, 111], ["Simple manometers", "TREATMENT", 0, 17], ["the pressure behind Valve C", "TREATMENT", 46, 73], ["the PEEP", "TREATMENT", 80, 88], ["Valve E", "TREATMENT", 124, 131], ["the PEEP", "TREATMENT", 138, 146], ["the ventilator", "TREATMENT", 154, 168]]], ["Pressure testing for valve leaks was done by submerging the valve in shallow water and observing for air bubbling.J o u r n a l P r e -p r o o fOur prototype successfully increased the PEEP delivered to one side of the system without affecting the other (Table 1) .", [["valve", "ANATOMY", 21, 26], ["valve", "MULTI-TISSUE_STRUCTURE", 21, 26], ["Pressure testing", "TEST", 0, 16], ["valve leaks", "PROBLEM", 21, 32], ["air bubbling", "PROBLEM", 101, 113], ["a l P r e -p r o o fOur prototype", "TREATMENT", 124, 157], ["the PEEP", "TREATMENT", 181, 189], ["valve", "ANATOMY", 21, 26], ["leaks", "OBSERVATION", 27, 32], ["valve", "ANATOMY", 60, 65], ["air bubbling", "OBSERVATION", 101, 113]]], ["With the collared valve 1 set at 5cm H20 and Valve 2 set to 5cm of H20, the total pressure before the collared valve was 10 and the pressure before valve 2 remained 5cm of H2O.J o u r n a l P r e -p r o o fTo test the integrity of the valve, it was pressure tested.", [["valve", "ANATOMY", 235, 240], ["H2O", "CHEMICAL", 172, 175], ["H2O", "CHEMICAL", 172, 175], ["valve", "MULTI-TISSUE_STRUCTURE", 111, 116], ["valve", "PATHOLOGICAL_FORMATION", 235, 240], ["the collared valve", "TREATMENT", 5, 23], ["Valve", "TREATMENT", 45, 50], ["H20", "TREATMENT", 67, 70], ["the total pressure", "TEST", 72, 90], ["the collared valve", "TREATMENT", 98, 116], ["the pressure before valve", "TREATMENT", 128, 153], ["the valve", "TREATMENT", 231, 240], ["collared valve", "OBSERVATION", 9, 23], ["Valve", "ANATOMY", 45, 50], ["collared valve", "OBSERVATION", 102, 116], ["valve", "ANATOMY", 235, 240]]], ["When operating as a single valve, the collared valve was able to hold up to 12.5 cm of H20 of pressure without leaking from around the valve stem.", [["valve stem", "ANATOMY", 135, 145], ["valve", "PATHOLOGICAL_FORMATION", 27, 32], ["valve", "PATHOLOGICAL_FORMATION", 47, 52], ["a single valve", "TREATMENT", 18, 32], ["the collared valve", "TREATMENT", 34, 52], ["leaking", "PROBLEM", 111, 118], ["collared valve", "OBSERVATION", 38, 52], ["leaking", "OBSERVATION", 111, 118], ["valve stem", "ANATOMY", 135, 145]]], ["When a second valve was connected in series, a total PEEP of 32 cm of H2O was achieved but the valve began to leak from around the cap even with small amounts of back pressure.", [["valve", "ANATOMY", 14, 19], ["valve", "ANATOMY", 95, 100], ["H2O", "CHEMICAL", 70, 73], ["H2O", "CHEMICAL", 70, 73], ["valve", "PATHOLOGICAL_FORMATION", 14, 19], ["valve", "PATHOLOGICAL_FORMATION", 95, 100], ["a second valve", "TREATMENT", 5, 19], ["a total PEEP", "TREATMENT", 45, 57], ["H2O", "TREATMENT", 70, 73], ["the valve", "TREATMENT", 91, 100], ["leak", "PROBLEM", 110, 114], ["valve", "OBSERVATION", 14, 19], ["valve", "ANATOMY", 95, 100], ["leak", "OBSERVATION", 110, 114], ["cap", "OBSERVATION_MODIFIER", 131, 134], ["small", "OBSERVATION_MODIFIER", 145, 150], ["amounts", "OBSERVATION_MODIFIER", 151, 158], ["back pressure", "OBSERVATION", 162, 175]]], ["The valve cap was removed, 7 wraps of joint thread tape was applied to the threads of the valve and the cap was rethreaded on the valve.", [["valve cap", "ANATOMY", 4, 13], ["joint", "ANATOMY", 38, 43], ["valve", "ANATOMY", 90, 95], ["cap", "ANATOMY", 104, 107], ["valve", "ANATOMY", 130, 135], ["valve cap", "MULTI-TISSUE_STRUCTURE", 4, 13], ["valve", "PATHOLOGICAL_FORMATION", 90, 95], ["valve", "PATHOLOGICAL_FORMATION", 130, 135], ["The valve cap", "TREATMENT", 0, 13], ["7 wraps of joint thread tape", "TREATMENT", 27, 55], ["the valve", "TREATMENT", 86, 95], ["the cap", "TREATMENT", 100, 107], ["the valve", "TREATMENT", 126, 135], ["valve", "ANATOMY", 4, 9], ["cap", "OBSERVATION_MODIFIER", 10, 13], ["joint", "ANATOMY", 38, 43], ["valve", "ANATOMY", 90, 95], ["cap", "OBSERVATION_MODIFIER", 104, 107], ["valve", "ANATOMY", 130, 135]]], ["On re-testing, the valve no longer leaked up to 61 cm of H2O, which was the maximum test pressure of the manomator.DISCUSSIONVentilator splitting is a method to share a single ventilator between multiple patients.", [["valve", "ANATOMY", 19, 24], ["H2O", "CHEMICAL", 57, 60], ["H2O", "CHEMICAL", 57, 60], ["valve", "PATHOLOGICAL_FORMATION", 19, 24], ["patients", "ORGANISM", 204, 212], ["patients", "SPECIES", 204, 212], ["the valve", "TREATMENT", 15, 24], ["the maximum test pressure", "TEST", 72, 97], ["a single ventilator", "TREATMENT", 167, 186], ["valve", "ANATOMY", 19, 24], ["61 cm", "OBSERVATION_MODIFIER", 48, 53]]], ["This practice is reserved for crisis situations when there are insufficient ventilators to meet demand.", [["crisis situations", "PROBLEM", 30, 47], ["insufficient ventilators", "TREATMENT", 63, 87]]], ["Unfortunately, during the beginning of the COVID-19 pandemic in New York this situation occurred, and multiple patients had to share ventilators.", [["patients", "ORGANISM", 111, 119], ["patients", "SPECIES", 111, 119], ["ventilators", "TREATMENT", 133, 144]]], ["Given the safety concerns about the inability to individualize ventilation parameters during ventilator sharing, improvements in ventilator splitting design are crucial.DISCUSSIONOur prototype collar successfully converts a standard bag-valve-mask PEEP valve to an inline PEEP valve.", [["ventilation parameters", "TEST", 63, 85], ["ventilator sharing", "TREATMENT", 93, 111], ["prototype collar", "TREATMENT", 183, 199], ["a standard bag-valve", "TREATMENT", 222, 242], ["mask PEEP valve", "TREATMENT", 243, 258], ["an inline PEEP valve", "TREATMENT", 262, 282], ["ventilator splitting", "OBSERVATION", 129, 149], ["valve", "ANATOMY", 237, 242], ["PEEP valve", "OBSERVATION", 248, 258], ["PEEP valve", "OBSERVATION", 272, 282]]], ["With this type of valve, a split ventilation system can be built with different PEEP settings for each patient.", [["valve", "PATHOLOGICAL_FORMATION", 18, 23], ["patient", "ORGANISM", 103, 110], ["patient", "SPECIES", 103, 110], ["valve", "TREATMENT", 18, 23], ["a split ventilation system", "TREATMENT", 25, 51], ["different PEEP settings", "TREATMENT", 70, 93], ["valve", "OBSERVATION", 18, 23]]], ["For example, one patient can receive a PEEP of 5 cm of H2O set at the ventilator while the other patient receives a total PEEP of 10 after having an inline PEEP valve like ours set to 5 cm of H2O inserted into their expiratory limb.", [["limb", "ANATOMY", 227, 231], ["H2O", "CHEMICAL", 55, 58], ["H2O", "CHEMICAL", 192, 195], ["H2O", "CHEMICAL", 55, 58], ["H2O", "CHEMICAL", 192, 195], ["patient", "ORGANISM", 17, 24], ["patient", "ORGANISM", 97, 104], ["limb", "ORGANISM_SUBDIVISION", 227, 231], ["patient", "SPECIES", 17, 24], ["patient", "SPECIES", 97, 104], ["a PEEP", "TREATMENT", 37, 43], ["H2O", "TREATMENT", 55, 58], ["the ventilator", "TREATMENT", 66, 80], ["a total PEEP", "TREATMENT", 114, 126], ["an inline PEEP valve", "TREATMENT", 146, 166], ["PEEP valve", "OBSERVATION", 156, 166], ["expiratory limb", "ANATOMY", 216, 231]]], ["A check valve on the inspiratory limb would also be inserted on the same side as the PEEP valve to prevent back-flow of the higher expiratory pressure into the other patients' lower pressure system.", [["valve", "ANATOMY", 8, 13], ["inspiratory limb", "ANATOMY", 21, 37], ["valve", "MULTI-TISSUE_STRUCTURE", 8, 13], ["inspiratory limb", "ORGANISM_SUBDIVISION", 21, 37], ["patients", "ORGANISM", 166, 174], ["patients", "SPECIES", 166, 174], ["A check valve on the inspiratory limb", "TREATMENT", 0, 37], ["the PEEP valve", "TREATMENT", 81, 95], ["valve", "OBSERVATION", 8, 13], ["inspiratory limb", "ANATOMY", 21, 37], ["PEEP valve", "OBSERVATION", 85, 95], ["flow", "OBSERVATION", 112, 116], ["expiratory pressure", "OBSERVATION", 131, 150], ["lower pressure", "OBSERVATION", 176, 190]]], ["Our valve did not leak when there was no back pressure, which is simulating a situation where the ventilator PEEP was set to 0.", [["valve", "ANATOMY", 4, 9], ["back", "ANATOMY", 41, 45], ["valve", "PATHOLOGICAL_FORMATION", 4, 9], ["leak", "PROBLEM", 18, 22], ["back pressure", "PROBLEM", 41, 54], ["the ventilator PEEP", "TREATMENT", 94, 113], ["valve", "ANATOMY", 4, 9], ["not", "UNCERTAINTY", 14, 17], ["leak", "OBSERVATION", 18, 22]]], ["However, with back pressure the valve stem seal began to leak.", [["valve stem", "ANATOMY", 32, 42], ["back pressure the valve stem seal", "TREATMENT", 14, 47], ["leak", "PROBLEM", 57, 61], ["valve", "ANATOMY", 32, 37], ["stem seal", "OBSERVATION", 38, 47], ["leak", "OBSERVATION", 57, 61]]], ["Although this was solved by the addition of thread tape, this is not an ideal solution.", [["thread tape", "TREATMENT", 44, 55]]], ["If further testing determine this collared valve is suitable for clinical use, it would be safest to keep the ventilator PEEP at 0 and use collared PEEP valves on each patients' expiratory limb to adjust individual expiratory pressures.", [["limb", "ANATOMY", 189, 193], ["valve", "MULTI-TISSUE_STRUCTURE", 43, 48], ["patients", "ORGANISM", 168, 176], ["limb", "ORGANISM_SUBDIVISION", 189, 193], ["patients", "SPECIES", 168, 176], ["further testing", "TEST", 3, 18], ["this collared valve", "TREATMENT", 29, 48], ["the ventilator PEEP", "TREATMENT", 106, 125], ["collared PEEP valves", "TREATMENT", 139, 159], ["each patients' expiratory limb", "TREATMENT", 163, 193], ["individual expiratory pressures", "TEST", 204, 235], ["PEEP valves", "OBSERVATION", 148, 159]]], ["In this situation the authors still recommend thread sealing tape as a backup safety measure.DISCUSSIONCommercial valves would be preferred.", [["thread sealing tape", "TREATMENT", 46, 65], ["a backup safety measure.DISCUSSIONCommercial valves", "TREATMENT", 69, 120]]], ["In fact, insufficient commercial valves could be found to test differential multiventilation system designs.", [["insufficient commercial valves", "TREATMENT", 9, 39], ["insufficient", "OBSERVATION_MODIFIER", 9, 21], ["commercial valves", "OBSERVATION", 22, 39]]], ["This lack of availability is what drove the authors to create alternatives.DISCUSSION3D-printed adjustable inline PEEP valve designs are available online.", [["printed adjustable inline PEEP valve designs", "TREATMENT", 88, 132], ["PEEP valve", "OBSERVATION", 114, 124]]], ["There is also the variable quality between 3D printers and 3D prints to consider.", [["variable", "OBSERVATION_MODIFIER", 18, 26]]], ["As our design relies on an FDA cleared standard medical device, the valve itself is inherently reliable.", [["valve", "ANATOMY", 68, 73], ["valve", "PATHOLOGICAL_FORMATION", 68, 73], ["an FDA", "TREATMENT", 24, 30], ["standard medical device", "TREATMENT", 39, 62], ["the valve", "TREATMENT", 64, 73], ["valve", "ANATOMY", 68, 73]]], ["The collar is 3D printed and therefore we recommend each valve be tested.J o u r n a l P r e -p r o o fIt is the authors' opinion that any 3D printed valve or adapter should be pressure tested prior to use.", [["valve", "PATHOLOGICAL_FORMATION", 57, 62], ["valve", "MULTI-TISSUE_STRUCTURE", 150, 155], ["The collar", "TREATMENT", 0, 10], ["each valve", "TREATMENT", 52, 62], ["3D printed valve", "TREATMENT", 139, 155], ["collar", "ANATOMY", 4, 10], ["valve", "OBSERVATION", 150, 155]]], ["If unable to perform elsewhere, this can be performed in the hospital by connecting the device to any positive pressure ventilating machine (cpap, bipap, mechanical ventilator).", [["any positive pressure ventilating machine", "TREATMENT", 98, 139], ["cpap", "TREATMENT", 141, 145], ["bipap", "TREATMENT", 147, 152], ["mechanical ventilator", "TREATMENT", 154, 175]]], ["Set the driving pressure to as high as possible (>40cm of H2O at minimum) to simulate all stresses.", [["H2O", "CHEMICAL", 58, 61], ["H2O", "CHEMICAL", 58, 61]]], ["Occlude the system to fully pressurize it and submerge the device in sterile water.", [["the device in sterile water", "TREATMENT", 55, 82], ["device", "OBSERVATION_MODIFIER", 59, 65]]], ["If bubbling occurs the device should be discarded.LIMITATIONSMost importantly this is a prototype and has not been tested in animals or humans.", [["humans", "ORGANISM", 136, 142], ["humans", "SPECIES", 136, 142], ["humans", "SPECIES", 136, 142], ["bubbling", "PROBLEM", 3, 11], ["the device", "TREATMENT", 19, 29]]], ["Further testing is needed before it can be safely deployed.", [["Further testing", "TEST", 0, 15]]], ["Aside from the issues with 3D printing listed above, the valve requires a small amount of sealant which could be a source of error.", [["valve", "PATHOLOGICAL_FORMATION", 57, 62], ["3D printing", "TREATMENT", 27, 38], ["the valve", "TREATMENT", 53, 62], ["a small amount of sealant", "TREATMENT", 72, 97], ["valve", "ANATOMY", 57, 62], ["small", "OBSERVATION_MODIFIER", 74, 79], ["amount", "OBSERVATION_MODIFIER", 80, 86], ["sealant", "OBSERVATION", 90, 97]]], ["If not applied properly it could create an air leak or enter the valve chamber and effect valve function.", [["valve", "ANATOMY", 65, 70], ["valve", "ANATOMY", 90, 95], ["valve", "MULTI-TISSUE_STRUCTURE", 90, 95], ["an air leak", "PROBLEM", 40, 51], ["the valve chamber", "TREATMENT", 61, 78], ["valve function", "TREATMENT", 90, 104], ["air leak", "OBSERVATION", 43, 51], ["valve", "ANATOMY", 65, 70], ["chamber", "ANATOMY_MODIFIER", 71, 78], ["effect valve", "OBSERVATION", 83, 95]]], ["The durability of the valve has not been tested and it may be more prone to cracking.", [["valve", "ANATOMY", 22, 27], ["valve", "PATHOLOGICAL_FORMATION", 22, 27], ["the valve", "TREATMENT", 18, 27], ["durability", "OBSERVATION_MODIFIER", 4, 14], ["valve", "ANATOMY", 22, 27]]], ["The assembled collared valve would need to be cleaned and sterilized.", [["valve", "ANATOMY", 23, 28], ["valve", "ORGAN", 23, 28], ["The assembled collared valve", "TREATMENT", 0, 28], ["collared valve", "OBSERVATION", 14, 28]]], ["Although not tested, plastic devices similar to this can be sterilized with non-heat methods such as used for endoscopes.CONCLUSIONInline PEEP valves are required to individualize ventilation parameters in a split ventilation setup.", [["plastic devices", "TREATMENT", 21, 36], ["non-heat methods", "TREATMENT", 76, 92], ["endoscopes", "TREATMENT", 110, 120], ["CONCLUSIONInline PEEP valves", "TREATMENT", 121, 149], ["ventilation parameters", "TEST", 180, 202], ["a split ventilation setup", "TREATMENT", 206, 231], ["PEEP valves", "OBSERVATION", 138, 149]]], ["The authors present a novel inline PEEP valve based on a standard BVM PEEP valve.", [["a novel inline PEEP valve", "TREATMENT", 20, 45], ["a standard BVM PEEP valve", "TREATMENT", 55, 80], ["PEEP valve", "OBSERVATION", 35, 45], ["PEEP valve", "OBSERVATION", 70, 80]]], ["A 3D printed collar is sealed to the valve and collects exhaled gases to return them to the ventilator.", [["valve", "ANATOMY", 37, 42], ["valve", "PATHOLOGICAL_FORMATION", 37, 42], ["A 3D printed collar", "TREATMENT", 0, 19], ["the valve", "TREATMENT", 33, 42], ["exhaled gases", "TEST", 56, 69], ["the ventilator", "TREATMENT", 88, 102], ["collar", "OBSERVATION", 13, 19], ["valve", "ANATOMY", 37, 42]]], ["With further testing our valve design could be used when commercial inline valves are not available.", [["valve", "ANATOMY", 25, 30], ["valve", "PATHOLOGICAL_FORMATION", 25, 30], ["valves", "MULTI-TISSUE_STRUCTURE", 75, 81], ["our valve design", "TREATMENT", 21, 37], ["commercial inline valves", "TREATMENT", 57, 81], ["valve", "OBSERVATION", 25, 30]]]], "712fc235ff427ff585348c996369e25524f76a9a": [["IntroductionOn the 11th of March 2020, the World Health Organization (2020) declared a pandemic triggered by the coronavirus disease (COVID-19 caused by the novel coronavirus SARS-CoV-2).IntroductionIn the absence of a specific treatment or vaccination, one-third of the world was recommended to stay at home to limit the spread of the contagion.", [["coronavirus disease", "DISEASE", 113, 132], ["coronavirus", "ORGANISM", 113, 124], ["coronavirus SARS-CoV-2", "ORGANISM", 163, 185], ["coronavirus", "SPECIES", 113, 124], ["coronavirus", "SPECIES", 163, 174], ["a pandemic", "PROBLEM", 85, 95], ["the coronavirus disease", "PROBLEM", 109, 132], ["COVID", "TEST", 134, 139], ["the novel coronavirus SARS", "PROBLEM", 153, 179], ["a specific treatment", "TREATMENT", 217, 237], ["vaccination", "TREATMENT", 241, 252], ["coronavirus disease", "OBSERVATION", 113, 132]]], ["Furthermore, the lockdown impacted individuals' health behaviors with a change in dietary habits (with increased home-cooking and consumption of snacks) but at the same time inducing a more sedentary lifestyle (for instance, due to the limitation to practice sports and similar physical activities outside; Arora & Grey, 2020) .IntroductionThis extraordinary change of habits has a dramatic impact also on the natural environment (Zambrano-Monserrate et al., 2020) .", [["dramatic", "OBSERVATION_MODIFIER", 382, 390]]], ["These authors pointed out some positive as well as negative consequences of the forced lockdown.", [["some positive", "PROBLEM", 26, 39], ["the forced lockdown", "PROBLEM", 76, 95]]], ["For example, limited use of motor vehicles has resulted in a reduction in NO2 concentration in countries such as France, Germany and Italy (European Space Agency, 2020).", [["NO2", "CHEMICAL", 74, 77], ["NO2", "CHEMICAL", 74, 77], ["NO2", "SIMPLE_CHEMICAL", 74, 77], ["motor vehicles", "TREATMENT", 28, 42], ["a reduction in NO2 concentration", "TREATMENT", 59, 91], ["reduction", "OBSERVATION_MODIFIER", 61, 70], ["NO2 concentration", "OBSERVATION", 74, 91]]], ["On the other hand, organic and inorganic waste raised due to the increased use of medical waste (masks and gloves), single-use plastic, and waste related to inappropriate storage and overbuying food (Jribi et al., 2020) .IntroductionThis study aims at contributing to the literature on individual differences and pro-environmental behaviors by looking at how during an uncertain situation (i.e. the COVID-19 pandemic) individuals with different levels of Need for Cognitive Closure (Kruglanski, 2004; Kruglanski & Webster, 1996) may engage in a series of thoughts and behaviors that result in damaging the environment (i.e. food waste).", [["organic and inorganic waste", "PROBLEM", 19, 46], ["medical waste (masks and gloves", "TREATMENT", 82, 113], ["This study", "TEST", 233, 243], ["the COVID", "TEST", 395, 404], ["Cognitive Closure", "TREATMENT", 464, 481]]], ["Starting from a call for more research in factors influencing food waste by Porpino (2016) , we aim at understanding whether individuals with a high (vs. low) need for cognitive closure react to the uncertainty brought by COVID-19 by perceiving having less food and therefore stockpiling more than needed, in turn producing also higher waste.IntroductionWe also test two moderating factors: whether such an outcome is more pronounced in women or men, and if there are differences in countries with different levels of food waste.", [["women", "ORGANISM", 437, 442], ["men", "ORGANISM", 446, 449], ["women", "SPECIES", 437, 442], ["men", "SPECIES", 446, 449], ["a high (vs. low)", "PROBLEM", 142, 158], ["cognitive closure", "TREATMENT", 168, 185], ["more pronounced", "OBSERVATION_MODIFIER", 418, 433]]], ["Second, both countries were under lockdown when we conducted our research, providing a natural setting to test our hypotheses.IntroductionIn the sections that follow, we provide a summary of the literature on food waste, mainly focusing on studies on the topic during the COVID-19 pandemic.", [["studies", "TEST", 240, 247], ["the COVID", "TEST", 268, 277]]], ["We then present a brief overview of the Need for Cognitive Closure and its effects on individuals' perceptions and behaviors.", [["Cognitive Closure", "DISEASE", 49, 66], ["Cognitive Closure", "TREATMENT", 49, 66]]], ["Finally, we introduce the role of gender and country of residence as moderators and present our hypotheses and our conceptual model.The impact of food waste during the coronavirus outbreakFood waste is a global issue for both developed and developing countries.", [["coronavirus", "SPECIES", 168, 179], ["the coronavirus outbreak", "PROBLEM", 164, 188], ["food waste", "OBSERVATION", 146, 156], ["waste", "OBSERVATION", 193, 198]]], ["An impressive amount of food that we buy goes from our fridge to our bin.", [["impressive", "OBSERVATION_MODIFIER", 3, 13], ["amount", "OBSERVATION_MODIFIER", 14, 20]]], ["During the COVID-19 pandemic, our habits changed due to the recommendations given by the government to stay at home.", [["the COVID", "TEST", 7, 16]]], ["For example, the amount of time that people could go to the supermarket were limited and people had more time for cooking.", [["people", "ORGANISM", 37, 43], ["people", "ORGANISM", 89, 95], ["people", "SPECIES", 37, 43], ["people", "SPECIES", 89, 95], ["amount", "OBSERVATION_MODIFIER", 17, 23]]], ["At the time of our research, the effect of the lockdown on the food waste habits had been investigated in a few studies presenting contradictory findings.", [["a few studies", "TEST", 106, 119]]], ["According to Jribi et al. (2020) in a study conducted in Tunisia on consumer awareness, attitudes, and behaviors during the pandemic, respondents reported better shopping planning.", [["a study", "TEST", 36, 43]]], ["On the other end, however, the authors found an increase in overcooking, inappropriate storage and overbuying of food that affects the food waste.", [["an increase in overcooking", "PROBLEM", 45, 71], ["inappropriate storage", "PROBLEM", 73, 94], ["increase", "OBSERVATION_MODIFIER", 48, 56]]], ["In another study, Dou et al. (2020) found how people in the USA and China reported having changed their food purchase behavior in favor of more takeout and delivering orders, wasting less food during the pandemic.", [["wasting", "DISEASE", 175, 182], ["people", "ORGANISM", 46, 52], ["people", "SPECIES", 46, 52]]], ["A positive attitude around food waste seemed to stem from consumers' awareness of limited supply and stocking of food and a perceived uncertainty of finding food in the future.The impact of food waste during the coronavirus outbreakOverall, these studies gave a first picture of the impact of household wastage during the COVID-19.", [["coronavirus", "ORGANISM", 212, 223], ["coronavirus", "SPECIES", 212, 223], ["these studies", "TEST", 241, 254], ["the COVID", "TEST", 318, 327], ["positive", "OBSERVATION_MODIFIER", 2, 10], ["food waste", "OBSERVATION", 190, 200]]], ["An exception relies on the study by Ling and Ho (2020) where the author proposed that panic buying and hoarding issues are the results of how uncertainty and selfinterest behaviors of most individual prevailed over collective interest.The impact of food waste during the coronavirus outbreakBy aiming at expanding these results, in this study we investigate the role need for cognitive closure (Kruglanski, 2004) and gender play in shaping food waste across different countries.Need for cognitive closure, uncertainty, and COVID-19Need for cognitive closure (NFC) has been defined as \"the individual's desire for a firm answer to a question, any firm answer, as opposed to confusion and/or ambiguity\" (Kruglanski, 2004, p.", [["panic", "DISEASE", 86, 91], ["hoarding", "DISEASE", 103, 111], ["confusion", "DISEASE", 673, 682], ["coronavirus", "ORGANISM", 271, 282], ["the study", "TEST", 23, 32], ["panic buying and hoarding issues", "PROBLEM", 86, 118], ["the coronavirus outbreakBy", "TREATMENT", 267, 293], ["this study", "TEST", 332, 342], ["cognitive closure (Kruglanski", "TREATMENT", 376, 405], ["cognitive closure", "TREATMENT", 487, 504], ["COVID", "TEST", 523, 528], ["cognitive closure", "TREATMENT", 540, 557], ["confusion", "PROBLEM", 673, 682], ["food waste", "OBSERVATION", 249, 259]]], ["6 ).Need for cognitive closure, uncertainty, and COVID-19Individuals with a high chronic NFC prefer order, predictability, avoid uncertainty, and they are intolerant to ambiguity (for a review Roets et al., 2015) .", [["cognitive closure", "TREATMENT", 13, 30], ["a high chronic NFC", "TREATMENT", 74, 92]]], ["A common characteristic of individuals with a high NFC is the tendency to make judgments without considering additional information, preserving or \"freezing\" their past knowledge.", [["a high NFC", "PROBLEM", 44, 54], ["high NFC", "OBSERVATION_MODIFIER", 46, 54]]], ["Research on individual differences has demonstrated how chronic NFC is positively related with a high level of intolerance of uncertainty (Berenbaum et al., 2008) , anxiety (Roets & Hiel, 2008) and risk avoidance (e.g. Disatnik & Steinhart, 2015) .", [["anxiety", "DISEASE", 165, 172], ["how chronic NFC", "PROBLEM", 52, 67], ["anxiety", "PROBLEM", 165, 172], ["chronic", "OBSERVATION_MODIFIER", 56, 63], ["NFC", "OBSERVATION", 64, 67]]], ["Schumpe et al. (2017) , propose how individuals with a high NFC express lower willingness to take an immediate and prolonged risky decision compared to people with a low need for closure.", [["people", "ORGANISM", 152, 158], ["people", "SPECIES", 152, 158], ["closure", "TREATMENT", 179, 186]]], ["Koscielniak et al. (2016) report similar results showing how NFC mediated the effect of low-risk aversion for older participants.", [["NFC", "PROTEIN", 61, 64], ["participants", "SPECIES", 116, 128]]], ["The COVID-19 pandemic creates a natural setting of uncertainty, risk, and anxiety that together with a direct impact on physical and mental health (e.g. Liu et al., 2020) also induces economic uncertainty (Baker et al., 2020; Mann et al., 2020) , and impacts environmental behavior (Zambrano-Monserrate et al., 2020).Need for cognitive closure, uncertainty, and COVID-19The current study aims at understanding how individuals with high (vs. low) chronic NFC behave in this global instability.", [["anxiety", "DISEASE", 74, 81], ["The COVID", "TEST", 0, 9], ["anxiety", "PROBLEM", 74, 81], ["cognitive closure", "TREATMENT", 326, 343], ["COVID", "TEST", 362, 367], ["The current study", "TEST", 370, 387], ["high (vs. low) chronic NFC", "PROBLEM", 431, 457], ["this global instability", "PROBLEM", 468, 491], ["global", "OBSERVATION_MODIFIER", 473, 479], ["instability", "OBSERVATION", 480, 491]]], ["Specifically, we propose that individuals with high NFC engaged more in stockpiling behaviors to deal with the uncertain and risky situation of being without food, even if this may have entailed higher levels of food waste -in line with their tendency of exhibiting lower pro-environmental behaviors.", [["lower pro-environmental behaviors", "PROBLEM", 266, 299]]], ["More formally, we expect a sequential mediating effect of the perception of lacking food and the higher stockpiling on the relationship between NFC and level of food waste.Gender and food wasteThere is not a general agreement about the relationship between individuals' gender and food waste.", [["lacking food", "PROBLEM", 76, 88]]], ["Some studies provided evidence that single women produce more food waste compared to single men (Koivupuro et al., 2012; Silvennoinen et al., 2015) .", [["women", "ORGANISM", 43, 48], ["men", "ORGANISM", 92, 95], ["women", "SPECIES", 43, 48], ["men", "SPECIES", 92, 95], ["Some studies", "TEST", 0, 12]]], ["On the contrary, other studies found that young people produce the same amount of food waste regardless of their gender (Principato et al., 2015) .", [["people", "ORGANISM", 48, 54], ["people", "SPECIES", 48, 54], ["other studies", "TEST", 17, 30]]], ["Regarding the level of awareness and concern about food waste, Cantaragiu (2019) found that, at any age, women tend to express higher concerns than men about the negative impact of food waste in social equity and family budget.", [["women", "ORGANISM", 105, 110], ["men", "ORGANISM", 148, 151], ["women", "SPECIES", 105, 110], ["men", "SPECIES", 148, 151]]], ["Furthermore, Lyndhurst (2007a Lyndhurst ( , 2007b found that, when women are responsible for cooking and feeding their own family, reported a high level of guiltiness if waste food.", [["women", "ORGANISM", 67, 72], ["women", "SPECIES", 67, 72]]], ["An explanation of these findings can be found in the increased responsibility of women in the household when they are older and live with their own family, and a consequent rise in concern about food waste (Lyndhurst, 2007a (Lyndhurst, , 2007b .Gender and food wasteIn this study, we investigate the moderating role of gender on the relationship between the NFC and the perception of lacking food in the household during the COVID-19 pandemic.", [["women", "ORGANISM", 81, 86], ["women", "SPECIES", 81, 86], ["this study", "TEST", 269, 279], ["the COVID", "TEST", 421, 430], ["pandemic", "PROBLEM", 434, 442], ["increased", "OBSERVATION_MODIFIER", 53, 62]]], ["This is particularly true in certain countries more than in others.", [["true", "OBSERVATION_MODIFIER", 21, 25]]], ["For example, in countries like India, women are more often responsible to provide sustenance for their own family (Sudershan et al., 2009) and be more concerned about the amount of food waste compared to other countries like the USA.", [["women", "ORGANISM", 38, 43], ["women", "SPECIES", 38, 43]]], ["Such a difference is further heightened by the access women have to employment, with a rate of 65% in the USA compared to the 26.97% of full-time employed women in India (The World Bank, 2020).Gender and food wasteBased on this assumption, we hypothesize a moderation effect of gender and country of residence on the relationship between the NFC and the perception of lacking food in the household.", [["women", "ORGANISM", 54, 59], ["women", "ORGANISM", 155, 160], ["women", "SPECIES", 54, 59], ["women", "SPECIES", 155, 160], ["a rate", "TEST", 85, 91]]], ["Specifically, we believe that the relationship between high NFC and the perception of lacking food would be stronger for Indian women compared to their USA counterparts.", [["women", "ORGANISM", 128, 133], ["USA counterparts", "ORGANISM", 152, 168], ["women", "SPECIES", 128, 133]]], ["Fig. 1 graphically represents our conceptual model.Participants and proceduresWe recruited five hundred and ninety respondents (52.5% males, M Age = 36.86, SD = 11.39) through Amazon Mechanical Turk in exchange of a $0.70 compensation.", [["Participants", "SPECIES", 51, 63], ["a $0.70 compensation", "TREATMENT", 214, 234]]], ["Only participants that had completed more than 1000 MTurk tasks with greater than 98% lifetime approval were recruited.", [["participants", "ORGANISM", 5, 17], ["participants", "SPECIES", 5, 17]]], ["Each participant voluntary participated in the survey providing a written informed consent that included information about anonymity, data use and storage and no risk of harm of the study.", [["participant", "SPECIES", 5, 16], ["the study", "TEST", 178, 187]]], ["Within the sample, two hundred and sixty-four respondents were resident in India (53.8% males, M Age = 31.75, SD = 8.16) and three hundred twenty-six respondents were resident in the United States (51.5% males, M Age = 40.99, SD = 11.98).MeasuresRespondents filled in the fifteen items NFC scale (Roets & Van Hiel, 2011) .", [["SD", "TEST", 110, 112], ["SD", "TEST", 226, 228]]], ["Example items of the scale include: \"I don't like situations that are uncertain\", \"I find that a well-ordered life with regular hours suits my temperament\", or \"I enjoy having a clear and structured mode of life.\" (on a seven-point Likert scale -1 = strongly disagree to 7 = strongly agree).", [["Likert scale", "TEST", 232, 244]]], ["The NFC scale demonstrated very good reliability in both subsamples (Crombach \u03b1 India = 0.93; Crombach \u03b1 United States = 0.95).", [["The NFC scale", "TEST", 0, 13], ["Crombach", "TEST", 69, 77], ["very", "OBSERVATION_MODIFIER", 27, 31], ["good", "OBSERVATION_MODIFIER", 32, 36]]], ["Next, participants were presented with the mediating and dependent variables.", [["participants", "SPECIES", 6, 18]]], ["Participants also assessed whether they had bought more food than usual (\"I bought more food/groceries than usual during the COVID-19 pandemic\") and if they had the perception to have wasted more food during the lockdown (\"I wasted more food/groceries than usual during the COVID-19 pandemic\").", [["Participants", "SPECIES", 0, 12]]], ["We then asked participants to fill a series of demographics: gender (male or female); age (as an open-ended question); nationality (as an open-ended question); employment status (as a categorical variable with six options: employed part-time, employed full time, unemployed seeking for occupation, unemployed not seeking for occupation, retired); and income.", [["participants", "SPECIES", 14, 26]]], ["As this latter variable may be particularly sensitive, we provided for each subsample the median income of the country where they are residents, asking them to report whether their income is above or below that figure on a seven-point Likert scale (1 = far below to 7 = far above).", [["Likert scale", "TEST", 235, 247]]], ["Respondents were then thanked and received their compensation.ResultsWe proceeded to amalgamate the two datasets for the final analysis.", [["the final analysis", "TEST", 117, 135]]], ["The descriptive statistics and the correlations for all the variables are available in Table 1 .ResultsFirst, we tested our propositions through sequential mediation model (PROCESS Model 6; 95% Confidence Intervals, 10,000 bootstrap resamples; Hayes, 2013) using the NFC as our predictor, the perception of lacking food at home and the purchase of extra food as mediators, and the perceived increase in food waste as the dependent variable.", [["food waste", "OBSERVATION", 403, 413]]], ["The model indicated a significant positive relationship between the NFC and the respondents' perception of lacking food at home during the COVID-19 lockdown (B = 0.46, SE = 0.06, p < .001).", [["lacking food", "PROBLEM", 107, 119], ["the COVID", "TEST", 135, 144], ["SE", "TEST", 168, 170], ["significant", "OBSERVATION_MODIFIER", 22, 33], ["positive", "OBSERVATION", 34, 42]]], ["Similarly, the NFC positively influenced individuals' tendency of stockpiling food (B = 0.18, SE = 0.06, p < .01).", [["NFC", "SIMPLE_CHEMICAL", 15, 18], ["stockpiling food", "PROBLEM", 66, 82], ["B", "TEST", 84, 85], ["SE", "TEST", 94, 96]]], ["As expected, also the relationship between the perceived lack of food and stockpiling is positive and significant (B = 0.52, SE = 0.04, p < .001).", [["B", "TEST", 115, 116], ["SE", "TEST", 125, 127], ["significant", "OBSERVATION_MODIFIER", 102, 113]]], ["NFC had also a positive impact on perceived food waste during the COVID-19 lockdown (B = 0.28, SE = 0.08 p < .001) and so did the two proposed mediators (perceived lack of food: B = 0.46, SE = 0.05, p < .001; stockpiling: B = 0.20, SE = 0.04, p < .001).", [["the COVID", "TEST", 62, 71], ["SE", "TEST", 95, 97], ["SE", "TEST", 188, 190], ["stockpiling", "TEST", 209, 220], ["B", "TEST", 222, 223], ["SE", "TEST", 232, 234]]], ["The indirect effects suggest a significant sequential mediation (NFC \u2192 Perceived Lack of food \u2192 Stockpiling \u2192 Waste; Total indirect effect = 0.20, SE = 0.04, LLCI = 0.12, ULCI = 0.29, p < .001).", [["Total indirect effect", "TEST", 117, 138], ["SE", "TEST", 147, 149], ["LLCI", "TEST", 158, 162], ["ULCI", "TEST", 171, 175], ["significant", "OBSERVATION_MODIFIER", 31, 42]]], ["We performed a moderated sequential mediation model (Model 83, 95% Confidence Intervals, 10,000 bootstrap resamples; Hayes, 2013) .ResultsAs the PROCESS add-on does not encompass two moderators for a sequential mediation model, we first recoded them into two dummies A. Brizi and A. Biraglia Personality and Individual Differences 168 (2021) 110396 (gender: \u22121 = males; +1 = females; country of residence: \u22121 = India; +1 = United States), to then compute an interaction term variable (gender * country of residence) that we used as the moderator.", [["PROCESS", "DNA", 145, 152], ["a sequential mediation model", "TREATMENT", 198, 226], ["Individual Differences", "TEST", 308, 330]]], ["We included gender and country of residence as covariates in the model (Fig. 3) .ResultsThe results suggest a significant sequential mediation effect (Total indirect effect = \u22120.04, SE = 0.03, LLCI = \u22120.09, ULCI = \u22120.01, p < .05).", [["a significant sequential mediation effect", "PROBLEM", 108, 149], ["Total indirect effect", "TEST", 151, 172], ["SE", "TEST", 182, 184], ["LLCI", "TEST", 193, 197], ["ULCI", "TEST", 207, 211], ["p", "TEST", 221, 222], ["significant", "OBSERVATION_MODIFIER", 110, 121]]], ["Importantly, a significant three-way interaction emerged between the NFC and the two moderators (\u22120.14; SE = 0.07, LLCI = \u22120.27, ULCI = \u22120.01, p < .05) on the perception of lacking food in the household.", [["SE", "TEST", 104, 106], ["LLCI", "TEST", 115, 119], ["ULCI", "TEST", 129, 133], ["p", "TEST", 143, 144], ["significant", "OBSERVATION_MODIFIER", 15, 26]]], ["By looking at the interaction in details, the effect was stronger among Indian women (0.63, SE = 0.17, LLCI = 0.31, ULCI = 0.96, p < .001) and American men (0.51, SE = 0.13, LLCI = 0.26, ULCI = 0.75, p < .001) than among Indian men (0.31, SE = 0.13, LLCI = 0.05, ULCI = 0.57, p < .05) and American women (0.24, SE = 0.13, LLCI = 0.06, ULCI = \u22120.02, p < .1; Fig. 4 ).DiscussionThe current research investigated psychological individual differences behind an important issue impacting the environment: food waste.", [["women", "ORGANISM", 79, 84], ["men", "ORGANISM", 152, 155], ["men", "ORGANISM", 228, 231], ["women", "ORGANISM", 298, 303], ["women", "SPECIES", 79, 84], ["men", "SPECIES", 152, 155], ["men", "SPECIES", 228, 231], ["women", "SPECIES", 298, 303], ["SE", "TEST", 92, 94], ["LLCI", "TEST", 103, 107], ["ULCI", "TEST", 116, 120], ["p", "TEST", 129, 130], ["SE", "TEST", 163, 165], ["LLCI", "TEST", 174, 178], ["ULCI", "TEST", 187, 191], ["p", "TEST", 200, 201], ["SE", "TEST", 239, 241], ["LLCI", "TEST", 250, 254], ["ULCI", "TEST", 263, 267], ["p", "TEST", 276, 277], ["American women", "TEST", 289, 303], ["SE", "TEST", 311, 313], ["LLCI", "TEST", 322, 326], ["ULCI", "TEST", 335, 339], ["p", "TEST", 349, 350], ["Fig.", "TEST", 357, 361]]], ["We found that during the lockdown caused by the COVID-19 pandemic, individuals with a high NFC perceived to waste more food compared people with low NFC.", [["people", "SPECIES", 133, 139], ["the COVID", "TEST", 44, 53], ["low NFC", "PROBLEM", 145, 152], ["low NFC", "OBSERVATION_MODIFIER", 145, 152]]], ["Thus, individuals with a high NFC seems to choose the individualistic strategy of buying more food even if this means leave less food to other people and waste more.", [["people", "ORGANISM", 143, 149], ["people", "SPECIES", 143, 149], ["a high NFC", "PROBLEM", 23, 33]]], ["By collecting data in different countries (India and the USA) we also found that gender and country of residence moderate the effect.", [["moderate", "OBSERVATION_MODIFIER", 113, 121]]], ["Notably, Indian women perceived to waste more food compared to American women and American and Indian men.DiscussionOur results contribute to previous literature on individual differences by unveiling the role of epistemic motivations as a precursor of pro-environmental behaviors.", [["women", "ORGANISM", 16, 21], ["women", "ORGANISM", 72, 77], ["men", "ORGANISM", 102, 105], ["women", "SPECIES", 16, 21], ["women", "SPECIES", 72, 77], ["men", "SPECIES", 102, 105]]], ["Furthermore, our study introduces two important moderators (gender and country of residence), providing further nuances about which individuals may be more inclined to engage in such behaviors.", [["individuals", "ORGANISM", 132, 143], ["our study", "TEST", 13, 22]]], ["By doing so, our results also contribute to highlight how gender roles impact the management of the household in different countries, with women being more concerned about food waste especially in countries where their role is still linked to more traditional values.DiscussionFrom a practical point of view, our study offers opportunities for policymakers to create ad hoc communication campaigns.", [["women", "ORGANISM", 139, 144], ["women", "SPECIES", 139, 144], ["our study", "TEST", 309, 318]]], ["For example, campaigns that address the individualistic benefits of buying only necessary food (for example to save money) could have higher efficacy on people with a high NFC.", [["people", "ORGANISM", 153, 159], ["people", "SPECIES", 153, 159], ["a high NFC", "PROBLEM", 165, 175]]], ["Conversely, A. Brizi and A. Biraglia Personality and Individual Differences 168 (2021) 110396 communication campaigns highlighting more cooperative benefits to act environmentally (e.g. to reduce the general carbon footprint) could be more efficient on people with a low NFC.", [["carbon", "CHEMICAL", 208, 214], ["people", "ORGANISM", 253, 259], ["people", "SPECIES", 253, 259], ["the general carbon footprint", "TREATMENT", 196, 224], ["a low NFC", "PROBLEM", 265, 274]]], ["As our results point out how women in India -who seem to be mostly responsible to look after the household -are also the individuals exhibiting the strongest effects, designing communications targeted to this segment could help alleviate such issue.", [["women", "ORGANISM", 29, 34], ["women", "SPECIES", 29, 34]]], ["Therefore, it is important to identify the key individuals responsible to the household food supply and the most appropriate channels to reach them (e.g., by looking at the type of media these individuals most frequently use).Limitations and future researchThis study opens potentially intriguing avenues for future research.", [["This study", "TEST", 257, 267], ["future research", "TEST", 309, 324]]], ["While in this study we did not measure pre-existing knowledge about the relationship between food waste and global warming, future research could investigate how individuals would behave with increased access to more information on the consequences of food waste on global warming.", [["this study", "TEST", 9, 19], ["global warming", "TREATMENT", 108, 122], ["global warming", "TREATMENT", 266, 280]]], ["A large body of research (e.g. Bulkeley, 2000; Norgaard, 2006) , assumes that a lack of information about the causes of global warming is the primary reason to not act environmentally.", [["global warming", "PROBLEM", 120, 134], ["large", "OBSERVATION_MODIFIER", 2, 7], ["body", "OBSERVATION_MODIFIER", 8, 12]]], ["It is possible to speculate that when people are properly informed by the negative effect that overbuying and food waste have on the environment, they may reduce or correct their inappropriate behavior.", [["people", "ORGANISM", 38, 44], ["people", "SPECIES", 38, 44]]], ["Therefore, if they receive precise information on how to act in the COVID-19 pandemic, they may also reduce their perception of anxiety and risky avoidance (Schumpe et al., 2017) and adopt environmental strategies.Limitations and future researchAdditionally, as the correlational nature of this study does not allow any causal claim, future research may test the effects on food waste by A. Brizi and A. Biraglia Personality and Individual Differences 168 (2021) 110396 manipulating the NFC and the level of uncertainty of the situation in a more controlled environment.", [["anxiety", "DISEASE", 128, 135], ["anxiety", "PROBLEM", 128, 135], ["this study", "TEST", 290, 300], ["Individual Differences", "TEST", 429, 451]]]], "PMC7492382": [["IntroductionPorcine respiratory disease complex (PRDC) is one of the most important swine health concerns to producers today.", [["respiratory disease", "DISEASE", 20, 39], ["PRDC", "DISEASE", 49, 53], ["IntroductionPorcine respiratory disease complex", "GENE_OR_GENE_PRODUCT", 0, 47], ["swine", "SPECIES", 84, 89], ["IntroductionPorcine respiratory disease complex", "PROBLEM", 0, 47], ["respiratory disease", "OBSERVATION", 20, 39]]], ["PRDC is most prevalent in large swine farms that implement a continuous production system, often containing around 6\u201320 weeks-old pigs (1, 2).", [["PRDC", "GENE_OR_GENE_PRODUCT", 0, 4], ["pigs", "ORGANISM", 130, 134], ["swine", "SPECIES", 32, 37], ["pigs", "SPECIES", 130, 134], ["swine", "SPECIES", 32, 37], ["PRDC", "TREATMENT", 0, 4], ["a continuous production system", "TREATMENT", 59, 89], ["most prevalent", "OBSERVATION_MODIFIER", 8, 22]]], ["Common clinical symptoms of PRDC include growth retardation, decreased feed efficiency, anorexia, lethargy, fever, cough, and dyspnea.IntroductionPorcine circovirus type 2 (PCV2) is the smallest non-enveloped, single-stranded, circular DNA virus within the genus Circovirus and the family Circoviridae (3).", [["PRDC", "DISEASE", 28, 32], ["growth retardation", "DISEASE", 41, 59], ["decreased feed efficiency", "DISEASE", 61, 86], ["anorexia", "DISEASE", 88, 96], ["lethargy", "DISEASE", 98, 106], ["fever", "DISEASE", 108, 113], ["cough", "DISEASE", 115, 120], ["dyspnea", "DISEASE", 126, 133], ["PRDC", "CANCER", 28, 32], ["IntroductionPorcine circovirus type 2", "ORGANISM", 134, 171], ["PCV2", "ORGANISM", 173, 177], ["DNA", "CELLULAR_COMPONENT", 236, 239], ["IntroductionPorcine circovirus", "SPECIES", 134, 164], ["IntroductionPorcine circovirus type 2", "SPECIES", 134, 171], ["Common clinical symptoms", "PROBLEM", 0, 24], ["PRDC", "PROBLEM", 28, 32], ["growth retardation", "PROBLEM", 41, 59], ["decreased feed efficiency", "PROBLEM", 61, 86], ["anorexia", "PROBLEM", 88, 96], ["lethargy", "PROBLEM", 98, 106], ["fever", "PROBLEM", 108, 113], ["cough", "PROBLEM", 115, 120], ["dyspnea", "PROBLEM", 126, 133], ["IntroductionPorcine circovirus type 2 (PCV2", "PROBLEM", 134, 177], ["the smallest non-enveloped", "PROBLEM", 182, 208], ["single-stranded, circular DNA virus", "PROBLEM", 210, 245], ["the family Circoviridae", "TREATMENT", 278, 301], ["decreased", "OBSERVATION_MODIFIER", 61, 70], ["feed efficiency", "OBSERVATION", 71, 86], ["cough", "OBSERVATION", 115, 120], ["dyspnea", "OBSERVATION", 126, 133], ["smallest", "OBSERVATION_MODIFIER", 186, 194], ["non-enveloped", "OBSERVATION_MODIFIER", 195, 208], ["genus Circovirus", "OBSERVATION", 257, 273]]], ["Currently, PCV2 is classified with six different genotypes, a-f (4\u20137) with PCV2d prevailing as the most frequent genotype currently circulating within the US and Korea (8, 9).", [["PCV2", "ORGANISM", 11, 15], ["PCV2", "SPECIES", 11, 15], ["PCV2d", "TREATMENT", 75, 80], ["the US", "TEST", 151, 157], ["PCV2", "OBSERVATION", 11, 15]]], ["PCV2 is the causative agent of PCV2-systemic disease as well as various other circovirus-related syndromes (10\u201312).IntroductionMycoplasma hyopneumoniae bacterium is one of the most important pathogens within the PRDC, and causes chronic respiratory conditions in pigs as the etiologic agent of enzootic pneumonia.", [["PRDC", "ANATOMY", 212, 216], ["respiratory", "ANATOMY", 237, 248], ["PCV2-systemic disease", "DISEASE", 31, 52], ["Mycoplasma hyopneumoniae bacterium", "DISEASE", 127, 161], ["pneumonia", "DISEASE", 303, 312], ["PCV2", "ORGANISM", 0, 4], ["PCV2", "ORGANISM", 31, 35], ["circovirus", "ORGANISM", 78, 88], ["Mycoplasma hyopneumoniae bacterium", "ORGANISM", 127, 161], ["PRDC", "CANCER", 212, 216], ["pigs", "ORGANISM", 263, 267], ["Mycoplasma hyopneumoniae", "SPECIES", 127, 151], ["pigs", "SPECIES", 263, 267], ["PCV2", "SPECIES", 0, 4], ["Mycoplasma hyopneumoniae", "SPECIES", 127, 151], ["pigs", "SPECIES", 263, 267], ["PCV2", "TREATMENT", 0, 4], ["PCV2", "PROBLEM", 31, 35], ["systemic disease", "PROBLEM", 36, 52], ["various other circovirus", "PROBLEM", 64, 88], ["related syndromes", "PROBLEM", 89, 106], ["IntroductionMycoplasma hyopneumoniae bacterium", "PROBLEM", 115, 161], ["chronic respiratory conditions", "PROBLEM", 229, 259], ["enzootic pneumonia", "PROBLEM", 294, 312], ["PCV2", "OBSERVATION", 31, 35], ["systemic disease", "OBSERVATION", 36, 52], ["circovirus", "OBSERVATION", 78, 88], ["Mycoplasma hyopneumoniae", "OBSERVATION", 127, 151], ["one of the most important", "OBSERVATION_MODIFIER", 165, 190], ["pathogens", "OBSERVATION", 191, 200], ["chronic", "OBSERVATION_MODIFIER", 229, 236], ["respiratory conditions", "OBSERVATION", 237, 259], ["enzootic", "OBSERVATION_MODIFIER", 294, 302], ["pneumonia", "OBSERVATION", 303, 312]]], ["Dry, non-productive coughing, and growth retardation are the most obvious clinical signs, although the majority of M. hyopneumoniae infections are subclinical (13).IntroductionPCV2 and M. hyopneumoniae are both known to affect swine herds worldwide.", [["coughing", "DISEASE", 20, 28], ["growth retardation", "DISEASE", 34, 52], ["M. hyopneumoniae infections", "DISEASE", 115, 142], ["M. hyopneumoniae", "ORGANISM", 115, 131], ["M. hyopneumoniae", "ORGANISM", 185, 201], ["M. hyopneumoniae", "SPECIES", 115, 131], ["M. hyopneumoniae", "SPECIES", 185, 201], ["swine", "SPECIES", 227, 232], ["M. hyopneumoniae", "SPECIES", 115, 131], ["M. hyopneumoniae", "SPECIES", 185, 201], ["swine", "SPECIES", 227, 232], ["Dry, non-productive coughing", "PROBLEM", 0, 28], ["growth retardation", "PROBLEM", 34, 52], ["M. hyopneumoniae infections", "PROBLEM", 115, 142], ["IntroductionPCV2", "TREATMENT", 164, 180], ["M. hyopneumoniae", "PROBLEM", 185, 201], ["non-productive", "OBSERVATION_MODIFIER", 5, 19], ["coughing", "OBSERVATION", 20, 28], ["most obvious", "OBSERVATION_MODIFIER", 61, 73], ["hyopneumoniae", "OBSERVATION_MODIFIER", 118, 131], ["infections", "OBSERVATION", 132, 142], ["hyopneumoniae", "OBSERVATION", 188, 201]]], ["PRDC development is often caused by a co-infection of these two pathogens (14).", [["PRDC", "ANATOMY", 0, 4], ["PRDC", "DISEASE", 0, 4], ["PRDC", "CANCER", 0, 4], ["a co-infection of these two pathogens", "PROBLEM", 36, 73], ["co-infection", "OBSERVATION", 38, 50]]], ["This in turn has resulted in an increase in animal treatment costs as well as in economic losses.", [["animal treatment costs", "TREATMENT", 44, 66], ["increase", "OBSERVATION_MODIFIER", 32, 40], ["animal treatment", "OBSERVATION", 44, 60], ["economic losses", "OBSERVATION", 81, 96]]], ["Vaccination within the Asian pork industry remains the most common and effective tool in controlling PCV2 and M. hyopneumoniae infection.", [["M. hyopneumoniae infection", "DISEASE", 110, 136], ["PCV2", "ORGANISM", 101, 105], ["M. hyopneumoniae", "ORGANISM", 110, 126], ["M. hyopneumoniae", "SPECIES", 110, 126], ["Asian pork", "SPECIES", 23, 33], ["PCV2", "SPECIES", 101, 105], ["M. hyopneumoniae", "SPECIES", 110, 126], ["Vaccination", "TREATMENT", 0, 11], ["M. hyopneumoniae infection", "PROBLEM", 110, 136], ["most common", "OBSERVATION_MODIFIER", 55, 66], ["hyopneumoniae", "OBSERVATION_MODIFIER", 113, 126], ["infection", "OBSERVATION", 127, 136]]], ["The recommended times of vaccination against PCV2 and M. hyopneumoniae are similar so the use of either a combination of two monovalent vaccines mixed into a combo prior to vaccination, or a ready-to-use combination vaccine containing PCV2 and M. hyopneumoniae are growing in popularity.", [["PCV2", "ORGANISM", 45, 49], ["M. hyopneumoniae", "ORGANISM", 54, 70], ["PCV2", "ORGANISM", 235, 239], ["M. hyopneumoniae", "ORGANISM", 244, 260], ["M. hyopneumoniae", "SPECIES", 54, 70], ["M. hyopneumoniae", "SPECIES", 244, 260], ["PCV2", "SPECIES", 45, 49], ["M. hyopneumoniae", "SPECIES", 54, 70], ["PCV2", "SPECIES", 235, 239], ["M. hyopneumoniae", "SPECIES", 244, 260], ["vaccination", "TREATMENT", 25, 36], ["PCV2", "PROBLEM", 45, 49], ["M. hyopneumoniae", "PROBLEM", 54, 70], ["two monovalent vaccines", "TREATMENT", 121, 144], ["vaccination", "TREATMENT", 173, 184], ["combination vaccine", "TREATMENT", 204, 223], ["PCV2", "PROBLEM", 235, 239], ["M. hyopneumoniae", "PROBLEM", 244, 260], ["hyopneumoniae", "OBSERVATION", 57, 70], ["hyopneumoniae", "OBSERVATION", 247, 260], ["growing", "OBSERVATION_MODIFIER", 265, 272]]], ["The objective of this study was to compare the efficacy of a combination of two monovalent vaccines mixed into a combo prior to vaccination with a ready-to-use bivalent vaccine containing PCV2 and M. hyopneumoniae.", [["PCV2", "ORGANISM", 188, 192], ["M. hyopneumoniae", "ORGANISM", 197, 213], ["M. hyopneumoniae", "SPECIES", 197, 213], ["PCV2", "SPECIES", 188, 192], ["M. hyopneumoniae", "SPECIES", 197, 213], ["this study", "TEST", 17, 27], ["two monovalent vaccines", "TREATMENT", 76, 99], ["vaccination", "TREATMENT", 128, 139], ["bivalent vaccine", "TREATMENT", 160, 176], ["PCV2", "PROBLEM", 188, 192], ["M. hyopneumoniae", "PROBLEM", 197, 213], ["M. hyopneumoniae", "OBSERVATION", 197, 213]]], ["The vaccines were evaluated with a dual M. hyopneumoniae and PCV2d challenge in pigs and conclusions were based on clinical, microbiological, immunological, and pathological outcomes.Ethical Statement ::: Materials and MethodsThis study was approved by the Seoul National University Institutional Animal Care and Use Committee (SNU-190712-5).Animals ::: Materials and MethodsPiglets were selected from commercial farms which tested free of porcine reproductive and respiratory syndrome virus (PRRSV) and M. hyopneumoniae based on breeding herd serology, and long term clinical and slaughter history.", [["SNU-190712-5", "CHEMICAL", 328, 340], ["porcine reproductive and respiratory syndrome", "DISEASE", 440, 485], ["M. hyopneumoniae", "ORGANISM", 40, 56], ["PCV2d", "ORGANISM", 61, 66], ["pigs", "ORGANISM", 80, 84], ["porcine reproductive and respiratory syndrome virus", "ORGANISM", 440, 491], ["PRRSV", "ORGANISM", 493, 498], ["M. hyopneumoniae", "ORGANISM", 504, 520], ["M. hyopneumoniae", "SPECIES", 40, 56], ["pigs", "SPECIES", 80, 84], ["porcine", "SPECIES", 440, 447], ["syndrome virus", "SPECIES", 477, 491], ["PRRSV", "SPECIES", 493, 498], ["M. hyopneumoniae", "SPECIES", 504, 520], ["M. hyopneumoniae", "SPECIES", 40, 56], ["pigs", "SPECIES", 80, 84], ["porcine", "SPECIES", 440, 447], ["respiratory syndrome virus", "SPECIES", 465, 491], ["PRRSV", "SPECIES", 493, 498], ["M. hyopneumoniae", "SPECIES", 504, 520], ["The vaccines", "TREATMENT", 0, 12], ["a dual M. hyopneumoniae", "PROBLEM", 33, 56], ["PCV2d challenge", "TREATMENT", 61, 76], ["This study", "TEST", 226, 236], ["MethodsPiglets", "TREATMENT", 368, 382], ["porcine reproductive", "PROBLEM", 440, 460], ["respiratory syndrome virus", "PROBLEM", 465, 491], ["M. hyopneumoniae", "PROBLEM", 504, 520], ["breeding herd serology", "TEST", 530, 552], ["hyopneumoniae", "OBSERVATION", 43, 56], ["respiratory syndrome", "OBSERVATION", 465, 485]]], ["A total of 60 colostrum-fed, cross-bred, conventional piglets were purchased at 7 days old from the selected facilities.", [["colostrum", "ORGANISM", 14, 23], ["piglets", "ORGANISM", 54, 61], ["piglets", "SPECIES", 54, 61], ["piglets", "SPECIES", 54, 61], ["A total of 60 colostrum", "TREATMENT", 0, 23], ["conventional piglets", "TREATMENT", 41, 61]]], ["Upon arrival, piglets were tested for PCV2 and PRRSV viremia as well as for nasal shedding of M. hyopneumoniae by real-time polymerase chain reaction (PCR).", [["nasal", "ANATOMY", 76, 81], ["viremia", "DISEASE", 53, 60], ["piglets", "ORGANISM", 14, 21], ["PCV2", "ORGANISM", 38, 42], ["PRRSV", "ORGANISM", 47, 52], ["nasal", "ORGANISM_SUBDIVISION", 76, 81], ["M. hyopneumoniae", "ORGANISM", 94, 110], ["piglets", "SPECIES", 14, 21], ["PRRSV", "SPECIES", 47, 52], ["M. hyopneumoniae", "SPECIES", 94, 110], ["PCV2", "SPECIES", 38, 42], ["PRRSV", "SPECIES", 47, 52], ["M. hyopneumoniae", "SPECIES", 94, 110], ["piglets", "TREATMENT", 14, 21], ["PCV2", "PROBLEM", 38, 42], ["PRRSV viremia", "PROBLEM", 47, 60], ["nasal shedding", "PROBLEM", 76, 90], ["M. hyopneumoniae", "PROBLEM", 94, 110], ["PCR", "TEST", 151, 154], ["PRRSV viremia", "OBSERVATION", 47, 60], ["hyopneumoniae", "OBSERVATION", 97, 110]]], ["Piglets were also tested and confirmed seronegative for PCV2 (SERELISA PCV2 Ab Mono Blocking, Synbiotics, Lyon, France), PRRSV (HerdCheck PRRS X3 Ab test, IDEXX Laboratories Inc., Westbrook, ME, USA), and M. hyopneumoniae (M. hyo.", [["Piglets", "ORGANISM", 0, 7], ["PCV2", "ORGANISM", 56, 60], ["PRRSV", "ORGANISM", 121, 126], ["M. hyopneumoniae", "ORGANISM", 205, 221], ["M. hyo", "ORGANISM", 223, 229], ["Piglets", "SPECIES", 0, 7], ["M. hyopneumoniae", "SPECIES", 205, 221], ["PCV2", "SPECIES", 56, 60], ["PRRSV", "SPECIES", 121, 126], ["M. hyopneumoniae", "SPECIES", 205, 221], ["PCV2", "PROBLEM", 56, 60], ["SERELISA PCV2 Ab Mono Blocking", "TREATMENT", 62, 92], ["Synbiotics", "TREATMENT", 94, 104], ["PRRSV", "TREATMENT", 121, 126], ["Ab test", "TEST", 146, 153], ["hyopneumoniae", "OBSERVATION", 208, 221]]], ["Ab test, IDEXX Laboratories Inc.), according to routine serological testing.Experimental Design ::: Materials and MethodsThe random number generator function (Excel, Microsoft Corporation, Redmond, Washington, USA) was used to randomly divide 60 pigs into 4 groups, each containing 15 pigs (Table 1).", [["pigs", "ORGANISM", 246, 250], ["pigs", "ORGANISM", 285, 289], ["pigs", "SPECIES", 246, 250], ["pigs", "SPECIES", 285, 289], ["pigs", "SPECIES", 246, 250], ["pigs", "SPECIES", 285, 289], ["Ab test", "TEST", 0, 7], ["routine serological testing", "TEST", 48, 75]]], ["The minimum sample size per each group was calculated as suggested by Cohen (15) using pwr package in R v.3.5.1 (R Core Team: a language and environment for statistical computing.", [["minimum", "OBSERVATION_MODIFIER", 4, 11], ["size", "OBSERVATION_MODIFIER", 19, 23]]], ["The minimum number of piglets needed per group was calculated using a 0.05 significance level, 0.4 effect size, and 70% power.", [["piglets", "ORGANISM", 22, 29], ["piglets", "SPECIES", 22, 29], ["size", "TEST", 106, 110], ["minimum", "OBSERVATION_MODIFIER", 4, 11], ["number", "OBSERVATION_MODIFIER", 12, 18]]], ["Under these parameters, the minimum number of pigs per group equated to 14.69, therefore, at least 15 piglets were designated per group.", [["pigs", "ORGANISM", 46, 50], ["piglets", "ORGANISM", 102, 109], ["pigs", "SPECIES", 46, 50], ["piglets", "SPECIES", 102, 109], ["minimum", "OBSERVATION_MODIFIER", 28, 35]]], ["Three groups of pigs, identified as VacA/Ch, VacB/Ch, and UnVac/Ch, were randomly assigned into 3 rooms.", [["pigs", "ORGANISM", 16, 20], ["VacA", "GENE_OR_GENE_PRODUCT", 36, 40], ["Ch", "GENE_OR_GENE_PRODUCT", 41, 43], ["VacA", "PROTEIN", 36, 40], ["Ch", "PROTEIN", 41, 43], ["VacB", "PROTEIN", 45, 49], ["UnVac", "PROTEIN", 58, 63], ["pigs", "SPECIES", 16, 20], ["pigs", "SPECIES", 16, 20], ["pigs", "TREATMENT", 16, 20]]], ["Pigs in an additional UnVac/UnCh group were randomly assigned into 1 room.", [["Pigs", "ORGANISM", 0, 4], ["Pigs", "SPECIES", 0, 4], ["Pigs", "TREATMENT", 0, 4]]], ["Each room uniformly constained 2 pens (7 or 8 pigs per pen) and each pig was assigned a pen randomly using the random number generator function (Excel, Microsoft Corporation).", [["pig", "ORGANISM", 69, 72], ["pigs", "SPECIES", 46, 50], ["pig", "SPECIES", 69, 72], ["pig", "SPECIES", 69, 72]]], ["Rooms and pens were consistent in design and were equipped with equipped with free-access to water and feed throughout the duration of the study.Experimental Design ::: Materials and MethodsPigs in the VacA/Ch group were vaccinated intramuscularly with FLEXcombo (Boehringer Ingelheim Vetmedica Inc., St. Joseph, Missouri, USA) at 21 days of age in accordance with the manufacturer's directions.", [["intramuscularly", "ANATOMY", 232, 247], ["Ch", "CHEMICAL", 207, 209], ["VacA", "GENE_OR_GENE_PRODUCT", 202, 206], ["VacA", "PROTEIN", 202, 206], ["the study", "TEST", 135, 144], ["Materials", "TREATMENT", 169, 178], ["MethodsPigs", "TREATMENT", 183, 194], ["the VacA/Ch group", "TREATMENT", 198, 215]]], ["FLEXcombo vaccine was prepared by mixing equal volumes of Ingelvac CiroFLEX (Serial No. 3091282A) and Ingelvac MycoFLEX (Serial No. 273052A).", [["FLEXcombo", "CHEMICAL", 0, 9], ["Ingelvac CiroFLEX", "CHEMICAL", 58, 75], ["FLEXcombo vaccine", "TREATMENT", 0, 17]]], ["Each pigs in VacA/Ch group received a 2 mL/dose of freshly mixed FLEXcombo vaccine.", [["Ch", "CHEMICAL", 18, 20], ["pigs", "ORGANISM", 5, 9], ["VacA", "GENE_OR_GENE_PRODUCT", 13, 17], ["VacA", "PROTEIN", 13, 17], ["pigs", "SPECIES", 5, 9], ["VacA/Ch group", "TREATMENT", 13, 26], ["freshly mixed FLEXcombo vaccine", "TREATMENT", 51, 82]]], ["Pigs in VacB/Ch group were intramuscularly vaccinated with a 2.0 mL dose of the ready-to-use combination vaccine Porcilis PCV M Hyo (Lot No.", [["Ch", "CHEMICAL", 13, 15], ["Pigs", "ORGANISM", 0, 4], ["VacB/Ch group", "ORGANISM", 8, 21], ["Pigs", "SPECIES", 0, 4], ["Pigs in VacB/Ch group", "TREATMENT", 0, 21], ["combination vaccine", "TREATMENT", 93, 112]]], ["UnVac/Ch and UnVac/UnCh pig groups were administered a 2.0 mL dose of phosphate buffered saline (PBS, 0.01M, pH 7.4) at 21 days old.Experimental Design ::: Materials and MethodsPigs in the VacA/Ch, VacB/Ch, and UnVac/Ch groups were anesthetized at \u221214 days post challenge (dpc, 42 days old), with a mixture of 2.2 mg/kg xylazine hydrochloride (Rumpon, Bayer Korea, Seoul, Korea), 2.2 mg/kg tiletamine hydrochloride, and 2.2 mg/kg zolazepam hydrochloride (Zoletil 50, Virbac Korea, Seoul, Korea) by intramuscular injection.", [["intramuscular", "ANATOMY", 498, 511], ["phosphate", "CHEMICAL", 70, 79], ["xylazine hydrochloride", "CHEMICAL", 320, 342], ["tiletamine hydrochloride", "CHEMICAL", 390, 414], ["zolazepam hydrochloride", "CHEMICAL", 430, 453], ["Zoletil 50, Virbac Korea", "CHEMICAL", 455, 479], ["phosphate", "CHEMICAL", 70, 79], ["xylazine hydrochloride", "CHEMICAL", 320, 342], ["Rumpon", "CHEMICAL", 344, 350], ["tiletamine hydrochloride", "CHEMICAL", 390, 414], ["zolazepam hydrochloride", "CHEMICAL", 430, 453], ["Zoletil", "CHEMICAL", 455, 462], ["phosphate buffered saline", "SIMPLE_CHEMICAL", 70, 95], ["VacA", "GENE_OR_GENE_PRODUCT", 189, 193], ["UnVac/Ch groups", "ORGANISM", 211, 226], ["xylazine", "SIMPLE_CHEMICAL", 320, 328], ["tiletamine", "SIMPLE_CHEMICAL", 390, 400], ["zolazepam hydrochloride", "SIMPLE_CHEMICAL", 430, 453], ["Zoletil", "SIMPLE_CHEMICAL", 455, 462], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 498, 511], ["VacA", "PROTEIN", 189, 193], ["pig", "SPECIES", 24, 27], ["pig", "SPECIES", 24, 27], ["UnVac/Ch", "TREATMENT", 0, 8], ["UnVac/UnCh pig groups", "TREATMENT", 13, 34], ["phosphate buffered saline (PBS", "TREATMENT", 70, 100], ["pH", "TEST", 109, 111], ["MethodsPigs", "TREATMENT", 170, 181], ["VacB/Ch", "TREATMENT", 198, 205], ["UnVac/Ch groups", "TREATMENT", 211, 226], ["xylazine hydrochloride", "TREATMENT", 320, 342], ["tiletamine hydrochloride", "TREATMENT", 390, 414], ["zolazepam hydrochloride", "TREATMENT", 430, 453], ["Zoletil", "TREATMENT", 455, 462]]], ["Post-anesthetization, they were immediately inoculated with an intratracheal challenge containing 7 mL of M. hyopneumoniae culture medium with 107 color changing units (CCU)/mL as described previously (16, 17).", [["hyopneumoniae", "ORGANISM", 109, 122], ["M. hyopneumoniae", "SPECIES", 106, 122], ["M. hyopneumoniae", "SPECIES", 106, 122], ["an intratracheal challenge", "TREATMENT", 60, 86], ["M. hyopneumoniae culture", "TEST", 106, 130]]], ["VacA/Ch, VacB/Ch, and UnVac/Ch pig groups were inoculated intranasally with 3 mL of tissue culture supernatant containing 1.2 \u00d7 105 TCID50/mL of PCV2d (SNUVR140004, GenBank no. KJ437506) at 0 dpc (56 days old) (12).Experimental Design ::: Materials and MethodsBlood and nasal swabs were collected at the following time points: \u221249 (7 days old), \u221235 (21 days old), \u22127 (42 days old), 0 (56 days old), 7 (63 days old), 14 (70 days old), and 21 (77 days old) dpc.", [["intranasally", "ANATOMY", 58, 70], ["tissue culture supernatant", "ANATOMY", 84, 110], ["Blood", "ANATOMY", 260, 265], ["nasal swabs", "ANATOMY", 270, 281], ["PCV2d", "CHEMICAL", 145, 150], ["VacA", "GENE_OR_GENE_PRODUCT", 0, 4], ["Ch", "GENE_OR_GENE_PRODUCT", 5, 7], ["VacB", "GENE_OR_GENE_PRODUCT", 9, 13], ["Ch", "GENE_OR_GENE_PRODUCT", 14, 16], ["UnVac/Ch pig", "ORGANISM", 22, 34], ["PCV2d", "SIMPLE_CHEMICAL", 145, 150], ["Blood", "ORGANISM_SUBSTANCE", 260, 265], ["nasal swabs", "MULTI-TISSUE_STRUCTURE", 270, 281], ["VacA", "PROTEIN", 0, 4], ["VacB", "PROTEIN", 9, 13], ["UnVac", "PROTEIN", 22, 27], ["pig", "SPECIES", 31, 34], ["pig", "SPECIES", 31, 34], ["VacA/Ch", "TEST", 0, 7], ["VacB/Ch", "TREATMENT", 9, 16], ["UnVac/Ch pig groups", "TREATMENT", 22, 41], ["tissue culture", "TEST", 84, 98], ["PCV2d", "TREATMENT", 145, 150], ["MethodsBlood", "TEST", 253, 265], ["nasal swabs", "TEST", 270, 281], ["nasal", "ANATOMY", 270, 275]]], ["An intravenous injection of sodium pentobarbital was used to sedate all pigs prior to euthanization by electrocution at 21 dpc as previously described (18).Clinical Observations ::: Materials and MethodsPigs were monitored daily for clinical signs and scored weekly using a score ranking system which ranged from 0 (normal) to 6 (severe dyspnea and abdominal breathing) (19).", [["intravenous", "ANATOMY", 3, 14], ["abdominal", "ANATOMY", 349, 358], ["sodium pentobarbital", "CHEMICAL", 28, 48], ["electrocution", "DISEASE", 103, 116], ["dyspnea", "DISEASE", 337, 344], ["sodium pentobarbital", "CHEMICAL", 28, 48], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 3, 14], ["sodium pentobarbital", "SIMPLE_CHEMICAL", 28, 48], ["pigs", "ORGANISM", 72, 76], ["abdominal", "ORGANISM_SUBDIVISION", 349, 358], ["pigs", "SPECIES", 72, 76], ["An intravenous injection of sodium pentobarbital", "TREATMENT", 0, 48], ["euthanization", "TREATMENT", 86, 99], ["MethodsPigs", "TREATMENT", 196, 207], ["clinical signs", "TEST", 233, 247], ["a score ranking system", "TEST", 272, 294], ["severe dyspnea", "PROBLEM", 330, 344], ["abdominal breathing", "PROBLEM", 349, 368], ["abdominal breathing", "ANATOMY", 349, 368]]], ["All observers involved in these processes were blinded to vaccination and type of vaccine status.", [["vaccination", "TREATMENT", 58, 69]]], ["At the end of the study, mortality rate was calculated for each group.", [["the study", "TEST", 14, 23], ["mortality rate", "TEST", 25, 39]]], ["Mortality rate was defined as the number of pigs that died divided by the number of pigs initially assigned to that group within the batch.", [["pigs", "ORGANISM", 44, 48], ["pigs", "ORGANISM", 84, 88], ["pigs", "SPECIES", 44, 48], ["pigs", "SPECIES", 84, 88], ["pigs", "SPECIES", 44, 48], ["pigs", "SPECIES", 84, 88], ["Mortality rate", "TEST", 0, 14]]], ["All pigs that died or were culled throughout the study were necropsied.Average Daily Weight Gain ::: Materials and MethodsThe live weight of each pig was measured at \u221235 dpc (21 days old), 0 dpc (56 days old), and 21 dpc (77 days old).", [["pigs", "ORGANISM", 4, 8], ["pig", "ORGANISM", 146, 149], ["pigs", "SPECIES", 4, 8], ["pig", "SPECIES", 146, 149], ["pigs", "SPECIES", 4, 8], ["pig", "SPECIES", 146, 149], ["the study", "TEST", 45, 54], ["Methods", "TREATMENT", 115, 122], ["The live weight", "TEST", 122, 137]]], ["Average daily weight gain (ADWG; grams/pig/day) was analyzed from the collected data over two time periods: (i) between 21 and 56 days of age and (ii) between 56 and 77 days of age.", [["pig", "SPECIES", 39, 42], ["ADWG", "TEST", 27, 31]]], ["ADWG during these two production stages was then calculated as the difference between the starting and final weight divided by the duration of the stage.", [["ADWG", "SIMPLE_CHEMICAL", 0, 4]]], ["Data for dead or removed pigs were included in the calculation.Quantification of M. hyopneumoniae in Nasal Swabs ::: Materials and MethodsA commercial kit (QIAamp DNA Mini Kit, QIAGEN, Valencia, California, USA) was used to extract DNA from nasal swabs prior to quantification of M. hyopneumoniae genomic DNA copy numbers by real-time PCR (20).Quantification of PCV2d DNA in Blood ::: Materials and MethodsA commercial kit (QIAamp DNA Mini Kit, QIAGEN) was used to extract DNA from serum samples prior to quantification of PCV2 genomic DNA copy numbers by use of real-time PCR (21).Serology ::: Materials and MethodsAll collected serum samples were tested using the commercially available M. hyopneumoniae (M. hyo.", [["nasal swabs", "ANATOMY", 241, 252], ["Blood", "ANATOMY", 375, 380], ["serum samples", "ANATOMY", 482, 495], ["serum samples", "ANATOMY", 630, 643], ["pigs", "ORGANISM", 25, 29], ["M. hyopneumoniae", "ORGANISM", 81, 97], ["DNA", "CELLULAR_COMPONENT", 232, 235], ["nasal swabs", "ORGANISM_SUBSTANCE", 241, 252], ["hyopneumoniae", "ORGANISM", 283, 296], ["DNA", "CELLULAR_COMPONENT", 305, 308], ["DNA", "CELLULAR_COMPONENT", 368, 371], ["Blood", "ORGANISM_SUBSTANCE", 375, 380], ["DNA", "CELLULAR_COMPONENT", 473, 476], ["serum samples", "ORGANISM_SUBSTANCE", 482, 495], ["PCV2", "ORGANISM", 523, 527], ["DNA", "CELLULAR_COMPONENT", 536, 539], ["serum samples", "ORGANISM_SUBSTANCE", 630, 643], ["M. hyopneumoniae", "ORGANISM", 689, 705], ["M. hyo", "ORGANISM", 707, 713], ["PCV2d DNA", "DNA", 362, 371], ["pigs", "SPECIES", 25, 29], ["M. hyopneumoniae", "SPECIES", 81, 97], ["M. hyopneumoniae", "SPECIES", 280, 296], ["M. hyopneumoniae", "SPECIES", 689, 705], ["M. hyopneumoniae", "SPECIES", 81, 97], ["M. hyopneumoniae", "SPECIES", 280, 296], ["PCV2", "SPECIES", 523, 527], ["M. hyopneumoniae", "SPECIES", 689, 705], ["dead", "PROBLEM", 9, 13], ["pigs", "TREATMENT", 25, 29], ["M. hyopneumoniae", "PROBLEM", 81, 97], ["Materials", "TEST", 117, 126], ["MethodsA", "TEST", 131, 139], ["nasal swabs", "TREATMENT", 241, 252], ["M. hyopneumoniae", "PROBLEM", 280, 296], ["PCR", "TEST", 335, 338], ["Materials", "TEST", 385, 394], ["MethodsA commercial kit (QIAamp DNA Mini Kit, QIAGEN)", "TREATMENT", 399, 452], ["serum samples", "TEST", 482, 495], ["PCV2", "PROBLEM", 523, 527], ["Serology", "TEST", 582, 590], ["All collected serum samples", "TEST", 616, 643], ["M. hyopneumoniae", "OBSERVATION", 81, 97], ["Nasal", "ANATOMY", 101, 106], ["nasal", "ANATOMY", 241, 246], ["PCV2d DNA", "OBSERVATION", 362, 371]]], ["Ab test, IDEXX Laboratories Inc.) and PCV2 (SERELISA PCV2 Ab Mono Blocking, Synbiotics) ELISA kits in accordance with the manufacturer's instructions.", [["PCV2", "ORGANISM", 38, 42], ["PCV2", "SPECIES", 38, 42], ["Ab test", "TEST", 0, 7], ["PCV2 (SERELISA PCV2 Ab Mono Blocking", "TREATMENT", 38, 74], ["Synbiotics)", "TREATMENT", 76, 87], ["ELISA kits", "TREATMENT", 88, 98]]], ["Serum samples were considered positive for M. hyopneumoniae antibody if the sample-to-positive (S/P) ratio was \u22650.4, while serum samples were considered to be positive for anti-PCV2 antibody if the reciprocal ELISA titer was >350.Enzyme-Linked Immunospot (ELISPOT) Assay ::: Materials and MethodsThe M. hyopneumoniae and PCV2d challenge strains were used in the in vitro stimulation of peripheral blood mononuclear cells (PBMC) so that the numbers of M. hyopneumoniae- and PCV2d-specific interferon-\u03b3 secreting cells (IFN-\u03b3-SC) could be quantified (21, 22).", [["Serum samples", "ANATOMY", 0, 13], ["sample", "ANATOMY", 76, 82], ["serum samples", "ANATOMY", 123, 136], ["peripheral blood mononuclear cells", "ANATOMY", 386, 420], ["PBMC", "ANATOMY", 422, 426], ["cells", "ANATOMY", 511, 516], ["Serum samples", "ORGANISM_SUBSTANCE", 0, 13], ["M. hyopneumoniae", "ORGANISM", 43, 59], ["serum samples", "ORGANISM_SUBSTANCE", 123, 136], ["anti-PCV2", "GENE_OR_GENE_PRODUCT", 172, 181], ["M. hyopneumoniae", "ORGANISM", 300, 316], ["PCV2d", "ORGANISM", 321, 326], ["peripheral blood mononuclear cells", "CELL", 386, 420], ["PBMC", "CELL", 422, 426], ["M. hyopneumoniae", "ORGANISM", 451, 467], ["PCV2d", "GENE_OR_GENE_PRODUCT", 473, 478], ["interferon-\u03b3", "GENE_OR_GENE_PRODUCT", 488, 500], ["cells", "CELL", 511, 516], ["IFN-\u03b3-SC", "GENE_OR_GENE_PRODUCT", 518, 526], ["M. hyopneumoniae antibody", "PROTEIN", 43, 68], ["anti-PCV2 antibody", "PROTEIN", 172, 190], ["peripheral blood mononuclear cells", "CELL_TYPE", 386, 420], ["PBMC", "CELL_TYPE", 422, 426], ["interferon", "PROTEIN", 488, 498], ["\u03b3 secreting cells", "CELL_TYPE", 499, 516], ["IFN", "PROTEIN", 518, 521], ["\u03b3", "PROTEIN", 522, 523], ["M. hyopneumoniae", "SPECIES", 43, 59], ["M. hyopneumoniae", "SPECIES", 300, 316], ["M. hyopneumoniae", "SPECIES", 451, 467], ["M. hyopneumoniae", "SPECIES", 43, 59], ["anti-PCV2", "SPECIES", 172, 181], ["M. hyopneumoniae", "SPECIES", 300, 316], ["M. hyopneumoniae", "SPECIES", 451, 467], ["Serum samples", "TEST", 0, 13], ["M. hyopneumoniae antibody", "TEST", 43, 68], ["the sample", "TEST", 72, 82], ["S/P) ratio", "TEST", 96, 106], ["serum samples", "TEST", 123, 136], ["anti-PCV2 antibody", "TEST", 172, 190], ["the reciprocal ELISA titer", "TEST", 194, 220], ["Enzyme", "TEST", 230, 236], ["Materials", "TREATMENT", 275, 284], ["Methods", "TREATMENT", 289, 296], ["The M. hyopneumoniae", "PROBLEM", 296, 316], ["PCV2d challenge strains", "TREATMENT", 321, 344], ["peripheral blood mononuclear cells", "PROBLEM", 386, 420], ["M. hyopneumoniae", "TEST", 451, 467], ["PCV2d", "TEST", 473, 478], ["secreting cells", "PROBLEM", 501, 516], ["IFN", "TEST", 518, 521], ["hyopneumoniae", "OBSERVATION", 303, 316], ["peripheral", "ANATOMY_MODIFIER", 386, 396], ["blood", "ANATOMY", 397, 402], ["mononuclear cells", "OBSERVATION", 403, 420], ["hyopneumoniae", "OBSERVATION", 454, 467], ["secreting cells", "OBSERVATION", 501, 516], ["SC", "ANATOMY", 524, 526]]], ["All results were expressed as the numbers of IFN-\u03b3-SC per million PBMC.", [["PBMC", "ANATOMY", 66, 70], ["IFN-\u03b3-SC", "GENE_OR_GENE_PRODUCT", 45, 53], ["PBMC", "CELL", 66, 70], ["IFN", "PROTEIN", 45, 48], ["PBMC", "CELL_TYPE", 66, 70], ["IFN", "TEST", 45, 48]]], ["The frequency of M. hyopneumoniae- and PCV2d-specific IFN-\u03b3-SC was considered to be positive if the number of M. hyopneumoniae- and PCV2d-specific IFN-\u03b3-SC was >20 cells/106 PBMC.Pathology ::: Materials and MethodsMacroscopic lung lesion severity was scored to estimate the percentage of the lung affected by pneumonia (23).Pathology ::: Materials and MethodsTwo veterinary pathologists (Chae and one graduate student) were blinded while examing lung and lymphoid tissue sections.", [["cells", "ANATOMY", 164, 169], ["PBMC", "ANATOMY", 174, 178], ["lung lesion", "ANATOMY", 226, 237], ["lung", "ANATOMY", 292, 296], ["lung", "ANATOMY", 446, 450], ["lymphoid tissue sections", "ANATOMY", 455, 479], ["pneumonia", "DISEASE", 309, 318], ["M. hyopneumoniae", "ORGANISM", 17, 33], ["PCV2d", "GENE_OR_GENE_PRODUCT", 39, 44], ["M. hyopneumoniae", "ORGANISM", 110, 126], ["PCV2d", "GENE_OR_GENE_PRODUCT", 132, 137], ["cells", "CELL", 164, 169], ["PBMC", "CELL", 174, 178], ["lung", "ORGAN", 226, 230], ["lung", "ORGAN", 292, 296], ["lung", "ORGAN", 446, 450], ["lymphoid tissue sections", "MULTI-TISSUE_STRUCTURE", 455, 479], ["IFN", "PROTEIN", 54, 57], ["IFN", "PROTEIN", 147, 150], ["PBMC", "CELL_TYPE", 174, 178], ["M. hyopneumoniae", "SPECIES", 17, 33], ["M. hyopneumoniae", "SPECIES", 110, 126], ["M. hyopneumoniae", "SPECIES", 17, 33], ["M. hyopneumoniae", "SPECIES", 110, 126], ["M. hyopneumoniae", "PROBLEM", 17, 33], ["PCV2d", "TREATMENT", 39, 44], ["M. hyopneumoniae", "PROBLEM", 110, 126], ["PCV2d", "TEST", 132, 137], ["SC", "TEST", 153, 155], ["Materials", "TREATMENT", 193, 202], ["MethodsMacroscopic lung lesion severity", "PROBLEM", 207, 246], ["pneumonia", "PROBLEM", 309, 318], ["hyopneumoniae", "OBSERVATION", 20, 33], ["Macroscopic", "OBSERVATION_MODIFIER", 214, 225], ["lung", "ANATOMY", 226, 230], ["lesion", "OBSERVATION", 231, 237], ["percentage", "OBSERVATION_MODIFIER", 274, 284], ["lung", "ANATOMY", 292, 296], ["pneumonia", "OBSERVATION", 309, 318], ["lung", "ANATOMY", 446, 450], ["lymphoid tissue", "OBSERVATION", 455, 470]]], ["Mycoplasmal pneumonia lesions were scored (0\u20136) based on the severity of peribronchiolar and perivascular lymphoid tissue hyperplasia (24).", [["Mycoplasmal pneumonia lesions", "ANATOMY", 0, 29], ["peribronchiolar", "ANATOMY", 73, 88], ["perivascular lymphoid tissue", "ANATOMY", 93, 121], ["pneumonia", "DISEASE", 12, 21], ["hyperplasia", "DISEASE", 122, 133], ["Mycoplasmal pneumonia lesions", "CANCER", 0, 29], ["peribronchiolar", "CANCER", 73, 88], ["perivascular lymphoid tissue", "TISSUE", 93, 121], ["Mycoplasmal pneumonia lesions", "PROBLEM", 0, 29], ["peribronchiolar and perivascular lymphoid tissue hyperplasia", "PROBLEM", 73, 133], ["pneumonia", "OBSERVATION", 12, 21], ["severity", "OBSERVATION_MODIFIER", 61, 69], ["peribronchiolar", "ANATOMY_MODIFIER", 73, 88], ["perivascular", "ANATOMY_MODIFIER", 93, 105], ["lymphoid tissue hyperplasia", "OBSERVATION", 106, 133]]], ["Interstitial pneumonia lesions were scored (0\u20136) based on the severity of interstitial pneumonia (19).", [["Interstitial pneumonia lesions", "ANATOMY", 0, 30], ["interstitial", "ANATOMY", 74, 86], ["Interstitial pneumonia", "DISEASE", 0, 22], ["interstitial pneumonia", "DISEASE", 74, 96], ["Interstitial pneumonia lesions", "PATHOLOGICAL_FORMATION", 0, 30], ["Interstitial pneumonia lesions", "PROBLEM", 0, 30], ["interstitial pneumonia", "PROBLEM", 74, 96], ["pneumonia", "OBSERVATION", 13, 22], ["interstitial", "ANATOMY_MODIFIER", 74, 86], ["pneumonia", "OBSERVATION", 87, 96]]], ["PCV2-associated lymphoid lesions were scored (0\u20135) based on the severity of lymphoid depletion and granulomatous inflammation (10, 25).Statistical Analysis ::: Materials and MethodsReal-time PCR data were transformed to log10 values prior to statistical analysis.", [["lymphoid lesions", "ANATOMY", 16, 32], ["lymphoid", "ANATOMY", 76, 84], ["granulomatous", "ANATOMY", 99, 112], ["lymphoid lesions", "DISEASE", 16, 32], ["lymphoid depletion", "DISEASE", 76, 94], ["granulomatous inflammation", "DISEASE", 99, 125], ["PCV2", "ORGANISM", 0, 4], ["lymphoid lesions", "PATHOLOGICAL_FORMATION", 16, 32], ["lymphoid", "CELL", 76, 84], ["PCV2", "PROBLEM", 0, 4], ["lymphoid lesions", "PROBLEM", 16, 32], ["lymphoid depletion", "PROBLEM", 76, 94], ["granulomatous inflammation", "PROBLEM", 99, 125], ["MethodsReal-time PCR data", "TEST", 174, 199], ["statistical analysis", "TEST", 242, 262], ["lymphoid", "OBSERVATION_MODIFIER", 16, 24], ["lesions", "OBSERVATION", 25, 32], ["lymphoid depletion", "OBSERVATION", 76, 94], ["granulomatous", "OBSERVATION_MODIFIER", 99, 112], ["inflammation", "OBSERVATION", 113, 125]]], ["Data were tested for normal distribution using the Shapiro-Wilk test.", [["the Shapiro-Wilk test", "TEST", 47, 68]]], ["One-way analysis of variance (ANOVA) was used to examine whether there were statistically significant differences among the four groups at each defined time point.", [["significant", "OBSERVATION_MODIFIER", 90, 101]]], ["Test results showing a statistical significance from one-way ANOVA were then subjected to a post-hoc test for a pairwise comparison with Tukey's adjustment.", [["a post-hoc test", "TEST", 90, 105], ["Tukey's adjustment", "TREATMENT", 137, 155]]], ["If the normality assumption was not met, the Kruskal-Wallis test was additionally performed.", [["the Kruskal-Wallis test", "TEST", 41, 64]]], ["Any results showing statistical significance from the Kruskal Wallis test were then subjected to the Mann-Whitney test with Tukey's adjustment to compare the differences among the groups.", [["the Kruskal Wallis test", "TEST", 50, 73], ["Tukey's adjustment", "TREATMENT", 124, 142]]], ["A value of P < 0.05 was considered to be significant.Clinical Observation ::: ResultsIn UnVac/Ch group pigs exhibited mild-to-moderate respiratory disease that was characterized by lethargy, coughing, and occasionally sneezing between 7 and 14 dpc.", [["respiratory", "ANATOMY", 135, 146], ["respiratory disease", "DISEASE", 135, 154], ["lethargy", "DISEASE", 181, 189], ["coughing", "DISEASE", 191, 199], ["pigs", "ORGANISM", 103, 107], ["pigs", "SPECIES", 103, 107], ["A value", "TEST", 0, 7], ["mild-to-moderate respiratory disease", "PROBLEM", 118, 154], ["lethargy", "PROBLEM", 181, 189], ["coughing", "PROBLEM", 191, 199], ["occasionally sneezing", "PROBLEM", 205, 226], ["mild", "OBSERVATION_MODIFIER", 118, 122], ["moderate", "OBSERVATION_MODIFIER", 126, 134], ["respiratory disease", "OBSERVATION", 135, 154], ["lethargy", "OBSERVATION", 181, 189]]], ["Moderate-to-severe respiratory disease that was characterized by coughing, depression, and pronounced abdominal breathing was also observed the same timeperiod.", [["respiratory", "ANATOMY", 19, 30], ["abdominal", "ANATOMY", 102, 111], ["respiratory disease", "DISEASE", 19, 38], ["coughing", "DISEASE", 65, 73], ["depression", "DISEASE", 75, 85], ["abdominal", "ORGANISM_SUBDIVISION", 102, 111], ["Moderate-to-severe respiratory disease", "PROBLEM", 0, 38], ["coughing", "PROBLEM", 65, 73], ["depression", "PROBLEM", 75, 85], ["pronounced abdominal breathing", "PROBLEM", 91, 121], ["-to-severe", "OBSERVATION_MODIFIER", 8, 18], ["respiratory disease", "OBSERVATION", 19, 38], ["coughing", "OBSERVATION", 65, 73], ["pronounced", "OBSERVATION_MODIFIER", 91, 101], ["abdominal breathing", "ANATOMY", 102, 121]]], ["At 21 dpc, symptoms in the UnVaqc/Ch group pigs regressed to mild-to-moderate respiratory disease.", [["respiratory", "ANATOMY", 78, 89], ["respiratory disease", "DISEASE", 78, 97], ["pigs", "ORGANISM", 43, 47], ["pigs", "SPECIES", 43, 47], ["symptoms", "PROBLEM", 11, 19], ["the UnVaqc/Ch group pigs", "TREATMENT", 23, 47], ["mild-to-moderate respiratory disease", "PROBLEM", 61, 97], ["mild", "OBSERVATION_MODIFIER", 61, 65], ["moderate", "OBSERVATION_MODIFIER", 69, 77], ["respiratory disease", "OBSERVATION", 78, 97]]], ["Pigs in VacA/Ch and VacB/Ch groups showed minimal respiratory diseases that was characterized by occisionally coughing and sneezing.", [["respiratory", "ANATOMY", 50, 61], ["respiratory diseases", "DISEASE", 50, 70], ["coughing", "DISEASE", 110, 118], ["sneezing", "DISEASE", 123, 131], ["Pigs", "ORGANISM", 0, 4], ["VacA", "GENE_OR_GENE_PRODUCT", 8, 12], ["VacA", "PROTEIN", 8, 12], ["Pigs", "SPECIES", 0, 4], ["Pigs in VacA/Ch and VacB/Ch groups", "TEST", 0, 34], ["minimal respiratory diseases", "PROBLEM", 42, 70], ["coughing", "PROBLEM", 110, 118], ["sneezing", "PROBLEM", 123, 131], ["minimal", "OBSERVATION_MODIFIER", 42, 49], ["respiratory diseases", "OBSERVATION", 50, 70], ["coughing", "OBSERVATION", 110, 118], ["sneezing", "OBSERVATION", 123, 131]]], ["No respiratory diseases were observed in pigs from UnVac/UnCh group.", [["respiratory", "ANATOMY", 3, 14], ["respiratory diseases", "DISEASE", 3, 23], ["pigs", "ORGANISM", 41, 45], ["pigs", "SPECIES", 41, 45], ["pigs", "SPECIES", 41, 45], ["respiratory diseases", "PROBLEM", 3, 23], ["respiratory", "ANATOMY", 3, 14], ["diseases", "OBSERVATION", 15, 23]]], ["The mean scores for respiratory disease from 0 to 21 dpc were signficantly higher (P < 0.05) in pigs from the UnVac/Ch group when compared with the VacA/Ch, VacB/Ch, and UnVac/UnCh groups (Figure 1).Average Daily Weight Gain ::: ResultsAll 4 groups were similar in average body weights at the start of the study (21 days of age).", [["respiratory", "ANATOMY", 20, 31], ["body", "ANATOMY", 273, 277], ["respiratory disease", "DISEASE", 20, 39], ["Ch", "CHEMICAL", 116, 118], ["pigs", "ORGANISM", 96, 100], ["VacA", "GENE_OR_GENE_PRODUCT", 148, 152], ["body", "ORGANISM_SUBDIVISION", 273, 277], ["VacA", "PROTEIN", 148, 152], ["pigs", "SPECIES", 96, 100], ["pigs", "SPECIES", 96, 100], ["The mean scores", "TEST", 0, 15], ["respiratory disease", "PROBLEM", 20, 39], ["the VacA/Ch", "TEST", 144, 155], ["VacB/Ch", "TREATMENT", 157, 164], ["UnVac/UnCh groups", "TREATMENT", 170, 187], ["the study", "TEST", 302, 311], ["respiratory disease", "OBSERVATION", 20, 39]]], ["Pigs from the VacA/Ch, VacB/Ch, and UnVac/UnCh groups had significantly higher (P < 0.05) ADWG between 56 and 77 days of age when compared with pigs in the UnVac/Ch group.", [["Ch", "CHEMICAL", 162, 164], ["Pigs", "ORGANISM", 0, 4], ["VacA", "GENE_OR_GENE_PRODUCT", 14, 18], ["UnVac", "GENE_OR_GENE_PRODUCT", 36, 41], ["UnCh", "GENE_OR_GENE_PRODUCT", 42, 46], ["pigs", "ORGANISM", 144, 148], ["VacA", "PROTEIN", 14, 18], ["Pigs", "SPECIES", 0, 4], ["pigs", "SPECIES", 144, 148], ["pigs", "SPECIES", 144, 148], ["VacB/Ch", "TREATMENT", 23, 30], ["UnVac/UnCh groups", "TEST", 36, 53], ["ADWG", "TEST", 90, 94]]], ["The overall ADWG results (from 21 to 77 days old) of pigs from the VacA/Ch, VacB/Ch, and UnVac/UnCh groups was significantly higher (P < 0.05) when compared with in the UnVac/Ch group.", [["Ch", "CHEMICAL", 175, 177], ["pigs", "ORGANISM", 53, 57], ["VacA", "GENE_OR_GENE_PRODUCT", 67, 71], ["pigs", "SPECIES", 53, 57], ["pigs", "SPECIES", 53, 57], ["pigs", "TREATMENT", 53, 57], ["the VacA/Ch", "TREATMENT", 63, 74], ["VacB/Ch", "TREATMENT", 76, 83], ["UnVac/UnCh groups", "TREATMENT", 89, 106]]], ["A significant difference was not calculated in the ADWG among the VacA/Ch, VacB/Ch, and UnVac/UnCh groups (Table 2).Genomic Quantification of M. hyopneumoniae and PCV2 ::: ResultsPrior to challenge, zero genomic copies of M. hyopneumoniae and PCV2 were detected in any of the pigs within the study.", [["VacA", "GENE_OR_GENE_PRODUCT", 66, 70], ["M. hyopneumoniae", "ORGANISM", 142, 158], ["PCV2", "ORGANISM", 163, 167], ["M. hyopneumoniae", "ORGANISM", 222, 238], ["PCV2", "ORGANISM", 243, 247], ["pigs", "ORGANISM", 276, 280], ["VacA", "PROTEIN", 66, 70], ["VacB", "PROTEIN", 75, 79], ["UnVac", "PROTEIN", 88, 93], ["M. hyopneumoniae", "SPECIES", 142, 158], ["M. hyopneumoniae", "SPECIES", 222, 238], ["pigs", "SPECIES", 276, 280], ["M. hyopneumoniae", "SPECIES", 142, 158], ["PCV2", "SPECIES", 163, 167], ["M. hyopneumoniae", "SPECIES", 222, 238], ["PCV2", "SPECIES", 243, 247], ["VacB/Ch", "TREATMENT", 75, 82], ["UnVac/UnCh groups", "TREATMENT", 88, 105], ["M. hyopneumoniae", "PROBLEM", 142, 158], ["M. hyopneumoniae", "PROBLEM", 222, 238], ["PCV2", "PROBLEM", 243, 247], ["the study", "TEST", 288, 297], ["significant", "OBSERVATION_MODIFIER", 2, 13], ["difference", "OBSERVATION", 14, 24], ["M. hyopneumoniae", "OBSERVATION", 142, 158], ["M. hyopneumoniae", "OBSERVATION", 222, 238]]], ["For genomic quantification of M. hyopneumoniae, pigs in the VacA/Ch group had significantly less (P < 0.05) M. hyopneumoniae genomic copies in their nasal swabs at 7 dpc when compared with the UnVac/Ch group.", [["nasal swabs", "ANATOMY", 149, 160], ["M. hyopneumoniae", "ORGANISM", 30, 46], ["pigs", "ORGANISM", 48, 52], ["VacA", "GENE_OR_GENE_PRODUCT", 60, 64], ["hyopneumoniae", "ORGANISM", 111, 124], ["nasal swabs", "MULTI-TISSUE_STRUCTURE", 149, 160], ["VacA", "PROTEIN", 60, 64], ["M. hyopneumoniae", "SPECIES", 30, 46], ["pigs", "SPECIES", 48, 52], ["M. hyopneumoniae", "SPECIES", 108, 124], ["M. hyopneumoniae", "SPECIES", 30, 46], ["pigs", "SPECIES", 48, 52], ["M. hyopneumoniae", "SPECIES", 108, 124], ["M. hyopneumoniae", "PROBLEM", 30, 46], ["pigs", "TREATMENT", 48, 52], ["the VacA/Ch group", "TEST", 56, 73], ["M. hyopneumoniae genomic copies", "PROBLEM", 108, 139], ["their nasal swabs", "TEST", 143, 160], ["M. hyopneumoniae", "OBSERVATION", 30, 46], ["nasal", "ANATOMY", 149, 154]]], ["Pigs in the VacA/Ch and VacB/Ch groups had significantly less (P < 0.05) M. hyopneumoniae genomic copies in their nasal swabs at 14 and 21 dpc when compared with the UnVac/Ch group (Figure 2A).Genomic Quantification of M. hyopneumoniae and PCV2 ::: ResultsFor genomic quantification of PCV2, pigs in the VacA/Ch group had a significantly lower (P < 0.05) number of genomic copies of PCV2 in their blood at 7 dpc when compared with the UnVac/Ch group.", [["nasal swabs", "ANATOMY", 114, 125], ["blood", "ANATOMY", 397, 402], ["Pigs", "ORGANISM", 0, 4], ["VacA", "GENE_OR_GENE_PRODUCT", 12, 16], ["Ch", "GENE_OR_GENE_PRODUCT", 17, 19], ["hyopneumoniae", "ORGANISM", 76, 89], ["nasal swabs", "MULTI-TISSUE_STRUCTURE", 114, 125], ["M. hyopneumoniae", "ORGANISM", 219, 235], ["PCV2", "ORGANISM", 240, 244], ["PCV2", "ORGANISM", 286, 290], ["pigs", "ORGANISM", 292, 296], ["VacA", "GENE_OR_GENE_PRODUCT", 304, 308], ["PCV2", "ORGANISM", 383, 387], ["blood", "ORGANISM_SUBSTANCE", 397, 402], ["VacA", "PROTEIN", 12, 16], ["VacA", "PROTEIN", 304, 308], ["Pigs", "SPECIES", 0, 4], ["M. hyopneumoniae", "SPECIES", 73, 89], ["M. hyopneumoniae", "SPECIES", 219, 235], ["pigs", "SPECIES", 292, 296], ["M. hyopneumoniae", "SPECIES", 73, 89], ["M. hyopneumoniae", "SPECIES", 219, 235], ["PCV2", "SPECIES", 240, 244], ["PCV2", "SPECIES", 286, 290], ["pigs", "SPECIES", 292, 296], ["Pigs", "TREATMENT", 0, 4], ["the VacA/Ch", "TEST", 8, 19], ["VacB/Ch groups", "TEST", 24, 38], ["M. hyopneumoniae genomic copies", "PROBLEM", 73, 104], ["their nasal swabs", "TEST", 108, 125], ["M. hyopneumoniae", "PROBLEM", 219, 235], ["genomic quantification", "TEST", 260, 282], ["PCV2", "PROBLEM", 286, 290], ["pigs", "TREATMENT", 292, 296], ["the VacA/Ch group", "TREATMENT", 300, 317], ["PCV2", "PROBLEM", 383, 387], ["VacA", "ANATOMY", 12, 16], ["nasal swabs", "ANATOMY", 114, 125], ["M. hyopneumoniae", "OBSERVATION", 219, 235], ["PCV2", "OBSERVATION", 286, 290]]], ["Pigs in the VacA/Ch and VacB/Ch groups had a significantly lower (P < 0.05) number of genomic copies of PCV2 in their blood at 14 and 21 dpc when compared with the UnVac/Ch group.", [["blood", "ANATOMY", 118, 123], ["Pigs", "ORGANISM", 0, 4], ["VacA", "GENE_OR_GENE_PRODUCT", 12, 16], ["PCV2", "ORGANISM", 104, 108], ["blood", "ORGANISM_SUBSTANCE", 118, 123], ["VacA", "PROTEIN", 12, 16], ["Pigs", "SPECIES", 0, 4], ["Pigs", "TREATMENT", 0, 4], ["the VacA/Ch", "TREATMENT", 8, 19], ["VacB/Ch groups", "TREATMENT", 24, 38], ["PCV2", "PROBLEM", 104, 108], ["VacA", "ANATOMY", 12, 16]]], ["Pigs in the VacA/Ch group had a significantly lower (P < 0.05) number of genomic copies of PCV2 in their blood at 14 dpc when compared with the VacB/Ch group.", [["blood", "ANATOMY", 105, 110], ["Ch", "CHEMICAL", 149, 151], ["Pigs", "ORGANISM", 0, 4], ["VacA", "GENE_OR_GENE_PRODUCT", 12, 16], ["PCV2", "ORGANISM", 91, 95], ["blood", "ORGANISM_SUBSTANCE", 105, 110], ["VacA", "PROTEIN", 12, 16], ["Pigs", "SPECIES", 0, 4], ["Pigs", "TREATMENT", 0, 4], ["PCV2", "PROBLEM", 91, 95], ["the VacB/Ch group", "TREATMENT", 140, 157], ["VacA", "OBSERVATION", 12, 16], ["PCV2", "OBSERVATION", 91, 95]]], ["No genomic copies of M. hyopneumoniae or PCV2 were detected in any of the pigs from the UnVac/UnCh group (Figure 2B).Immune Responses Against M. hyopneumoniae ::: ResultsELISA was used to assess pig antibody responses against M. hyopneumoniae.", [["M. hyopneumoniae", "ORGANISM", 21, 37], ["PCV2", "ORGANISM", 41, 45], ["pigs", "ORGANISM", 74, 78], ["M. hyopneumoniae", "ORGANISM", 142, 158], ["pig", "ORGANISM", 195, 198], ["M. hyopneumoniae", "ORGANISM", 226, 242], ["M. hyopneumoniae", "SPECIES", 21, 37], ["pigs", "SPECIES", 74, 78], ["M. hyopneumoniae", "SPECIES", 142, 158], ["pig", "SPECIES", 195, 198], ["M. hyopneumoniae", "SPECIES", 226, 242], ["M. hyopneumoniae", "SPECIES", 21, 37], ["PCV2", "SPECIES", 41, 45], ["pigs", "SPECIES", 74, 78], ["M. hyopneumoniae", "SPECIES", 142, 158], ["pig", "SPECIES", 195, 198], ["M. hyopneumoniae", "SPECIES", 226, 242], ["M. hyopneumoniae", "PROBLEM", 21, 37], ["PCV2", "PROBLEM", 41, 45], ["pig antibody responses", "TEST", 195, 217], ["M. hyopneumoniae", "PROBLEM", 226, 242], ["M. hyopneumoniae", "OBSERVATION", 21, 37], ["PCV2", "OBSERVATION", 41, 45], ["hyopneumoniae", "OBSERVATION", 229, 242]]], ["Pigs in the VacA/Ch and VacB/Ch groups had significantly higher (P < 0.05) M. hyopneumoniae ELISA S/P ratios between \u221214 and 21 dpc when compared with the UnVac/Ch groups.", [["Pigs", "ORGANISM", 0, 4], ["VacA", "GENE_OR_GENE_PRODUCT", 12, 16], ["hyopneumoniae", "ORGANISM", 78, 91], ["VacA", "PROTEIN", 12, 16], ["Pigs", "SPECIES", 0, 4], ["M. hyopneumoniae", "SPECIES", 75, 91], ["M. hyopneumoniae", "SPECIES", 75, 91], ["Pigs", "TREATMENT", 0, 4], ["the VacA/Ch", "TEST", 8, 19], ["VacB/Ch groups", "TEST", 24, 38], ["M. hyopneumoniae ELISA S/P ratios", "TEST", 75, 108], ["the UnVac/Ch groups", "TREATMENT", 151, 170], ["VacA", "ANATOMY", 12, 16]]], ["Antibodies against M. hyopneumoniae were not detected in any of the pigs from the UnVac/UnCh group (Figure 3A).Immune Responses Against M. hyopneumoniae ::: ResultsThe number of M. hyopneumoniae-specific IFN-\u03b3-SC quantified in the PBMC of individual pigs was used to categorize T cell response.", [["PBMC", "ANATOMY", 231, 235], ["T cell", "ANATOMY", 278, 284], ["M. hyopneumoniae", "ORGANISM", 19, 35], ["pigs", "ORGANISM", 68, 72], ["M. hyopneumoniae", "ORGANISM", 136, 152], ["M. hyopneumoniae", "ORGANISM", 178, 194], ["IFN-\u03b3-SC", "GENE_OR_GENE_PRODUCT", 204, 212], ["PBMC", "CELL", 231, 235], ["pigs", "ORGANISM", 250, 254], ["T cell", "CELL", 278, 284], ["IFN", "PROTEIN", 204, 207], ["PBMC", "CELL_TYPE", 231, 235], ["M. hyopneumoniae", "SPECIES", 19, 35], ["pigs", "SPECIES", 68, 72], ["M. hyopneumoniae", "SPECIES", 136, 152], ["M. hyopneumoniae", "SPECIES", 178, 194], ["pigs", "SPECIES", 250, 254], ["M. hyopneumoniae", "SPECIES", 19, 35], ["pigs", "SPECIES", 68, 72], ["M. hyopneumoniae", "SPECIES", 136, 152], ["M. hyopneumoniae", "SPECIES", 178, 194], ["pigs", "SPECIES", 250, 254], ["Antibodies", "TEST", 0, 10], ["M. hyopneumoniae", "PROBLEM", 19, 35], ["M. hyopneumoniae", "PROBLEM", 178, 194], ["individual pigs", "TREATMENT", 239, 254], ["hyopneumoniae", "OBSERVATION", 22, 35], ["M. hyopneumoniae", "OBSERVATION", 178, 194]]], ["Pigs from the VacA/Ch and VacB/Ch groups had a significantly higher (P < 0.05) number of M. hyopneumoniae-specific IFN-\u03b3-SC in their PBMC between \u221214 and 21 dpc when compared with pigs from the UnVac/Ch group.", [["PBMC", "ANATOMY", 133, 137], ["Ch", "CHEMICAL", 200, 202], ["Pigs", "ORGANISM", 0, 4], ["VacA", "GENE_OR_GENE_PRODUCT", 14, 18], ["M. hyopneumoniae", "ORGANISM", 89, 105], ["IFN-\u03b3-SC", "GENE_OR_GENE_PRODUCT", 115, 123], ["PBMC", "CELL", 133, 137], ["pigs", "ORGANISM", 180, 184], ["VacA", "PROTEIN", 14, 18], ["IFN", "PROTEIN", 115, 118], ["PBMC", "CELL_TYPE", 133, 137], ["Pigs", "SPECIES", 0, 4], ["M. hyopneumoniae", "SPECIES", 89, 105], ["pigs", "SPECIES", 180, 184], ["M. hyopneumoniae", "SPECIES", 89, 105], ["pigs", "SPECIES", 180, 184], ["Pigs", "TREATMENT", 0, 4], ["the VacA/Ch", "TREATMENT", 10, 21], ["VacB/Ch groups", "TREATMENT", 26, 40], ["M. hyopneumoniae", "PROBLEM", 89, 105], ["hyopneumoniae", "OBSERVATION", 92, 105]]], ["The mean numbers of M. hyopneumoniae-specific IFN-\u03b3-SC in the UnVac/UnCh group remained at basal levels (<20 cells/106 PBMC) throughout the study (Figure 3B).Immune Responses Against Porcine Circovirus Type 2 ::: ResultsELISA was used to assess pig antibody responses PCV2.", [["UnVac/UnCh", "ANATOMY", 62, 72], ["cells", "ANATOMY", 109, 114], ["PBMC", "ANATOMY", 119, 123], ["M. hyopneumoniae", "ORGANISM", 20, 36], ["IFN-\u03b3-SC", "GENE_OR_GENE_PRODUCT", 46, 54], ["UnVac", "CANCER", 62, 67], ["UnCh", "CANCER", 68, 72], ["cells", "CELL", 109, 114], ["PBMC", "CELL", 119, 123], ["pig", "ORGANISM", 245, 248], ["PCV2", "ORGANISM", 268, 272], ["IFN", "PROTEIN", 46, 49], ["PBMC", "CELL_TYPE", 119, 123], ["M. hyopneumoniae", "SPECIES", 20, 36], ["Porcine", "SPECIES", 183, 190], ["pig", "SPECIES", 245, 248], ["M. hyopneumoniae", "SPECIES", 20, 36], ["pig", "SPECIES", 245, 248], ["M. hyopneumoniae", "PROBLEM", 20, 36], ["basal levels", "TEST", 91, 103], ["PBMC", "TEST", 119, 123], ["the study", "TEST", 136, 145], ["pig antibody responses PCV2", "TREATMENT", 245, 272], ["M. hyopneumoniae", "OBSERVATION", 20, 36]]], ["Pigs in the VacA/Ch and VacB/Ch groups had significantly higher (P < 0.05) PCV2 ELISA titers between \u221214 and 21 dpc when compared with those in the UnVac/Ch groups.", [["Pigs", "ORGANISM", 0, 4], ["VacA", "GENE_OR_GENE_PRODUCT", 12, 16], ["PCV2", "ORGANISM", 75, 79], ["VacA", "PROTEIN", 12, 16], ["Pigs", "SPECIES", 0, 4], ["Pigs", "TREATMENT", 0, 4], ["the VacA/Ch", "TEST", 8, 19], ["VacB/Ch groups", "TEST", 24, 38], ["PCV2 ELISA titers", "TEST", 75, 92], ["VacA", "ANATOMY", 12, 16]]], ["Antibodies against PCV2 were not detected in any of the pigs from the UnVac/UnCh group (Figure 4A).Immune Responses Against Porcine Circovirus Type 2 ::: ResultsPigs from the VacA/Ch and VacB/Ch groups had a significantly higher (P < 0.05) number of PCV2d-specific IFN-\u03b3-SC in their PBMC between \u221214 and 21 dpc when compared with pigs in the UnVac/Ch group.", [["PBMC", "ANATOMY", 283, 287], ["Ch", "CHEMICAL", 348, 350], ["PCV2", "ORGANISM", 19, 23], ["pigs", "ORGANISM", 56, 60], ["VacA", "GENE_OR_GENE_PRODUCT", 175, 179], ["Ch", "GENE_OR_GENE_PRODUCT", 180, 182], ["VacB/Ch groups", "ORGANISM", 187, 201], ["PCV2d", "GENE_OR_GENE_PRODUCT", 250, 255], ["IFN-\u03b3-SC", "GENE_OR_GENE_PRODUCT", 265, 273], ["PBMC", "CELL", 283, 287], ["pigs", "ORGANISM", 330, 334], ["VacA", "PROTEIN", 175, 179], ["IFN", "PROTEIN", 265, 268], ["PBMC", "CELL_TYPE", 283, 287], ["pigs", "SPECIES", 56, 60], ["Porcine", "SPECIES", 124, 131], ["pigs", "SPECIES", 330, 334], ["PCV2", "SPECIES", 19, 23], ["pigs", "SPECIES", 56, 60], ["pigs", "SPECIES", 330, 334], ["Antibodies", "TEST", 0, 10], ["PCV2", "PROBLEM", 19, 23], ["ResultsPigs", "TEST", 154, 165], ["the VacA/Ch", "TEST", 171, 182], ["VacB/Ch groups", "TEST", 187, 201], ["PCV2d", "TEST", 250, 255]]], ["Pigs from the VacA/Ch group had significantly higher (P < 0.05) numbers of PCV2d-specific IFN-\u03b3-SC in their PBMC at 21 dpc when compared with pigs in the VacB/Ch group.", [["PBMC", "ANATOMY", 108, 112], ["Ch", "CHEMICAL", 159, 161], ["Pigs", "ORGANISM", 0, 4], ["VacA", "GENE_OR_GENE_PRODUCT", 14, 18], ["PCV2d", "SIMPLE_CHEMICAL", 75, 80], ["IFN-\u03b3-SC", "GENE_OR_GENE_PRODUCT", 90, 98], ["PBMC", "CELL", 108, 112], ["pigs", "ORGANISM", 142, 146], ["VacA", "PROTEIN", 14, 18], ["IFN", "PROTEIN", 90, 93], ["PBMC", "CELL_TYPE", 108, 112], ["Pigs", "SPECIES", 0, 4], ["pigs", "SPECIES", 142, 146], ["pigs", "SPECIES", 142, 146], ["the VacA/Ch group", "TEST", 10, 27], ["PCV2d", "TEST", 75, 80]]], ["The mean numbers of PCV2d-specific IFN-\u03b3-SC in the UnVac/UnCh group remained at basal levels (<20 cells/106 PBMC) throughout the study (Figure 4B).Pathology ::: ResultsPigs in the VacA/Ch and VacB/Ch groups had significantly lower (P < 0.05) macroscopic lung lesion scores, microscopic mycoplasmal and interstitial lung lesion scores, and microscopic lymphoid lesions at 21 dpc when compared with pigs from the UnVac/Ch group.", [["UnVac/UnCh", "ANATOMY", 51, 61], ["cells", "ANATOMY", 98, 103], ["PBMC", "ANATOMY", 108, 112], ["lung lesion", "ANATOMY", 254, 265], ["mycoplasmal", "ANATOMY", 286, 297], ["interstitial lung lesion", "ANATOMY", 302, 326], ["lymphoid lesions", "ANATOMY", 351, 367], ["Ch", "CHEMICAL", 417, 419], ["PCV2d", "GENE_OR_GENE_PRODUCT", 20, 25], ["IFN-\u03b3-SC", "GENE_OR_GENE_PRODUCT", 35, 43], ["UnVac", "CANCER", 51, 56], ["UnCh", "GENE_OR_GENE_PRODUCT", 57, 61], ["cells", "CELL", 98, 103], ["PBMC", "CELL", 108, 112], ["VacA", "GENE_OR_GENE_PRODUCT", 180, 184], ["Ch", "GENE_OR_GENE_PRODUCT", 185, 187], ["lung", "ORGAN", 254, 258], ["interstitial lung lesion", "PATHOLOGICAL_FORMATION", 302, 326], ["lymphoid lesions", "PATHOLOGICAL_FORMATION", 351, 367], ["pigs", "ORGANISM", 397, 401], ["PCV2d", "PROTEIN", 20, 25], ["IFN", "PROTEIN", 35, 38], ["PBMC", "CELL_TYPE", 108, 112], ["VacA", "PROTEIN", 180, 184], ["VacB", "PROTEIN", 192, 196], ["pigs", "SPECIES", 397, 401], ["pigs", "SPECIES", 397, 401], ["The mean numbers", "TEST", 0, 16], ["PCV2d", "TEST", 20, 25], ["basal levels", "TEST", 80, 92], ["PBMC", "TEST", 108, 112], ["the study", "TEST", 125, 134], ["Pathology", "TEST", 147, 156], ["ResultsPigs", "TEST", 161, 172], ["the VacA/Ch", "TEST", 176, 187], ["VacB/Ch groups", "TEST", 192, 206], ["macroscopic lung lesion scores", "PROBLEM", 242, 272], ["microscopic mycoplasmal and interstitial lung lesion scores", "PROBLEM", 274, 333], ["microscopic lymphoid lesions", "PROBLEM", 339, 367], ["VacA", "ANATOMY", 180, 184], ["lower", "OBSERVATION_MODIFIER", 225, 230], ["lung", "ANATOMY", 254, 258], ["lesion", "OBSERVATION", 259, 265], ["mycoplasmal", "OBSERVATION_MODIFIER", 286, 297], ["interstitial", "ANATOMY_MODIFIER", 302, 314], ["lung", "ANATOMY", 315, 319], ["lesion", "OBSERVATION", 320, 326], ["microscopic lymphoid lesions", "OBSERVATION", 339, 367]]], ["Macroscopic and microscopic lung lesions, and micriscopic lymphoid lesions were not observed in pigs from the UnVac/UnCh group (Table 3).DiscussionBoth presentations of the evaluated vaccines (a combination of two monovalent vaccines mixed into a combo prior to vaccination, or a ready-to-use bivalent vaccine) proved efficacious in the protection of pigs against M. hyopneumoniae and PCV2d challenge.", [["lung lesions", "ANATOMY", 28, 40], ["micriscopic lymphoid lesions", "ANATOMY", 46, 74], ["PCV2d", "CHEMICAL", 385, 390], ["lung lesions", "PATHOLOGICAL_FORMATION", 28, 40], ["micriscopic lymphoid lesions", "CANCER", 46, 74], ["pigs", "ORGANISM", 96, 100], ["pigs", "ORGANISM", 351, 355], ["M. hyopneumoniae", "ORGANISM", 364, 380], ["PCV2d", "ORGANISM", 385, 390], ["pigs", "SPECIES", 96, 100], ["pigs", "SPECIES", 351, 355], ["M. hyopneumoniae", "SPECIES", 364, 380], ["pigs", "SPECIES", 96, 100], ["pigs", "SPECIES", 351, 355], ["M. hyopneumoniae", "SPECIES", 364, 380], ["Macroscopic and microscopic lung lesions", "PROBLEM", 0, 40], ["micriscopic lymphoid lesions", "PROBLEM", 46, 74], ["the evaluated vaccines", "TREATMENT", 169, 191], ["two monovalent vaccines", "TREATMENT", 210, 233], ["vaccination", "TREATMENT", 262, 273], ["bivalent vaccine", "TREATMENT", 293, 309], ["M. hyopneumoniae", "PROBLEM", 364, 380], ["PCV2d challenge", "TREATMENT", 385, 400], ["microscopic", "OBSERVATION_MODIFIER", 16, 27], ["lung", "ANATOMY", 28, 32], ["lesions", "OBSERVATION", 33, 40], ["micriscopic lymphoid lesions", "OBSERVATION", 46, 74], ["hyopneumoniae", "OBSERVATION", 367, 380]]], ["The study included a successful challenge infection as all infected pigs tested positive for M. hyopneumoniae and PCV2d by PCR testing of nasal swabs and blood, respectively.", [["nasal swabs", "ANATOMY", 138, 149], ["blood", "ANATOMY", 154, 159], ["infection", "DISEASE", 42, 51], ["pigs", "ORGANISM", 68, 72], ["M. hyopneumoniae", "ORGANISM", 93, 109], ["PCV2d", "ORGANISM", 114, 119], ["nasal swabs", "MULTI-TISSUE_STRUCTURE", 138, 149], ["blood", "ORGANISM_SUBSTANCE", 154, 159], ["pigs", "SPECIES", 68, 72], ["M. hyopneumoniae", "SPECIES", 93, 109], ["pigs", "SPECIES", 68, 72], ["M. hyopneumoniae", "SPECIES", 93, 109], ["PCV2d", "SPECIES", 114, 119], ["The study", "TEST", 0, 9], ["a successful challenge infection", "PROBLEM", 19, 51], ["all infected pigs", "PROBLEM", 55, 72], ["M. hyopneumoniae", "PROBLEM", 93, 109], ["PCR testing", "TEST", 123, 134], ["nasal swabs", "TEST", 138, 149], ["infection", "OBSERVATION", 42, 51], ["nasal swabs", "ANATOMY", 138, 149]]], ["The present data demonstrated that the two most prominent and costly diseases, PCVAD and enzootic pneumonia, can be prevented with either form of a combination vaccine, two monovalents which are mixed onsite prior to vaccination (a combination of two monovalent vaccines mixed into a combo prior to vaccination) or a ready-to-use vaccine.", [["PCVAD", "DISEASE", 79, 84], ["pneumonia", "DISEASE", 98, 107], ["costly diseases", "PROBLEM", 62, 77], ["PCVAD", "PROBLEM", 79, 84], ["enzootic pneumonia", "PROBLEM", 89, 107], ["a combination vaccine", "TREATMENT", 146, 167], ["vaccination", "TREATMENT", 217, 228], ["two monovalent vaccines", "TREATMENT", 247, 270], ["a combo prior to vaccination", "TREATMENT", 282, 310], ["vaccine", "TREATMENT", 330, 337], ["most prominent", "OBSERVATION_MODIFIER", 43, 57], ["costly", "OBSERVATION_MODIFIER", 62, 68], ["diseases", "OBSERVATION", 69, 77], ["enzootic", "OBSERVATION_MODIFIER", 89, 97], ["pneumonia", "OBSERVATION", 98, 107]]], ["Growth performance was the most critical parameter evaluated throughout the study and should be given preccedece when evaluating the efficacy of a vaccine (26).", [["the study", "TEST", 72, 81], ["preccedece", "TREATMENT", 102, 112], ["a vaccine", "TREATMENT", 145, 154]]], ["Vaccination and challenge by either method resulted in significant growth performance improvement when compared with the unvaccinated-challenged group.", [["Vaccination", "TREATMENT", 0, 11], ["significant growth performance", "PROBLEM", 55, 85], ["significant", "OBSERVATION_MODIFIER", 55, 66], ["growth", "OBSERVATION_MODIFIER", 67, 73]]], ["Although ADWG was numerically higher in the mixable combo-vaccinated group than in the ready-to-use bivalent-vaccinated group, it was not determined as statistically significant.DiscussionField conditions were mimicked through the vaccination-infection model design of this study.", [["infection", "DISEASE", 243, 252], ["ADWG", "SIMPLE_CHEMICAL", 9, 13], ["ADWG", "TEST", 9, 13], ["this study", "TEST", 269, 279], ["higher", "OBSERVATION_MODIFIER", 30, 36]]], ["Analysis of diagnostic cases and serological surveyance under Korean field conditions (C. Chae, personal observation) has concluded that pigs are generally prone to M. hyopneumoniae infection at 5\u20137 weeks of age and to PCV2 infection at 7\u20139 weeks of age, which eventually leads to a PRDC outbreak at 11\u201316 weeks of age.", [["M. hyopneumoniae infection", "DISEASE", 165, 191], ["PCV2 infection", "DISEASE", 219, 233], ["PRDC", "DISEASE", 283, 287], ["pigs", "ORGANISM", 137, 141], ["M. hyopneumoniae", "ORGANISM", 165, 181], ["PCV2", "ORGANISM", 219, 223], ["pigs", "SPECIES", 137, 141], ["M. hyopneumoniae", "SPECIES", 165, 181], ["pigs", "SPECIES", 137, 141], ["M. hyopneumoniae", "SPECIES", 165, 181], ["PCV2", "SPECIES", 219, 223], ["diagnostic cases", "TEST", 12, 28], ["serological surveyance", "TEST", 33, 55], ["M. hyopneumoniae infection", "PROBLEM", 165, 191], ["PCV2 infection", "PROBLEM", 219, 233], ["hyopneumoniae", "OBSERVATION", 168, 181], ["PCV2 infection", "OBSERVATION", 219, 233]]], ["These natural-occurring infection timeframes were kept in mind when designing this study, which is why pigs were inoculated with M. hyopneumoniae at 6 weeks of age followed by PCV2 inoculation at 8 weeks of age.", [["infection", "DISEASE", 24, 33], ["pigs", "ORGANISM", 103, 107], ["M. hyopneumoniae", "ORGANISM", 129, 145], ["PCV2", "ORGANISM", 176, 180], ["pigs", "SPECIES", 103, 107], ["M. hyopneumoniae", "SPECIES", 129, 145], ["pigs", "SPECIES", 103, 107], ["M. hyopneumoniae", "SPECIES", 129, 145], ["PCV2", "SPECIES", 176, 180], ["infection timeframes", "PROBLEM", 24, 44], ["this study", "TEST", 78, 88], ["M. hyopneumoniae", "PROBLEM", 129, 145], ["PCV2 inoculation", "TREATMENT", 176, 192], ["infection", "OBSERVATION", 24, 33]]], ["In this sequential infection model, M. hyopneumoniae infection followed by PCV2 reproduced PCVAD experimentally, mimicking natural cases in the field as described in the previous study (27).", [["infection", "DISEASE", 19, 28], ["M. hyopneumoniae infection", "DISEASE", 36, 62], ["M. hyopneumoniae", "ORGANISM", 36, 52], ["PCV2", "ORGANISM", 75, 79], ["M. hyopneumoniae", "SPECIES", 36, 52], ["M. hyopneumoniae", "SPECIES", 36, 52], ["PCV2", "SPECIES", 75, 79], ["this sequential infection model", "PROBLEM", 3, 34], ["M. hyopneumoniae infection", "PROBLEM", 36, 62], ["PCV2", "PROBLEM", 75, 79], ["the previous study", "TEST", 166, 184], ["infection", "OBSERVATION", 19, 28], ["hyopneumoniae", "OBSERVATION_MODIFIER", 39, 52], ["infection", "OBSERVATION", 53, 62]]], ["Vaccination of pigs with PCV2 and M. hyopneumoniae at 3 weeks of age provided statistically significant protection against M. hyopneumoniae at 6 weeks of age and against PCV2 at 8 weeks of age.DiscussionLarge opportunities still exist to develop a better understooding of protective immunity against M. hyopneumoniae.", [["pigs", "ORGANISM", 15, 19], ["PCV2", "ORGANISM", 25, 29], ["M. hyopneumoniae", "ORGANISM", 34, 50], ["M. hyopneumoniae", "ORGANISM", 123, 139], ["PCV2", "ORGANISM", 170, 174], ["M. hyopneumoniae", "ORGANISM", 300, 316], ["pigs", "SPECIES", 15, 19], ["M. hyopneumoniae", "SPECIES", 34, 50], ["M. hyopneumoniae", "SPECIES", 123, 139], ["M. hyopneumoniae", "SPECIES", 300, 316], ["pigs", "SPECIES", 15, 19], ["PCV2", "SPECIES", 25, 29], ["M. hyopneumoniae", "SPECIES", 34, 50], ["M. hyopneumoniae", "SPECIES", 123, 139], ["PCV2", "SPECIES", 170, 174], ["M. hyopneumoniae", "SPECIES", 300, 316], ["Vaccination of pigs", "TREATMENT", 0, 19], ["PCV2", "PROBLEM", 25, 29], ["M. hyopneumoniae", "PROBLEM", 34, 50], ["M. hyopneumoniae", "PROBLEM", 123, 139], ["PCV2", "PROBLEM", 170, 174], ["M. hyopneumoniae", "PROBLEM", 300, 316], ["hyopneumoniae", "OBSERVATION", 303, 316]]], ["As a non-invasive pathogen that can induce pneumonia, cell-mediated immune response must play a significant immulogical role.", [["cell", "ANATOMY", 54, 58], ["pneumonia", "DISEASE", 43, 52], ["cell", "CELL", 54, 58], ["a non-invasive pathogen", "PROBLEM", 3, 26], ["pneumonia", "PROBLEM", 43, 52], ["pneumonia", "OBSERVATION", 43, 52]]], ["A consistent correlation between the induction of cell-mediated immunity and the severity of pneumonic lesions has been demonstrated (28, 29).", [["cell", "ANATOMY", 50, 54], ["pneumonic lesions", "ANATOMY", 93, 110], ["pneumonic", "DISEASE", 93, 102], ["cell", "CELL", 50, 54], ["pneumonic lesions", "PATHOLOGICAL_FORMATION", 93, 110], ["cell-mediated immunity", "TREATMENT", 50, 72], ["pneumonic lesions", "PROBLEM", 93, 110], ["pneumonic", "OBSERVATION_MODIFIER", 93, 102], ["lesions", "OBSERVATION", 103, 110]]], ["A significant difference was not found between the two sets of vaccines used in this study, in terms of elicited cell-mediated immune response and protective effect against M. hyopneumoniae challenge.", [["cell", "ANATOMY", 113, 117], ["cell", "CELL", 113, 117], ["M. hyopneumoniae", "ORGANISM", 173, 189], ["M. hyopneumoniae", "SPECIES", 173, 189], ["M. hyopneumoniae", "SPECIES", 173, 189], ["vaccines", "TREATMENT", 63, 71], ["this study", "TEST", 80, 90], ["M. hyopneumoniae challenge", "PROBLEM", 173, 199], ["significant", "OBSERVATION_MODIFIER", 2, 13], ["difference", "OBSERVATION", 14, 24], ["immune response", "OBSERVATION", 127, 142], ["hyopneumoniae", "OBSERVATION", 176, 189]]], ["The strain of M. hyopneumponiae was identical in both sets of vaccines (VacA/Ch and VacB/Ch groups) but the vaccine adjuvants varied (30).", [["M. hyopneumponiae", "ORGANISM", 14, 31], ["VacA", "GENE_OR_GENE_PRODUCT", 72, 76], ["VacB/Ch groups", "ORGANISM", 84, 98], ["VacA", "PROTEIN", 72, 76], ["VacB", "PROTEIN", 84, 88], ["M. hyopneumponiae", "SPECIES", 14, 31], ["M. hyopneumponiae", "SPECIES", 14, 31], ["M. hyopneumponiae", "PROBLEM", 14, 31], ["vaccines", "TREATMENT", 62, 70], ["VacA/Ch and VacB/Ch groups", "TREATMENT", 72, 98], ["the vaccine adjuvants", "TREATMENT", 104, 125], ["M. hyopneumponiae", "OBSERVATION", 14, 31]]], ["Although adjuvant formulation in particular is known to affect the immunogenicity and protective effect of inactivated whole-cell M. hyopneumoniae bacterins (31), an effect on efficacy against M. hyopneumoniae was not observed in the present study.DiscussionBoth vaccines evaluated in this study were based on the PCV2a genotype.", [["whole-cell M. hyopneumoniae bacterins", "ORGANISM", 119, 156], ["M. hyopneumoniae", "ORGANISM", 193, 209], ["PCV2a", "GENE_OR_GENE_PRODUCT", 314, 319], ["M. hyopneumoniae", "SPECIES", 130, 146], ["M. hyopneumoniae", "SPECIES", 193, 209], ["M. hyopneumoniae", "SPECIES", 130, 146], ["M. hyopneumoniae", "SPECIES", 193, 209], ["adjuvant formulation", "TREATMENT", 9, 29], ["inactivated whole-cell M. hyopneumoniae bacterins", "PROBLEM", 107, 156], ["M. hyopneumoniae", "PROBLEM", 193, 209], ["the present study", "TEST", 230, 247], ["DiscussionBoth vaccines", "TREATMENT", 248, 271], ["this study", "TEST", 285, 295], ["hyopneumoniae", "OBSERVATION", 196, 209]]], ["PCV2d viremia was still reduced in pigs from PCV2a-based vaccination and PCV2d-challenge when compared with unvaccinated and challenged pigs.", [["viremia", "DISEASE", 6, 13], ["PCV2a", "CHEMICAL", 45, 50], ["PCV2d", "CHEMICAL", 73, 78], ["PCV2d", "SIMPLE_CHEMICAL", 0, 5], ["pigs", "ORGANISM", 35, 39], ["PCV2a", "ORGANISM", 45, 50], ["PCV2d", "SIMPLE_CHEMICAL", 73, 78], ["pigs", "ORGANISM", 136, 140], ["pigs", "SPECIES", 35, 39], ["pigs", "SPECIES", 136, 140], ["pigs", "SPECIES", 35, 39], ["pigs", "SPECIES", 136, 140], ["PCV2d viremia", "PROBLEM", 0, 13], ["PCV2a-based vaccination", "TREATMENT", 45, 68], ["PCV2d", "TREATMENT", 73, 78], ["viremia", "OBSERVATION", 6, 13]]], ["Reduction of PCV2d Viremia is clinically meaningful as PCV2d is currently the predominant PCV2 genotype circulating within Asian pig herds (8).", [["Viremia", "DISEASE", 19, 26], ["PCV2d", "CHEMICAL", 55, 60], ["PCV2d", "GENE_OR_GENE_PRODUCT", 13, 18], ["PCV2", "ORGANISM", 90, 94], ["pig", "ORGANISM", 129, 132], ["pig", "SPECIES", 129, 132], ["Asian pig herds", "SPECIES", 123, 138], ["PCV2d Viremia", "PROBLEM", 13, 26], ["PCV2d Viremia", "OBSERVATION", 13, 26], ["predominant", "OBSERVATION_MODIFIER", 78, 89], ["PCV2", "OBSERVATION", 90, 94]]], ["The reduction of PCV2 viremia is well-correlated with protection against PCV2 infection (32\u201334).", [["viremia", "DISEASE", 22, 29], ["PCV2 infection", "DISEASE", 73, 87], ["PCV2", "ORGANISM", 17, 21], ["PCV2", "ORGANISM", 73, 77], ["PCV2", "SPECIES", 17, 21], ["PCV2", "SPECIES", 73, 77], ["PCV2 viremia", "PROBLEM", 17, 29], ["PCV2 infection", "PROBLEM", 73, 87], ["reduction", "OBSERVATION_MODIFIER", 4, 13], ["PCV2 viremia", "OBSERVATION", 17, 29], ["infection", "OBSERVATION", 78, 87]]], ["Both types of vaccines elicited the PCV2d-specific IFN-\u03b3-SC which is critical in reducing the amount of PCV2 viremia within pigs (35\u201337).", [["viremia", "DISEASE", 109, 116], ["PCV2d", "SIMPLE_CHEMICAL", 36, 41], ["IFN-\u03b3-SC", "GENE_OR_GENE_PRODUCT", 51, 59], ["PCV2", "ORGANISM", 104, 108], ["pigs", "ORGANISM", 124, 128], ["IFN", "PROTEIN", 51, 54], ["pigs", "SPECIES", 124, 128], ["PCV2", "SPECIES", 104, 108], ["vaccines", "TREATMENT", 14, 22], ["the PCV2d", "TEST", 32, 41], ["PCV2 viremia", "PROBLEM", 104, 116], ["PCV2 viremia", "OBSERVATION", 104, 116]]], ["PCV2d viremia and lymphoid lesion reduction is both attributed to the induction of protective cell-mediated imminuty.", [["lymphoid lesion", "ANATOMY", 18, 33], ["cell", "ANATOMY", 94, 98], ["viremia", "DISEASE", 6, 13], ["lymphoid lesion reduction", "DISEASE", 18, 43], ["lymphoid lesion", "PATHOLOGICAL_FORMATION", 18, 33], ["cell", "CELL", 94, 98], ["PCV2d viremia", "PROBLEM", 0, 13], ["lymphoid lesion reduction", "TREATMENT", 18, 43], ["protective cell-mediated imminuty", "TREATMENT", 83, 116], ["viremia", "OBSERVATION", 6, 13], ["lymphoid lesion", "OBSERVATION", 18, 33]]], ["The two vaccines elicited different cell-mediated immune responses and levels of PCV2d viremia against PCV2d challenge.", [["cell", "ANATOMY", 36, 40], ["viremia", "DISEASE", 87, 94], ["PCV2d", "CHEMICAL", 103, 108], ["cell", "CELL", 36, 40], ["PCV2d", "SIMPLE_CHEMICAL", 81, 86], ["The two vaccines", "TREATMENT", 0, 16], ["PCV2d viremia", "TREATMENT", 81, 94], ["PCV2d challenge", "TREATMENT", 103, 118]]], ["Although both vaccines used in this study have the same baculovirus system for the expression of the ORF2 subunit of PCV2, each vaccine contained a unique antigen preparation by use of the baculovirus expression system (38).", [["baculovirus", "ORGANISM", 56, 67], ["ORF2", "GENE_OR_GENE_PRODUCT", 101, 105], ["PCV2", "ORGANISM", 117, 121], ["baculovirus", "ORGANISM", 189, 200], ["ORF2 subunit", "PROTEIN", 101, 113], ["baculovirus", "SPECIES", 56, 67], ["PCV2", "SPECIES", 117, 121], ["baculovirus", "SPECIES", 189, 200], ["both vaccines", "TREATMENT", 9, 22], ["this study", "TEST", 31, 41], ["the same baculovirus system", "TREATMENT", 47, 74], ["the ORF2 subunit of PCV2", "TREATMENT", 97, 121], ["each vaccine", "TREATMENT", 123, 135], ["a unique antigen preparation", "TREATMENT", 146, 174], ["the baculovirus expression system", "TREATMENT", 185, 218]]], ["This as well as differences in adjuvant formulation between the vaccines may be as the reasoning behind the differences in protective cell-mediated immunity and induction and reduction of both PCV2 viremia and lymphoid lesions.", [["cell", "ANATOMY", 134, 138], ["lymphoid lesions", "ANATOMY", 210, 226], ["viremia", "DISEASE", 198, 205], ["lymphoid lesions", "DISEASE", 210, 226], ["cell", "CELL", 134, 138], ["PCV2", "ORGANISM", 193, 197], ["lymphoid lesions", "PATHOLOGICAL_FORMATION", 210, 226], ["PCV2", "SPECIES", 193, 197], ["adjuvant formulation", "TREATMENT", 31, 51], ["the vaccines", "TREATMENT", 60, 72], ["protective cell-mediated immunity", "TREATMENT", 123, 156], ["induction", "TREATMENT", 161, 170], ["reduction", "TREATMENT", 175, 184], ["both PCV2 viremia", "PROBLEM", 188, 205], ["lymphoid lesions", "PROBLEM", 210, 226], ["PCV2 viremia", "OBSERVATION", 193, 205], ["lymphoid lesions", "OBSERVATION", 210, 226]]], ["Further studies are needed to elucidate these differences between the two vaccines.DiscussionThis comparative study under experimental conditions was the first evaluation between a combination of two monovalent vaccines mixed into a combo prior to vaccination and a ready-to-use bivalent vaccine of PCV2 and M. hyopneumoniae.", [["PCV2", "ORGANISM", 299, 303], ["M. hyopneumoniae", "ORGANISM", 308, 324], ["M. hyopneumoniae", "SPECIES", 308, 324], ["PCV2", "SPECIES", 299, 303], ["M. hyopneumoniae", "SPECIES", 308, 324], ["Further studies", "TEST", 0, 15], ["the two vaccines", "TREATMENT", 66, 82], ["This comparative study", "TEST", 93, 115], ["the first evaluation", "TEST", 150, 170], ["two monovalent vaccines", "TREATMENT", 196, 219], ["vaccination", "TREATMENT", 248, 259], ["bivalent vaccine", "TREATMENT", 279, 295], ["PCV2", "PROBLEM", 299, 303], ["M. hyopneumoniae", "PROBLEM", 308, 324], ["hyopneumoniae", "OBSERVATION", 311, 324]]], ["Vaccination remains the most efficient and economical method to-date for the control of PCVAD and enzootic pneumonia.", [["PCVAD", "DISEASE", 88, 93], ["pneumonia", "DISEASE", 107, 116], ["PCVAD", "SPECIES", 88, 93], ["Vaccination", "TREATMENT", 0, 11], ["PCVAD", "PROBLEM", 88, 93], ["enzootic pneumonia", "PROBLEM", 98, 116], ["enzootic", "OBSERVATION_MODIFIER", 98, 106], ["pneumonia", "OBSERVATION", 107, 116]]], ["More than 70 percent of Korean pigs receive vaccines to protect against PCV2 and M. hyopneumoniae (http://www.kahpha.or.kr) as PCVAD and enzootic pneumonia remain the two most prominent and costly diseases that affect swine.", [["pneumonia", "DISEASE", 146, 155], ["pigs", "ORGANISM", 31, 35], ["PCV2", "ORGANISM", 72, 76], ["M. hyopneumoniae", "ORGANISM", 81, 97], ["swine", "ORGANISM", 218, 223], ["pigs", "SPECIES", 31, 35], ["M. hyopneumoniae", "SPECIES", 81, 97], ["swine", "SPECIES", 218, 223], ["pigs", "SPECIES", 31, 35], ["PCV2", "SPECIES", 72, 76], ["M. hyopneumoniae", "SPECIES", 81, 97], ["swine", "SPECIES", 218, 223], ["Korean pigs", "TREATMENT", 24, 35], ["vaccines", "TREATMENT", 44, 52], ["PCV2", "PROBLEM", 72, 76], ["M. hyopneumoniae", "PROBLEM", 81, 97], ["PCVAD", "PROBLEM", 127, 132], ["enzootic pneumonia", "PROBLEM", 137, 155], ["hyopneumoniae", "OBSERVATION", 84, 97], ["enzootic", "OBSERVATION_MODIFIER", 137, 145], ["pneumonia", "OBSERVATION", 146, 155], ["most prominent", "OBSERVATION_MODIFIER", 171, 185]]], ["An important advantage in using either a combination of two monovalent vaccines mixed into a combo prior to vaccination or a ready-to-use bivalent vaccine exists as either reduces the number of injections administered to the pig.", [["pig", "ORGANISM", 225, 228], ["pig", "SPECIES", 225, 228], ["pig", "SPECIES", 225, 228], ["two monovalent vaccines", "TREATMENT", 56, 79], ["vaccination", "TREATMENT", 108, 119], ["bivalent vaccine", "TREATMENT", 138, 154], ["injections", "TREATMENT", 194, 204]]], ["The results of this study demonstrate a strategic method in controlling two important diseases for swine producers and practitioners.Data Availability StatementAll datasets generated for this study are included in the article/supplementary material.Ethics StatementThe animal study was reviewed and approved by Seoul national university Instituional Animal Care and Use Committee (SNU-190712-5).Author ContributionsSY performance of the experimental trials, data analysis, and writing of the manuscript.", [["SNU-190712-5", "CHEMICAL", 381, 393], ["swine", "SPECIES", 99, 104], ["swine", "SPECIES", 99, 104], ["this study", "TEST", 15, 25], ["swine producers", "TREATMENT", 99, 114], ["this study", "TEST", 187, 197], ["The animal study", "TEST", 265, 281], ["data analysis", "TEST", 458, 471]]], ["TO, KP, and HC preparation of the inoculum and lab analysis.", [["KP", "CHEMICAL", 4, 6], ["the inoculum", "TREATMENT", 30, 42], ["lab analysis", "TEST", 47, 59]]], ["CC development of protocol, design of the study, review of the final manuscript, and approval for publication.", [["CC", "CHEMICAL", 0, 2], ["the study", "TEST", 38, 47]]]]}